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Abstract
The transmission of painful messages from the periphery involves complex 
interactions between excitatory and inhibitory neurotransmitter systems in the 
spinal dorsal hom. The balance between these receptor events determines the 
level of pain transmission. Within the spinal cord, neuronal sensitization plays a 
key role in altering the ascending messages to the brain.
Morphine, widely used in pain control, acts on inhibitory mu opioid receptors 
located both on small diameter primary afferent fibres and postsynaptic sites.
The aim of my studies was to determine how various excitatory transmitter 
systems at spinal levels are modulated by morphine in rats.
The activation of the receptor for substance P, the NK-1 receptor, and the 
NMDA receptor for glutamate, on dorsal hom neurons are thought to contribute 
to wind-up pain and central sensitisation underlying a number of abnormal 
clinical pain states.
Using in vivo electrophysiological studies and behavioural measures, I have 
studied the relations between peripheral inputs and central sensitisation using 
NK-1 and NMDA receptor agonists and further used a surgical neuropathic 
model and investigated the actions of morphine on the neuronal activity and pain 
behaviours.
I have also investigated NMDA receptors located on peripheral endings of 
sensory nerves, and found a lack of functional effects of these receptors in 
pathophysiological states.
Finally, the role of the excitatory 5HT3 receptor was assessed using the 
antagonist ondansetron in the neuropathic pain model, as was the combination of 
morphine and ondansetron which was more effective in inhibiting some of the 
pain behaviour seen in neuropathic pain than ondansetron alone.
The actions of morphine, at a non-sedating dose, could overcome central 
sensitisation, the actions of ondansetron confirm the role of descending 
facilitations after nerve injury and the results demonstrate how the balance 
between excitation and inhibition can alter the level of pain and its control.
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Chapter 1:
Introduction
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1. Introduction
1.1 Pain transmission, neuropathic pain and aim
1.1.1 Pain transmission
Pain has been defined by the International Association for the Study of Pain as 
“An unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage” (Merskey and 
Bogduk 1994). Pain is normally transmitted from the periphery, through the 
spinal cord, to supraspinal sites. However, the spinal cord is more than just a 
relay for pain transmission, as this is the level where afferent input from the 
periphery and descending controls from supraspinal sites converge and ‘gate’ 
pain (Melzack and Wall 1965).
Additionally, the neurotransmission of pain in the spinal cord dorsal hom 
involves complex interactions between many excitatory and inhibitory 
neurotransmitters/neuromodulators, receptors and channels (Dickenson 1995). 
These transmitters, receptors and channels come from either the afferent fibres, 
intrinsic neurones or descending fibres (Wilcox and Seybold 1997). The balance 
between excitatory and inhibitory events is what leads to whether or not pain 
transmission occurs, and with which intensity. Therefore, pain transmission is 
not straightforward and demonstrates plasticity. Pain control is normally 
achieved either by selective blockade of excitatory transmission, or enhancement 
of inhibitory transmission (Dickenson 1995; Dickenson 1997).
1.1.2 Neuropathic pain
Neuropathic pain has been defined by the International Association for the Study 
of Pain (IASP) as “Pain initiated or caused by a primary lesion or dysfunction in 
the nervous system”. Neuropathic pain may be subdivided according to the 
location of the lesion/dysfunction (peripheral versus central). Part of this study 
will revolve around peripheral neuropathic pain. Peripheral neuropathic pain can
16
arise from diseases such as diabetes mellitus, herpes zoster, HIV, from nerve 
compression such as that resulting from tumours, or from neuroma formation 
following amputation or trauma (Suzuki and Dickenson 2000).
Symptoms of neuropathic pain are both negative, such as sensory deficits and 
positive. The positive symptoms are subclassified as evoked pain to different 
mechanical and thermal stimuli such as tactile allodynia, hyperalgesia, 
continuous pain, such as burning or stabbing pain, or paroxysmal pain, such as 
shooting or lancinating pain (Attal and Bouhassira 1999). Positive symptoms 
seem to occur when the nervous system ‘compensates’ for the sensory loss and 
becomes hyperexcitable (Suzuki and Dickenson 2000).
1.1.3 Hyperalgesia and allodynia
i) Definitions
As mentioned above, the overall painful sensation experienced, following 
neurotransmission, from the periphery to the spinal cord, is not directly 
proportional to the intensity of the painful stimulus at the periphery. Pain 
transmission is ‘plastic’, and not a linear relationship between stimulus and 
response. Hyperalgesia is the term used to describe an amplified pain response to 
a mildly noxious stimulus, whereas allodynia is the term used to describe pain 
due to a non-painful stimulus (Petrenko, Yamakura et al. 2003).
Earlier, there were two theories that attempted to explain the mechanisms 
underlying neuropathic pain. One of them postulated peripheral mechanisms 
were involved, whilst the other postulated central mechanisms were involved 
(Treede, Meyer et al. 1992). Nowadays, it is recognised that the mechanisms 
underlying neuropathic pain include a combination of both peripheral and central 
mechanisms of sensitisation (Treede, Meyer et al. 1992).
Following tissue damage in the periphery, there is a primary area of pain around 
the injury site, this is termed primary hyperalgesia and is thought to involve
17
sensitisation of nociceptors (C- and A8- diameter primary afferent fibres which 
convey the sensation of pain from the periphery to the spinal cord) at the 
periphery (peripheral sensitisation) (Caterina, Gold et al. 2005; Meyer,
Ringkamp et al. 2006). Whereas a secondary area of pain not related to the injury 
site is termed secondary hyperalgesia/allodynia, the mechanisms of which are 
thought to be sensitisation of spinal cord dorsal hom neurons (central 
sensitisation) (Treede, Meyer et al. 1992; Urban, Zahn et al. 1999). Sensitisation 
is the neurophysiological correlate of hyperalgesia and is defined as a leftward 
shift of the stimulus-response curve, relating the size of the neural response to the 
intensity of the stimulus (Treede, Meyer et al. 1992).
ii) Thermal hyperalgesia
Hyperalgesia due to heat occurs only at the primary injury site, and is thought to 
involve the sensitisation of C- and A8-fibres. At the secondary injury site, heat 
responses are either unchanged or decreased (Meyer and Campbell 1981; Raja, 
Campbell et al. 1984; Treede, Meyer et al. 1992; Magerl, Fuchs et al. 2001; 
Meyer, Ringkamp et al. 2006).
iii) Mechanical hyperalgesia/allodynia
Hyperalgesia/allodynia due to mechanical stimuli occurs both at the primary and 
secondary injury sites, due to both peripheral and central sensitisation 
mechanisms, respectively. Mechanical allodynia is demonstrated by a lowering 
of the activation threshold to mechanical stimuli, and the increase of both the 
responses to suprathreshold stimuli and the receptive fields of both A8- and C- 
fibres following injury (Meyer, Ringkamp et al. 2006). Finally, there are two 
different types of mechanical allodynia: dynamic allodynia, which is thought to 
be mostly transmitted by Ap-fibres and static allodynia, which is thought to be 
mostly transmitted by A8-fibres (Field, Bramwell et al. 1999).
18
P r i m a r y  h y p e r a l g e s i a  ( p e r i p h e r a l  s e n s i t i s a t i o n )
Figure 1.1- The red circle represents the primary area around the injury site where heat and 
mechanical hyperalgesia occur due to peripheral sensitisation and the larger circle represents the 
secondary uninjured site where mechanical hyperalgesia and allodynia occur due to central 
sensitisation.
1.1.4 Animal models of neuropathic pain and what they measure
Experimentally, at the dorsal hom neuronal level, nerve injury causes increases 
in spontaneous activity of dorsal hom neurons and receptive field sizes of 
neurons in response to low-intensity mechanical stimuli (Chapman, Suzuki et al.
1998; Suzuki, Kontinen et al. 2000; Suzuki and Dickenson 2002). However, 
asides from the previously discussed, it has been shown that behavioural and 
neuronal studies show opposite sides to neuropathic pain, where behavioural 
studies seem to reflect mostly positive symptoms, whereas studies undertaken at 
the neuronal level reflect mostly negative symptoms, such as the decrease in the 
size of C-fibre-evoked responses (Suzuki and Dickenson 2002).
In behavioural studies investigating hyperalgesia and allodynia, researchers 
usually measure threshold responses, since the animals are free to move once a 
stimulus is noxious. Hyperalgesia and allodynia to any stimuli investigated in my 
study will be termed ‘hypersensitivity’, since it is important to differentiate 
between measurements made on humans to those made on animals (Per Hansson,
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personal communication). Hypersensitivity to mechanical, heat and cold stimuli 
will be investigated in the behavioural sections of this study.
There are three widely used models of neuropathic pain: chronic constriction 
injury (CCI), partial sciatic tight ligation (PSTL) and selective spinal ligation 
(SNL), all of which result in the rapid onset of allodynia and hyperalgesia (Kim 
and Chung 1992). Evoked hypersensitivities to thermal, tactile and cold stimuli 
are usually the responses measured in most models of neuropathic pain. These 
stimulus-dependent responses vary in their onset, intensity and existence between 
the different models, and are measured because they are readily quantifiable and 
are also experienced to some degree in humans clinically. Stimulus-independent 
responses such as spontaneous pain remain harder to quantify in behavioural 
studies of animal models (Koltzenburg and Scadding 2001; Mogil and Crager 
2004).
The model which will be used in this study will be Kim and Chung’s selective 
spinal nerve ligation, which involves the complete ligation of L5 and L6 spinal 
nerves branching off the sciatic nerve. The sciatic nerve is the major nerve 
providing the sensory and motor innervation of the lower hindlimb and foot. The 
advantages of this model over the other two are that the number and types of 
injured fibres are well controlled, and that the levels of injured and intact spinal 
segments are completely separated. This model gives rise to thermal, tactile and 
cold hypersensitivity, as well as spontaneous, stimulus independent, dorsal hom 
neuronal activity (Kim and Chung 1992).
1.1.5 Pharmacological treatments in neuropathic pain
So far, only “1 in 3 patients get adequate pain relief’ (Sindrup and Jensen 1999) 
and “At best, no more than 50% of patients benefit from available drugs” 
(Hansson and Dickenson 2005). Neuropathic pain management in patients has 
included the use of morphine, tramadol, gabapentin, different sodium channel 
blockers and the use of combination therapy. There is clearly not one dmg which 
may decrease all of the symptoms of neuropathic pain, simply because so many
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mechanisms are underlying the pathology of this disease, from the periphery, to 
the spinal cord to supraspinal sites. Additionally, new directions of research have 
included investigating the use of peripheral NMDA receptor antagonists in 
neuropathic pain (Jang, Kim et al. 2004), as well the use of the 5HT3 antagonist 
ondansetron, the latter of which has caused some pain relief in neuropathic 
patients (McCleane, Suzuki et al. 2003).
1.1.6 Morphine
Morphine is an opioid that is derived from opium, which is released by scraping 
the seed pod of the opium poppy, or ‘papaver somniferum The analgesic 
properties of opioids have been discovered and used by mankind for thousands of 
years, in many different cultures. Morphine exerts its analgesic action by acting 
on p opioid receptors, which are located on nociceptive primary afferent fibres, 
the spinal cord and supraspinal sites as well, and is thought of as the ‘gold 
standard in pain control’ (Dickenson and Kieffer 2006; Schug and Gandham 
2006). Morphine is available in many different forms, and may be delivered via 
different routes, such as tablets, capsules, suspension and through epidural and 
intrathecal routes. However, the side-effects associated with morphine, such as 
respiratory depression, sedation, euphoria, constipation, as well as tolerance, lead 
to limits in dose-escalation of this drug (Dickenson and Kieffer 2006; Schug and 
Gandham 2006).
Furthermore, plasticity is also seen with morphine, since there have been some 
reports of ‘morphine-insensitive’ pain, where morphine was shown to have a 
reduced efficacy, such as some types of neuropathic pain (Woolf and Wall 1986; 
Amer and Meyerson 1988), whereas morphine has been shown to be even more 
efficient in inflammatory pain states (Kayser, Chen et al. 1991; Dickenson 1997).
Now it is recognised that neuropathic pain is not ‘resistant’ to morphine 
(Rowbotham, Reisner-Keller et al. 1991; Yamamoto and Yaksh 1992; Sindrup 
and Jensen 1999; Suzuki, Chapman et al. 1999; Attal, Guirimand et al. 2002; 
Hansson and Dickenson 2005), but variably responsive to morphine, according to
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the dose, route of administration and type of neuropathic pain treated (Suzuki, 
Chapman et al. 1999). Therefore, dose-escalation is needed for morphine to 
inhibit some types of neuropathic pain. However, in order to not resort to higher 
doses which inevitably lead to unacceptable side-effects, the combination of 
opioids with other agents, such as gabapentin, have been used to treat 
neuropathic pain (Gilron, Bailey et al. 2005; Raja and Haythomthwaite 2005).
1.1.7 General aim
The general aim of this study was to investigate the modulation of excitatory 
transmission in the rat spinal cord by morphine. To do this, morphine efficacy in 
two different models of nociception where the ‘nociceptive balance’ was tipped 
towards spinal excitation, an acute chemical and a chronic surgical neuropathic 
model of nociception, was investigated. Additionally, in the neuropathic pain 
model, the combination of morphine with ondansetron, an anti-emetic drug 
which has been newly found to have analgesic properties (McCleane, Suzuki et 
al. 2003), was also studied. Furthermore, peripheral NMDA receptors in 
neuropathic pain were also investigated, since this area has not been extensively 
studied. In vivo electrophysiology and behavioural techniques were used as 
investigative tools.
1.2 Primary afferent fibres
There are highly specialised sensory fibres that convey to the central nervous 
system information about the state and the environment of the organism, and the 
most investigated and of relevance in this study are cutaneous sensory fibres. 
Primary afferent fibres have a peripheral terminal that comprises of sensory 
nerve endings, a central terminal that comprises of dendrites, and their cell 
bodies lie in the dorsal root ganglion (DRG). Three types of primary afferent 
fibres have been described (Meyer, Ringkamp et al. 2006):
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Small-diameter (0.4-1.2pm) primary afferent fibres are called C-fibres, they are 
unmyelinated, and conduct slowly (0.5-2.0m/sec). Medium-diameter (2-6pm) 
primary afferent fibres are called A8-fibres and are myelinated and of 
intermediate speed (12-30m/sec). Large-diameter (>10pm) primary afferent 
fibres are called Ap-fibres, these fibres transmit non-noxius stimuli, are 
myelinated and fast-conducting (30-100m/sec) (Millan 1999).
A subpopulation of C-fibres respond exclusively to gentle warming, whereas a 
subpopulation of the A8-fibres, as well as some C-fibres, respond exclusively to 
gentle cooling (Caterina, Gold et al. 2005; Meyer, Ringkamp et al. 2006).
Texture and shape of touch sensation are encoded by activity in different classes 
of low-threshold myelinated afferents (Ap-fibres), which end in specialised cells. 
The slowly adapting type 1 afferents end in Merkel cells, whereas type 2 end in 
Ruffini corpuscles. Rapidly adapting afferents end in Meissner corpuscles or 
surrounding hair follicles, whereas Pacinian afferents end in corpuscles of the 
same name (Caterina, Gold et al. 2005).
1.3 Nociceptors
In normal acute pain, noxious stimuli are transmitted from the skin in the 
periphery to the dorsal horn via nociceptors. Nociceptors is the term given for the 
C- and A8-fibres which respond to high-threshold, noxious stimuli, encoding its 
location and intensity. Some of these nociceptors are polymodal in that they 
encode thermal, mechanical and chemical stimulus modalities, which all cause 
injury, whereas others have more specialised response properties (Caterina, Gold 
et al. 2005; Meyer, Ringkamp et al. 2006). As opposed to the previously 
mentioned low-threshold myelinated afferents, the axons of nociceptors end as 
free nerve endings in dermal and epidermal layers of the skin (Patapoutian, Peier 
et al. 2003).
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Furthermore, nociceptors do not exhibit spontaneous activity, and even though 
they have a higher threshold of activation than low-threshold myelinated 
afferents, their threshold of activation is still lower than what can be perceived as 
a painful sensation. It is thought that a painful sensation is only evoked following 
temporal and/or spatial summation of nociceptor input, as shown when the firing 
of a single action potential by a C-fibre in human microneurography studies did 
not cause pain (Treede, Meyer et al. 1992).
1.4 Stimulus modality conduction in unmyelinated and myelinated fibres
Unmyelinated nociceptors that respond to mechanical and heat stimuli are termed 
CMH (C-fibre mechano-heat-sensitive nociceptors), whereas A8-fibres that 
respond to the aforementioned stimuli are called AMH (A8-fibre mechano-heat- 
sensitive nociceptors), and most of these two fibre types also respond to chemical 
stimuli and are thus considered polymodal (Caterina, Gold et al. 2005; Meyer, 
Ringkamp et al. 2006). Furthermore, although in both groups, many nociceptors 
are Mechanically Sensitive Afferents (MSA), Mechanically Insensitive Afferents 
(MIA) have also been described. The latter either have high mechanical 
thresholds or are insensitive to mechanical stimuli, are sometimes termed ‘silent 
nociceptors’ (Meyer, Ringkamp et al. 2006), and become sensitised following 
injury (Caterina, Gold et al. 2005).
CMH fibres exhibit both fatigue, and sensitisation to repeated stimuli. Fatigue is 
when the response to the second of two identical stimuli is less than the response 
to the first, which is why in some cases, time for recovery of the nociceptors 
must elapse between each painful stimuli. Sensitisation is when the response to 
the second of two (or more) identical stimuli is greater than the response to the 
first stimulus (Slugg, Meyer et al. 2000; Meyer, Ringkamp et al. 2006).
Furthermore, there are two types of A8-fibre nociceptors. ‘Type 1 ’ A-fibre 
nociceptors are activated by heat, mechanical and chemical stimuli, but their heat 
threshold to short stimuli is so high that they have previously been called ‘High
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Threshold Mechanoceptors’. They have a low threshold in response to long- 
duration stimuli and become sensitised after repetitive heat stimulation and tissue 
injury. Their conduction velocity is between that of A8- and Ap-fibres, and they 
are located in both hairy and glabrous skin. As opposed to ‘Type 1 ’, most ‘Type 
2’ A-fibre nociceptors are MI As, have a low activation threshold to heat stimuli 
of both short and long-duration and have a conduction velocity similar to that of 
normal A8-fibres and are found in hairy skin only (Millan 1999; Meyer, 
Ringkamp et al. 2006).
These aforementioned primary afferent fibres will relay the noxious and 
innocuous thermal and mechanical stimuli, in the parts of the study using 
electrophysiological and behavioural techniques, and these primary afferents will 
also be electrically evoked and separated according to their conduction speed in 
the part of the study using in vivo electrophysiology.
1.5 Primary afferent fibres may be grouped using different molecular 
markers
Finally, nociceptors may be grouped according to molecular markers, which are 
molecules that are either found on the cell surface, or stored and released from 
inside primary afferents or enzymes. Nociceptors are therefore divided into two 
groups, which mildly overlap. Group 1 are peptidergic neurons, which contain 
peptides such as substance P, calcitonin gene related peptide, somatostatin and 
are TrkA-positive (TrkA- nerve growth factor receptor). These peptidergic 
neurons comprise almost 40% of DRG cells, and centrally project to lamina 
(layer) I and lamina II outer, of the spinal cord dorsal horn (mostly C-fibres). 
Group 2 are non-peptidergic, contain fluoride-resistant acid phosphatase (FRAP), 
bind the plant lectin IB4 (from Griffonia simplicifolia) and comprise almost 30% 
of DRG neurons. These non-peptidergic neurons project mostly to lamina II 
inner (mostly A8-fibres), of the spinal cord dorsal hom (Urban and Randic 1984; 
Snider and McMahon 1998; Meyer, Ringkamp et al. 2006).
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1.6 Peripheral terminal
At their peripheral level, nociceptors have receptors/channels that are either 
directly or indirectly (through secondary mechanisms) activated by damage to 
tissues/nerves via different kinds of stimuli (thermal, mechanical, chemical). The 
functional receptors that detect noxious stimuli then transduce the different forms 
of stimuli into action potential generation in the primary afferent fibres, the result 
of which is neurotransmitter release onto dorsal hom neurons, at the central 
terminal of these fibres. Furthermore, primary afferent fibres also have the 
capacity to release substances peripherally as well, by a process called the axon 
reflex, all of which will be described in the following section (Caterina, Gold et 
al. 2005).
1.6.1 Channels and receptors at the periphery
Sequentially, a noxious stimuli of thermal, chemical and/or mechanical nature 
needs to be transduced into electrical signals in order for spike initiation, 
followed by action potential generation, to result in transmitter release. 
Furthermore, action potential generation only occurs if the depolarising currents 
generated following signal transduction are large enough. Although there is still a 
lot to be known about how different stimulus modalities can cause the initiation 
and the generation of an action potential, it is thought that this mechanism is 
spun into action once there is an exchange of ions across the cell membrane, 
which changes the electrical properties of the cell. There are many receptor and 
channel families throughout the nervous system, whose activation leads to 
membrane depolarisation, either directly via the opening of cation channels or 
indirectly via the production of intracellular signalling cascades which sensitise 
depolarising cation channels to the aforementioned noxious stimuli (Woolf and 
Salter 2000; Caterina, Gold et al. 2005).
1.6.2 Signal transduction receptors/channels
i) TRP channels
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TRP (Transient Receptor Potential) family of proteins is named after its role in 
Drosophila phototransduction. TRP receptors are involved in coding for light, 
cold, mechanical distension, acidity and heat, and they are expressed in sensory 
neurons, as well as other locations. TRP channels have four subunits (thought to 
be homo- or heteromeric), with each subunit having six transmembrane domains, 
a pore formed between the 5th and 6th transmembrane domains and a voltage 
sensor. Most TRP channels have variable permeability to Ca2+, and they are non- 
selective cation channels (Lee, Lee et al. 2005; Meyer, Ringkamp et al. 2006).
TRPV1 (TRP-vanilloid receptor) is a channel which is activated by noxious heat 
(>42°C), capsaicin (chemical found in red peppers) and activated as well as 
potentiated by protons. TRPV 1 is expressed highly in small to medium diameter 
neurons within dorsal root ganglia, especially capsaicin sensitive peptidergic 
neurons (Caterina, Schumacher et al. 1997). Therefore, most unmyelinated 
fibres, and some of the type 2 A8-fibres, are capsaicin-sensitive (Magerl, Fuchs 
et al. 2001). In mice lacking this channel, noxious heat-evoked responses were 
decreased, and this channel was found to contribute significantly to some types 
of tissue injury- induced thermal hypersensitivity (Complete Freund’s Adjuvant 
and mustard oil) (Caterina, Leffler et al. 2000). But many other TRP as well as 
other types of channels, are also involved in thermosensation, and thus the fact 
that in these TRPV 1-deficient mice, heat response was not abolished completely 
(Patapoutian, Peier et al. 2003; Meyer, Ringkamp et al. 2006).
TRPV2 is another channel that transduces heat responses higher than, or equal to, 
52°C, and is expressed predominantly on medium-diameter DRG neurons. This 
channel is thought to underlie the heat response of high-threshold type 1 A5- 
fibres, and is not sensitive to either capsaicin or protons (Patapoutian, Peier et al. 
2003; Meyer, Ringkamp et al. 2006).
TRPV3 and TRPV4 are two more TRP channels that are thought to contribute to 
warm sensation, with TRPV4 also thought to be activated by stretch, making it
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have a role in mechanotransduction as well (Wood 2004; Meyer, Ringkamp et al. 
2006).
ii) ASIC channels
The Acid Sensing Ion Channel belongs to the epithelial amiloride sensitive Na+ 
channel/degenerin (ENaC/DEG) family, and is gated by a reduction in pH. The 
ASIC subunits may assemble in homo- or heteromultimeric channels, with two 
transmembrane domains each, and distinct acid sensitivities, ion selectivities and 
activation/desensitisation kinetics (Caterina, Gold et al. 2005; Lee, Lee et al.
2005). This channel is also found in sensory neurons, and to date, at least three 
subtypes have been identified (ASIC1-ASIC3) (Wood, Abrahamsen et al. 2004).
iii) P2X channels
Purinergic receptor subtype X channels (P2X) are ATP-gated (adenosine 
trisphosphate- released from damaged tissues and elicits pain sensation in
2 1 j
humans) extracellular ion channels, that allow the entry of Ca and Na once 
opened and have seven different subunits (P2X1-P2X7). Some of these receptor 
subunits can be found both at the peripheral and central terminal of primary 
afferent fibres, as well as in dorsal horn neurons and microglia (Nakatsuka and 
Gu 2006). Of these, P2X3, expressed highly in non-peptidergic, IB4-positive 
neurons, and P2X4, expressed in microglia (Lee, Lee et al. 2005; Meyer, 
Ringkamp et al. 2006), have been shown to play an important role in both acute 
and pathological pain states, of inflammatory and neuropathic nature, 
respectively (McCleskey 2003; Tsuda, Shigemoto-Mogami et al. 2003; Tsuda, 
Inoue et al. 2005).
iv) P2X channels and microglia in neuropathic pain
5-10% of the glia in the CNS are microglia, which are thought of as the 
macrophages of the CNS. Normally, microglia are thought to be in a resting 
state, however, following peripheral nerve injury, spinal microglia become
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activated, change their shape and increase their expression of the P2X4 receptor 
(McCleskey 2003; Salter 2005). This increased expression of the P2X4 receptor 
by microglia is thought to be one of the mechanisms underlying tactile allodynia 
following neuropathic pain (Tsuda, Inoue et al. 2005), since the pharmacological 
blockade of this receptor, or the administration of its antisense in neuropathic 
animals has been shown to alleviate tactile allodynia. Furthermore, in normal 
rats, the administration of microglia with induced and stimulated P2X4 receptors 
was sufficient to cause tactile allodynia (Tsuda, Shigemoto-Mogami et al. 2003).
1.6.3 Signal transduction due to thermal versus mechanical stimuli
As opposed to thermal and chemical transducing receptors and channels, it is still 
not well known which receptors/channels are involved in transducing 
mechanosensation. Some of the channels thought to be involved include the 
bacterial osmosensitive ion channels MscL and MscS, TRPV4 and P2X3 (Wood, 
Abrahamsen et al. 2004).
Therefore, in my study, these aforementioned receptors and channels are some of 
the receptors/channels that are postulated to be activated when the neurons that 
are being recorded from are responding to thermal and mechanical stimuli. This 
is also true for the thermal, mechanical and cold response elicited during 
behavioural tests in the free-moving animal.
1.6.4 Mechanisms involved in peripheral tissue damage and axonal reflex
i) Inflammatory mediators
Following tissue damage in the periphery, many substances are released, which 
either directly, by acting on their own receptors, or indirectly, by enhancing the 
nociceptive response of other substances, cause hyperalgesia. Some of the many 
inflammatory substances include bradykinin, prostaglandins, serotonin, 
histamine, protons, adenosine, ATP, nerve growth factor (NGF), cytokines,
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substance P and possibly glutamate (Kidd and Urban 2001; Caterina, Gold et al. 
2005; Meyer, Ringkamp et al. 2006).
ii) Substance P, calcitonin gene-related peptide and the axon reflex
Substance P (SP) and calcitonin gene-related peptide (CGRP) are neuropeptides 
that are released from both the peripheral and the central terminals of small- 
diameter peptidergic nociceptors. When one branch of the nociceptor terminal is 
activated by injury in the periphery, this leads to orthodromic action potential 
generation into the axon, as well as antidromic action potential generation into 
other branches. SP and CGRP are thus released by this ‘axon reflex’ from the 
peripheral terminal of nociceptors (Bumstock 1977), where they act as 
vasoactive substances and cause plasma extravasation from post-capillary 
venules (SP) and vasodilatation from arterioles (CGRP) (Hagermark, Hokfelt et 
al. 1978). These events lead to the wheal and flare response seen post-cutaneous 
injury. SP can also cause the release of histamine from mast cells, whereby 
histamine, in turn, can lead to more vasodilation and oedema (Caterina, Gold et 
al. 2005; Meyer, Ringkamp et al. 2006). The axon reflex will be further 
discussed later, when investigating the role of peripheral NMDA receptors in 
neuropathic pain.
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Figure 1.2- Following tissue damage, numerous inflammatory mediators are released at the 
periphery, such as prostaglandins (PGs), protons (H+), adenosine trisphosphate (ATP), bradykinin 
(BK), serotonin (5HT), glutamate (Glu), substance P (SP) and calcitonin gene related peptide 
(CGRP), which lead to the activation and sensitisation o f peripheral receptors and channels 
(peripheral sensitisation) and thus action potential generation. Transmitter release and dorsal horn 
neuronal excitability follow the action potential generation, and lead to central sensitisation. 
Adapted with permission from Prof. A. H. Dickenson.
1.6.5 Peripheral mechanisms in neuropathic pain
In the periphery, after nerve injury, the electrical properties of primary afferent 
fibres changes, and a newfound hyperexcitability, shown by ongoing 
spontaneous activity, arises. This activity is called ‘ectopic’ activity, in that it 
arises independent of any stimulus, and its points of origin include the DRG and 
the injured peripheral nerve (neuroma and regions of demyelination) (Song, Hu 
et al. 1999) (Kajander, Wakisaka et al. 1992). Even though ectopic activity arises 
from all types of primary afferent fibres, it seems to mostly occur in A-fibres 
(Attal and Bouhassira 1999).
Furthermore, when the insulation/myelination of the nerves is disrupted 
following nerve injury, impulses carried in one nerve fibre may be transmitted to
CNS
C-fibre
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Hypera lges ia
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a neighbouring fibre. This is called ephatic transmission, or cross-talk. 
Additionally, sympathetic nerve fibres may sprout on the DRG after injury, and 
in doing so, may contribute to the pain (Garry and Tanelian 1997; Attal and 
Bouhassira 1999; Moalem, Grafe et al. 2005).
Therefore, following peripheral nerve injury, and the increased ectopic activity 
and cross-talk, there is constant ongoing input being delivered into the spinal 
cord. This increased activity heightens the excitability of dorsal horn neurons, 
initially through the activation of excitatory receptors/channels and enzymes, and 
then by altering gene expression and glial activation (Salter 2005).
1.6.6 Channels involved in signal propagation
Action potential generation is due to two channels, a tetrodotoxin-sensitive 
voltage-gated sodium (Na+) channel and a delayed rectifier type of potassium 
(K+) channel. The voltage-gated Na+ channel opens rapidly and transiently, when 
the membrane is depolarised beyond -60 to -40mV, and causes Na+ to enter the 
neuron and further depolarise it. The membrane potential goes back to normal 
when these Na+ channels are inactivated, and when the delayed opening on K+ 
channels allows K+ out of the cell (repolarisation) (Caterina, Gold et al. 2005).
i) Na channels
Voltage-gated Na+ channels in mammals consist of a single family of nine 
related functional a-subunits (Nay 1.1-Nay 1.9), associated with two accessory p- 
subunits. The a-subunit is large and has four homologous domains, which form 
the voltage sensor and channel pore, whereas the P subunit plays a role in the 
biophysical properties of the channel (density and plasma membrane 
distribution). The best way to distinguish between Na+ channels is based on their 
sensitivity to tetrodotoxin (TTX): Nayl.l, 1.2, 1.3, 1.4, 1.6 and 1.7 are TTX- 
sensitive, whereas Nayl.5, 1.8 and 1.9 are TTX-resistant. Nayl.6 is the TTX- 
sensitive channel found on myelinated axons, whereas Nay 1.7 is expressed
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preferentially in the periphery, on unmyelinated sensory neurons (Caterina, Gold 
et al. 2005; Lee, Lee et al. 2005; Julius and McCleskey 2006; Meyer, Ringkamp 
et al. 2006). Nav1.8 and Nay 1.9 are preferentially expressed on sensory neurons, 
both peptidergic and IB4-positive, but Nay 1.9 is found mostly on IB4-positive 
neurons. Since there are no subtype-specific antagonists which exist, experiments 
are usually carried out with mutant mice lacking the specific channels (Wood and 
Baker 2001). Work with mutant mice, which lack either the Nay 1.7 or Nayl .8 
channel or both, showed that these subtypes may be involved in setting pain 
thresholds and inflammatory pain, but not neuropathic pain (Akopian, Souslova 
et al. 1999; Nassar, Levato et al. 2005; Amir, Argoff et al. 2006).
ii) Na channels in neuropathic pain
Following nerve injury, changes in Na ion channel expression and redistribution 
seems to be involved in ectopic activity generation. There seems to be an up- 
regulation of Nay 1.3 in injured neurones, which was a previously silent, 
embryonic type of Na channels. This Na channel subtype is of the TTX-S 
variety, and after nerve injury, allows the Na current in DRG neurones to reprime 
and recover from inactivation rapidly, which seems to be a feature well needed 
for the generation of ectopic activity (Woolf and Mannion 1999; Suzuki and 
Dickenson 2000; Zimmermann 2001; Ji and Strichartz 2004). Furthermore,
Nayl. 1, Nayl .8 and Nayl .9 are downregulated, after nerve injury. However, 
following nerve injury, Nayl.8 seems to accumulate in uninjured axons found in 
the hyperexcitable sciatic nerve (Wang, Sun et al. 2002; Ji and Strichartz 2004). 
Nevertheless, the role of Nay 1.8 in neuropathic pain is questionable, since it was 
previously shown that treatment with antisense to this channel decreased 
neuropathic pain in the SNL model in rats, whereas a newer study using Nayl .8- 
null mice showed that abnormal neuropathic pain developed even in these 
animals (Nassar, Levato et al. 2005; Amir, Argoff et al. 2006).
Additionally, the importance of Na channels in the pathophysiology of 
neuropathic pain was further proved when the administration of Na channel 
blockers such as local anaesthetics (eg: lignocaine) (Rowbotham, Reisner-Keller
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et al. 1991; Ossipov, Lopez et al. 1995) and some anticonvulsants (eg: 
carbamazepine and lamotrigine) (Sindrup and Jensen 1999) was shown to reduce 
pain associated with nerve injury. These drugs are all use-dependent, and block 
Na channels at therapeutic doses (Dickenson, Matthews et al. 2002).
Furthermore, the ability of topical lignocaine to also reduce neuropathic pain in 
patients shows that these drugs exert their actions partly at the periphery 
(Campbell, Raja et al. 1988). Indeed, the local administration of bupivacaine at 
the sciatic nerve 15 minutes before injuring it in rats delayed the onset of thermal 
hyperesthesia, and thus injury discharge induced facilitation of dorsal horn 
neurons in the CCI model (Yamamoto, Shimoyama et al. 1993).
iii) K channels
K+ channels are extremely diverse in structure and function, and thus have been 
classified and reclassified numerous times, with two types of nomenclature still 
used for these channels (Gutman, Chandy et al. 2003). The delayed rectifier K+ 
channels mentioned above are voltage-gated, with six transmembrane (TM) 
domains where the pore lies between the fifth and sixth TM domain. The Kyi .4 
subtype is thought to be the nociceptive delayed rectifier, since it is found in 
most sensory neurons where Nay 1.8 is expressed, whereas Kyl.l and Kyi.2 are 
found on large-diameter sensory neurons (Lee, Lee et al. 2005; Julius and 
McCleskey 2006).
Another class of K+ channels that is not voltage-gated is coded by the gene 
KCNQ, two of which, the M channel and the H channel, return the potential to 
resting after the activation of many G protein-coupled receptors (Gutman,
Chandy et al. 2003). The M channel has been found to be expressed in both 
capsaicin-sensitive and insensitive small-diameter primary afferents, as well as in 
large-diameter non-nociceptive primary afferents (Lee, Lee et al. 2005; Julius 
and McCleskey 2006). The importance of the currents of the M channel in the 
latter neurons was not great, since the subthreshold currents were dominated by 
other types of K+ currents, and retigabine, an M channel opener, was not found to
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have a great effect of the Ap fibre-mediated response during in vivo 
electrophysiology (Passmore, Selyanko et al. 2003).
iv) K channels in neuropathic pain
Less is known about the role of K channels in neuropathic pain, however, many 
voltage-gated K channels seem to be downregulated in the DRGs ipsilateral to 
nerve injury (Wang, Sun et al. 2002; Lee, Lee et al. 2005). Furthermore, the M 
channel has been shown to play a role in controlling neuronal excitability, since 
retigabine inhibited nociceptive fibre-mediated responses in normal and 
neuropathic rats (SNL model), as well as showed an analgesic effect in an 
inflammatory model of pain (carrageenan) (Passmore, Selyanko et al. 2003).
1.6.7 Channels involved in neurotransmitter release
i) Ca channels
Following the generation of the action potential generation and the depolarisation 
of the cell, neurotransmitters are released at the central terminal of primary 
afferent fibres, onto spinal cord dorsal horn neurons. If the neurotransmitters 
were excitatory, then secondary excitatory events in spinal cord dorsal horn 
neurons also occur, and these excitatory events depend on the entry of 
extracellular Ca2+ into the cell, one way of which is via voltage-dependent Ca2+ 
channels (VDCC) (Caterina, Gold et al. 2005).
VDCCs include the L (dihydropyridine, phenylalkylamine and benzothiazepine- 
sensitive), N (co-Conotoxin-GVIA and SNX-sensitive), P (co-Agatoxin-IVA- 
sensitive), R and T subtypes. The L subtype belongs to gene family 1 (Cayl), the 
N, P and R subtypes belong to gene family 2 (Cay2), whereas the T subtype 
belongs to gene family 3 (Cav3). The L, N, P and R subtypes are VDCCs that are 
activated by large depolarisation (high threshold) (Vanegas and Schaible 2000; 
Caterina, Gold et al. 2005). The L subtype is found mostly at cell bodies and
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dendrites, whereas the N, P and R subtypes are located at synaptic sites and the N 
and P are involved with transmitter release. The T subtype is activated by low 
voltage, is found in neuronal and non-neuronal cells and is thought to play a role 
in regulation of neuronal excitability (Vanegas and Schaible 2000; Julius and 
McCleskey 2006). Each of these channels consists of a large a  1-subunit, which 
forms the pore and voltage sensitivity, as well as an intracellular p-subunit, a 
trans-membrane a28-subunit and a y-subunit (in skeletal muscle), the last three 
subunits being involved in modulating expression and gating (Caterina, Gold et 
al. 2005).
The N and P channels are found throughout the brain and spinal cord, but the N 
channel is predominantly found in laminae I and II of the spinal cord dorsal horn 
(Vanegas and Schaible 2000), further showing its role in neurotransmitter 
release, as this is the primaiy site for neurotransmitters released from the central 
terminal of primary afferents to exert their effects on dorsal horn neurons. The N 
channel is thought to mediate the spinal release of the peptides substance P 
(Holz, Dunlap et al. 1988) and calcitonin gene-related peptide, whereas both the 
N and P channels are thought to mediate the release of the excitatory amino acid 
glutamate (Dickie and Davies 1992; Turner 1998).
ii) Ca channels in neuropathic pain
The increase of intracellular calcium is linked to both neurotransmitter release, 
and thus the ensuing synaptic transmission, as well as phosphorylation and 
activation of many excitatory channels, receptors and enzymes (see section 
1.7.4). The N channel has been shown to be involved in both acute and chronic 
pain transmission. Following neuropathic pain, the efficacy of co-Conotoxin- 
GVIA, the N channel antagonist, was increased, as well as the expression of its 
pore-forming a l  P subunit in the superficial dorsal horn (Matthews and 
Dickenson 2001; Cizkova, Marsala et al. 2002; Suzuki and Dickenson 2006). 
Furthermore, this antagonist also inhibited both phases of the formalin response 
(Diaz and Dickenson 1997). The P channel antagonist, co-Agatoxin-IVA, has
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been shown to inhibit both inhibitory and excitatory transmission (Vanegas and 
Schaible 2000). As opposed to the N channel, the P channel is thought to play a 
smaller role in pain transmission, since the administration of its antagonist did 
inhibit the second phase of formalin inflammation (Diaz and Dickenson 1997), 
however, the same antagonist did not inhibit neuronal responses in normal and 
neuropathic rats as much as the N channel blocker did (Matthews and Dickenson 
2001).
Additionally, gabapentin, one of the most effective drugs licensed for the 
treatment of neuropathic pain, has been found to bind to a unique site on the a28 
subunit which is found in all VDCCs, and which is upregulated in injured DRGs 
following nerve injury (Wang, Sun et al. 2002; Ji and Strichartz 2004), leading to 
increased neurotransmission and hyperexcitability of dorsal horn neurons. 
Consequently, gabapentin has been shown to inhibit both stimulus-independent 
and evoked responses of dorsal horn neurons (Dickenson, Matthews et al. 2002; 
Suzuki, Rahman et al. 2005; Suzuki and Dickenson 2006), as well as abnormal 
pain behaviour following nerve injury (Field, McCleary et al. 1999).
1.7 Spinal cord dorsal horn
1.7.1 Dorsal horn anatomy
The spinal cord is made up of segments, each of which corresponds to relaying 
information to and from the periphery and the central nervous system. Each 
segment of the spinal cord is made up of the dorsal horn, which is involved with 
receiving, transmitting and altering sensory information from primary afferent 
fibres to supraspinal sites, and the ventral horn which is involved with the 
generation of motor effects from spinal and supraspinal sites to the periphery 
(Willis 1985; Todd and Koerber 2006). The spinal cord dorsal horn is therefore 
the ‘first synapse’ where the central terminals of the primary afferent fibres 
impinge, mostly through dorsal roots, on dorsal hom neurons. Information from 
the periphery is either transmitted to supraspinal sites unaltered, or altered by
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spinal events before it reaches higher sites. Furthermore, local reflexes are 
produced by neurons in the spinal cord (Willis 1985; Todd and Koerber 2006).
This study investigates cutaneous sensory information from the hindlimbs of rats, 
which means the area of focus where neurons are recorded from, where some of 
the drugs used will be applied in both the electrophysiological and behavioural 
parts of the study, and where neuropathic surgery is performed to affect, is the 
L4-L6 (lumbar) segments of the spinal cord dorsal hom.
Besides the central terminals of primary afferent fibres which arborise in the 
different layers of the dorsal hom, there are different types of neurons which 
exist in the dorsal hom too. Neurons intrinsic to the dorsal hom are called 
intemeurons. The majority of dorsal hom neurons are intemeurons, which can be 
either excitatory (glutamatergic) or inhibitory (enkephalinergic/GABA-ergic), 
and thus may modify pain transmission at the spinal level. Furthermore, the 
dorsal hom has neurons which project to supraspinal sites, called projection 
neurons, and descending neurons, which descend from supraspinal sites onto the 
dorsal hom and also modify pain transmission (Todd and Koerber 2006). 
Moreover, spinal cord dorsal hom neurons are divided into two main classes: 
nociceptive-specific neurons, which respond to stimuli of a noxious nature, and 
wide dynamic range neurons, which respond to noxious, as well as innocuous 
stimuli (Menetrey, Giesler et al. 1977; Fields and Basbaum 1978; Coghill, Mayer 
et al. 1993).
The spinal cord was organised into ten laminae by Rexed (1952), according to 
local cytoarchitecture (pattern of arrangement- size and packing density of 
neurons). Laminae I-VI make-up the dorsal hom, laminae VII-IX the ventral 
hom and lamina X is the substantia grisea centralis (or gray matter surrounding 
the central canal). Laminae I-II compose the superficial dorsal hom, whereas 
laminae IV-VI compose the deep dorsal hom (Rexed 1952; Sorkin and Carlton
1997). Nociceptive-specific cells (NS) are predominant in the superficial dorsal 
hom, whereas wide-dynamic range cells (WDR) are predominant in the deep 
dorsal hom, although both types can be found in the superficial and deep dorsal
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horn (Menetrey, Giesler et al. 1977; Fields and Basbaum 1978; Treede, Meyer et 
al. 1992; Coghill, Mayer et al. 1993). In vivo electrophysiology recordings in this 
study are made from deep, wide dynamic range dorsal hom neurons.
i) Lamina I
This ‘marginal layer’ is a thin layer which covers the most dorsal and lateral side 
of the dorsal hom. It contains intemeurons (mostly), projection neurons (larger 
than intemeurons), as well as the central terminations of some A8- and C-fibres 
(Light and Perl 1979; Light and Perl 1979; Millan 1999; Todd and Koerber 
2006). Neurons in this layer have different sizes and shapes, which include 
fusiform, pyramidal and multipolar shapes (Rexed 1952; Lima and Coimbra 
1986). It is thought that each cell morphology mainly subserves different 
stimulus modalities, so that nociceptive-specific cells (responding to heat/pinch) 
are mostly fusiform, thermoceptive-specific cells (responding to innocuous 
cooling) are mostly pyramidal, and polymodal cells (responding to 
heat/pinch/cold) are mostly multipolar in shape (Han, Zhang et al. 1998). 
Furthermore, 80% of the lamina I projection neurons have been shown to drive 
pathological pain states (Suzuki, Morcuende et al. 2002; Todd 2002), and some 
projection neurons have been shown to be modality specific (Dostrovsky and 
Craig 1996). Therefore, the neurons in this area of the dorsal hom are thought to 
relay to supraspinal sites sensory information of a mainly nociceptive and 
thermoceptive nature (Han, Zhang et al. 1998).
ii) Lamina II
This lamina is also called the ‘Substantia Gelatinosa’, due to its gelatinous 
appearance in unstained sections owing to the lack of myelinated fibres (Todd 
and Koerber 2006). This layer is divided into lamina IIo (outer) and lamina Hi 
(inner). Cells in this lamina are very tightly packed in general, smaller in size and 
more densely packed in lamina IIo than lamina Hi. The majority of neurons in 
this lamina are intemeurons, as well as some central terminals of primary 
afferent fibres (Rexed 1952; Light and Perl 1979; Todd and Koerber 2006).
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Lamina IIo receives the central terminations of C-fibres, whereas lamina Ili 
receives central terminations from both A8- and C-fibres (Light and Perl 1979; 
Light and Perl 1979; Todd and Koerber 2006).
iii) Laminae III and IV
These laminae are also called the ‘Nucleus Proprius’ (Rexed 1952; Millan 1999). 
Lamina III is parallel to laminae I and II, but also broader, with cells larger and 
less densely packed than those in lamina II (Rexed 1952). Most cells in lamina 
III are intemeurons, and there are also some projection neurons in the nucleus 
proprius (Todd and Koerber 2006). Compared with lamina III, lamina IV has 
more cells with different shapes and sizes, and overall larger cells (Rexed 1952). 
The central terminals of A(3- and A8-fibres terminate in the nucleus propius. 
Some nucleus proprius cells also receive polysynaptic input from C-fibres (Light 
and Perl 1979; Light and Perl 1979; Millan 1999; Dostrovsky and Craig 2006).
iv) Laminae V and VI
With overall less cells than lamina IV, lamina V has a lateral zone, with many 
large, darkly stained cells, and a medial zone with medium-sized, lighter cells. 
Lamina VI is also made up of a medial zone, with compactly grouped small- or 
medium-sized cells, and a lateral zone with looser grouped larger cells (Rexed 
1952). In these deeper laminae, A8- and Ap-fibres terminate in lamina V, whose 
cells also receive polysynaptic input from C-fibres (Light and Perl 1979; Millan 
1999; Dostrovsky and Craig 2006; Todd and Koerber 2006).
1.7.2 Dorsal horn pharmacology
The pharmacology of the dorsal hom is rich, with neurotransmitters and 
neuromodulators coming from the central terminals of primary afferent fibres, 
the dorsal hom neurons themselves, as well as from descending fibres. 
Neurotransmitters and modulators are predominantly either excitatory or
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inhibitory, according to the type and the location of the receptor they act on. In 
the spinal cord dorsal hom, the major excitatory transmitters are glutamate and 
substance P, and their activation of the NMD A and the NK-1 receptors 
respectively, is thought to play a role in central sensitisation. The major 
inhibitory systems in the spinal cord are GABA (gamma-amino butyric acid) and 
the opioids (Dickenson 1995).
1.7.3 Excitatory transmitter systems
1.7.3.1 Glutamate
One of the most important excitatory amino acids in the transmission of pain is 
glutamate. It has been previously shown that microiontophoretic administration 
of glutamate causes neuronal excitation in the spinal cord (Curtis, Phillis et al. 
1960). Furthermore, glutamate has been shown to be released after electrical and 
noxious stimulation, and its uptake and release are decreased after dorsal 
rhizotomy (De Biasi and Rustioni 1988). Glutamate is found in many primary 
afferent terminals, both large and small, which end in laminaes I, III and IV and 
in small dorsal root ganglion cells (Battaglia and Rustioni 1988; De Biasi and 
Rustioni 1988). Additionally, glutamate has also been shown to be co-localised 
with peptides such as SP and/or CGRP (Battaglia and Rustioni 1988; De Biasi 
and Rustioni 1988), and the release of all of these after a noxious stimulus seems 
to show that they play a role in nociception. This release however, is differential 
between peptides and amino acids (Aanonsen and Wilcox 1987; Mjellem-Joly, 
Lund et al. 1992; Dickenson 1997).
Glutamate has been shown to be involved in the transmission of both acute and 
long-lasting pain, and its actions are exerted through its ionotropic receptors 
kainate, the alpha-amino3-hydroxy-5-methyl-4-isoxazoleproprionic acid 
(AMPA) receptor and N-methyl-D-aspartate (NMDA) receptor and its 
metabotropic receptors (mGlu) (Watkins and Evans 1981; Woodruff, Foster et al. 
1987; Dickenson 1995).
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i) Actions of glutamate at the NMDA receptor
The NMDA receptor-channel is important in memory, plasticity, motor function 
and neurodegenerative disorders in the central nervous system (Petrenko, 
Yamakura et al. 2003). This receptor-channel is found at peripheral, spinal, as 
well as supraspinal sites (Jacquet 1988; Carlton, Hargett et al. 1995; Coggeshall 
and Carlton 1997). Furthermore, even though the activation of the NMDA 
receptor in the rat periacqueductal gray (PAG) has been shown to cause analgesia 
(Jacquet 1988), the activation of the NMDA receptor in the spinal cord dorsal 
hom is known to play a major role in the development of plastic changes which 
lead to spinal hyperexcitability and persistent pain (Dickenson 1997).
a) NMDA receptor location
Most spinal NMDA receptors have been found, using autoradiographic receptor 
binding studies, to be within lamina II of the dorsal hom, and although most 
receptors were thought to be only postsynaptic, the presence of presynaptic 
NMDA receptors on the central terminals of primary afferent C-fibres has 
recently been shown (Liu, Wang et al. 1994; Coggeshall and Carlton 1997; 
Petrenko, Yamakura et al. 2003). These ‘ autoreceptors ’ are thought to provide a 
positive feedback for postsynaptic NMDA receptor activation, by increasing the 
release of SP from these primary afferent terminals on which substance P (SP) 
and glutamate are co-localised (Liu, Mantyh et al. 1997; Malcangio, Fernandes et 
al. 1998).
b) NMDA receptor activation and wind-up
The physiological activation of the NMDA receptor-channel requires many 
processes, as it is both ligand and voltage gated (Dickenson 1990). One of the 
processes needed to take place is the binding of glutamate and the co-agonist 
glycine to their respective sites. The second is the summation of non-NMDA 
depolarisations, caused by excitatory amino acids and peptides acting on their 
respective receptors, which removes the resting magnesium block of the channel
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(Salt 1986; Xu, Dalsgaard et al. 1992; Dickenson 1997). Due to these processes 
which need to occur before NMDA receptor-channel activation, this receptor- 
channel is thought to be involved in polysynaptic, and not monosynaptic, pain 
transmission, since it is not involved in baseline pain transmission but becomes 
activated following repetitive noxious stimuli (Cahusac, Evans et al. 1984; 
Dickenson and Sullivan 1990; Yamamoto and Yaksh 1992; Yaksh, Hua et al. 
1999).
When the magnesium block in the NMDA receptor channel is removed, the 
channel becomes permeable to calcium and monovalent ions (Petrenko, 
Yamakura et al. 2003). This influx of calcium ions, if it lasts for a long period, 
could lead to cell death, and could be one of the way genes are induced (eg: c- 
Fos, which has been taken to be a marker for neuronal activity), thus affecting 
both the cell and its surroundings in the long term (Dickenson 1994; Carpenter 
and Dickenson 1999; Carpenter and Dickenson 2001). Following the activation 
of the NMDA receptor channel, there is an increased state of responsiveness in 
spinal neurones, which is termed wind-up, and which is sensitive to blockade by 
antagonists at the NMDA receptor (Dickenson and Sullivan 1987). Wind-up was 
first described by (Mendell 1966) as the increase in responses of the deep dorsal 
hom neurones to repetitive C-fibre stimulation, despite the input into the spinal 
cord staying constant. Wind-up lasts for a couple of minutes, and shows that the 
NMDA receptor-channel could play a role in central hypersensitivity (Dickenson 
1990).
c) NMDA receptor subunits
NMDA receptors comprise of NR1, NR2 (A, B, C, and D) and NR3 (A and B) 
subunits. The formation of functional NMDA receptor channels needs a 
combination of NR1, and at least one of the NR2 subunits, with the glutamate 
binding site located on the NR2 subunit, whereas the glycine binding site is 
located on the NR1 subunit (Petrenko, Yamakura et al. 2003). All inotropic 
glutamate receptor families are thought to be tetrameric assemblies, with each 
subunit consisting of an extracellular N-terminal, four transmembrane domains
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(TM1-4) and an intracellular C-terminal (Palmer, Cotton et al. 2005). The ligand- 
binding domain is thought to reside in a pocket made between the extracellular 
N-terminal region and the extracellular loop between TM3 and TM4, whereas the 
pore is formed from a membrane-residing domain which follows TM1 (Kew and 
Kemp 2005; Palmer, Cotton et al. 2005).
The most obvious feature of this receptor channel, which is subunit dependent, is 
its sensitivity to magnesium block (eg: NR2A and NR2B subunits have a high 
sensitivity for magnesium block whereas NR2C and NR2D containing receptors 
have a low sensitivity for magnesium block). The NR2B and NR2D subunits 
have been identified in the central terminal of some primary afferents (Marvizon, 
McRoberts et al. 2002; Petrenko, Yamakura et al. 2003).
Additionally, the two most common subunits which are found in the spinal cord 
are NR2A and NR2B, found mostly in laminae III/IV and laminae I/II 
respectively, however, some studies have detected low levels of mRNA for both 
the NR2C and the NR2D subunits in the spinal cord as well. Whilst the NR2C 
subunit has been shown to be mostly found in the cerebellum by some studies, 
the NR2D subunit has been shown to be found ‘extrasynaptic’ in the spinal cord 
(Petrenko, Yamakura et al. 2003; Nagy, Watanabe et al. 2004).
d) The role of the NMDA receptor in pain states
The NMDA receptor mediated events have physiological roles, as was first 
shown using the formalin test in an in vivo electrophysiological study. This test 
showed that after formalin injection in the hindpaw, there is a first immediate 
phase of activity in the dorsal hom neuron corresponding to where the formalin 
was injected (both superficial, 0-250pm, and deep, 500-1000pm, neurones were 
tested), which lasts for 10 minutes, and a second phase which occurs 25 minutes 
after that and lasts for 60 minutes. Only the second phase involved NMDA 
receptor activation, since it was reduced by NMDA antagonists. Furthermore, 
this second phase was independent of the first phase, but both phases required 
afferent input, since blockade of peripheral inputs with local anaesthetics before
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each phase blocked the two phases for 15 minutes (Haley, Sullivan et al. 1990). 
This experiment has also been done behaviourally (Coderre and Van Empel
1994).
Therefore, whereas the AMPA receptor has been shown to be involved in the 
mediation of acute spinal pain transmission, the NMDA receptor is involved in 
prolonged pain (Chapman and Dickenson 1995; Dickenson 1997), in both the 
induction and initiation of hyperalgesia and allodynia underlying central 
hypersensitivity, as well as the maintenance of neuronal responses in pain models 
such as neuropathic and inflammatory ones, since the ‘abnormal’ pain of these, 
and not the acute nociception, is reduced by NMDA receptor antagonists 
(Coderre and Van Empel 1994; Chapman and Dickenson 1995; Dickenson 1997; 
Yaksh, Hua et al. 1999; Yoshimura and Yonehara 2001).
e) The behaviour following NMDA receptor activation in animal studies
The intrathecal application of NMDA receptor agonists causes nociceptive 
behaviour and leads to thermal hyperalgesia and mechanical allodynia. 
Hyperalgesia due to intrathecal NMDA has also been shown by the tail-flick and 
pressure tests in both rats and mice (Mjellem-Joly, Lund et al. 1992; Yaksh, Hua 
et al. 1999). The behaviour which arises following intrathecal administration of 
NMDA in rat and mouse includes biting, scratching and licking behaviour 
(BSL), as well as vocalisation at higher doses, which has been taken to indicate 
that sensory pathways have been activated and could be thus concluded to be 
nociceptive. However, the intrathecal administration of quisqualate and kainic 
acid, which are excitatory amino acids that do not act on the NMDA receptor, 
also cause caudally directed biting, which is not followed by hyperalgesia. This 
means that care must be taken when drawing conclusions from BSL behaviour 
(Aanonsen and Wilcox 1987). This behaviour also arises from the administration 
of intrathecal tachykinins (Aanonsen and Wilcox 1987; Raigorodsky and Urea 
1987; Sakurada, Manome et al. 1990; Davis and Inturrisi 1999).
ii) Actions of glutamate at other receptors
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a) The AMPA receptor
This receptor is involved in synaptic transmission and thus responsible in setting 
baseline nociceptive transmission (Chapman and Dickenson 1995; Dickenson 
1997; Yaksh 2006). Furthermore, the AMPA receptor is found primarily in 
lamina II of the dorsal hom, as well as other laminae within the spinal cord, with 
some reports showing that they also exist on primary afferent fibres (Coggeshall 
and Carlton 1997; Millan 1999). Additionally, even though each inotropic 
glutamate receptor family was named after its selective agonist, the AMPA 
receptor also responds to kainate (Kew and Kemp 2005). Finally, the AMPA 
receptor, once activated, is more selective to Na than Ca , in dorsal hom 
neurons (Millan 1999).
b) Peripheral receptors
Glutamate receptors have been identified in sensory neuron cell bodies in the 
DRG and on the peripheral terminals of primary afferent axons in both rat hairy 
and glabrous skin (Carlton, Hargett et al. 1995; Coggeshall and Carlton 1998), 
and in normal hairy skin (Kinkelin, Brocker et al. 2000).
In addition, numerous studies have shown that glutamate and its ionotropic 
receptors (NMDA, AMPA and kainate) may play a role in peripheral nociceptive 
transmission. Mechanical hyperalgesia (Zhou, Bonasera et al. 1996), allodynia 
(Carlton, Hargett et al. 1995) and thermal hyperalgesia (Jackson, Graff et al.
1995) have been demonstrated following intraplantar glutamate and glutamate 
agonists, which can blocked by the corresponding intraplantar antagonists.
Additionally, some studies show that peripheral glutamate receptors may play a 
role in inflammatory pain. The study by Wang et al, in 1997, has shown that the 
unilateral intraplantar administration of NMDA causes a dose-dependent increase 
in c-Fos (marker for neuronal activity) expression on the ipsilateral spinal cord 
dorsal hom (Wang, Liu et al. 1997). Furthermore, the latter study also showed
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that the intraplantar co-administration of the NMDA antagonist MK-801 with 
formalin decreased c-Fos expression usually seen when formalin is administered 
on its own. In another study, the intraplantar administration of the NMDA 
antagonist MK-801 or the AMPA/kainate antagonist CNQX decreased the 
thermal hyperalgesia which occurs following carrageenan inflammation 
(Jackson, Graff et al. 1995). Furthermore, the intraplantar administration of 
glutamate antagonists decreased the lifting and licking behaviour which occur 
due to formalin behaviour, but not the flinching behaviour (Davidson,
Coggeshall et al. 1997; Davidson and Carlton 1998).
In yet another study, NMDA, AMPA and kainate receptors in cutaneous nerves 
seem to be upregulated in unmyelinated and myelinated axons, 48 hours after 
CFA inflammation in the inflamed paw as opposed to the non-inflamed one. This 
could be part of the mechanism underlying peripheral sensitisation (Carlton and 
Coggeshall 1999). Moreover, the intraplantar administration of the NMDA 
antagonist MK-801, but not that of the non-NMDA antagonist CNQX, reduced 
the mechanical hyperalgesia seen following CFA inflammation (Leem, Hwang et 
al. 2001). Furthermore, in a study using an in vitro skin-nerve preparation, the 
levels of peripheral NMDA receptors were increased and decreased in 
conjunction with the level of the CFA inflammation. Additionally in this study, a 
lower dose of NMDA was required to sensitise nociceptors to thermal stimuli in 
inflamed skin, when compared to normal skin and the sensitisation was reversed 
by the intraplantar application of the NMDA antagonist MK-801 (Du, Zhou et al. 
2003).
There is no shortage of endogenous glutamate to act on these receptors, since it 
has been postulated to originate from keratinocytes, macrophages, Schwann 
cells, blood serum as well as possibly from the primary afferents themselves 
(Kinkelin, Brocker et al. 2000; Ji and Strichartz 2004; Meyer, Ringkamp et al.
2006). Indeed, the study by deGroot et al, found that glutamate content increased 
significantly in the dialysate collected from rat hindpaw following electrical 
stimulation of the sciatic nerve, using parameters which would activate low 
threshold mechanoceptors (Ap fibres), which convey non-noxious input, and
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high threshold afferents (A5+C fibres), which convey noxious input.
Furthermore, selective activation of C-fibres, by capsaicin treatment to the sciatic 
nerve, also resulted in an increase in peripheral glutamate in this study (deGroot, 
Zhou et al. 2000).
iii) Peripheral NMDA receptors and neuropathic pain
Not many investigations have been done to establish whether peripheral 
glutamate receptors may play a role in neuropathic pain. One study by Jang et al, 
has shown that by performing an L5 spinal nerve ligation (SNL) which was 
preceded by L5 DR (dorsal rhizotomy, to stop the signal from getting to the 
spinal cord and thus allow only peripheral access of SNL-induced signals), long­
term mechanical hyperalgesia in the affected hindpaw of the rat occurred, whose 
induction and maintenance was significantly reduced by the intraplantar 
administration of the NMDA antagonist MK-801 (Jang, Kim et al. 2004).
Furthermore, one human study showed that the administration of topical 
ketamine cream (an NMDA antagonist) reduced the hyperalgesia and allodynia 
seen in CPRS I (complex regional pain syndrome type I) (Ushida, Tani et al.
2002), whereas another study showed that the topical administration of a cream 
containing a combination of amitriptyline (tricyclic antidepressant, prevents the 
reuptake of noradrenaline and serotonin) and ketamine decreased neuropathic 
pain (Lynch, Clark et al. 2005).
To summarise, glutamate receptors have been localised in the periphery, have 
been shown to be exogenously activated and the local administration of 
antagonists at the glutamate receptors has been shown to decrease pain states of 
inflammatory as well as neuropathic nature. Furthermore, glutamate has been 
shown to be released peripherally following stimulation of the sciatic nerve. 
Therefore, it could be postulated that endogenous glutamate could be released 
from the peripheral terminals of primary afferent fibres, possibly in a mechanism 
akin to the axon reflex (described in section 1.6.4 ii), following neuropathic pain 
states. Consequently, the possibility that glutamate, acting on the peripheral
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NMDA receptor, has a role in the mechanism underlying the pain behaviour due 
to neuropathic pain, will be investigated in this study.
1.7.3.2 Substance P
Substance P (SP) is a neuropeptide from the neurokinin (tachykinin) family, 
found in many small diameter primary afferents, which terminate mainly in the 
superficial laminae, in the dorsal horn; although some penetrate deeper (Lamotte, 
Pert et al. 1976; Randic and Miletic 1977; Yaksh, Jessell et al. 1980; Laneuville, 
Dorais et al. 1988; Todd, McGill et al. 2000; Todd 2002). SP is implicated in 
anxiety, mood, stress, smooth muscle contraction, regulation of immune 
response, as well as secretion from both exocrine and endocrine glands (Garret, 
Carruette et al. 1991; Yip and Chahl 1999; Suzuki, Hunt et al. 2003). However, 
SP also plays a role as a neurotransmitter in the central nervous system, which is 
released after high intensity noxious stimulation (Yaksh, Jessell et al. 1980; 
Dickenson 1997; Suzuki, Hunt et al. 2003).
i) SP is co-released with other peptides from primary afferent fibres
After C-fibre activation, there is also co-release of neurokinin A (NKA) 
(Laneuville, Dorais et al. 1988) and calcitonin-gene related peptide (CGRP), 
which are also primary afferent peptides released by noxious stimulus and excite 
dorsal horn neurones, as well as co-release of the excitatory amino acid 
glutamate (Battaglia and Rustioni 1988; De Biasi and Rustioni 1988; Doyle and 
Hunt 1999; Yaksh, Hua et al. 1999). Without CGRP, SP released by C-fibres will 
only activate the NK-1 receptor in the vicinity of the site of release. However, 
because CGRP binds to the peptidase which degrades SP, CGRP extends the 
release zone for SP to cover much of the dorsal horn (Hokfelt, Zhang et al. 1994; 
Dickenson 1995; Dickenson 1997; Dray 1997). Therefore, transmission 
following the release of SP is through volume transmission (Coggeshall and 
Carlton 1997).
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Furthermore, SP has been shown to cause further release of glutamate from 
primary afferent fibres (Hua, Chen et al. 1999). In turn, as mentioned previously, 
glutamate, via presynaptic NMDA receptor activation, has been shown to 
increase the evoked release of SP (Malcangio, Fernandes et al. 1998). Finally, the 
release of SP from the activation of TRPV1 receptors in primary afferent axons 
has also been shown to be dependent on the activation of presynaptic NMDA 
receptors, in vitro (Lao, Song et al. 2003).
As mentioned previously, the peripheral release of SP and CGRP from the 
peripheral endings of sensory neurons leads to neurogenic inflammation and thus 
peripheral sensitisation, whereas their central release in the spinal cord leads to 
dorsal horn excitability and possibly central sensitisation, which will be 
discussed next (Dray 1997).
ii) The NK-1 receptor composition and internalisation
SP acts preferentially on the neurokinin 1 (NK-1) receptor. The NK-1 receptor is 
a G-protein-coupled receptor, whose activation leads to an increase in inositol 
trisphosphate levels, which in turn causes the release of calcium from 
intracellular stores (Rusin, Ryu et al. 1992; Alvarez-Vega, Baamonde et al.
1998). Furthermore, like other G-protein-coupled receptors, the NK-1 receptor is 
composed of an extracellular N (amino) terminal domain, seven transmembrane 
domains and an intracellular C (carboxy) domain (Khawaja and Rogers 1996).
Once the NK-1 receptor has been activated by SP or any NK-1 agonist, both 
agonist and receptor are rapidly internalised (within 5 minutes) into the 
cytoplasm (Trafton, Abbadie et al. 1999). The receptor is phosphorylated prior to 
internalisation, which uncouples it from the G-protein and which means the 
signalling ends before internalisation. This internalisation does not occur when 
an antagonist binds the NK-1 receptor, and lasts for 60 minutes after agonist 
binding, with the ‘recycled’ receptors returning and becoming evenly distributed 
on the surface around 30 minutes after that (Trafton and Basbaum 2000; Wang 
and Marvizon 2002).
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iii) The NK-1 receptor location and projections
NK-1 receptors are found on intrinsic dorsal horn neurons, in the superficial 
layers predominantly, with lower levels found in the deep layers (Todd 2002; 
Suzuki, Hunt et al. 2003). Some studies have also postulated the existence of 
presynaptic NK-1 ‘autoreceptors’, on the central terminals of primary afferent 
fibres (Malcangio and Bowery 1999). NK-1-expressing lamina I neurons make 
some collateral projections to deeper layers, but are mostly nociceptive-specific 
projection neurons (nearly 80% of lamina I projection neurons express the NK-1 
receptor), which terminate mainly within the parabrachial area of the brainstem. 
These cells greatly outnumber the laminae III-IV cells with this same receptor, 
which also project to regions of the brainstem involved in pain mechanisms 
(Todd, McGill et al. 2000; Todd, Puskar et al. 2002).
iv) The role of the NK-1 receptor in pain states
Numerous studies over the years have shown that the NK1 receptor only has 
roles in central states of hypersensitivity and not acute pain (Xu, Dalsgaard et al. 
1992; Chapman and Dickenson 1993; Dickenson 1995; Ma and Woolf 1997; 
Yaksh, Hua et al. 1999; Yoshimura and Yonehara 2001; Suzuki, Hunt et al.
2003). The application of NK-1 agonists has been shown to produce slow 
excitatory transmission of dorsal horn neurons (Urban and Randic 1984) and 
decrease pain thresholds, whilst antagonist administration blocked excitation of 
dorsal horn neurons and prevented the development of inflammation-induced 
thermal and mechanical hyperalgesia in behavioural studies (Randic and Miletic 
1977; Henry 1980; Kellstein, Price et al. 1990; Dickenson 1997; Ma and Woolf 
1997; Field, McCleary et al. 1998; Li and Zhao 1998; Doyle and Hunt 1999). 
Furthermore, RP-67,580, an NK-1 antagonist, was capable of inhibiting the 
second phase of the formalin response (Chapman and Dickenson 1993; Seguin, 
Le Marouille-Girardon et al. 1995; Honore, Menning et al. 1999).
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Additionally, the activation of the NK-1 receptor in the dorsal horn is thought to 
play an important role in enhancing NMDA transmission, by aiding in the 
removal of the magnesium block. The final result of which is wind-up and 
central hypersensitivity (Urban and Randic 1984; Dougherty and Willis 1991; 
O'malley, Calligaro et al. 1991; Xu, Dalsgaard et al. 1992; Dickenson 1997; 
Doyle and Hunt 1999). The NK-1-mediated enhancement of NMDA-mediated 
events was shown when NK-1 antagonists were shown to reduce half of the pain 
behaviour which occurs following intrathecal NMDA administration (Trafton 
and Basbaum 2000) and to reduce the wind-up response (Xu, Dalsgaard et al. 
1992).
Furthermore, following chronic inflammation using complete Freund’s adjuvant 
(CFA), there has been a reported increase in the expression of both SP and the 
NK-1 receptor in the dorsal horn, and the normally SP-ffee large diameter 
sensory neurons also begin to express tachykinins. The latter was thought to 
contribute to the development of mechanical allodynia following injury, since 
these large diameter neurons respond to non-noxious stimuli that can now release 
SP. However, electrical stimulation of these large diameter sensory neurons 
following inflammation did not cause any NK-1 receptor internalisation, so it is 
still uncertain how relevant the expression of SP on large diameter primary 
afferents is (Trafton and Basbaum 2000).
v) The behaviour which follows the activation of the NK-1 receptor in 
animal studies
Moreover, intrathecal SP and NK-1 agonist administration has been shown to 
cause thermal and mechanical hyperalgesia, allodynia, and compulsive biting, 
scratching and licking of the hindlimbs by rats in behavioural studies (Seybold, 
Hylden et al. 1982; Holland, Goldstein et al. 1993; Picard, Boucher et al. 1993; 
Dickenson 1997). The aversive behaviour elicited by intrathecal SP is thought to 
involve the spinal NK-1 as well as the NMDA and non-NMDA receptors, since 
not only is SP thought to act directly on the NK-1 receptor, but it is also thought
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to induce the release of glutamate from the spinal cord (Hylden and Wilcox 
1982; Okano, Kuraishi et al. 1993).
vi) Ablating the NK-l-expressing neurons
Finally, the fact that the NK-1 receptor, like other G-protein-coupled receptors, 
internalises when activated, made it possible to selectively ablate the neurons this 
receptor is expressed on, by administering a conjugate of its agonist ‘SP’ with the 
toxin ‘saporin’. This meant that the neuron would take up the toxin, as the NK-1 
receptor was activated and internalised by SP, which would lead to cell death 
(Mantyh, Rogers et al. 1997). Selectively ablating lamina I neurons expressing 
the NK-1 receptor led to a great loss of capsaicin-induced hyperalgesia (Mantyh, 
Rogers et al. 1997). This ablation also removed wind-up and decreased central 
sensitisation, as seen in an electrophysiological experiment testing the formalin 
response (Suzuki, Morcuende et al. 2002). The receptive field (peripheral area of 
the cell which responds to the stimuli) size of spinal neurons, and their ability to 
code accurately for both mechanical and thermal stimuli were also reduced in 
this experiment (Suzuki, Morcuende et al. 2002). Furthermore, it was shown that 
these NK-1 expressing lamina I neurons are needed for the generation of long­
term potentiation (LTP, “use-dependent, long-lasting modification of synaptic 
strength”) in deep dorsal horn neurons (Rygh, Suzuki et al. 2006).
1.7.4 The postulated role of the NMDA and NK-1 receptors in central 
sensitisation
The mechanism underlying secondary hyperalgesia following injury, where a 
painful sensation to mechanical stimuli is felt outside the area of injury in the 
periphery, has been postulated by most to be due to the central sensitisation of 
dorsal horn neurons (Treede, Meyer et al. 1992).
A cascade of events is thought to underlie the increase in dorsal horn excitability 
following injury. The activation of both the NMDA and the NK-1 receptors by 
glutamate and SP from primary afferent fibres, and by intrathecal NMDA and
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NK-1 receptor agonists, leads to increases in intracellular calcium, either through 
a direct increase in calcium influx through an open channel or through the 
generation of inositol trisphosphate, which leads to the release of calcium from 
intracellular stores, respectively. This rise in intracellular calcium causes the 
activation of many enzymes, including cyclo-oxygenase 2 (COX-2) and nitric 
oxide synthase (NOS), which are required for the generation of prostanoids and 
NO respectively, and the activation of many kinases (eg: protein kinase C 
TKC’). These prostanoids and NO retrogradely diffuse after their synthesis and 
release in the spinal cord, and facilitate further transmitter release from the 
primary afferents, and thus more glutamate and peptides to be released, whereas 
the kinases lead to phosphorylation and further activation of membrane receptors 
and channels, which subsequently causes a further increase in intracellular 
calcium (Chen and Huang 1992; Rusin, Ryu et al. 1992; Dougherty, Palecek et 
al. 1993; Rusin, Bleakman et al. 1993; Rusin, Jiang et al. 1993; Yaksh, Hua et al.
1999).
In my study, in order to investigate excitatory transmission in the rat spinal cord, 
each of the NMDA receptor agonist NMDA, and the NK-1 receptor agonist [Sar9 
Met (O2)1 ^ -Substance P (Sar-SP), will be administered intrathecally, and their 
effects on the deep wide dynamic range neurons will be investigated using in 
vivo electrophysiology. Furthermore, each of intrathecal NMDA, and intrathecal 
Sar-SP will also be used to induce the acute chemical model of pain, in the 
behavioural part of the study.
1.7.5 The postulated role of the NK-1 and the NMDA receptors in 
neuropathic pain
Changes in the excitatory transmitter systems occur following peripheral nerve 
injury, as both SP and CGRP immunoreactivity in both the DRG and the dorsal 
horn is decreased, whereas spinal NK-1 receptor levels are increased (Sommer 
and Myers 1995). Furthermore, even though NMDA receptor immunoreactivity 
in the dorsal horn remains unchanged following peripheral nerve injury, 
glutamate uptake in the dorsal horn has been shown to be decreased, which
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means that more glutamate is available to act at its respective receptors (Binns, 
Huang et al. 2005).
In addition, the role of the NK-1 and the NMDA receptors in central sensitisation 
(see section 1.7.4) means that these two receptors, via the mechanisms discussed 
above, also play a role following nerve injury. Indeed, the administration of NK- 
1 and NMDA antagonists, as well as antiserum against SP (Wu, Schwasinger et 
al. 2005), in different models of neuropathic pain, has been shown to decrease 
the behavioural pain hypersensitivities (Davar, Hama et al. 1991; Yamamoto, 
Shimoyama et al. 1993; Hao and Xu 1996; Chaplan, Malmberg et al. 1997; 
Wegert, Ossipov et al. 1997; Coudore-Civiale, Courteix et al. 1998; Field, 
McCleary et al. 1998; Coudore-Civiale, Courteix et al. 2000; Gonzalez, Field et 
al. 2000; Cahill and Coderre 2002) and dorsal horn neuron changes 
(Cumberbatch, Carlson et al. 1998) associated with the disease. However, the 
clinical use of many of the NK-1 and NMDA antagonists at effective doses is 
usually hampered by unacceptable side-effects, such as motor disturbances 
(Coderre and Van Empel 1994; Suzuki, Matthews et al. 2001).
1.7.6 Inhibitory transmitter systems
1.7.6.1 GABA
Even though no GABA receptor agonist or antagonist is used in this study, I will 
briefly detail GABA, since it is a very important inhibitory transmitter system. 
GABA (gamma-amino butyric acid) is the major inhibitory transmitter in the 
central nervous system (Dickenson, Chapman et al. 1997). GABA in the spinal 
cord is used in 20-50% of all neuronal synapses and acts via two receptors, 
GABA-A (predominantly) and GABA-B (Coggeshall, Zhou et al. 1997; Sieghart, 
Fuchs et al. 1999).
Both GABA-A and GABA-B receptors are found on the central terminals of 
primary afferents and spinal cord intemeurons, predominantly in lamina II as
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well as the rest of the spinal cord (Coggeshall and Carlton 1997; Slonimski, 
Abram et al. 2004).
It has been shown that GABA acts as a tonic control for excitatory transmission, 
more specifically, that GABA intemeurons control the input of low-threshold 
afferent fibres (Dickenson, Chapman et al. 1997; Dickenson, Matthews et al.
2002). This tonic GABA control seems to be enhanced in inflammation and 
decreased in neuropathic pain (Dickenson, Chapman et al. 1997). Indeed, it has 
been shown that the spinal administration of bicuculline, a GABA-A antagonist, 
caused facilitation of superficial and deep dorsal horn neuron responses in 
normal animals (Reeve, Dickenson et al. 1998; Seagrove, Suzuki et al. 2004), 
whilst the administration of midazolam, a benzodiazepine which enhances 
GABA-A function by binding to a modulatory site, decreased dorsal horn 
responses in neuropathic animals (Kontinen and Dickenson 2000).
1.7.6.2 Opioids
The opioidergic system is also a very important inhibitory system in the 
transmission of pain. Opioid is a term given to any substance with ‘morphine- 
like’ effects, which is blocked by antagonists like naloxone. Endogenous opioids 
include Met- and Leu-Enkephalins, P-Endorphin and Dynorphin. The three main 
types of opioid receptors, which are G-protein-coupled receptors, are p, 8 and k . 
Each of these receptors is associated with different functional effects. Naloxone 
has a high affinity for the p receptor, but will also act on 8 and k, in moderately 
higher concentrations (Kosterlitz 1985; Dickenson and Kieffer 2006).
A fourth opioid receptor, ‘opioid receptor-like (ORL1) orphan receptor’ was 
isolated by severeal laboratories between 1994 and 1995. This latest receptor has 
no affinity for opioid ligands, and stayed an ‘orphan’ until late 1995, when two 
groups separately isolated its endogenous ligand, called nociceptin or orphanin 
FQ (Meunier 1997). Most of the analgesic opioids, as mentioned above, are p- 
receptor agonists. It is this receptor which is responsible for most of the analgesic
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effects and major side-effects (respiratory depression, sedation, euphoria, 
dependence) of opioids (Dickenson 1994).
i) The location of opioid receptors
p opioid receptors are found most abundantly (approximately 70%) on the 
central terminals of small- and medium-diameter (C and A5) primary afferent 
terminals (Besse, Lombard et al. 1990; deGroot, Coggeshall et al. 1997; Zhang, 
Bao et al. 1998). In the spinal cord, autoradiographic and immunohistochemical 
studies have shown that the highest levels of opioid receptors are present around 
the C-fibre terminal zones in lamina I and II, whereas lower levels are found in 
deeper laminae. It is suggested that p receptors form 70% of the total opioid sites 
in the rat spinal cord, whilst 5 receptors form 24% and k  receptors form 6% of 
these (Lamotte, Pert et al. 1976; Duggan, Hall et al. 1977; Besse, Lombard et al. 
1992; Dickenson 1994; Mansour, Fox et al. 1994; Dickenson and Kieffer 2006). 
Furthermore, there are opioid receptors located on supraspinal sites, such as the 
rostroventral medulla (Yaksh 1997; Dickenson and Kieffer 2006), which will be 
discussed in section 1.8.2 iv.
ii) The mechanisms of action of opioid receptors
The opioid receptors are coupled to Go/Gi inhibitory proteins. Like other 
receptors which belong to the G-protein family, these receptors have an 
extracellular N terminal domain, seven transmembrane domains and an 
intracellular C terminal tail. At the membrane level, morphine binds to the p- 
opioid G-protein-coupled receptor, causing a conformational change which leads 
to the opening of inwardly rectifying potassium channels, which causes a 
neuronal hyperpolarisation (Dickenson 1994; Matthews and Dickenson 2002; 
Dickenson and Kieffer 2006).
The hyperpolarisation of the neurons due to the membrane actions of opioids 
ultimately reduces calcium entry into all of the fibres and neurons which contain
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these receptors, such as the central terminals of the primary afferent fibres and 
spinal cord neurons. The three different locations of opioid receptors, which 
include the primary afferent terminals, the spinal cord and the 
midbrain/brainstem, leads to opioids exerting their effects via three mechanisms 
of action. Opioids primarily have an inhibitory presynaptic action on the central 
terminals of primary afferent fibres, which leads to the inhibition of transmitter 
release (Lombard and Besson 1989; Kangrga and Randic 1991; Besse, Lombard 
et al. 1992; Mansour, Fox et al. 1994; Dickenson and Kieffer 2006).
Furthermore, opioids acting on their postsynaptic receptors cause a decrease in 
synaptic transmission. Alternatively, this postsynaptic action may produce 
disinhibition by inhibiting the first neuron in a circuit of two neurons, where the 
second cell is controlled by the first inhibitory neuron. This leads to the second 
cell becoming active and thus the term disinhibition. The overall actions of 
opioids cause decreased transmission and neuronal excitability and are thus 
mostly inhibitory (Lamotte, Pert et al. 1976; Duggan, Hall et al. 1977; Jessell and 
Iversen 1977; Yaksh, Jessell et al. 1980; Duggan and North 1983; Hylden and 
Wilcox 1983; Lombard and Besson 1989; Kayser, Chen et al. 1991; Dickenson
1997).
iii) The efficacy of opioids in different pain models
Plasticity is manifested in opioid systems, since morphine has been reported to 
have reduced efficacy in neuropathic pain (Amer and Meyerson 1988), detailed 
in section 1.7.7, whilst being more effective in some inflammatory models 
(Kayser, Chen et al. 1991) than in normal animals (Dickenson and Kieffer 2006).
As mentioned previously, opioids exert most of their actions on their presynaptic 
receptors, which are higher in number than their postsynaptic receptors found on 
intrinsic spinal cord dorsal horn neurons (Lamotte, Pert et al. 1976; Duggan, Hall 
et al. 1977; Besse, Lombard et al. 1992; Dickenson 1994; Mansour, Fox et al. 
1994). However, the theory that opioid effectiveness is decreased when used in a 
situation where opioids are limited to act on their postsynaptic receptors, has 
yielded conflicting results (Henry 1976; Dickenson 1997; Cheunsuang, Maxwell
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et al. 2002). Most studies wishing to investigate this in acute pain models usually 
use the activation of the NMDA or the NK-1 receptors, both known to be located 
postsynaptic on the spinal cord dorsal horn, and whose activation shifts the 
balance in the spinal cord towards excitation.
One study has investigated the efficacy of different intrathecal opioid receptor 
agonists on inhibiting the behaviour and thermal hyperalgesia (using the tail flick 
test) associated with intrathecal SP in mice. It was found that all agonists 
inhibited both the behaviour and the hyperalgesia, but that 8 agonists were more 
potent than morphine in doing so (Hylden and Wilcox 1982; Hylden and Wilcox 
1983), but this was contradicted when Trafton et al showed that it was p 
receptor activation which was most potent in reducing NK-1 internalisation 
(Trafton, Abbadie et al. 1999).
However, the study by Alvarez-Vega et al showed that morphine was not very 
efficient in reducing the BSL behaviour which arises following intrathecal 
septide, and was even less effective in reducing the BSL behaviour following 
intrathecal NMDA administration in mice (Alvarez-Vega, Baamonde et al.
1998). This was also shown in the study by (Bossut, Frenk et al. 1988), where it 
was demonstrated that different doses of intrathecal morphine were ineffective in 
inhibiting the behaviour which arises following intrathecal SP. The study by 
Aanonsen et al, showed that intrathecal DAGO (an agonist more p selective than 
morphine) was more effective than intrathecal morphine in reducing the 
behaviour and hyperalgesia associated with intrathecal NMDA administration in 
mice, and that the doses of both agonists required to inhibit the hyperalgesia were 
less than those needed to inhibit the behaviour (Aanonsen and Wilcox 1987).
Another study investigated the effect of each of Sar-SP (NK-1 agonist) and 
DAMGO (p opioid agonist) in vitro on postsynaptic superficial dorsal horn 
neurons which express the NK-1 receptor (Cheunsuang, Maxwell et al. 2002). 
They showed that Sar-SP depolarised these cells initially, whereas DAMGO 
produced small direct postsynaptic hyperpolarisations of these cells, which were
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not as profound as the presynaptic block caused by DAMGO on the C-fibre 
evoked response, thus showing the smaller effect of p opioid agonists when they 
are not acting presynaptically.
Wind-up of dorsal horn neurons, as mentioned in section 1.7.3, is a response 
mediated by the activation of the NMDA receptor channel (Dickenson and 
Sullivan 1987), found mostly postsynaptic on spinal cord neurons (Coggeshall 
and Carlton 1997). This response has been shown to be resistant to low doses of 
intrathecal morphine, and needs higher doses of morphine to inhibit it (Chapman 
and Dickenson 1992; Chapman, Haley et al. 1994), since the intrathecal 
morphine needs to act on both its presynaptic and less numerous postsynaptic p- 
opioid receptors (Lombard and Besson 1989; Besse, Lombard et al. 1990), to 
abolish it.
Finally, the study by Yamamoto et al showed that the administration of 
intrathecal morphine was effective in reducing the behaviour elicited by 
treatment with formalin, when morphine was given both pre- and post-formalin 
treatment in rats, whereas the NMDA receptor antagonist MK-801 was more 
effective only when administered pre-formalin treatment (Yamamoto and Yaksh 
1992). Therefore, this study showed morphine to be effective as an analgesic in a 
situation where both the NMDA and the NK-1 receptors are thought to be 
activated.
In the first part of my study, the inhibitory effect of morphine on spinal cord 
dorsal horn neurons will be investigated. Following that, the modulation, by 
morphine, of the excitation of the spinal cord dorsal horn neurons and the 
behavioural and nociceptive response, which occur when each of the NMDA and 
the NK-1 receptors is activated by its respective agonist, will be studied.
1.7.7 Morphine and neuropathic pain
60
As discussed previously, opioid receptors are located on the central terminals of 
the primary afferent fibres, mostly the peptidergic, small- and medium-diameter 
sensory neurons (deGroot, Coggeshall et al. 1997; Zhang, Bao et al. 1998), on 
descending controls from the RVM, such as ON cells (Porreca, Burgess et al.
2001), and to a lesser degree on neurons intrinsic to the spinal cord dorsal horn 
(Zhang, Bao et al. 1998). Therefore, theoretically, opioid receptors seem to be 
well placed to control the excess activity which occurs in all three 
aforementioned locations, and which contribute to the plasticity seen in 
neuropathic pain.
Following nerve injury, the changes in inhibitory transmitter systems vary, with 
reports showing that GABA-ergic tone is decreased, increased or unchanged 
following peripheral nerve injury (Sommer and Myers 1995; Hwang and Yaksh 
1997; Kontinen, Stanfa et al. 2001), whereas Met-enkephalin immunoreactivity 
is increased in the dorsal horn. Additionally, p opioid receptor immunoreactivity 
increased following the C.C.I model and decreased after the tight ligation model 
of neuropathy. Therefore, the type of injury sometimes dictates the 
reorganisation which occurs in the central nervous system following peripheral 
nerve injury. Additionally, the two ‘morphine-resistant’ substances, 
cholecystokinin (CCK) and dynorphin, are both increased in primary afferent 
fibres and the spinal cord dorsal hom respectively, and are detailed further below 
(Hokfelt, Zhang et al. 1994; Nahin, Ren et al. 1994; Sommer and Myers 1995; 
Cameron, differ et al. 1997; Goff, Burkey et al. 1998; Malmberg and Basbaum 
1998; Honore, Rogers et al. 2000; Lee, Sohn et al. 2001; Wang, Sun et al. 2002).
Peripheral nerve injury also results in the activation and up-regulation of the NK- 
1 receptor expressed on projection neurons, which are the origin of the 
descending serotonergic facilitations (see section 1.9.4), which are enhanced 
following neuropathy and which cause further central sensitisation in the dorsal 
hom spinal cord (Nichols, Lopez et al. 1997). Therefore, the peripheral and 
spinal events occurring following peripheral nerve injuiy shift the balance of the 
spinal cord towards excitation (Dickenson and Kieffer 2006).
61
Furthermore, p-receptor-expressing neurons in the RVM seem to be implicated 
in the increase of descending facilitations following peripheral nerve injury, 
since the ablation of these cells with the p-receptor agonist ‘dermorphin’ 
conjugated with the toxin ‘saporin’ decreased abnormal pain following 
neuropathy and not normal pain. These p-receptor expressing cells are postulated 
to include ON cells. Therefore, supraspinal sites also serve to enhance spinal 
cord excitation, following peripheral nerve injury (Porreca, Burgess et al. 2001; 
Porreca, Ossipov et al. 2002; Vera-Portocarrero, Zhang et al. 2006).
i) Clinical studies
There have been conflicting results as to the responsiveness of neuropathic pain 
syndromes to opioids. Some studies have shown that neuropathic pain states are 
less responsive to opioids (Amer and Meyerson 1988), whereas others have 
shown that opioid responsiveness depended on dose titration, using more potent 
opioid agonists than those previously used, as well as on the type of neuropathic 
pain syndrome (Portenoy, Foley et al. 1990; Rowbotham, Reisner-Keller et al. 
1991; Jadad, Carroll et al. 1992; Sindrup and Jensen 1999; Attal, Guirimand et 
al. 2002; Hansson and Dickenson 2005).
ii) Dynorphin and cholecystokinm
The decrease in opioid responsiveness following neuropathic pain injury has 
been originally attributed to the loss of p-opioid receptors on the central 
terminals of primary afferent fibres. However, even though following some types 
of peripheral nerve injury, such as peripheral axotomy, dorsal root section and 
dorsal rhizotomy, p-opioid receptors have been shown to be down-regulated in 
DRG and dorsal hom neurons (Lamotte, Pert et al. 1976; Besse, Lombard et al. 
1992; deGroot, Coggeshall et al. 1997; Zhang, Bao et al. 1998; Dickenson and 
Suzuki 2005), in other types of nerve injury, such as the SNL and other sciatic 
nerve ligation models, the loss of these receptors is too small to be the main 
cause of decreased opioid responsiveness (Besse, Lombard et al. 1992; Nichols,
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Lopez et al. 1997; Porreca, Tang et al. 1998). Furthermore, in the CCI model of 
nerve injury, there is an increase in the number of p-opioid receptors (deGroot, 
Coggeshall et al. 1997; Porreca, Tang et al. 1998).
Therefore, it has been shown that one of the reasons opioids have been less 
effective in some types of neuropathic pain syndromes is due to increases in 
spinal dynorphin and cholecystokinin levels. Since this study uses morphine 
administration in neuropathic rats, both dynorphin and cholecystokinin will be 
detailed.
a) Dynorphin
Dynorphin is a neuropeptide which is a kappa opioid agonist and thought to have 
both antinociceptive opioid properties, as well as non-opioid pro-nociceptive 
properties (thought to be mediated via the NMDA receptor). Spinal dynorphin 
increases in segments which belong to the entry of the injured nerve as well as 
other segments adjacent, once descending facilitations are activated following 
peripheral nerve injury (Bian, Ossipov et al. 1999; Dickenson and Kieffer 2006). 
This means that dynorphin, like descending facilitations, is involved with the 
maintenance of neuropathic pain and not the initiation (Ossipov, Lai et al. 2001; 
Burgess, Gardell et al. 2002). The increase in spinal dynorphin correlates well 
with neuropathic pain symptoms such as thermal hyperalgesia, as well as 
morphine resistance (Ossipov, Lai et al. 2000). Furthermore, it has been shown 
that when an antiserum against dynorphin was administered intrathecally 
following peripheral nerve injury, this aided intrathecal morphine in alleviating 
tactile allodynia, which was previously resistant to spinal morphine (Bian, 
Ossipov et al. 1999; Wu, Schwasinger et al. 2005).
b) CCK
Cholecystokinin (CCK) is a neuropeptide, which has been shown to be a 
physiological antagonist to the effects of opioids (Sullivan, Hewett et al. 1994). 
This neuropeptide acts on both CCKa and CCKb receptors, and both
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neuropeptide and receptors are located in primary afferent fibres and dorsal hom 
neurons (Xu, Puke et al. 1993; Zhang, Bao et al. 1998). Following nerve injury, 
both CCK and CCKb receptors are upregulated in the DRG and in the spinal cord 
(Xu, Puke et al. 1993; Nichols, Bian et al. 1995; Zhang, Bao et al. 1998). The 
efficacy of spinal morphine following peripheral nerve injury has been shown to 
be decreased in some neuropathic pain models. The administration of intrathecal 
morphine in combination with a CCKB receptor antagonist has been shown to 
restore the efficacy of spinal morphine following peripheral nerve injury, and 
enhance the antinociceptive effects of spinal morphine in normal animals (Xu, 
Puke et al. 1993; Sullivan, Hewett et al. 1994; Nichols, Bian et al. 1995).
iii) Dynamic/static allodynia, thermal hyperalgesia and morphine
As mentioned previously, different primary afferent fibres relay the sensations of 
dynamic allodynia (Ap-fibres), tactile (static) allodynia (A8-fibres) and thermal 
hyperalgesia (C-fibres) (Field, Bramwell et al. 1999). There has been conflicting 
results following numerous studies as to which one of the previously discussed 
hypersensitivities is reduced by morphine, following peripheral nerve injury. 
Some studies have shown that morphine was able to alleviate thermal 
hyperalgesia (Yamamoto and Yaksh 1991; Yamamoto and Yaksh 1992; Lee, 
Kayser et al. 1994; Backonja, Miletic et al. 1995; Wegert, Ossipov et al. 1997; 
Catheline, Le Guen et al. 2001; Wu, Schwasinger et al. 2005), other studies have 
shown that morphine was effective in reducing tactile allodynia (Bian, Nichols et 
al. 1995; Lee, Chaplan et al. 1995; Field, McCleary et al. 1999; Zhao, Tall et al. 
2004) or pain due to mechanical pressure (Attal, Chen et al. 1991).
The majority of the studies which showed morphine having an effect on thermal 
hyperalgesia were using spinal morphine, whereas the majority of the studies 
which showed morphine having an effect on tactile allodynia were using the 
systemic or supraspinal route of administration. This led to the conclusion that 
following nerve injury, thermal hyperalgesia seems to be mediated mostly 
spinally, whereas tactile allodynia seems to be mediated supraspinally. 
Furthermore, this further proves that thermal hyperalgesia is mainly relayed via
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C-fibres, since these fibres are where most of the presynaptic p-opioid receptors 
are expressed and this stimulus modality seems to be the most responsive to 
opioid therapy, following peripheral nerve injury (Wegert, Ossipov et al. 1997; 
Ossipov, Bian et al. 1999).
To date only the clinical study by (Attal, Guirimand et al. 2002), using systemic 
morphine, has shown an effect of this drug on dynamic allodynia following 
central pain states such as pain following a stroke or spinal cord injury. Since 
dynamic allodynia is mediated via primary afferent fibres which do not express 
p-opioid receptors (Ap fibres), it is not surprising that another study showed that 
morphine was not effective against this type of pain following neuropathy (Field, 
McCleary et al. 1999). It is known that there are less postsynaptic p opioid 
receptors than there are presynaptic ones and therefore, in order for morphine to 
be able to alleviate dynamic allodynia, morphine must be acting predominantly 
via its postsynaptic receptors, and thus higher doses of morphine are needed 
(Dickenson and Suzuki 2005).
iv) Route of administration of morphine
Even though some studies have shown that intrathecal morphine was still 
effective in decreasing abnormal pain/ hyperexcitability of dorsal hom neurons 
due to peripheral nerve injury (Yamamoto and Yaksh 1991; Suzuki, Chapman et 
al. 1999; Suzuki and Dickenson 2002; Zhao, Tall et al. 2004; Suzuki and 
Dickenson 2006), most studies have shown that the efficacy of spinal morphine 
is lost following nerve injury, and that morphine is more effective when 
administered systemically or supraspinally (Bian, Nichols et al. 1995; Lee, 
Chaplan et al. 1995; Nichols, Bian et al. 1995; Nichols, Lopez et al. 1997; 
Wegert, Ossipov et al. 1997; Bian, Ossipov et al. 1999; Pertovaara and Wei
2003). Additionally, many studies have shown that the efficacy of spinal 
morphine is restored following the administration of topical bupivacaine (Na 
channel blocker) or spinal MK-801 (NMDA receptor antagonist) (Yamamoto
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and Yaksh 1992; Ossipov, Lopez et al. 1995; Nichols, Lopez et al. 1997; Bian, 
Ossipov etal. 1999).
In the part of my study investigating neuropathic pain, systemic morphine will be 
administered on its own in SNL rats, to study its ability to inhibit the thermal, 
cold and tactile hypersensitivities seen in this model.
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Figure 1.3- A summary o f some o f the excitatory and inhibitory transmitters and the receptors 
and channels they affect, which have been investigated in this study, in the spinal cord dorsal 
hom. The presynaptic and postsynaptic opioid receptors, and the inhibitory effects o f their 
activation are shown in red. The excitatory effects o f the activation o f the NK-1 and the NMDA 
receptors are shown in blue. AC- adenylate cyclase, IP3- inositol trisphosphate, SP- substance P, 
Glu- glutamate, NK1- neurokinin 1 receptor, NMDA- n-methyl-D-aspartic acid receptor, Mg2+- 
magnesium, Ca2+- calcium, Na+- sodium and K+- potassium.
1.8 Ascending and descending systems
1.8.1 Ascending systems
The axons of projection neurons in the spinal cord traverse to numerous 
supraspinal sites via tracts located in the white matter of the spinal cord (Willis 
and Westlund 1997; Dostrovsky and Craig 2006). Because pain is made up of an 
affective as well as a discriminative sensory component, these supraspinal sites 
are numerous and varied and include the thalamus, the periacqueductal gray, the 
parabrachial region and limbic structures, to name but a few (Willis and 
Westlund 1997).
Some ascending systems also play a role in the activation of descending controls, 
back onto the spinal cord to alter pain transmission, either by facilitation or 
inhibition. There exists numerous ascending pain pathways: the ‘classical’ 
monosynaptic spinothalamic, spinomesencephalic, spinoreticular tracts, the 
‘newer’ spinoparabrachial tract and the polysynaptic spinocervical and 
postsynaptic dorsal column pathways (Willis and Westlund 1997; Millan 1999; 
Dostrovsky and Craig 2006).
i) The spinothalamic (STT) tract
STT cells originate from laminae I and laminae IV-VI, as well as from the 
ventral hom, and project to the contralateral (most cells) thalamus (Fields and 
Basbaum 1978; Willis 1985; Willis and Westlund 1997; Dostrovsky and Craig 
2006). It has been shown that many STT cells are nociceptive, and this pathway 
has now been shown to be linked with the sensations of pain, temperature and 
itch. Lesions in this pathway lead to the loss of sensation on the contralateral side 
(Willis 1985; Craig, Zhang et al. 2002; Dostrovsky and Craig 2006). As well as 
the sensory component of pain, cells in this tract are also thought to play a role in 
the motivational-affective aspect of pain, in addition to activating descending 
controls (Millan 1999).
ii) The spinomesencephalic tract
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Many of the cells in the spinomesencephalic tract are nociceptive, and the origins 
of these cells are distributed in the spinal cord in the same way as those of the 
STT (Willis 1985; Willis and Westlund 1997). The cells, through this tract, 
project mainly contralaterally to the periacqueductal gray (PAG), which could 
contribute to aversive behaviour (Willis and Westlund 1997; Millan 1999).
iii) The spinoreticular tract
Many of the cells of this tract originate from the deep dorsal hom, the ventral 
hom and as has been shown lately, some cells also originate from the superficial 
dorsal hom (Fields and Basbaum 1978; Willis 1985; Willis and Westlund 1997). 
These cells project, mainly contralaterally but also ipsilaterally, to the reticular 
formation of the brainstem (lateral reticular nucleus LRN, nucleus 
parogigantocellularis NPGC/NGC), are mostly nociceptive and could activate 
descending inhibition (Millan 1999).
iv) The spinoparabrachial tract
A group of cells that surround the brachium conjunctivum from the dorsolateral 
pons (pPB) to the mesencephalon (mPB) division is called the parabrachial area 
(Bester, Menendez et al. 1995). Cells which project to the parabrachial area are 
mostly from lamina I neurons, the majority of which express the NK-1 receptor, 
with a few projections from lamina IV-VI neurons (Todd 2002; Suzuki, Rygh et 
al. 2004). These cells are predominantly nociceptive specific (Bester, Matsumoto 
et al. 1997; Bester, Chapman et al. 2000), and project to the parabrachial nucleus 
(PBN). The parabrachial nucleus in turn, has numerous links to the brainstem 
reticular formation cells, and projects to the hypothalamus, amygdala and the 
midline, intralaminar and ventrobasal thalamus, the periacqueductal gray (PAG) 
and the ventrolateral medulla (Gauriau and Bernard 2002; Rahman, Suzuki et al. 
2003; Hunt and Bester 2005; Dostrovsky and Craig 2006). This means that cells 
in this tract play a role in the motivational-affective component of pain, as well 
as autonomic and endocrine roles (Millan 1999; Suzuki, Rygh et al. 2004; 
Dostrovsky and Craig 2006).
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v) The spinocervical tract
This pathway starts from the spinal cord dorsal hom and relays in the lateral 
cervical nucleus, at the C1-C3 level. The neurons of the lateral cervical nucleus 
then ascend to many thalamic nuclei, through the cervicothalamic tract; and to 
the midbrain (including the PAG), through a cervicomesencephalic pathway. 
Spinocervical tract cells respond mostly to tactile stimuli, however, some of them 
do respond to stimuli of a noxious intensity (Willis and Westlund 1997; Millan
1999).
vi) The postsynaptic dorsal column (PSDC-Iemniscal) tract
The PSDC pathway which starts from lumbosacral segments projects to the 
gracile dorsal column nuclei (DCN) of the caudal medulla. The origins of the 
PSDC are cells that are innervated by ‘serotonin-only’ fibres, and are located in 
laminae III-V and X. Direct projection neurons to the DCN from the dorsal hom 
also exist, and these are thought to modulate tactile information. DCN neurons 
then project to thalamic nuclei, to the superior colliculus, with some neurons 
descending back to the spinal cord. Finally, due to the effect of descending 
serotonergic pathways, through PSDC cells, on the rostral transmission of tactile 
information, this tract is postulated to play a role in the mechanical allodynia 
seen in neuropathic pain states (Fields and Basbaum 1978; Willis and Westlund 
1997; Millan 1999).
vii) Labelling and convergence
The question of labelled lines, where pain transmission was thought to occur via 
distinct pathways from the periphery to supraspinal sites, versus convergence, 
where pain transmission was thought to occur via numerous factors which 
interacted at many levels from the periphery to supraspinal sites, is one that has 
been asked for a very long time (Melzack and Wall 1965). The new way of 
looking at pain processing is that it is through both labelled lines and 
convergence (Millan 1999; Craig 2002; Craig 2003). Therefore, even though the
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description of the aforementioned tracts is accurate, the general consensus now is 
that projections from superficial laminae modulate mostly the motivational- 
affective component of pain, whereas projections from deeper laminae modulate 
mostly the discriminative-sensory component of pain, and that these two 
components of pain do not work independently of each other (Millan 1999; Hunt 
and Mantyh 2001; Gauriau and Bernard 2002; Hunt and Bester 2005; Dickenson 
and Kieffer 2006).
1.8.2 Descending controls
As mentioned previously, ascending systems may modulate descending controls, 
either inhibitory or facilitatory, onto the spinal cord. These descending controls, 
in turn, may also modulate the activity in ascending systems. Thus by a neuronal 
loop, pain transmission is either amplified or decreased, at the spinal level. Since 
most descending pathways originate from the brainstem, this loop is called ‘the 
spino-bulbo-spinal loop’. Furthermore, the pharmacology of descending controls 
involves many transmitter systems including the opioidergic, noradrenergic and 
serotonergic networks. In my study, the descending serotonergic system will be 
investigated (Besson and Chaouch 1987; Millan 1999; Millan 2002).
i) Origins of descending controls
Reynolds, in 1969, achieved analgesia during abdominal surgery on rats, by 
electrically stimulating a region of the midbrain periacqueductal gray (Reynolds 
1969). This and many other studies have consequently showed that there are 
supraspinal sites that exert control of pain transmission at the spinal level via 
descending fibres. The interaction of these descending controls with spinal 
transmission can occur at many levels, including the central terminals of primary 
afferent fibres, intrinsic excitatory/inhibitory intemeurons and projection 
neurons. Furthermore, each of the many transmitters involved may exert different 
effects on pain transmission, according to the receptor subtype it acts on 
(Basbaum, Fields et al. 1984; Wei, Dubner et al. 1999; Millan 2002).
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Descending controls to the spinal cord dorsal hom arise from numerous 
brainstem nuclei, including the rostroventral medulla and the parabrachial 
nucleus. The most investigated of the descending pathways is the one from the 
PAG via the Rostroventral Medulla (RVM), the latter being where most of the 
dorsolateral funiculus (DLF) and ventrolateral funiculis (VLF) axons descend to 
the spinal cord from the brainstem. The spinal cord terminations of these 
projections occur at laminae I, II, and V, which contain neurons that respond to 
stimuli of a noxious intensity (Fields and Heinricher 1985; Besson and Chaouch 
1987; Fields, Heinricher et al. 1991; Heinricher 1997; Millan 2002).
ii) The PAG
The PAG has many neurons using numerous transmitters and receives and 
projects to several areas. Rostrally, the PAG projections include the 
diencephalons, hypothalamus and limbic forebrain, whereas caudally, the PAG 
projects to many nuclei in the parabrachial area (including the locus coeruleus), 
the RVM (including the Nucleus Raphe Magnus- NRM), with very few direct 
spinal projections (Fields and Heinricher 1985; Besson and Chaouch 1987; 
Heinricher 1997; Willis and Westlund 1997). Opioid peptides and receptors are 
prominent in the PAG, and a microinjection of morphine or other opioid peptides 
in this area causes analgesia which can be reversed by naloxone. Opioids are 
thought to activate descending inhibitory neurons from the PAG to the spinal 
cord via the RVM by inhibiting GABA intemeurons, which otherwise inhibit this 
output neuron to the RVM (disinhibition) (Heinricher 1997).
iii) The RVM
The ventral aspect of the rostral medulla (RVM), as mentioned above, is a very 
important connection between the PAG and the spinal cord dorsal hom. The 
RVM contains the nucleus raphe magnus (NRM), as well as the nearby reticular 
formation, which includes the nucleus reticularis magnocellularis (NRMC). 
Within the RVM, the areas where the descending cells originate include the 
NRM, the nucleus reticularis gigantocellularis pars a  (Rgca) and the nucleus
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reticularis paragigantocellularis lateralis (Rpgl) (Basbaum and Fields 1984; 
Besson and Chaouch 1987; Heinricher 1997; Willis and Westlund 1997; Suzuki, 
Rygh et al. 2004).
Inactivation of the RVM (using electrolytic lesions or a local anaesthetic) 
decreases PAG-induced analgesia. However, the fact that the activation of the 
RVM (electrically or with glutamate/morphine microinjections) causes analgesia, 
as well as the fact that there are reciprocal connections back to the PAG, as well 
as other supraspinal sites from the RVM, show that this area is not just a relay for 
PAG-induced analgesia. Indeed, the RVM is not just involved in controlling 
sensory information, but also plays a role in homeostatic functions. Furthermore, 
even though there are intrinsic spinal cord neurons that contain 5-HT, the RVM 
is an important source of this transmitter in the spinal cord (Basbaum, Fields et 
al. 1984; Fields and Heinricher 1985; Besson and Chaouch 1987; Heinricher 
1997; Willis and Westlund 1997; Suzuki, Rygh et al. 2004).
iv) ON, OFF and neutral cells
Three different classes of cells have been shown to exist in the RVM: ON cells, 
OFF cells and neutral cells. They have been classified according to the abrupt 
change in firing that they show, just before a lightly anaesthetised rat flicks its 
tail in the tail flick test. ON cells suddenly increase their firing before the tail 
flick occurs, OFF cells suddenly stop firing before the tail flick occurs and 
neutral cells show no change in their activity with relation to the tail flick (Fields, 
Heinricher et al. 1991; Heinricher 1997). Morphine administration in the RVM 
has been shown to suppress ON cell firing, activate OFF cell firing and have no 
effect on neutral cell firing. Opioid receptors are expressed on ON cells and 
therefore, morphine administration into the RVM directly inhibits these cells. 
These ON cells are also inhibited when morphine is administered into the PAG, 
causing disinhibition of inhibitory PAG-RVM outputs, as mentioned above. OFF 
cells on the other hand are activated by opioid-mediated disinhibition, and by 
output from the PAG. Therefore, ON cells are thought to play a facilitatory role 
in pain transmission, OFF cells are thought to play an inhibitory role, whereas
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neutral cells do not seem to play a role in pain transmission (Fields, Heinricher et 
al. 1991; Heinricher 1997; Porreca, Burgess et al. 2001; Dickenson and KiefFer 
2006).
v) Descending inhibitions or descending facilitations?
Whereas it was previously shown that electrical and glutamate microinjections in 
the RVM inhibited spinal nociception (Reynolds 1969; Besson and Chaouch 
1987), it was later discovered that RVM stimulation both inhibits and facilitates 
spinal cord nociception. Therefore, low intensity electrical and low concentration 
of chemical stimulation in the RVM is thought to mostly facilitate spinal cord 
transmission (both noxious and non-noxious), via descending projections in the 
ventrolateral funiculi and spinal serotonin (5-HT) and cholecystokinin receptors, 
whereas high intensity/concentration of electrical/chemical stimulation in the 
RVM is thought to mostly inhibit spinal cord transmission, via dorsolateral 
funiculi projections and spinal monoaminergic receptors (Besson and Chaouch 
1987; Urban and Gebhart 1999; Zhuo and Gebhart 2002).
Furthermore, studies using spinalisation, lesions and local anaesthetic injections 
in the RVM have shown that descending facilitations from the RVM may play an 
important role in secondary hyperalgesia, and thus central sensitisation arising 
from different pain states of chemical, inflammatory and neuropathic origin 
(Urban, Jiang et al. 1996; Mansikka and Pertovaara 1997; Urban and Gebhart 
1999; Urban, Zahn et al. 1999). Therefore, it is now known that both inhibitory 
and facilitatory descending controls arise from the RVM at any one time, that 
these descending controls are enhanced following persistent pain states, the 
extent of which depends on the pathophysiological state of the animal and the 
stimulus modality being tested (Kauppila, Kontinen et al. 1998; Wei, Dubner et 
al. 1999; Zhuo and Gebhart 2002).
vi) Descending controls in neuropathic pain
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Central sensitisation does not just rely on events which occur in the spinal cord, 
but also relies on descending controls from supraspinal sites onto the spinal cord. 
Following peripheral nerve injury, spinal sensitisation is initiated by afferent 
input and maintained by afferent input (to a certain extent) and descending 
facilitations (Vera-Portocarrero, Zhang et al. 2006). Descending facilitations 
from the RVM are activated and enhanced 6 days following peripheral nerve 
injury (Kauppila, Kontinen et al. 1998; Burgess, Gardell et al. 2002), and serve to 
heighten the excitability of the spinal cord and thus also aid in non-noxious 
stimuli being perceived as noxious. Therefore, the role of these descending 
facilitations seems to be the maintenance of neuropathic pain, and not the 
initiation, which also means that the mechanisms underlying the initiation of 
nerve injury are different from those needed to maintain it (Ossipov, Lai et al. 
2001; Burgess, Gardell et al. 2002).
vii) Thermal versus mechanical hypersensitivity in neuropathic pain- from 
the periphery to supraspinal sites
As discussed previously, thermal hyperalgesia and allodynia to mechanical 
stimuli are mechanistically distinct, following neuropathic pain. Whereas thermal 
hyperalgesia is thought to be conducted mostly via C-fibres and to be mostly 
spinally mediated, mechanical allodynia has different subtypes, is thought to be 
conducted via myelinated primary afferents, and is thought to be mediated 
supraspinally (Kauppila 1997; Kauppila, Kontinen et al. 1998; Ossipov, Lai et al. 
2000; Chen, King et al. 2004).
a) Thermal hyperalgesia
Thermal hyperalgesia is thought to be conducted mostly via C-fibres, since it is 
blocked by capsaicin and resiniferatoxin administration, each of which is known 
to desensitise C-fibres. Furthermore, this symptom of neuropathic pain is 
responsive to morphine administration, and it is also known that p-opioid 
receptors are located on C-fibres. Finally, thermal hyperalgesia is also thought to 
be mostly spinally mediated, since it was reduced by both local Na channels
74
blockers which do not penetrate the CNS, and amplified by increased spinal 
dynorphin levels. However, intra-RVM Na channel blockers and spinal 
transection also decreased thermal hypersensitivity following neuropathic pain, 
therefore descending facilitations are also partly involved in the maintenance of 
thermal hypersensitivity (Bian, Ossipov et al. 1998; Field, Bramwell et al. 1999; 
Ossipov, Lai et al. 2000; Chen, King et al. 2004).
b) Mechanical allodynia
It has long been known that brush-evoked pain is distinct from pain due to 
punctuate stimuli (Price, Bennett et al. 1989; Koltzenburg and Handwerker 
1994). To explain how touch-conducting Ap-fibres could signal pain, it was 
initially suggested that a structural reorganisation in the spinal cord dorsal horn 
had occurred, where AP-fibres started sprouting into lamina II, which is where 
most pain-signalling fibres terminate (Woolf, Shortland et al. 1992). However, it 
was later shown that the tracer used ‘CB-HRP’ (B unit of cholera toxin- 
horseradish perodixase), which normally only labels the central terminals of 
myelinated afferents, was also taken up by small DRG ganglions following 
peripheral axotomy. Therefore, central sensitisation, due to the initial afferent 
barrage, and maintained by the enhanced descending facilitations, is now thought 
to be the reason behind large-diameter Ap-fibres conveying painful sensation 
instead of innocuous touch (Campbell, Raja et al. 1988; Koltzenburg and 
Handwerker 1994; Suzuki and Dickenson 2000).
The increase in descending facilitations, and thus spinal sensitisation, following 
peripheral nerve injury is part of the mechanism underlying tactile and cold 
evoked responses more than it is for thermal hyperalgesia (Pertovaara, Wei et al. 
1996; Kauppila 1997; Kauppila, Kontinen et al. 1998). This was shown when 
lidocaine, administered intra-RVM was capable of reversing both tactile 
allodynia and thermal hypersensitivity, whereas lidocaine in the periphery, which 
does not have central effects, was only capable of reducing thermal 
hypersensitivity (Chen, King et al. 2004). Furthermore, in the SNL model,
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lidocaine in each of the RVM and PAG caused an antiallodynic effect, which 
was not opioid-mediated since it was not reversed by naloxone (Pertovaara, Wei 
et al. 1996). Additionally, spinalisation completely abolished tactile allodynia in 
SNL rats (Bian, Ossipov et al. 1998).
1.9 Serotonin
Whereas SP and glutamate play an exclusively excitatory role in the spinal cord 
dorsal horn, serotonin (5-HT), due to its complex action on many serotonergic 
receptors, has been shown to play a dual, pronociceptive (Jordan, Kenshalo et al. 
1978; Ali, Wu et al. 1996; Oyama, Ueda et al. 1996; Calejesan, Ch'ang et al.
1998; Green, Scarth et al. 2000; Zeitz, Guy et al. 2002; Suzuki, Rahman et al.
2004) and antinociceptive role (Jordan, Kenshalo et al. 1978; Yaksh and Wilson 
1979; Alhaider, Lei et al. 1991; Crisp, Stafinsky et al. 1991; Oyama, Ueda et al. 
1996; Jones, Peters et al. 2005).
Most of the serotonin in the spinal cord comes from descending controls, which, 
like serotonin, have been previously shown to play an inhibitory, rather than a 
facilitatory role in pain transmission (Reynolds 1969; Fasmer, Berge et al. 1983; 
Maxwell, Leranth et al. 1983; Besson and Chaouch 1987; Zhuo and Gebhart
2002). However, newer studies have shown that the dual action of serotonin is 
probably due to the type of serotonergic receptor being activated (with the 5HT3 
receptor being responsible for the excitatory effects), the dose of the agonist used 
(most studies showing the inhibitory actions of serotonin used high doses of 
agonists), the stimulus modality used and the pathophysiological state of the 
animal (Fasmer, Berge et al. 1985; Bardin, Bardin et al. 1997; Suzuki, Rahman et 
al. 2004; Conte, Legg et al. 2005; Donovan-Rodriguez, Urch et al. 2006).
1.9.1 5-HT receptor subtypes
To date, seven families of serotonergic receptors have been indentified (5HT1- 
5HT7), each with many subgroups, all of which belong to the G-protein family 
of receptors, except the one investigated in this study, the 5HT3 receptor. The
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5HT3 receptor is a ligand-gated ion channel receptor which, when activated, is 
permeable mostly to monovalent cations, and to Ca2+. Two receptor subunits 
have been identified so far, the 5HT3A and the 5HT3B. It has been shown that 
functional receptors are either made from 5HT3 A homopentamers, and 5HT3 A 
and 5HT3B heteromers. The homomeric receptors are thought to be 
preferentially located in the central nervous system, whereas the heteromeric 
receptors are thought to be found in the periphery (Maricq, Peterson et al. 1991; 
Dubin, Huvar et al. 1999; Morales and Wang 2002; Conte, Legg et al. 2005).
1.9.2 5HT3 receptor location
5HT3A immunoreactivity was most densely found in the superficial dorsal horn, 
most of which is thought to be due to 5HT3 receptors on the terminals of primary 
afferent fibres. Rhizotomy did not abolish binding sites and immunoreactivity for 
5HT3 receptors, which means that some of the receptors are found on intrinsic 
dorsal horn neurons. Furthermore, 5HT3 receptors are thought to be 
predominantly (80%) located on a subset of primary afferent fibres which are 
myelinated (as shown by N52 immunoreactivity- a marker for neurofilaments 
linked with myelinated primary afferents), and thus of the A5-fibre variety, since 
these fibres terminate in the superficial layers of the dorsal horn. Less (13%) 
5HT3A immunoreactivity was found in capsaicin-sensitive neurons, and even 
less of these receptors were found to be located in peptidergic and IB4-positive 
primary afferent fibres (Maxwell, Leranth et al. 1983; Kidd, Laporte et al. 1993; 
Tecott, Maricq et al. 1993; Kia, Miquel et al. 1995; Zeitz, Guy et al. 2002; 
Maxwell, Kerr et al. 2003; Conte, Legg et al. 2005).
1.9.3 5HT3 receptor- nociceptive or antinociceptive?
Initially, the studies which attributed an antinociceptive role to the 5HT3 receptor 
claimed that this was done via this receptor’s activation of inhibitory GABA- 
ergic (Alhaider, Lei et al. 1991; Peng, Lin et al. 1996) and enkephalinergic 
intemeurons (Tsuchiya, Yamazaki et al. 1999). However, even though 5-HT was 
found to be co-localised with glutamate decarboxylase (GAD), the enzyme
77
which synthesises GABA, 5HT3A immunoreactivity was not found to be co­
localised with this enzyme, which means that this receptor is not located on 
inhibitory cells (Maxwell, Maxwell et al. 1996; Zeitz, Guy et al. 2002; Conte, 
Legg et al. 2005).
Furthermore, even though 5-HT caused the depression of most spinothalamic 
tract neurons in a study using primates, some of these STT neurons were also 
excited by 5-HT (Jordan, Kenshalo et al. 1978). Indeed, the intrathecal injection 
of 5-HT in mice has been shown to cause biting, scratching and licking 
behaviour reminiscent of that of intrathecal SP, which was reduced by the same 
compound which reduced the behaviour arising from SP. SP and 5-HT have thus 
been shown to have an interaction at the spinal level, further proved by the 
finding that a subpopulation of NK-1 receptors in laminae III-IV receive 
numerous contacts from 5-HT axons (Fasmer, Berge et al. 1983; Fasmer and Post 
1983; Eide and Hole 1989; Stewart and Maxwell 2000).
Moreover, the blockade of the 5HT3 receptor by its antagonist ondansetron has 
been shown to inhibit both phases of the formalin response (Green, Scarth et al.
2000). It has also been recently shown that the blockade of the 5HT3 receptor 
with ondansetron reduces tactile allodynia following spinal cord injury (Oatway, 
Chen et al. 2004), and natural-evoked responses of dorsal horn neurons, which 
arise from cancer-induced bone pain (Donovan-Rodriguez, Urch et al. 2006) and 
nerve injury (Suzuki, Rahman et al. 2004), and may cause analgesia in humans 
with chronic neuropathic pain (McCleane, Suzuki et al. 2003).
However, serotonin does not facilitate acute or carrageenan-induced pain (Green, 
Scarth et al. 2000; Rahman, Suzuki et al. 2004), and thus the conclusion is that 
descending serotonergic facilitations, and their actions on the excitatory 5HT3 
receptor, are enhanced following chronic pain states. Furthermore, even though 
the RVM is thought to be the primary source of descending serotonergic control, 
and some RVM neurons that respond to noxious stimuli have been labelled as 
serotonergic, neither ON nor OFF cells seem to contain 5-HT (Gao and Mason 
2000).
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Nearly 80% of the spinothalamic and spinoparabrachial projection neurons from 
lamina I express the NK-1 receptor. Additionally, it has been shown that the 
parabrachial area connects with both the amygdala and hypothalamus, among 
other areas in the brainstem, which in turn may modulate descending 
monoaminergic controls onto the spinal cord. The axons of descending 
serotonergic neurons have been shown to terminate in lamina I, as well as have 
an association with projection neurons in this lamina (Todd, McGill et al. 2000; 
Todd 2002; Todd, Puskar et al. 2002). The ablation of lamina I projection 
neurons which express the NK-1 receptor, using the intrathecal administration of 
SP-saporin (Mantyh, Rogers et al. 1997), has led to a decrease in receptive field 
size of neurons, an altered coding of mechanical and thermal stimuli and 
decreased wind-up of deep dorsal hom neurons (thus decreased central 
sensitisation) (Suzuki, Morcuende et al. 2002). Most of the aforementioned 
effects were also achieved when ondansetron was intrathecally administered to 
block descending serotonergic facilitations (Suzuki, Rahman et al. 2004). 
Therefore, the NK-1-positive projection neurons are thought to be the origin of 
the spino-bulbo-spinal loop which affects pain transmission at the spinal cord 
level, via the activation of descending serotonergic facilitations (Conte, Legg et 
al. 2005; Suzuki, Rahman et al. 2005).
1.9.4 The 5HT3 receptor in neuropathic pain
The enhanced descending facilitations following neuropathic pain belong to the 
spinal-bulbo-spinal loop which has NK-1 expressing projection neurons at its 
origin, and descending serotonergic facilitations at its ‘end’. The ablation of 
these neurons with the use of SP conjugated to ‘saporin’ result in a decrease in 
both hypersensitivity responses and excitability of deep dorsal hom neurons. 
These effects, as mentioned above, also occur when the 5HT3 receptor is blocked 
with spinal ondansetron (Suzuki, Rahman et al. 2004; Suzuki, Rahman et al. 
2005; Rahman, Suzuki et al. 2006).
The 5HT3 receptor antagonist ondansetron has been clinically used for many 
years as an anti-emetic drug. However, this dmg has been shown to be able to
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decrease mechanical-evoked response in deep dorsal hom neurons, which occurs 
following experimental peripheral nerve injury, to a greater extent in nerve 
injured than normal animals (Suzuki, Rahman et al. 2004). Furthermore, in a 
model of spinal cord injury, ondansetron also reduced mechanical allodynia 
which occurred in this model (Oatway, Chen et al. 2004). Finally, in a clinical 
study, ondansetron has been shown to be effective in patients with neuropathic 
pain, two hours following a single intravenous administration (McCleane, Suzuki 
et al. 2003).
In my study, the 5HT3 antagonist ondansetron will be intrathecally administered 
in rats with a model of neuropathic pain, to see whether this antagonist can 
reduce some of the hypersensitivities seen in neuropathic animals, and thus 
further investigate whether the descending serotonergic facilitations are enhanced 
following peripheral nerve injury, as has been previously shown (Suzuki,
Rahman et al. 2004). In addition, ondansetron, in combination with morphine, 
will be used to compare the efficacy of the former on its own, and to investigate 
whether its effects increase when combined with morphine, to inhibit the 
thermal, tactile and cold hypersensitivity seen in neuropathic rats.
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Figure 1.4- A summary o f the spino-bulbo-spinal loop theory. Noxious input from the periphery 
arrives via nociceptive primary afferent fibres, such as C-fibres, which release substance P (SP) 
and glutamate (Glu) and impinge upon superficial (laminae I-II) spinal cord dorsal hom neurons, 
which express the neurokinin 1 (NK-1) receptor and the n-methyl-D-aspartic acid (NMDA) 
receptor. NK-1 expressing lamina I projection neurons also project supraspinally via the 
parabrachial area to the amygdala and hypothalamus, which in tun project to the periacqueductal 
gray area (PAG). The PAG has neurons projecting to the rostral ventral medulla (RVM), which 
has descending fibres projecting back to the spinal cord. Following nerve injury, descending 
facilitations from the RVM are enhanced and facilitate pain transmission in the spinal cord by 
acting on the serotonergic ion channel receptor 5HT3, which is expressed on a subset o f primary 
afferent fibres. Adapted with permission from Dr. R. Suzuki.
1.10 Aim
The general aim of my study is to investigate the interaction between the 
excitatory systems in the spinal cord with the inhibitory actions of morphine, in 
rats. In order to achieve this, I have used two pain models which reflect central 
sensitisation: an acute, chemical model of nociception, whereby each of the 
spinal NK-1 and NMDA receptors is activated using Sar-SP and NMDA,
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respectively; and a chronic, surgical model of nerve injury, whereby the L5 and 
L6 spinal nerves branching off the sciatic nerve will be ligated.
By directly comparing the effects of the activation of each of the NK-1 and 
NMDA receptors, I was aiming to shed more light on the role of each of these 
receptors in central sensitisation. Following that, my aim was to directly compare 
the efficacy of systemic morphine to modulate the effects which occur following 
the activation of each of these receptors, and extend these comparisons as to 
which mechanisms underlying the abnormal hypersensitivity which occur 
following nerve injury are more sensitive to morphine control, since both the 
spinal NK-1 and the NMDA receptors have been shown to play a role in the 
abnormal hypersensitivity seen following nerve injury.
Furthermore, I will investigate whether peripheral NMDA receptors are involved 
in the abnormal pain behaviour seen in this model of nerve injury, using the 
intraplantar administration of MK-801, the NMDA receptor antagonist, since it 
would be clinically beneficial for topical NMDA antagonists to be used in 
treating pain following nerve injury, devoid of central side effects. And finally, I 
will further investigate whether descending serotonergic facilitations are 
enhanced following the SNL model, by using the 5HT3 antagonist ondansetron 
via the intrathecal route, and also study whether the effectiveness of either 
ondansetron or systemic morphine is increased when these two drugs are used in 
combination, and thus their interaction in the central processing of chronic pain 
transmission.
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Chapter 2 
Methods
• 
•
2. Methods
2.1 Animals
The animals used were male, adult (190-250g) Sprague-Dawley rats, obtained 
from University College London. All rats were housed in a 12 hour light/dark 
cycle with free access to food and water. All experimental procedures were 
approved by the UK Home Office and follow the guidelines of the International 
Association for the Study of Pain (Zimmermann, 1983).
2.2 In vivo electrophysiology
Electrophysiological studies were conducted in the same way as previously 
described (Urch et al., 2003a). Anaesthesia was induced with 3.5% Halothane 
(Concord Pharmaceuticals Ltd) in N2O (300cm /min) and O2 (150cm /min) in 
the anaesthesia box. As soon as the rat lost its righting reflex, it was placed on a 
heating blanket (regulated to stay at 37°C with a rectal probe- Harvard 
Homeothermic Blanket Control Unit), the anaesthetic was reduced to 2.8% and 
was given through a nose cone. Before proceeding, deep anesthesia was checked 
for by pinching the hindpaw, to test for complete areflexia (loss of reflexes). A 
tracheotomy was made, and the shaped end of a polyethylene tube (80-100mm) 
was inserted into the trachea. At this point, the cone was removed and the 
anaesthetic was delivered straight into the cannula, with the dose lowered to 
1.5%.
The rat was then secured into the ear bars of the stereotaxic frame, after which 
the anesthetic delivery and rectal probe/temperature were checked. A 
laminectomy was made in a small area above and below the base of the ribs, to 
expose the spinal cord at L1-L3 vertebral level. A parylene-coated tungsten 
electrode (A-M Systems, USA) was inserted, medial to the central vessel, into 
the cord. This was used to extracellularly record dorsal hom neurons receiving 
afferent input from the glabrous tissue of the hindpaw. Gentle tapping and
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noxious pinch were used as search stimulus to find the neuron, the depth of 
which was made and identified by the number of revolutions done by the fine 
control manipulator on the headset (Narishige, Japan).
The responses of each of input, Ap fibres, A8 fibres, post-discharge, wind-up 
(after electrical stimuli), brush, von Frey filaments (Scientific Marketing 
Associates, UK) 1, 5, 9, 15, 30, 75g and heat 35, 40 45 48 and 50°C were 
investigated in this experiment. The system used to amplify, filter, discriminate 
the cells and apply isolated electrical stimuli was Neurolog (Digitimer, UK) and 
Tektronix TDS 1002 two digital storage oscilloscope was used to visualise 
neurons. This system was coupled to a Dell computer with Spike 2 software 
through a CED interface (Cambridge Electronic Design, Cambridge, UK).
First, the signal from the recording electrode is transferred to the Neurolog data 
capture system, which amplifies, filters and feeds the neuronal signal to the audio 
speakers and the oscilloscope. This is followed by the action potentials being 
discriminated and in turn fed to the computer system through the CED 1401 
interface. The action potentials evoked were recorded on the latch counter and 
visualised and counted on the oscilloscope, with the post-stimulus time 
histogram (PSTH) shown on the computer display.
Transcutaneous electrical stimuli were given via needles inserted in the area most 
responsive in the receptive field (the area on the hindpaw which responds to 
electrical and natural stimuli) of the cell. These needles are connected to a 
Neurolog stimulus isolator which is linked to the Neurolog system. This system 
pre-sets the frequency of stimulation at 0.5Hz, duration for 2 milliseconds and 
amplitude of the current at 3x the C-fibre threshold, as well as the number of 
pulses (16) via a period generator, digital width, pulse buffer and counter. 
Therefore, a train of 16 stimuli was given at 3x the C-fibre threshold current, 
which was taken as the lowest amplitude required to evoke a C-fibre response. 
The natural stimuli was applied on the same area for 10 seconds, with care taken 
not to touch the needles, as this would lead to the cell being stimulated further.
85
Heat responses were done with a constant water jet over the same area, at the 
specific temperature needed, for the same time.
Input is a measure of neuronal activity after the first electrical stimulus, before 
any hyperexcitability has taken place. A(3, A8 and C-fibre evoked responses 
(after the train of 16 electrical stimuli) were separated according to latency, and 
these were 0-20, 20-90 and 90-300ms respectively. Any response after the C- 
fibre band (300-800ms) was considered as the cell’s post-discharge, due to its 
hyperexcitability. Wind-up is calculated by subtracting (16 x input) from the total 
number of evoked action potentials.
For the characterisation experiments, each neuron isolated was tested electrically 
and naturally as above, but without drug addition. One extra temperature was 
performed, and this was 42 °C.
2.3 Acute chemical model of nociception
2.3.1 Lumbar catheterisation
Rats weighing 190-205g were housed separately in cages before and after the 
surgical procedure, to avoid damage to the catheters. The lumbar catheterisation 
was undertaken using a modified method by Storkson et al (Storkson et a l ,
1996).
Before the surgery, the catheters were prepared. Each catheter was made by 
cutting PE-10 tubing (outer diameter 0.6mm, Portex) into 28cm, and stretching 
10cm at one end of the tube in 60°C water and then dipping it in room 
temperature water to retain the stretch. The stretched end was then threaded 
through a sterile, 4cm length, 19-gauge needle, which served as a guide cannula 
during surgery. The catheter was then shortened to 28cm again, and flushed 
through with saline. Furthermore, two marks were made on the catheter, one was 
3 cm from the stretched tip and was covered under the guide cannula, whereas the 
second was made 3cm from the hub of the needle, and was visible at all time.
86
Each rat was induced with 5% halothane and 2% oxygen. The latter was 
maintained throughout surgery. When the rat lost its righting reflex, it was put on 
a nose cone at 3% halothane, and its back was shaved. Once the rat had lost its 
flexor reflex, anaesthesia was lowered to 1.5%, and an incision was made with a 
scalpel blade in the midline which extended from its caudal ribs to below its hip 
bones. The guide cannula was inserted between the two vertebrae which lie on 
the same horizontal level as the ventral iliac spine, at a 45° angle. After that, the 
catheter was pushed through rostrally until the visible mark reached the hub of 
the needle, which was 3cm into the spinal subarachnoid space and ended by the 
caudal ribs, or L1-L3 vertebrae. This area corresponds to the L4-L6 lumbar 
spinal segment area, which also corresponds to where the input from the 
hindpaws comes in.
The insertion was sometimes met with a bit of resistance and so to make it easier 
at times, the spinal cord was raised manually and made kyphotic. The right 
position of insertion was confirmed by three things: the first was a flick of the 
tail or twitch of the hindpaws, the second was the easy insertion of the catheter 
after the initial resistance was overcome, and the third was the spinal fluid 
backflowing through the catheter. After that, the guide cannula was removed 
carefully, and the catheter was fixed with cyanoacrylate gel (RS) at the puncture 
site. A hole was made using another needle, 3cm from the occipital region, and 
the free end of the catheter was tunnelled under the skin and out using this hole. 
The catheter was fixed at 2 other places on the inside of the skin, as well as on 
the hole it was coming out of the skin from, and it was cut down to 20cm and 
cauterised. The wound was sealed using wound clips, and the rat was left to 
recover in a heated chamber at 32°C.
After the surgery, rats were checked for motor dysfunction. If the rats showed 
any sign of motor deficit, they were not used in this study and were humanely 
culled. The location of the catheters was verified at the end of every experiment 
by three ways: the first was hindpaw paralysis after the intrathecal administration 
of Lidocaine (Dobos et al., 2003). The second was by the intrathecal injection of
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Pontamine Blue dye (Raymond A. Lamb), after humanely culling the rat, and 
finding the dye localised on the dorsal area by the caudal ribs following 
dissection. Finally, the third method was by dissecting the rat and finding the 
catheter in the middle of the spinal cord, at the dorsal area, by the caudal ribs. 
Any animal whose catheter was not found in the aforementioned location had its 
results discarded.
2.3.2 Biting, scratching and licking behaviour (BSL)
The biting, scratching and licking and grooming behaviour which followed every 
intrathecal administration of each of NMDA and Sar-SP was observed and timed 
using a stopwatch.
2.3.3 Thermal hypersensitivity
Thermal hypersensitivity was assessed using the Hargreaves test (Hargreaves et 
al, 1988). Each rat was placed in a clear plastic chamber with a glass bottom, 
which was covered with a grill on top, and allowed to acclimatise for at least 15 
minutes. Testing only began when the rats had stopped their exploratory 
behaviour and their grooming. A radiant heat source was placed under the glass 
floor, exactly in the middle of the plantar side of the hindpaw. The intensity of 
the light beam was set so that the baselines of the rats fell between 10-15 
seconds, and cut-off was set at 30 seconds to prevent tissue injury (Davis et a l , 
2001; Davis et a l , 1999).
The radiant heat source was made up of a high intensity projector lamp bulb 
which projected through the aperture in the top of a movable case. Any 
movement of the rat which involved its hindpaw was detected by a photoelectric 
cell which was aimed at the aperture and which turned off both the lamp and the 
electric clock. Finally, withdrawal latency to the nearest 0.1 second was 
determined using the electronic clock circuit and microcomputer (Ugo Basile, 
Italy). Unless the animal was already moving and exploring, withdrawal of the 
hindpaw and/or licking were considered as positive responses. Furthermore, if 
the animal urinated or defecated in the cage, it was removed, the bottom of the 
cage was wiped and it was placed back inside it and given time to re-acclimatise
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before being tested. This re-acclimatisation did not take more than 1 minute once 
the animal had already acclimatised to the cage before.
Three baselines which lay between 10-15 seconds were taken each time, before 
any drug was added. The rats were tested every 5 minutes for the baselines and 
for the duration of the experiment (which was 60 minutes), after drug 
administration. However, in the experiments where two drugs were being 
administered, some timepoints were missed in order to prepare the second 
injection.
a)
Morphine NMDA
Inject Test Test Inject Test Test Test Test Test Test Test
I------- „ I -------._-I-------- „ I ------- . . .I — ---- 1— ------1- „ I --------- _I--------„ I ------- - I
-25 -20 -1 5 ----- >0 5 10 15 20 25 30 35min
b)
MK-801 NMDA
Inject Test Test Inject Test Test Test Test Test Test Test
I------- __I-------„_I------- „ I ------ „ I — ---- 1_ _ _ ----- 1_ _ . „ I -------- _I------- __I-------- I
-25 -20 -1 5 ----- >0 5 10 15 20 25 30 35min
c)
Morphine Sar-SP
Inject Test Inject Test Test Test Test Test Test Test Test Test
I------- . . .I ------ — I------- _I--------.1------ _I------- _I------- I - ----- 1---- — I---- - I - ---- - I
-10 -5 0 ----- > 10 15 20 25 30 35 40 45 50min
d)
RP-67,580 Sar-SP
Inject Test Inject Test Test Test Test Test Test Test Test Test
I------ „ I ------ — I------- -I-------- I------ _I------- .1-------- I „ ----- 1---- _„I---- — I.---- - I
-10 -5 0 -----> 10 15 20 25 30 35 40 45 50min
Figure 2.1. Timecourse o f  each set o f  thermal hypersensitivity experiments which involved two 
drugs: a) morphine+NMDA b) MK-801+NMDA c) morphine+ Sar-SP d) RP-67,580+Sar-SP
2.3.4 Paw withdrawal threshold assessment
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Tactile hypersensitivity was measured using the Chaplan method, which is based 
on the Dixon up-down method (Chaplan et al., 1994). Each rat was placed in a 
plastic cage with a wire mesh bottom (Ugo Basile, Italy), and they were left to 
acclimatise until all exploratory/grooming behaviour ceased. A series of eight 
von Frey filaments (North Coast Medical Inc, Morgan Hill, California) were 
used in this method, and these were 0.4, 0.6, 1, 2, 4, 6, 8 and 15g. The von Frey 
hair was placed perpendicular to the middle of the plantar surface of the rat 
hindpaw, and force was applied until the von Frey hair bent against the paw and 
was kept there for 6 seconds.
Testing began with von Frey hair 2g, consecutively, in an ascending manner, 
until a positive response was reached. A positive response was taken as licking, 
withdrawal of the paw or flinching. In the absence of a positive response, the 
next von Frey up was used, and when there was a positive response, the previous 
von Frey was used. Once the response threshold has been crossed, which is when 
the first positive response occurs, this is considered as the first response and is 
followed by a total of six responses (positive or negative). Positive responses 
were assigned the letter X and negative responses were assigned the letter O. 
When there were continuous positive responses starting from 2g down to 0.4g, 
the paw withdrawal threshold was taken to be 0.25g and when there were 
continuous negative responses from 2g up to 15g, the paw withdrawal threshold 
was taken to be 15g.
Paw withdrawal threshold in grams (g) was calculated using ‘FlashDixon’ 
software, a kind gift from Dr.Micheal Ossipov, from the University of Arizona. 
The XO pattern derived from each rat was typed into the formula, along with the 
number of the last von Frey hair used, and the paw withdrawal threshold was 
calculated. The calculation used in the software was based on Chaplan et al,
1994. The formula was:
50%g threshold= (10lxf+KS,)/l 0,000
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Xf here was the value (in log units) of the final von Frey hair used, K was the 
tabular value which was based on the response pattern and modified from Dixon, 
and 5 was the mean difference (in log units) between stimuli.
The rats were tested at three timepoints for each experiment.
a)
Morphine NMDA
Inject Test Inject Test Test
I---------1------ . „ I ------- ._I_---- — I
-25 -20 0 5 30min
b)
MK-801 NMDA
Inject Test Inject Test Test
I---------1------ .„ I ------- — I
-25 -20 0 5 30min
c)
Morphine Sar-SP
Inject Test Inject Test Test
I---------1------ __I------- —I
-10 -5 0 20 50min
d)
RP-67,580 Sar-SP
Inject Test Inject Test Test
I---------- 1-------_„I------- ._I_---- —I
-10 -5 0 20 50min
Figure 2.2. Timecourse o f  each set o f tactile hypersensitivity experiments which involved two 
drugs: a) morphine+NMDA b) MK-801+NMDA c) morphine+Sar-SP d) RP-67,580+Sar-SP
2.3.5 Assessment of ambulation
Rotarod (model 7750, Ugo Basile, Italy) experiments were undertaken when a 
specific drug was known to cause sedation, or known to cause motor effects. 
Rats were left in their cages to acclimatise to the room where the rotarod 
instrument is placed until all grooming and exploratory activity ceased. The
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rotarod used was set to accelerate from 0-20 revolutions per minute (rpm) over 
60 seconds, and the time taken for the rat to fall from the beam was timed using a 
stopwatch. Cut-off was taken as 180 seconds, and only the rats which stayed on 
the beam, for a minimum of 60 seconds in two previous training session were 
chosen for this experiment (Donovan-Rodriguez et a l, 2005).
2.4 Peripheral NMDA receptor study- Spinal Nerve Ligation model
In this part of the study, rats weighing 140-170g were used at the time of surgery. 
Anaesthesia was induced with 4% halothane in 66% nitrous oxide and 33% 
oxygen. When the rat lost its righting reflex, it was removed out of the induction 
box and its nose placed inside a nose cone, lying on its front, and the halothane 
was reduced to 3%. The back was shaved for 2cm above and below the hipbone, 
and once areflexia was achieved, a longitudinal incision was made to part the 
skin around the hipbone area. Anaesthesia was reduced to 1.5%, and the left 
paraspinal muscles were separated, with pointed tweezers, from the spinous 
processes at the L4-S2 level (Kim et a l, 1992).
Once the sacrum, a shiny, crescent-shaped bone, was identified, the L6 
transverse process was gently removed with a small rongeur. The L5 and L6 
spinal nerves were identified and ligated, using 6-0 silk thread, distal to the 
dorsal root ganglion and proximal to the sciatic nerve formation. Once 
haemostasis was achieved, the wound was sutured with 3-0 thread and the skin 
was closed with wound clips. For the sham operated animals, all the 
aforementioned steps were done, except the actual tying of the nerves (Kim et 
al, 1992).
Following the surgery, the rats were observed for normal weight gain and 
behaviour. The lesioned paw was mildly deformed, resembling a claw, and the 
rats exhibited some guarding behaviour at times, but that was acceptable as long 
as the rats were gaining weight, grooming and were normally active.
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Placed in the same mesh-bottom Plexiglas cages that were described above and 
following the same behavioural guidelines, rats were tested for tactile 
hypersensitivity using von Frey filaments 1, 5 and 9g. These filaments were 
placed 10 times for 2-3 seconds each time, at the ‘hotspots’ (areas on the plantar 
surface that are responsive to stimuli). A positive response was recorded when 
the rat either withdrew, licked or held its paw in the air following withdrawal for 
a few seconds (Kim et a l , 1992). The number of times, out of ten, that the rat 
withdrew its contralateral paw was subtracted from the number of times the rat 
withdrew its ipsilateral paw. This was called the ‘difference score’.
Rats were also tested for cold hypersensitivity, by placing a single drop of 
acetone on the plantar surface of their paws, five times. The ‘difference score’ 
was also calculated here (Chapman et a l , 1998).
If sham rats demonstrated tactile and cold hypersensitivity, they were not used in 
the study and were humanely culled.
2.5 Morphine and ondansetron in neuropathic pain study- Spinal nerve 
ligation and lumbar catheterisation
For this part of the study, the spinal nerve ligation was performed on rats 
weighing 190-205g, since the rats were also to undergo lumbar catheterisation at 
the same time of their spinal nerve ligation surgery. The lumbar catheterisation 
was performed before the spinal nerve ligation, and care was taken not to tug at 
the cannula when performing the spinal nerve ligation surgery.
If the rat was dragging its paw, the animal was not used and was humanely 
culled.
2.6 Drugs
2.6.1 In vivo electrophysiology drugs
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Morphine Sulphate (morphine, 0.1, 1 and lOpg, Thornton and Ross), naloxone 
(50pg, Sigma) [Sar9, Met (02)n]-Substance P (Sar-SP, 1 and lOpg, Tocris) and 
N-methyl-d-aspartic acid (NMDA, 5, 50 and 500ng, Sigma) were administered 
intrathecally in a 50pl volume with a Hamilton syringe.
For the set of pharmacological experiments using morphine alone, three 
consecutive controls, where the readings for all of the above were not more than 
10% different, were followed by each of three morphine doses. Each dose was 
left for 20 minutes, then followed for one hour, with testing being done every 20 
minutes. This was followed by a reversal with naloxone (same route and test 
time).
For the set of pharmacological experiments using the different doses of the NK-1 
agonist Sar-SP alone and the NMDA agonist NMDA alone, the three consecutive 
stable controls were followed by the intrathecal administration of each agonist. 
Each agonist was left for 10 minutes, then followed for one hour, with testing 
being done every 20 minutes.
For the set of pharmacological experiments using morphine and Sar-SP, the three 
consecutive stable controls were followed by the intrathecal administration of 
1 pg Sar-SP. This was left for 10 minutes before a set of electrical and natural 
stimuli was performed. This was followed by adding 1 pg morphine, which was 
left for 20 minutes, then tested 3 times every 20 minutes for one hour. Finally, 
50pg naloxone was added, left for 20 minutes and tested as mentioned above. All 
drugs were dissolved in saline.
2.6.2 Acute chemical model of nociception
Morphine (3mg/kg) and dizocilpine maleate (MK-801, 0.1 mg/kg, Tocris) were 
administered subcutaneously. NMDA (0.3pg), [Sar9, Met (0 2)n]-Substance P 
(Sar-SP, 3pg), a racemic form of 7,7-diphenyl-2-[l-imino-2(2-methoxyphenyl)- 
ethyl] perhydroisoindol-4-one (RP-67580, 3pg, Tocris), Dimethylsulphoxide
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(DMSO, 20% in saline, Sigma) and Lidocaine (200pg, Hameln Pharmaceuticals 
Ltd) were all administered intrathecally. All drugs were dissolved in 0.9% saline, 
except for RP-67,580, which was dissolved in DMSO, but diluted in saline after 
that, and Lidocaine which was ready for use from the ampoule. The drugs which 
were diluted in saline had saline administered via the same route as the drug as a 
vehicle control, whereas RP-67,580 had intrathecal 20% DMSO as a vehicle 
control. NMDA was neutralised to pH 7 with IN sodium hydroxide (NaOH, 
sigma). All intrathecal injections were flushed with 0.9% sterile saline (Braun), 
and the total volume in the catheter was 24pl for a 20cm catheter.
Each drug was initially tested alone to check the exact timepoint it reached its 
peak effect, and all drugs were compared to saline controls. When two drugs 
were tested together, they were administered so that they reached their peak 
action at the same time: Morphine and MK-801 reached their peak each at 30 
minutes post subcutaneous injection, NMDA reached its peak at 5 minutes post 
intrathecal administration, Sar-SP reached its peak at 20 minutes post intrathecal 
administration, and RP-67,580 reached its peak at 30 minutes after intrathecal 
administration. Furthermore, DMSO was tested in the thermal and mechanical 
experiments to check if it had any effects of its own.
In the NMDA part of the study, ‘NMDA treated rats’ refers to the group of rats 
which received NMDA intrathecally only, ‘morphine+NMDA treated rats’ refers 
to the group of rats which received morphine subcutaneously, followed by 
intrathecal NMDA and ‘MK-801+NMDA treated rats’ refers to the group of rats 
which received MK-801 subcutaneously, followed by intrathecal NMDA. In the 
NK-1 part of the study, ‘Sar-SP treated rats’ refers to the group of rats which 
only received intrathecal Sar-SP, ‘morphine+Sar-SP treated rats’ refers to the 
group of rats which received subcutaneous morphine followed by intrathecal Sar- 
SP and ‘RP-67,580+Sar-SP treated rats’ refers to the group of rats which 
received intrathecal RP-67,580 followed by intrathecal Sar-SP. In the parts of the 
study where two drugs have been administered to the rats, ‘timepoints’ will be 
used to refer to the minutes post NMDA administration in the NMDA study and
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post Sar-SP in the NK-1 study. When only one drug or saline alone has been 
administered, ‘timepoint’ will refer to the minutes post administration of the 
drug/saline.
2.6.3 Peripheral NMDA receptor study
NMDA (0.7, 3.7 and 7.3jag) and MK-801 (0.4pg) were administered intraplantar, 
in a volume of 50pl when each drug was administered alone. Testing for thermal 
hypersensitivity was done every 5 minutes, for one hour, with the three different 
doses of NMDA, and at 5, 30 and 60 minutes post-administration for each of 
NMDA and MK-801 during tactile hypersensitivity testing.
NMDA (7.3pg) and MK-801 (0.4pg) were also co-administered in a total 
volume of 50pl (25pi each), and testing was at 5, 30 and 60 minutes after 
administration, for tactile hypersensitivity testing.
Morphine (3mg/kg) was administered subcutaneously and tested at 5, 30 and 60 
minutes alone and when administered 25 minutes previous to NMDA 
intraplantar, for tactile hypersensitivity testing.
NMDA and saline were neutralised to pH 7 with IN sodium hydroxide. Saline 
vehicle controls were administered via the same route sis each drug tested.
2.6.4 Morphine and ondansetron in neuropathic pain
Morphine was administered via the same route and using the same dose as the 
previous experiment. Ondansetron (10 and 20pg, Zofran, Glaxo-Smithkline) was 
administered intrathecally in a 1 Oju.1 volume. Both drugs were also administered 
as a combination at the same time, but via the different routes, and saline was 
administered via the same routes as the drugs as a vehicle control.
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When testing for thermal hypersensitivity, testing was done at 5, 15, 30, 45 and 
60 minutes following the administration of each drug alone, as well as when both 
drugs were administered in combination.
When testing for tactile and cold hypersensitivity, testing was done at 15, 30, 45 
and 60 minutes following the administration of each drug alone and in 
combination.
In this part of the study, an Area Under the Curve (AUC) was constructed and 
calculated using the GraphPad Prism 4.02 software, to compare whether an 
overall, global effect had occurred with each drug/drug combination used.
2.7 Statistical analysis
All data was graphed and analysed using GraphPad Prism 4.02 and SPSS vl2. 
Unless otherwise stated, all data is presented as mean±SEM.
Continuous data was analysed using a student’s t-test, to compare two groups. 
One way ANOVA, followed by a Dunnett’s post-hoc test was used to compare 
more than two groups to a single control. One way ANOVA, followed by a 
Tukey post-hoc test was used to compare more than two groups of treatment over 
a time course in the behavioural experiments, or over numerous temperatures or 
von Frey strengths in the in vivo electrophysiology experiments. Non-continuous 
data was analysed using a Mann-Whitney test when comparing two groups.
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Chapter 3:
A study investigating the effects of morphine, [Sar9 
Met (02)n]-Substance P and NMDA on rat deep 
wide dynamic range dorsal horn neurons, using in 
vivo electrophysiology
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3. A study investigating the effects of morphine, [Sar9 Met (02)n]-Substance 
P and NMDA on rat deep wide dynamic range dorsal horn neurons, using in 
vivo electrophysiology
3.1 Introduction
The opioid system is one of the most important inhibitory ones in the central 
nervous system. Morphine, acting on the p-opioid receptor, exerts its inhibitory 
action along three important sites: the central terminals of the primary afferent 
fibres, the spinal cord dorsal horn and on supraspinal sites such as the PAG and 
the RVM (Dickenson, 1994) (see section 1.7.6.2).
At the spinal cord level, it has been shown that the number of presynaptic p- 
opioid receptors exceeds that of the postsynaptic ones (Besse et a l , 1992; Besse 
et a l , 1990; Lombard et al., 1989; Mansour et al., 1994). Additionally, these p- 
opioid receptors have been found to be located on mostly small- (C) and 
medium-diameter (A5) peptidergic primary afferent fibres (deGroot et a l, 1997; 
Zhang et a l, 1998). During in vivo electrophysiology, the electrical response 
evoked by large-diameter Ap-fibres, as well as brush, the natural response 
evoked conveyed by these fibres, remains unchanged following morphine 
administration. This has been concluded to be due to the lack of p-opioid 
receptors on Ap-fibres (deGroot et a l, 1997; Zhang et a l, 1998), which means 
that morphine has to act mostly on its postsynaptic receptors, which are less than 
the presynaptic ones, and therefore, larger doses of morphine may be needed to 
inhibit this response (Besse et a l, 1992; Besse et a l, 1990; Dickenson, 1997b; 
Lamotte et a l, 1976; Mansour et a l, 1994).
Therefore, morphine was postulated to be less effective in inhibiting responses 
once its action is mostly limited to its postsynaptic receptors (Dickenson, 1997b). 
This can be also seen with the decreased efficacy of low doses of morphine on 
the electrically evoked wind-up response of dorsal horn neurons (Chapman et a l, 
1992; Chapman et a l, 1994b; Dickenson et al., 1986). Wind-up, as mentioned
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previously, is dependent on the activation of the NMDA receptor, which is 
located mostly postsynaptic on the spinal cord dorsal horn neurons (Coggeshall 
et al., 1997a; Liu et al., 1994) and whose activation depends on non-NMDA 
depolarisations following the activation of both the AMP A and the NK-1 
receptors (Salt, 1986; Urban et al., 1984; Xu et a l, 1992). The NK-1 receptor is 
also located mostly on the postsynaptic dorsal horn neurons, although along with 
the NMDA receptor, both receptors have been shown by some studies to be 
located presynaptically as well (Coggeshall et al., 1997a; Liu et al., 1994; 
Malcangio et al., 1999; Todd, 2002).
The intrathecal administration of each of SP (or other NK-1 agonists) and 
NMDA has been shown to cause the excitation of the responses of dorsal horn 
neurons (Bentley et a l, 1995; Chapman et al., 1994a; Henry, 1976; Randic et a l, 
1977), as well as behaviour indicative of sensation, such as biting, scratching and 
licking (BSL) (Aanonsen et a l, 1987; Seybold et a l, 1982).
Therefore, the aim of this part of my study was to establish how effective 
intrathecal morphine administration would be on the dorsal horn neuronal 
responses elicited, once the balance of the spinal cord pharmacology was shifted 
towards postsynaptic excitation, using each of the potent and selective NK-1 and 
NMDA receptor agonists Sar-SP and NMDA, to activate their respective 
receptors, and thus once morphine has to act predominantly via its postsynaptic 
receptors.
3.2 Methods
In this part of my study, the animals and the method which will be used are the 
same as those described in sections 2.1 and 2.2.
Briefly, a tracheotomy was performed on an anaesthetised male, Sprague- 
Dawley rat, weighing between 200-250g, and this was followed by a 
laminectomy which exposed the L1-L3 vertebral levels. A tungsten electrode
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was then used to record extracellularly from deep wide dynamic range dorsal 
horn neurons (Urch et al., 2003a).
After three consecutive stable controls, where the evoked responses to electrical 
and natural stimuli were not different by more than 10%, each drug was applied 
intrathecally in a volume of 50pl, as the protocol described in section 2.6.1. The 
three doses of morphine, 0.1, 1 and lOpg, and the three doses of NMDA, 5, 50 
and 500ng, were administered cumulatively, on the same day and animal. 
However, the two doses of Sar-SP, 1 and lOpg, were administered separately, on 
different experimental days.
In the part of my study investigating morphine on its own, morphine was left for 
twenty minutes following its administration, after which, the testing began every 
twenty minutes for one hour. This protocol was used since it has been shown in 
previous studies that peak morphine action occurred between 20 to 40 minutes 
after administration (Suzuki et al., 1999).
In the part of my study investigating Sar-SP and NMDA each on its own, each 
agent was left for 10 minutes before testing began, after which testing was done 
every 20 minutes for one hour. This dosing protocol was loosely based on the 
study by Chapman et al, however, whereas their study tested only electrical 
parameters every 10 minutes, I had to extend the testing to every 20 minutes, 
since I was testing both electrical and natural evoked responses (Chapman et al., 
1994a).
In the part of my study investigating the effects of morphine (1 pg) on the 
responses of deep WDR neurons following the activation of the NK-1 receptor, 
Sar-SP (lpg) was left for 10 minutes, following which, the aforementioned 
electrical and natural evoked parameters were tested, before the addition of 
morphine. Morphine (lpg) was left on the spinal cord for 20 minutes, and then 
the electrical and natural evoked responses were tested every 20 minutes for one 
hour. Since the largest changes from baseline following each of Sar-SP and
101
morphine administration occurred between 20 and 40 minutes (Rygh et a l , 
2006), I felt the two timepoints of administering Sar-SP and morphine were 
justified.
3.3 Results
3.3.1 Characterisations of deep, wide dynamic range and nociceptive- 
specific neurons
A total of 75 cells were used to characterise deep wide dynamic range (WDR) 
dorsal horn neurons. The way these 75 cells coded to the mechanical von Frey 
and thermal heat stimuli categorises them as wide dynamic range cells (figs. 3.1 
and 3.2) (Menetrey et a l, 1977; Urch et al., 2003b). All cells used in my study 
were deep, wide dynamic range (WDR) dorsal horn neurons.
mean±SEM
cell depth (pm) 830±29
AP-fibre threshold (mA) 0.8±0.02
C-fibre threshold (mA) 2±0.1
input evoked response 26±2
AP-fibre evoked response 90±5
A5-fibre evoked response 80±5
C-fibre evoked response 309±18
post-discharge response 168±21
wind-up evoked response 143±29
brush evoked response 234±26
Table 3.1. Electrophysiological characteristics o f  the electrical and brush evoked responses in rat 
deep wide dynamic range dorsal horn neurons. Response= number o f  action potentials evoked, 
n=75.
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Fig. 3 .1 - Heat evoked responses o f  wide dynamic range neurons in the deep dorsal horn (n=75).
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Fig. 3.2- von Frey evoked responses o f  wide dynamic range neurons in the deep dorsal horn 
(n=75).
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Trace 1- A post-stimulus time histogram (PSTH) showing the evoked A(3- (0-20msec), A8- (20- 
90msec), C-fibres (90-300msec) and post-discharge (300-800msec) responses o f  a deep WDR 
dorsal horn neurons following a train o f 16 electrical stimuli, msec- latency in milliseconds. 
Adapted with permission from Dr. R. Suzuki.
A total of 33 ‘atypical’ deep cells were also characterised. The electrical evoked 
responses of the deep WDR and ‘atypical’ neurons were comparable, however, 
the natural evoked responses of the deep WDR neurons were larger than those of 
deep ‘atypical’ neurons (tables 3.1, 3.2 and figs. 3.1-3.4).
mean±SEM
cell depth (fim) 790±92
Ap-fibre threshold (mA) 0.9±0.04
C-fibre threshold (mA) 2.2±0.1
input evoked response 19±3
Ap-fibre evoked response 95±10
A8-fibre evoked response 60±9
C-fibre evoked response 326±29
post-discharge response 205±29
wind-up evoked response 264±40
Brush evoked response 59±10
Table 3.2- Electrophysiological characteristics o f  the electrical and brush evoked responses in rat 
deep ‘atypical’ dorsal horn neurons. Response^ number o f  action potentials evoked, n=33.
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Fig. 3.3- Heat evoked responses o f ‘atypical’ neurons in the deep dorsal horn (n=33).
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Fig. 3.4- von Frey evoked responses o f ‘atypical’ neurons in the deep dorsal horn (n=33).
3.3.2 The effect of intrathecal morphine on the evoked responses of deep 
WDR neurons
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mean±SEM
cell depth (pm) 831±40
Ap-fibre threshold (mA) 0.8±0.03
C-fibre threshold (mA) 1.4±0.2
No. of cells with wind-up 4 out of 8
Table 3.3- Electrophysiological characteristics o f the rat deep wide dynamic range dorsal horn 
neurons.
The intrathecal administration of morphine dose O.lpg did not have an effect on 
any of the electrically or naturally evoked responses of deep WDR neurons (figs. 
3.5-3.14). Furthermore, any significant inhibitory effect of the other doses of 
morphine used was reversed by intrathecal 50pg naloxone (n=7).
i) Electrical parameters
Electrically evoked input response was significantly inhibited by both 1 and 
10 pg of intrathecal morphine (p<0.05, n=8) (fig. 3.5).
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Fig. 3.5- The effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) on the 
electrical evoked input response in deep WDR dorsal horn neurons. Reversal by naloxone dose 
50 jig is shown in green. *P<0.05, where a significant inhibition from the control (black) is seen. 
n=8 for control and morphine, n=7 for naloxone reversal, one way ANOVA followed by 
Dunnett’s post-hoc test.
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Neither the electrically evoked Ap- nor the A8 responses were significantly 
inhibited by any of the doses of intrathecal morphine (n=8) (figs. 3.6 and 3.7).
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Fig. 3.6- The lack o f effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) on 
the electrical evoked AP-fibre response in deep WDR dorsal horn neurons. Reversal by naloxone 
dose 50 pg is shown in green. n=8 for control and morphine, n=7 for naloxone.
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Fig. 3.7- The lack o f effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) on 
the electrical evoked A8-fibre response in deep WDR dorsal horn neurons. Reversal by naloxone 
dose 50 pg is shown in green. n=8 for control and morphine, n=7 for naloxone reversal.
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The C-fibre evoked response was significantly reduced by morphine doses 1 and 
lOpg (p<0.05, n=8) (fig. 3.8).
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Fig. 3.8- The effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) on the 
electrical evoked C-fibre response in deep WDR dorsal horn neurons. Reversal by naloxone dose 
50 fig is shown in green. *P<0.05, where a significant inhibition from the control (black) is seen. 
n=8 for control and morphine, n=7 for naloxone reversal, one way ANOVA followed by 
Dunnett’s post-hoc test.
Only lOpg morphine significantly inhibited the electrically evoked post­
discharge response of deep WDR neurons (p<0.05, n=8) (fig. 3.9).
Furthermore, morphine did not seem to have a tendency to inhibit the wind-up 
evoked response. However, since 1 Opg morphine significantly inhibited the post­
discharge of the neurons, and post-discharge is a measure of neuronal excitability 
and thus an indication of wind-up, and since only 4 out of the 8 cells exhibited 
any wind-up, care should be taken in interpreting these results, as an ‘n’ number 
of at least 6 is needed before valid analysis is made (fig. 3.10). However, even 
when the wind-up of a single cell was plotted (fig. 3.11), it was seen that 
morphine had no tendency to change the slope of the wind-up response (n=l).
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Fig. 3.9- The effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) on the 
electrical evoked post-discharge response in deep WDR dorsal horn neurons. Reversal by 
naloxone dose 50 pg is shown in green. *P<0.05, where a significant inhibition from the control 
(black) is seen. n=8 for control and morphine, n=7 for naloxone reversal, one way ANOVA 
followed by Dunnetf s post-hoc test.
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Fig. 3.10- The lack o f effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) 
on the electrical evoked wind-up response in deep WDR dorsal horn neurons. Reversal by 
naloxone dose 50 pg is shown in green. n=4 for all.
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Fig. 3.11- The lack o f effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) 
on the slope o f electrical evoked wind-up response o f a single, deep, WDR dorsal horn neuron 
(black). n=l.
ii) Natural parameters
None of the three doses of morphine had any effect on the brush evoked response 
(n=8) (fig. 3.12). However, both morphine doses 1 and lOpg significantly 
inhibited von Frey evoked responses, for each of von Frey 5, 15, 30 and 75g 
(p<0.05, n=8) (fig. 3.13). Additionally, these two doses of morphine also 
significantly inhibited the thermal evoked responses of deep WDR neurons, at 
each of temperatures 45, 48 and temperature 50°C (p<0.05, n=8) (fig. 3.14).
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Fig. 3.12- The lack o f effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg (purple) 
on the brush evoked response in deep WDR dorsal horn neurons. Reversal by naloxone dose 
50 pg is shown in green. n=8 for control and morphine, n=7 for naloxone reversal.
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Fig. 3.13a- The effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg 
(purple) on the von Frey evoked response in deep WDR dorsal horn neurons. Reversal 
by naloxone dose 50 pg is shown in green. *P<0.05, where a significant inhibition from 
the control (black) is seen. n=8 for control and morphine, n=7 for naloxone reversal. One way 
ANOVA followed by Tukey post-hoc test.
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Fig. 3.13b- The effect o f the three doses o f intrathecal morphine (O.lpg- red, lpg- blue, lOpg- 
purple) on the 1, 5, 9 and 15g von Frey evoked responses in deep wide dynamic range dorsal 
horn neurons in closer detail. Reversal by naloxone dose 50pg is shown in green. *P<0.05, where 
a significant inhibition from the control (black) is seen. n=8 for control and morphine, n=7 for 
naloxone reversal. One way ANOVA followed by Tukey post-hoc test.
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Fig. 3.14- The effect o f intrathecal morphine doses 0.1 (red), 1 (blue) and lOpg 
(purple) on the heat evoked response in deep WDR dorsal horn neurons. Reversal by 
naloxone dose 50 pg is shown in green. *P<0.05, where a significant inhibition from the 
control (black) is seen. n=8 for control and morphine, n=7 for naloxone reversal. One way 
ANOVA followed by Tukey post-hoc test.
3.3.3 The effect of intrathecal Sar-SP on the evoked responses of deep WDR 
neurons
Mean±SEM
cell depth (pm) 680±58
Ap-fibre threshold (mA) 0.7±0.01
C-fibre threshold (mA) 1.7±0.1
no. of cells with wind-up 6 out of 6
Table 3.4- Electrophysiological characteristics o f the rat deep wide dynamic range dorsal horn 
neurons.
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Mean±SEM
cell depth (pm) 856±56
Ap-fibre threshold (mA) 0.9±0.07
C-fibre threshold (mA) 2.5±0.3
no. of cells with wind-up 8 out of 8
Table 3.5- Electrophysiological characteristics o f the rat deep wide dynamic range dorsal horn 
neurons.
Since the two doses of Sar-SP used in this study were administered on different 
days and animals, it was essential to determine whether there were 
significant differences in the baseline responses in each set of animals used. As 
can be seen from figures 3.15-3.18, there were no significant differences in the 
baseline responses between both sets of animals.
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Fig. 3.15- A comparison o f the baseline electrical evoked responses o f  the deep WDR 
dorsal horn neurons used in the study investigating the different doses o f Sar-SP, prior to the 
administration o f dose 1 pg (black, n=6) and dose lOpg (red, n=8).
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Fig. 3.16- A comparison o f the baseline brush evoked response o f the deep WDR
dorsal horn neurons used in the study investigating the different doses o f Sar-SP, prior to the
administration o f dose lpg (black, n=6) and dose lOpg (red, n=8).
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Fig. 3.17- A comparison o f the baseline von Frey evoked responses o f  the deep WDR 
dorsal horn neurons used in the study investigating the different doses o f Sar-SP, prior to the 
administration o f dose 1 pg (black, n=6) and dose 1 Opg (red, n=8).
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Fig. 3.18- A comparison o f the baseline thermal evoked responses o f the deep WDR 
dorsal horn neurons used in the study investigating different doses of Sar-SP, prior to the 
administration o f dose lpg (black, n=6) and dose lOpg (red, n=8).
i) The effect of Sar-SP on the electrical evoked responses
Neither dose of Sar-SP used caused any significant effects on the electrical 
evoked responses of deep WDR dorsal horn neuron. Additionally, even when 
each dose of Sar-SP was tested on the wind-up exhibited by its respective single 
cell, there did not seem to be a significant change (figs. 3.19-3.22).
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Fig. 3.19- The lack o f effect o f intrathecal 1 |ig Sar-SP (red) on electrical
evoked responses o f deep WDR dorsal horn neurons. Control responses are shown in
black. n=6.
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Fig. 3.20- The lack o f effect o f intrathecal 10fig Sar-SP (red) on electrical evoked responses of 
deep WDR dorsal horn neurons. Control responses are shown in 
black. n=8.
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Fig. 3.21 - The lack o f effect o f intrathecal 1 |ig Sar-SP (red) on the slope o f the electrical evoked 
wind-up response o f a single, deep, WDR dorsal horn neuron (black). n=l.
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Fig. 3.22- The lack o f effect o f intrathecal lOpg Sar-SP (red) on the slope pf the electrical evoked 
wind-up response o f a single, deep, WDR dorsal horn neuron (black). n = l.
ii) The effect of Sar-SP on the natural evoked responses
The intrathecal administration of Sar-SP dose 10}j.g did not cause a significant 
difference in any of the brush, von Frey and thermal evoked responses (see figs.
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3.26, 3.27 and 3.28). However, whilst Sar-SP dose 1 jj.g had no effect on the 
brush (fig. 3.23) and von Frey evoked responses (fig. 3.24), this dose of Sar-SP 
caused a significant facilitation in the thermal evoked response at temperature 
45°C (p<0.05, n=6) (fig. 3.25).
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Fig. 3.23- The lack o f effect o f intrathecal lpg Sar-SP (red) on brush
evoked response o f deep WDR dorsal horn neurons. Control responses are shown in
black. n=6.
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Fig. 3.24- The lack o f  effect o f intrathecal 1 pg Sar-SP (red) on von Frey evoked responses of 
deep WDR dorsal horn neurons. Control responses are shown in black. n=6.
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Fig. 3.25- The effect o f intrathecal 1 ug Sar-SP (red) on thermal evoked responses o f deep WDR 
dorsal horn neurons. *P<0.05, where a significant facilitation from the control (black) is seen. 
n=6, /-test.
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Fig. 3.26- The lack o f effect o f intrathecal lOpg Sar-SP (red) on brush
evoked response o f deep WDR dorsal horn neurons. Control responses are shown in
black. n=8.
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Fig. 3.27- The lack o f effect o f intrathecal lOpg Sar-SP (red) on von Frey evoked responses o f  
deep WDR dorsal horn neurons. Control responses are shown in black. n=8.
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Fig. 3.28- The lack o f effect o f intrathecal lOpg Sar-SP (red) on thermal evoked 
responses o f deep WDR dorsal horn neurons. Control responses are shown in black. n=8.
3.3.4 The effects of Sar-SP on morphine’s inhibitory action of the evoked 
responses of deep WDR neurons
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mean±SEM
cell depth (pm) 822±50
Ap-fibre threshold (mA) 0.9±0.07
C-fibre threshold (mA) 1.3±0.2
no. of cells with wind-up 5 out of 10
Table 3.6- Electrophysiological characteristics o f the rat deep wide dynamic range dorsal horn 
neurons.
When Sar-SP (l|ig) was left for ten minutes, it had no effect on any of the 
electrical or the natural evoked responses of deep WDR dorsal horn neurons 
(figs. 3.29-3.31).
i) Effects on the electrical evoked response of deep WDR neurons
In the presence of Sar-SP, morphine (1 pg) caused significant inhibition on each 
of electrically evoked input and C-fibre responses (p<0.05, n=10) (fig. 3.29).
Furthermore, even though in this section too, wind-up was exhibited by only 5 
cells, this response did not seem to have a tendency to be inhibited by morphine, 
in the presence of Sar-SP, just as this response also did not seem to have a 
tendency to be inhibited when morphine was administered on its own (fig. 3.10). 
This was also true when the wind-up of a single cell was plotted (fig. 3.30). 
However, due to the small ‘n’ number, no statistical analysis could be made.
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Fig. 3.29- The effect o f intrathecal morphine (lpg, blue), when preceded by 
intrathecal Sar-SP (lpg , red), on electrical evoked responses o f deep WDR dorsal horn neurons. 
Reversal by naloxone dose 50 pg is shown in purple. *P<0.05, where morphine induces a 
significant inhibition from the control (black) and following intrathecal Sar-SP administration 
(red). n=10 for all except for wind-up evoked response, where n=5, and naloxone reversal, where 
n=9, one way ANOVA followed by Dunnett’s post-hoc test.
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Fig. 3.30- The lack o f effect o f intrathecal 1 pg morphine (blue), when preceded by intrathecal 
1 pg Sar-SP (red), on the slope of the electrical evoked wind-up response o f a single, deep, WDR 
dorsal horn neuron (control=black). n=l.
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ii) Effects on the natural evoked response of deep WDR neurons
In the presence of Sar-SP, morphine (1 pg) had no effect on brush evoked 
responses of deep WDR neurons (3.31). However, morphine, in the presence of 
Sar-SP, significantly inhibited the von Frey evoked response of deep WDR 
neurons (fig. 3.32). This was seen at von Frey 5, 9, 30 and 75g (p<0.05, n=9). 
Overall, morphine, whether alone or in the presence of Sar-SP, was shown to 
inhibit to the same extent both innocuous and noxious mechanical stimuli, as 
seen by the broad range of von Frey monofilaments which were inhibited.
Furthermore, morphine, in the presence of Sar-SP, significantly inhibited the 
thermal evoked response of deep WDR dorsal horn neurons (fig. 3.33). This 
significant inhibition was seen at temperatures 45, 48 and 50°C (p<0.05, n=10).
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Fig. 3.31- The lack o f effect o f intrathecal morphine (lpg, blue), when pre-treatment with 
intrathecal Sar-SP (SSP, lpg, red) has occurred, on brush evoked response o f deep WDR dorsal 
horn neurons. Reversal by naloxone dose 50 pg is shown in purple. n=6 for all except naloxone 
reversal, where n=5.
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Fig. 3.32a- The effect o f intrathecal l(ig morphine alone (purple, n=8) and the effect o f morphine 
when pre-treatment with intrathecal Sar-SP has occurred (blue, n=10) on von Frey evoked 
responses o f deep WDR dorsal horn neurons. The effect o f intrathecal lpg Sar-SP alone (red, 
n=10) on these responses is also shown. Naloxone reversal is shown in green (m=8). *P<0.05, 
where morphine induces a significant inhibition from the control (black, n=10) and following 
intrathecal Sar-SP administration (red). One way ANOVA followed by Tukey post-hoc test.
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Fig.3.32b- The effect o f intrathecal lpg morphine alone (purple, n=8) and the effect o f morphine 
when pre-treatment with intrathecal Sar-SP has occurred (blue, n=10) on the l, 5, 9 and 15g von 
Frey evoked responses in deep wide dynamic range dorsal horn neurons in closer detail. Reversal 
by naloxone dose 50pg is shown in green (n=8). *P<0.05, where a significant inhibition from the 
control (black, n=10) is seen, on von Frey 5 and 15g evoked response by morphine alone and on 
von Frey 5 and 9g evoked response by morphine when pre-treatment with Sar-SP has occurred. 
One way ANOVA followed by Tukey post-hoc test.
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Fig. 3.33- The effect o f intrathecal 1 pg morphine alone (purple, n=8) and the effect o f morphine 
when pre-treatment with intrathecal Sar-SP has occurred (blue, n=10) on thermal evoked 
responses o f deep WDR dorsal horn neurons. The effect o f intrathecal 1 pg Sar-SP alone (red, 
n=10) on these responses is also shown. Naloxone reversal is shown in green (n=8). *P<0.05, 
where morphine induces a significant inhibition from the control (black, n=10) and following 
intrathecal Sar-SP administration (red). One way ANOVA followed by Tukey post-hoc test.
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3.3.5 The effect of intrathecal NMDA on the evoked responses of deep WDR 
neurons
mean±SEM
cell depth (jam) 886±77
Ap-fibre threshold (mA) 0.8±0.02
C-fibre threshold (mA) 1.6±0.2
no. of cells with wind-up 7 out of 7
Table 3.7- Electrophysiological characteristics o f  the rat deep wide dynamic range dorsal horn 
neurons.
None of the doses of NMDA used exerted any significant effects on any of the 
electrical and natural evoked responses of deep WDR dorsal horn neurons (figs. 
3.34-3.38). In the case of the electrical evoked responses, all the doses of NMDA 
used showed a tendency to decrease the response from the control, except for the 
AS (all doses) and wind-up evoked responses (doses 50 and 500ng), which 
showed a tendency to increase (fig. 3.34). In the case of brush and von Frey 
evoked responses, all doses of NMDA used also showed a tendency towards 
decreasing the response from the baseline control (fig. 3.36-37). Finally, both 
doses 50 and 500ng of NMDA showed a tendency to reduce the thermal evoked 
response from baseline, whereas dose 5ng of NMDA showed the same thermal 
evoked response as that of the baseline control (fig. 3.38).
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Fig. 3.34- The lack o f effect o f  intrathecal NMDA doses 5 (red), 50 (blue) and 500ng (purple) on 
electrical evoked responses o f deep WDR dorsal horn neurons. Control responses are shown in 
black. n=7.
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Fig. 3.35- The lack o f effect o f intrathecal NMDA doses 5 (red), 50 (blue) and 500ng (purple) on 
the slope of the electrical evoked wind-up response o f a single, deep, WDR dorsal horn neuron 
(black). n=l.
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Fig. 3.36- The lack o f effect o f intrathecal NMDA doses 5 (red), 50 (blue) and 500ng (purple) on 
brush evoked responses o f deep WDR dorsal horn neurons. Control responses are shown in 
black. n=6.
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Fig. 3.37- The lack o f effect o f  intrathecal NMDA doses 5 (red), 50 (blue) and 500ng (purple) on 
von Frey evoked responses o f deep WDR dorsal horn neurons. Control responses are shown in 
black. n=6.
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Fig. 3.38- The lack o f effect o f intrathecal NMDA doses 5 (red), 50 (blue) and 500ng (purple) on 
thermal evoked responses of deep WDR dorsal horn neurons. Control responses are shown in 
black. n=6.
3.4 Discussion
3.4.1 The effects of morphine on electrical and natural evoked responses of 
deep WDR neurons
Morphine had an inhibitory effect on electrical evoked input and C-fibre 
responses, as well as on both innocuous and noxious von Frey forces and thermal 
evoked dorsal horn responses in this study. This inhibitory effect of morphine is 
in agreement with previous electrophysiological studies in the cat (Duggan et a l , 
1983) and rat spinal cord (Dickenson, 1997b; Dickenson et al., 1986; Duggan et 
al., 1983).
Whereas a previous study (Dickenson et al., 1986) showed a facilitatory effect of 
low doses of morphine (0.5 and 0.8pg) on the C-flbre response of spinal cord 
dorsal horn neurons, the lowest dose of morphine used in this study (0.1 pg) did 
not cause any effects on the responses of deep WDR neurons, which is in
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agreement with another in vivo electrophysiology study using the same dose and 
route of administration of morphine (Suzuki et a l , 1999). Furthermore, all of the 
inhibitory actions of morphine were reversed following the administration of 
naloxone, which is also in agreement with the aforementioned study (Suzuki et 
al., 1999).
i) The effect of morphine on the electrical evoked responses of deep dorsal 
horn neurons
Both 1 and 1 Opg of intrathecal morphine significantly inhibited the electrically 
evoked input response, which is a measure of neuronal activity after the first 
electrical stimulus, before any hyperexcitability occurs (Urch et al., 2003b). 
Furthermore, these two doses of intrathecal morphine also inhibited the C-fibre 
response, which is in agreement with a previous electrophysiological study 
which used the same doses of morphine as those used here (Suzuki et a l , 1999).
The hyperexcitability of the cell occurs following numerous electrical stimuli and 
is an indication of postsynaptic factors at play. Furthermore, it has been 
previously shown that most (approximately 70%) p-opioid receptors are located 
on the presynaptic central terminals of C-fibres, since levels of these receptors 
decrease greatly following peripheral axotomy and dorsal rhizotomy (Besse et 
al., 1992; deGroot et a l, 1997; Zhang et a l, 1998). Therefore, since postsynaptic 
p-opioid receptors are less in number than their presynaptic counterparts, it is not 
surprising that morphine acting on p-opioid receptors would be more effective in 
inhibiting neuronal responses which occur prior to any neuronal 
hyperexcitability.
Furthermore, even though the C-fibre evoked response is measured after 16 
electrical stimuli at 3x the C-fibre threshold, and thus when neuronal 
hyperexcitability has occurred, morphine is able to inhibit the C-fibre response, 
since the majority of presynaptic p-opioid receptors reside on the central 
terminals of small-diameter primary afferent fibres (Besse et a l, 1990; deGroot
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et a l, 1997; Zhang et a l, 1998). Moreover, the activation of the presynaptic jn- 
opioid receptors by morphine leads to decreased transmitter release, by opening 
K+ channels and causing neuronal hyperpolarisation, which leads to a reduction 
in the opening of voltage-dependent Ca2+ channels (Besse et a l, 1990;
Dickenson, 1994; Kangrga et a l, 1991).
Neither the Ap-fibre nor the A5-fibre responses were affected by any of the 
morphine doses. However, there was a non-significant tendency with the highest 
morphine dose used in reducing the A8-fibre response, whereas no such tendency 
was seen with the Ap-fibre response, p-opioid receptors, as mentioned 
previously, are mostly found on the central terminals of small diameter (C- 
fibres), and to a certain extent medium-diameter (A8-fibres), primary afferent 
fibres, but not on large-diameter primary afferent fibres (Ap-fibres) (Besse et a l , 
1992; Besse et a l, 1990; deGroot et a l, 1997; Lamotte et a l, 1976; Mansour et 
a l, 1994; Zhang et a l, 1998). Since there are no p-opioid receptors located on 
large-diameter primary afferent fibres, this means that morphine needs to act on 
its postsynaptic p-opioid receptors, which are less in number than its presynaptic 
receptors, to inhibit the Ap-fibre response, which means really large doses of 
morphine would be needed to inhibit the Ap-fibre response. However, since 
some of the medium-diameter primary afferent fibres do have p-opioid receptors, 
it was expected that the A8-fibre response would be significantly inhibited by 
morphine, which did not happen in my study. Perhaps higher doses of morphine 
were also required to decrease the A8-fibre response, since the highest dose of 
morphine used in my study was starting to show a tendency to reduce this 
response.
Post-discharge was significantly inhibited only by morphine dose lOpg. The 
post-discharge of the neuron is a measure of the number of action potentials after 
the C-fibre response, and is thus a function of the hyperexcitability of the cell. As 
mentioned above, neuronal hyperexcitability is a measure of postsynaptic events, 
p-opioid receptors located postsynaptically have been shown to be less numerous 
than their presynaptic counterparts (Besse et a l, 1992), therefore, only the larger
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dose of morphine was able to inhibit the postsdischarge response (Lombard et 
al., 1989).
Furthermore, morphine had no effect on the electrically evoked wind-up 
response. Wind-up occurs due to the activation of the NMDA receptor channel, 
and is manifested as the summation of the cell’s response, whereby the same 
repeated stimulus leads to a larger response (Dickenson, 1990; Mendell, 1966). 
Therefore, even though lower doses of morphine which act on the presynaptic p- 
opioid receptors inhibit transmitter release from C-fibres and thereby decrease 
input, which in turn decreases postsynaptic excitation, low doses of morphine 
which do inhibit input and C-fibre evoked responses do not significantly inhibit 
wind-up response (Chapman et al., 1994b; Dickenson et al., 1986). That is 
because lower doses of morphine only decrease and do not abolish input, which 
means that there will still be some input causing some postsynaptic excitation, 
and thus wind-up breaks through these inhibitions as stimulation continues 
(Chapman, 1994; Chapman et al., 1994b).
Furthermore, since wind-up also has a postsynaptic component, as it is mediated 
by the NMDA receptor which is located postsynaptically, low doses of morphine 
are not enough to cause inhibition since morphine’s action, as has been 
established before, is predominantly presynaptic (Besse et al., 1992; Dickenson,
1997a; Zhang et al., 1998). Indeed, a previous study has shown that a higher dose 
of morphine (50pg) can inhibit wind-up by acting on both pre- and postsynaptic 
receptors (Chapman et al., 1992; Chapman et a l , 1994b). However, since 10pg 
of morphine significantly inhibited the electrically evoked post-discharge 
response, and sine the cell’s post-discharge is an indication of the cell ‘winding- 
up’, and since there were only 4 neurons which exhibited wind-up in my study, I 
cannot make a conclusion on the efficacy of morphine in inhibiting the 
electrically evoked wind-up response in my study.
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ii) The effect of morphine on the natural evoked responses of deep dorsal 
horn neurons
None of the doses of morphine had any effect on the brush evoked response, 
which is thought to be mediated via Ap-fibres (Koltzenburg et a l, 1994a), which 
was expected, since there are no opioid receptors on the central terminals of 
large-diameter primary afferent fibres (Besse et al., 1992; Besse et al., 1990; 
deGroot et al., 1997; Lamotte et a l, 1976; Mansour et a l , 1994; Zhang et a l,
1998).
Furthermore, both doses 1 and 10pg morphine significantly inhibited the von 
Frey, innocuous and noxious, and the noxious thermal evoked responses.
Noxious mechanical and thermal stimuli are encoded by numerous channels on 
the peripheral terminals of small- and medium-diameter primary afferent fibres 
(see sections 1.6.1,1.6.2 and 1.6.3), and innocuous mechanical stimuli is 
encoded by large-diameter primary afferent fibres (Caterina et a l , 2005; Meyer 
et a l, 2006; Wood et a l, 2004). Therefore, since p-opioid receptors exist on the 
central terminals of both small- and medium-diameter primary afferent fibres, 
morphine inhibited both noxious mechanical and thermal evoked responses.
Moreover, doses 1 and lOpg of morphine have been shown to inhibit innocuous 
as well as noxious mechanical evoked neuronal responses, of wide dynamic 
range neurons (Dickenson et a l, 2006; Suzuki et a l, 1999), which is what 
happened in this part of my study when even innocuous von Frey 5g evoked 
responses were significantly inhibited by both doses, p-opioid receptors, as 
mentioned previously, are not found on the large-diameter primary afferent fibres 
which mediate innocuous mechanical evoked responses. Therefore, the fact that 
these low doses of morphine inhibited this innocuous mechanical response (von 
Frey 5g) and not the electrical evoked Ap response or brush evoked response 
could be due to the fact low doses of morphine are not enough to act on the less 
numerous postsynaptic p-opioid receptors (Besse et a l, 1990; Lombard et a l,
1989) to inhibit electrically evoked Ap response or the brush evoked response.
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However, it could be postulated that the innocuous von Frey 5g evoked response 
was a weak response, mediated by a mixture of Ap- and A8-fibres, which could 
be inhibited by the low doses of morphine acting on their postsynaptic receptors 
(Suzuki et al., 1999; Suzuki et a l , 2002a).
iii) Conclusion
The majority (70%) of p-opioid receptors are located on the central terminals of 
small- and medium-diameter primary afferent fibres (Besse et al., 1992; Besse et 
al., 1990; deGroot et al., 1997; Zhang et al., 1998). Therefore, the effects of 
intrathecal low doses of morphine would be mostly the consequence of 
presynaptic receptor activation. Indeed, intrathecal morphine was effective in 
inhibiting the presynaptically-mediated responses, such as electrically evoked 
input response, and the small- and medium-diameter primary afferent fibre 
responses to mechanical and thermal stimuli.
3.4.2 The effects of each of Sar-SP and NMDA on electrical and natural 
evoked responses of deep WDR neurons
i) The interaction between the NK-1 and the NMDA receptor
The NK-1 receptor is activated by the peptide SP, which is found co-localised in 
primary afferent fibres with glutamate, one of the agonists needed to activate the 
NMDA receptor (Battaglia et al., 1988; De Biasi et al., 1988). It has been shown 
by previous studies that the release of each of SP and glutamate positively 
modulates the release of the other, probably via presynaptic NK-1 and NMDA 
receptors (Lao et al., 2003; Liu et al., 1997; Liu et al., 1994; Malcangio et al.,
1998a), as well as via the diffusion of prostanoids and nitric oxide, which are 
generated by the activation of each of the NK-1 and NMDA receptors through 
second messengers and enzymes, and which cause retrograde transmitter release 
from primary afferent fibres following injury (Rusin et a l, 1993a; Yaksh et al., 
1999).
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The activation of the NMDA receptor causes an increased state of spinal 
neuronal responsiveness, termed wind-up, which is blocked by NMDA receptor 
antagonists (Dickenson et al., 1987), and partly blocked by NK-1 receptor 
antagonists (Xu et a l , 1992). Wind-up was initially described by Mendell, in 
1966, as the increase in response of deep dorsal horn neurons following 
repetitive C-fibre stimulation, even though the input to the spinal cord stays 
constant. Wind-up can be initiated by electrical stimulation at rates of nearly 
0.5Hz, but not at 0.1 Hz (Dickenson et al., 2002b). The physiological activation 
of the NMDA receptor complex requires glutamate and glycine binding (ligand- 
gating), as well as the summation of slow non-NMDA depolarisations (voltage-
*y i
gating), which remove the Mg block via the action of excitatory amino acids 
and neuropeptides (including SP) acting on their respective receptors (Kellstein 
et al., 1990; O'malley et al., 1991; Salt, 1986; Urban et al., 1984; Xu et al.,
1992).
Indeed, the activation of the NK-1 receptor has been shown to enhance the 
activation and the effects of the NMDA receptor channel, via both the 
aforementioned summation of the slow depolarisations which occur following 
the NK-1 receptor activation (and non-NMDA receptor activation) and the 
activation of second messenger systems. The former was seen when an NK-1 
antagonist was effective in partly reducing the wind-up response of the flexor 
reflex elicited by the electrical conditioning stimulus, and following states of 
increased release of peptides and excitatory amino acids, such as inflammation 
(Thompson et al., 1990; Xu et al., 1992). The latter was seen following the 
activation of the second messenger cascade, which occurs after NK-1 receptor 
activation, which leads to increases in intracellular calcium and protein kinase 
levels, that activate more enzymes, receptors and channels, including the NMDA 
receptor, and leads to facilitation of dorsal horn nociceptive transmission and 
central sensitisation (Chen et a l, 1992; Dougherty et al., 1993; Ikeda et al.,
2003; Rusin et a l, 1993a; Rusin et a l, 1993b; Rusin et a l, 1992; Yaksh et al.,
1999).
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There are many studies charting the spinal interaction between the NK-1 and 
NMDA receptor activation, and their role in central sensitisation. A behavioural 
study showed that the co-administration of SP and NMDA potentiated the biting 
and scratching behaviour seen following the application of each agonist alone in 
mice (Mjellem-Joly et al., 1991). Additionally, the studies by Cumberbatch et al 
(1995), and Chizh et al (1995) showed, using in vivo electrophysiology of 
spinalised rats, that NK-1 agonists increased dorsal horn neuronal responses 
(former) and NK-1 antagonists reduced dorsal horn neuronal responses (latter) 
following NMDA receptor activation (Chizh et al., 1995; Cumberbatch et al., 
1995). Moreover, the studies by Dougherty et al (1991, 1993 and 1995), showed 
the potentiation of primate spinothalamic tract neuronal responses following the 
co-administration of NMDA and SP, as well as increased responses to 
mechanical stimuli (noxious and innocuous), in cells which were already excited 
by the administration of excitatory amino acids alone (Dougherty et al., 1995; 
Dougherty et al., 1993; Dougherty et al., 1991).
In addition, in vitro studies showed that SP potentiated the effects of NMDA 
induced depolarisations, using superficial spinal dorsal horn neurons isolated 
from young rats (Rusin et al., 1993a; Rusin et al., 1993b; Rusin et al., 1992) and 
rat primary sensory neurons (Wu et al., 2004). Furthermore, the study by 
Chapman et al (1994) showed that the intrathecal co-administration of SP and 
NMDA facilitated all of the A8-fibre evoked responses, post-discharge and 
wind-up of rat deep dorsal horn neurons (Chapman et a l, 1994a). Finally, it was 
shown that the activation of the spinal NK-1 and the NMDA receptors is needed 
in order to induce the long-term potentiation (LTP , “use-dependent, long-lasting 
modification of synaptic strength”) of superficial neurons in spinalised rats (Liu 
e ta l, 1998).
Further linking the NK-1 and NMDA receptors with each other and the 
generation of central sensitisation are studies using the formalin response, an 
inflammatory model whereby there are two phases of dorsal horn neuronal 
activity following the intraplantar injection of formalin. Using in vivo 
electrophysiology, it was shown that the second phase of the formalin response,
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which starts after the acute phase in 25 minutes and lasts for 60 minutes, is 
reduced by each of NMDA (Haley et al., 1990) and NK-1 receptor antagonists 
(Chapman et al., 1993). An NK-1 antagonist also reduced the second phase of 
the formalin response in a behavioural study, which measured mouse hindpaw 
licking and biting as an indication of pain behaviour (Gonzalez et al., 2000), 
whereas in another behavioural study, the intrathecal co-administration of both 
SP and NMDA decreased the biting and licking response in both phases of the 
formalin test in mice (Mjellem-Joly et a l , 1992). In addition, c-Fos 
immunoreactivity expression measured in the superficial and deep dorsal horn 
three hours after formalin injection in freely moving rats was also significantly 
reduced by a high dose of an NK-1 antagonist, and by the combination of both 
the NK-1 and NMDA receptor antagonists at doses where each of these two 
antagonists was not very effective (Chapman et al., 1996).
ii) Sar-SP
In my study, the intrathecal administration of the NK-1 agonist Sar-SP, which is 
longer acting and more potent than SP (Yip et al., 1999), did not cause a 
significant facilitation in any of the electrical and natural evoked responses of 
deep WDR neurons, except for the 45°C thermal evoked response. The thermal 
facilitation seen in my study is in agreement with two earlier studies which 
showed the facilitation of dorsal horn neuronal responses to thermal stimuli in 
the cat by SP (Henry, 1976), and in the rat by Sar-SP (Rygh et al., 2006). The 
study by Rygh et al, showed, in rat superficial NK-1 expressing projection 
neurons, that Sar-SP facilitated the heat-evoked response to temperatures 45 and 
48°C, and that also following LTP induction, that noxious heat evoked responses 
are facilitated in deep WDR neurons. Thus further proving the role of NK-1 
receptors in central sensitisation states, as well as in facilitating heat-evoked 
responses of dorsal horn neurons.
The role of the NK-1 receptor in pain transmission is still not clear, with some 
stating that SP is more of a neuromodulator, than a ‘traditional’ neurotransmitter 
(Chapman et a l, 1996; Dougherty et al., 1995; Kellstein et al., 1990). Previous
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studies investigating the effects of the intrathecal administration of SP, or other 
NK-1 agonists, have resulted in these agents causing mostly excitatory responses, 
whether on a neuronal level (Cheunsuang et al., 2002; Henry, 1976; Kellstein et 
al., 1990; Nagy et al., 1993; Randic et a l, 1977; Xu et al., 1992), or on a 
behavioural level (Seybold et al., 1982). The study by Cheunsuang et al showed, 
using in vitro electrophysiology, that the application of Sar-SP, at a dose higher 
than the ones used in my study, caused great depolarisations of superficial dorsal 
hom neurons, whereas that of Nagy et al showed similar prolonged postsynaptic 
depolarisations of neurons in laminae II-IV, using SP-methyl ester.
The studies by Henry (1976) and Randic et al (1977), both used in vivo 
electrophysiology of the cat dorsal hom, whereas Kellstein et al (1990) 
investigated the rat dorsal hom. Henry, investigating deep dorsal hom neurons 
showed excitation of half of the units tested by SP, whereas Randic et al showed 
the excitation of all of the superficial dorsal hom neurons tested. Kellstein et al 
showed, in laminae III-VII neurons, an increased C-fibre evoked response with 
SP, a decrease in C-fibre evoked response with an NK-1 antagonist, and no effect 
by either NK-1 agonist or antagonist on A-fibre evoked response and 
spontaneous activity of the neurons.
In addition, also in agreement with our study, Chapman et al, in 1994, showed 
that different doses of intrathecal SP on its own, had no effect on the electrically 
evoked deep WDR neuronal responses (Chapman et al., 1994a). Furthermore, 
some studies have shown that NK-1 receptor activation only serves to enhance 
the effects of NMDA receptor activation, and that NK-1 agonists on their own 
had no effects on dorsal hom neuronal responses of spinalised rats (Cumberbatch 
et al., 1995), or on all of the background activity, mechanical and thermal 
cutaneous stimulation in primate spinothalamic tract neurons (Dougherty et al., 
1995). Moreover, the study by Fleetwood-Walker et al (1990) showed that SP 
and other NK-1 agonists, only caused a decrease in the brush-evoked responses, 
but caused no changes in responses to noxious heat or noxious mechanical 
stimuli and the spontaneous activity in cat spinocervical tract neurons 
(Fleetwood-Walker et al., 1990).
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Upon closer scrutiny, most of the spinal cord dorsal hom neuronal studies 
showing a facilitatory effect of NK-1 receptor agonists were using superficial 
dorsal hom neurons, where nociceptive-specific neurons outnumber WDR 
neurons (Cheunsuang et a l, 2002; Coghill et al., 1993; Randic et al., 1977; Rygh 
et al., 2006), whereas my study investigated deep WDR neurons. The study by 
Henry, in 1976, which was performed on laminae IV-VI of the cat spinal cord, 
showed that only half the units investigated were excited by intrathecal synthetic 
SP (Henry, 1976). Therefore, one reason for why only one heat evoked response 
was facilitated in my study and not other heat or mechanical evoked responses, 
could be due to the fact that deep WDR neurons exhibit larger dorsal hom 
neuronal evoked responses than the superficial dorsal hom neurons, as shown in 
my study as well as in a previous study (Seagrove et a l, 2004). Therefore, it 
could be easier to significantly facilitate heat and mechanical evoked responses 
in superficial neurons than in deep neurons.
Furthermore, thermal stimuli is conducted mainly via C-fibres and some type 2 
A8-fibres, with the TRPV1 channel at their peripheral termination (Caterina et 
al., 1997; Magerl et al., 2001), and most of the C-fibres are peptidergic (Meyer et 
al, 2006; Snider et a l, 1998; Urban et a l, 1984), releasing SP at their central 
terminals and thought to also express the NK-1 receptor at their central terminals 
(Malcangio et a l, 1999). Therefore, even though NK-1 receptors have been 
shown to be located mostly postsynaptic, in superficial laminae (Todd, 2002), 
one could conclude that another reason why Sar-SP facilitated thermal and not 
mechanical evoked responses could be due to Sar-SP activating some presynaptic 
NK-1 receptors on peptidergic C-fibres which convey thermal sensation. 
However, previous studies on presynaptic NK-1 receptors have postulated that 
these were inhibitory autoreceptors (Malcangio et a l, 1999) and furthermore, 
none of the other heat-evoked responses were facilitated in my study. Therefore, 
there must be other factors involved in why Sar-SP only facilitated the heat- 
evoked response of one temperature and not the others, such as the neuronal 
population (discussed above) and/or the dose of Sar-SP used.
140
iii) NMDA
In my study, the intrathecal administration of NMDA (5, 50 and 500ng) did not 
cause any significant excitation of the electrical evoked responses, which could 
be attributed to the fact that electrical stimulation was made at 3x the C-fibre 
threshold, whereas it should have been done at 1.5x the C-fibre threshold 
(Chapman et al., 1994a), and that different doses of intrathecal NMDA should 
have been used to cause increases in some of the natural evoked responses of 
deep dorsal hom neurons (Sher et al., 1990). Additionally, shorter testing times 
might have been needed to show the effects of NMDA, since I showed in my 
behavioural study (chapter 4) that the excitatory effects of intrathecal NMDA 
disappear after 5 minutes, and in the study by Chapman et al, only ten minutes 
were given between each set of testing. However, due to the fact that in my 
study, all of electrical, bmsh, von Frey and heat evoked responses were 
measured, a 20 minute gap between testing was needed to fit in all these stimuli, 
as well as give the neuron time to recuperate.
In previous studies, the antagonism of the NMDA receptor in the dorsal hom has 
been shown to decrease the hyperexcitability of dorsal hom neurons, including 
wind-up of dorsal hom neurons in vivo (Chapman et al., 1995; Dickenson, 
1997a; Haley et a l, 1990), reduce c-Fos expression in deep dorsal hom neurons 
following the spinal nerve ligation model (Lee et al., 2002), as well as pain 
behaviour in different pain models, such as inflammation (Coderre et a l, 1994; 
Ma et a l, 1998), and nerve injury (Wegert et al., 1997). However, the activation 
of the NMDA receptor channel in previous electrophysiological experiments, as 
in my study, using the intrathecal administration of the agonist NMDA, has not 
always yielded clear-cut excitations of rat dorsal hom neurons (Chapman et al.,
1994a), and primate spinothalamic tract neurons (some which were actually 
inhibited) (Dougherty et al., 1995), which was also the case with the NK-1 
receptor.
Indeed, the study by Chapman et al, in 1994, showed that when the neuron was 
being electrically stimulated at 3x the C-fibre threshold, the intrathecal 
administration of the same doses of NMDA as the ones used in my study was
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ineffective in exciting the neuron (Chapman et al., 1994a). This electrical 
stimulation had to be reduced to 1.5x the C-fibre threshold for a significant 
excitation of the deep WDR neurons to be achieved: dose 5ng significantly 
facilitated wind-up, whereas dose 50ng significantly facilitated the C-fibre, A8- 
fibre and post-discharge response, and higher doses showed a tendency to inhibit 
the responses, showing a biphasic effect of NMDA, as well as a fine line between 
the doses that were excitatory and those that were ineffective (Chapman et al., 
1994a). Furthermore, a previous study showed an NMDA-induced increase in 
spontaneous activity, noxious pinch and brush evoked responses of rat deep 
dorsal hom neurons, but this study used spontaneously firing neurons, did not use 
any electrical stimulation of the neurons, and the doses of intrathecal NMDA 
used were higher than those used in my study (Sher et al., 1990).
iv) Conclusion
Even though the effects of NK-1 and NMDA receptor activation have been 
shown by the majority of studies to be excitatory on the spinal cord dorsal hom 
neurons (Chapman et al., 1994a; Henry, 1976; Randic et al., 1977; Sher et al., 
1990), some studies have shown no effects (Dougherty et al., 1995; Fleetwood- 
Walker et al., 1990), others have shown both excitation and inhibition (Chapman 
et al., 1994a; Dougherty et al., 1995) and others still have shown the excitatory 
effects of only the combined activation of both receptors (Chapman et al., 1994a; 
Dougherty et al., 1992; Dougherty et al., 1995; Dougherty et al., 1993).
In my study, there was no overall excitation of dorsal hom neuronal responses by 
either of intrathecal Sar-SP or NMDA (except for the facilitation of the 45°C 
thermal evoked response by lpg Sar-SP), which could be due to the doses used, 
the depth and type of the neurons studies and the electrical stimulation being at 
3x the C-fibre threshold, rather than a lack of effect of the activation of each of 
these two receptor systems on dorsal hom neuronal responses.
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3.4.3 The effects of morphine, in the presence of Sar-SP, on electrical and 
natural evoked responses of deep WDR neurons
Some studies show a reduced efficacy of morphine inhibition in pain states, such 
as neuropathic pain (Amer et a l , 1988), and the wind-up model, which is known 
to occur following spinal NMDA receptor activation (Chapman et a l, 1992; 
Chapman et a l, 1994b), which in turn requires the NK-1 receptor activation to 
enhance its (NMDA receptor) effects (Dougherty et a l, 1995; Rusin et al, 
1993a). As it turns out, it is more specifically the dynamic allodynia, resulting 
from nerve injury, and thought to be conveyed mostly by Ap-fibres, which is less 
responsive to morphine administration (Field et a l, 1999a; Field et a l, 1999b), 
than other types of hypersensitivities such as thermal and static allodynia (Field 
et a l, 1999b; Wegerte/a/., 1997).
Both the NK-1 and the NMDA receptors are found located mostly postsynaptic 
in the spinal cord dorsal hom (Coggeshall et a l, 1997a; Liu et a l, 1994; Todd, 
2002), an area where less postsynaptic p-opioid receptors exist, in relation to 
their presynaptic counterparts (Besse et a l, 1992; Besse et a l, 1990; Zhang et 
a l , 1998). Additionally, p-opioid receptors are mostly found on small- and 
medium- primary afferent fibre terminals, and not on large-diameter Ap-fibres 
(Besse et a l, 1992; Besse et a l, 1990; deGroot et a l, 1997; Lamotte et a l, 1976; 
Mansour et a l, 1994; Zhang et a l, 1998), which means that any effect of 
morphine on Ap-fibres or responses conveyed by Ap-fibres such as 
brush/dynamic allodynia would require morphine to act via its less numerous 
postsynaptic p-opioid receptors. Therefore, higher doses of morphine would be 
required to inhibit wind-up and even higher doses would be needed to inhibit 
Ap-fibre responses than those required to inhibit responses where morphine can 
act predominantly on its presynaptic receptors (Chapman et a l, 1992; Chapman 
et a l, 1994b), such as electrically evoked input and C-fibre responses, as well as 
noxious thermal and mechanical evoked responses.
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Since both the NK-1 and the NMDA receptors are found mostly postsynaptic 
(Coggeshall et al., 1997b; Todd, 2002), and the activation of each is known to 
facilitate dorsal hom neuronal responses via the postsynaptic receptors, it was 
hoped that the administration of each of Sar-SP and NMDA would induce the 
facilitation of the responses of dorsal hom neurons, which would be followed by 
investigating the efficacy of morphine in inhibiting these responses.
Unfortunately, the only response which was facilitated was the 45°C thermal 
evoked response by Sar-SP, and it was seen that morphine was as effective 
following Sar-SP administration, in inhibiting the dorsal hom neuronal 
responses, as it was when administered alone.
3.4.4 Conclusion
Even though morphine in my study was as effective in inhibiting dorsal hom 
neuronal responses on its own, as following the administration of Sar-SP, and 
even though at higher doses morphine can inhibit postsynaptic responses of 
dorsal hom neurons, such as wind-up, the administration of either Sar-SP and 
NMDA in my study did not yield a clear-cut response. This could be due to the 
depth and the type of the neurons used, the doses used, or the gaps left in 
between testing time, rather than a conclusive lack of effect of the activation of 
either the NK-1 or the NMDA receptor on dorsal hom neurones. Therefore, the 
overall conclusion from this study will be that morphine is effective in inhibiting 
dorsal hom neuronal responses following the activation of the NK-1 receptor 
with Sar-SP, but a different technique will be used in the next chapter to further 
investigate the modulation of excitatory transmission in the rat spinal cord by 
morphine.
In this chapter, I regrettably could not fully investigate the effects of morphine on 
excitatory transmission in the rat spinal cord, due to the fact that no overall 
dorsal hom neuronal excitation could be induced following either of intrathecal 
Sar-SP or NMDA administration. Therefore, in the next chapter, I will
144
investigate the effects of morphine on the BSL behaviour and 
thermal/mechanical hypersensitivities that arise following the intrathecal 
administration of each of the NMDA and the NK-1 receptors, using as agonists 
NMDA and Sar-SP, respectively. Furthermore, it would be interesting to directly 
compare the effects of the activation of each of these receptors, as well as 
morphine’s effect on them, and try to relate them to what is actually seen in some 
chronic pain states.
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Chapter 4:
A study investigating the effectiveness of morphine 
in inhibiting the behaviour and nociceptive 
response which arise following the activation of 
each of the NMDA and NK-1 receptors
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4. A study investigating the effectiveness of morphine in inhibiting the 
behaviour and nociceptive response which arise following the activation of 
each of the NMDA and NK-1 receptors
4.1 Introduction
The NMDA and NK-1 receptors are located mostly postsynaptic in the spinal 
cord dorsal hom (Coggeshall and Carlton 1997), and their activation and 
interaction in the spinal cord is thought to partly underlie the hyperexcitability of 
spinal cord dorsal hom neurons, such as wind-up and central sensitisation 
(Dickenson and Sullivan 1987; Xu, Dalsgaard et al. 1992; Liu and Sandkuhler 
1998), as well as thermal and tactile hypersensitivities which occur following 
different models of nerve injury (Yamamoto and Yaksh 1992; Wegert, Ossipov 
et al. 1997; Field, McCleary et al. 1998; Wu, Schwasinger et al. 2005) and 
inflammation (Ma, Allchome et al. 1998).
Previous studies have shown the reduced efficacy of morphine in decreasing 
wind-up (Dickenson and Sullivan 1986) and abnormal pain following nerve 
injury (Amer and Meyerson 1988), whereas other studies have shown that it is a 
question of increased doses, route of administration and timing of administration 
which determines the efficacy of morphine in these models (Woolf and Wall 
1986; Portenoy, Foley et al. 1990; Rowbotham, Reisner-Keller et al. 1991; 
Chapman and Dickenson 1992; Jadad, Carroll et al. 1992; Chapman, Haley et al. 
1994; Suzuki, Chapman et al. 1999).
Many previous studies have investigated the effects of morphine on the biting, 
scratching and licking behaviour that arises following the direct activation of 
each of the spinal NMDA and the NK-1 receptors by their respective receptors, 
and these either concluded significant inhibition (Hylden and Wilcox 1982; 
Hylden and Wilcox 1983) or decreased effects of morphine in these pain states 
(Aanonsen and Wilcox 1987; Bossut, Frenk et al. 1988; Alvarez-Vega, 
Baamonde et al. 1998) (see sections 1.73.1,1.73.2,1.7.4 and 1.7.6.2).
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Furthermore, some studies have investigated the effects of morphine on either 
thermal or tactile hypersensitivity, which arises following either the direct 
activation of each of the these two receptors with their respective agonists 
(Hylden and Wilcox 1982), or the secondary activation of these two receptors 
following inflammatory (Yamamoto and Yaksh 1992; Ma, Allchome et al. 1998) 
and neuropathic pain states (Yamamoto and Yaksh 1991). However, not many 
studies have investigated and directly compared the effects of morphine on both 
thermal and tactile hypersensitivity, which arise following the direct activation of 
each of these receptors, with their respective agonists.
Since the activation of the spinal NMDA and NK-1 receptors partly underlie 
states of central sensitisation, such as the wind-up model (Dickenson 1997) and 
the pain hypersensitivity seen following nerve injury (Field, McCleary et al.
1998; Suzuki, Matthews et al. 2001), then the modulation of each of these two 
receptors by morphine would help shed more light on the efficacy of morphine in 
these pain models.
Therefore, the effects of morphine on the BSL behaviour and thermal/mechanical 
hypersensitivities that arise following the activation of each of the NMDA and 
the NK-1 receptors, using as agonists NMDA and Sar-SP, respectively, will be 
investigated in this chapter.
4.2 Methods
The methods used in this section have been described in detail in the 
methodology chapter, in sections 2.1 and 23.
Briefly, male, Sprague-Dawley rats weighing 190g will be intrathecally 
catheterised in the lumbar area by using a modified version of the Storkson et al 
method (Storkson, Kjorsvik et al. 1996). This method of catheterisation via the 
sacral route was thought to cause less motor damage than the one involving 
catheterisation through the atlanto-occipital membrane (Yaksh and Rudy 1976), 
since the cannula length would be only 3 cm, as opposed to 6cm, in an adult rat.
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However, both methods were comparable in terms of success rate (personal 
communication with R. Suzuki and Y. Wong).
The rats were then habituated, then tested for thermal hypersensitivity, using the 
Hargreaves test (Hargreaves, Dubner et al. 1988), and for tactile hypersensitivity 
using the Chaplan method of determining the paw withdrawal threshold 
(Chaplan, Bach et al. 1994), following the intrathecal administration of each of 
the NMDA receptor agonist NMDA, and the NK-1 receptor agonist Sar-SP.
The subcutaneous administration of morphine (3mg/kg), and the intrathecal 
administration of each of NMDA (0.3 pg) and Sar-SP (3pg), will be done, and 
responses to thermal and tactile stimuli will be measured, in order to determine 
the efficacy of morphine on such responses following the activation of each 
receptor. Furthermore, the reversal of the tactile and the thermal hypersensitivity 
induced by intrathecal NMDA and Sar-SP will be attempted with the intrathecal 
administration of the non-competitive NMDA receptor antagonist MK-801 
(0.1 mg/kg) (Kemp, Foster et al. 1987), and that of the potent, non-peptide NK-1 
receptor antagonist RP-67,580 (3pg), respectively (Rupniak, Carlson et al. 2003). 
The dosing protocol is explained in detail in section 2.6.2.
In the section of this chapter investigating the effects of intrathecal Sar-SP, the 
grooming behaviour following the BSL behaviour which occurred after Sar-SP 
administration lasted for 21 ±7 minutes. The grooming was too excessive for me 
to be able to quantify whether any paw withdrawal before timepoint 20 minutes 
was due to thermal hypersensitivity or grooming. Therefore, in this part of the 
study, it is only starting from 20 minutes post-intrathecal Sar-SP that paw 
withdrawal will be considered to be due to thermal hypersensitivity only and not 
grooming movements which cut off the Hargreaves beam prematurely. This 
timing of the actions of Sar-SP has been confirmed by an earlier study (Rygh, 
Suzuki et al. 2006).
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Finally, the tactile hypersensitivity which occurred following either of intrathecal 
NMDA or Sar-SP administration could not be followed as extensively as thermal 
hypersensitivity, because the series of stimuli needed to determine tactile 
hypersensitivity took longer than just placing a radiant heat source under the 
hindpaw in the Hargreaves test. Therefore, for tactile hypersensitivity, there were 
only three timepoints to draw conclusions from, whereas with thermal 
hypersensitivity, testing was done every 5 minutes for 60 minutes.
4.3 Results
4.3.1 Biting, scratching and licking behaviour
i) Intrathecal Saline
None of the rats that were intrathecally injected with 0.9% sterile saline exhibited 
any biting, scratching and licking behaviour (BSL, n=6).
ii) Intrathecal NMDA
a) NMDA alone- The intrathecal administration of NMDA (0.3pg, n=8) 
immediately caused 5±1 minutes of caudally directed biting, scratching and 
licking, as opposed to the intrathecal saline controls which did not cause any of 
this behaviour.
b) Morphine+NMDA- The subcutaneous administration of Morphine (3mg/kg), 
25 minutes before that of NMDA (0.3 pg) in the morphine+NMDA treated rats 
caused a significant decrease in the BSL behaviour, when compared to the 
NMDA treated rats, from 5±1 to 2±1 minutes (p<0.05, n=8, /-test).
c) MK-801+NMDA- The subcutaneous injection of MK-801 (0.1 mg/kg), 25 
minutes prior to that of NMDA (0.3 pg) in the MK-801+NMDA treated rats
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(n=8) caused no significant difference in the BSL behaviour, when compared to 
the NMDA treated rats.
iii) Intrathecal Sar-SP
a) Sar-SP alone- The intrathecal administration of Sar-SP (3 pig, n=6) 
immediately led to 21 ±7 minutes of caudally directed biting, scratching and 
licking and grooming, as opposed to the intrathecal administration of saline 
alone, which did not cause this behaviour.
b) Morphine+Sar-SP- The subcutaneous injection of Morphine (3mg/kg), 10 
minutes before administering Sar-SP (3pg) in the morphine+Sar-SP treated rats 
(n=8) did not cause any significant difference in the BSL and grooming 
behaviour, when compared to the Sar-SP treated rats.
c) RP-67,580 alone- The intrathecal administration of RP-67,580 (3pg, n=6) on 
its own caused 2±1 min of caudally directed BSL and grooming behaviour.
d) DMSO alone- The intrathecal administration of 20% DMSO (n=10) caused no 
BSL or grooming behaviour.
e) RP-67,580+Sar-SP- The intrathecal administration of RP-67,580 (3pg), 10 
minutes before that of Sar-SP (3pg) in the RP-67580+Sar-SP treated rats (n=8) 
caused no significant difference in the BSL and grooming behaviour when 
compared to the Sar-SP treated rats.
4.3.2 Behavioural response to thermal stimuli using radiant heat
i) Saline control experiments
Neither the subcutaneous (n=l 1), nor the intrathecal (sterile, n=6) administration 
of saline resulted in a significant change in paw withdrawal latency following
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thermal stimuli, from the baseline response. Additionally, there was no 
significant difference in paw withdrawal latency to thermal stimuli between 
subcutaneous and intrathecal saline, when the two different routes of 
administration were compared (fig. 4.1).
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Fig. 4.1- The lack of effect o f subcutaneous (black, 0.25ml, n=l 1) and intrathecal (red, 24pl, n=6) 
saline on the rat paw withdrawal latency following thermal stimuli. BL depicts pre-drug baseline 
responses.
ii) Morphine experiments
The subcutaneous administration of morphine (3mg/kg) caused a significant 
increase in paw withdrawal latency, and thus analgesia, when compared to the 
saline control in all of the timepoints tested (p<0.05, n=l 1) (fig.4.2).
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Fig. 4.2- The effects of subcutaneous morphine (red, 3mg/kg) and subcutaneous saline (black, 
0.25ml) on rat paw withdrawal latency following thermal stimuli, n=l 1. BL depicts pre-drug 
baseline responses. Morphine caused a significant increase in paw withdrawal latency when 
compared to the saline control. *P<0.05, where a significant increase in paw withdrawal latency, 
caused by morphine, when compared to the saline control, is seen, /-test.
iii) NMDA experiments
a) NMDA alone- When compared to the intrathecal saline control, NMDA 
(0.3 pg) significantly decreased paw withdrawal latency to thermal stimuli and 
caused thermal hypersensitivity, 5 minutes after its intrathecal administration 
(p<0.05, n=8). After 5 minutes, the response to thermal stimuli resumed baseline 
latencies, until timepoints 20, and 25 minutes, when the paw withdrawal latency 
was significantly increased (p<0.05, n=8), and timepoint 50 minutes, when the 
paw withdrawal latency was significantly decreased (p<0.05, n=8). The latter 
will be noted as a return to baseline level since it still falls within 10-15 seconds, 
which were taken as baseline during the control experiment (fig.4.3).
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Fig. 4.3- The effects of intrathecal NMDA (red, 0.3pg, n=8) and intrathecal saline (black, 24jnl, 
n=6) on rat paw withdrawal latency following thermal stimuli. BL depicts pre-drug baseline 
responses. NMDA caused thermal hypersensitivity when compared to the saline control.
*P<0.05, where a significant change in paw withdrawal latency caused by NMDA, when 
compared to the saline control, is seen, Mest.
b) Morphine+NMDA- The subcutaneous administration of morphine (3mg/kg) 
twenty-five minutes before intrathecal NMDA (0.3pg) in the morphine+NMDA 
treated rats prevented NMDA-induced thermal hypersensitivity following 
NMDA administration. Furthermore, morphine, in the morphine+NMDA treated 
rats, seemed to synergise with the previously-seen NMDA-induced increase in 
paw withdrawal latency to thermal stimuli, since paw withdrawal latency in these 
animals was increased, albeit non-significantly, to a higher level than in the rats 
which were only treated with morphine. Moreover, there was a significant 
increase in the baseline latency following morphine administration, in the 
morphine+NMDA treated rats, when compared to the NMDA treated rats 
(p<0.05, n=8). This was taken into consideration and was the baseline used to 
statistically analyse the data. Finally, the administration of morphine pre-NMDA 
in the morphine+NMDA treated rats seemed to increase paw withdrawal to 
higher latencies than those seen with morphine administration on its own (fig. 
4.4).
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Fig. 4.4- The effects of the combination of morphine+NMDA (blue, n=8) and NMDA alone (red, 
0.3pg, n=8), morphine alone (purple, 3mg/kg, n=l I) and saline control (black, 24pl, n=6) on the 
rat paw withdrawal latency following thermal stimuli. BL depicts pre-drug baseline responses. 
NMDA caused a significant thermal hypersensitivity, when compared to saline control.
Morphine, when administered prior to NMDA, was seen to significantly inhibit the NMDA- 
induced thermal hypersensitivity and also significantly increased paw withdrawal latency 
following thermal stimuli when compared to saline control. Furthermore, morphine on its own 
also caused an increase in paw withdrawal latency to thermal stimuli when compared to NMDA 
on its own and saline control. §P<0.05, where a significant increase from the baseline is seen 
following morphine administration (blue), /-test. *P<0.05, where a significant increase in paw 
withdrawal latency caused by morphine+NMDA, when compared to NMDA alone, is seen. 
#P<0.05, where a significant decrease in paw withdrawal latency was caused by NMDA alone, 
when compared to saline control. 4P<0.05, where a significant increase in paw withdrawal 
latency was caused by each o f morphine alone and morphine+NMDA, when compared to saline 
control. tP<0.05, where a significant increase in paw withdrawal latency was caused by 
morphine alone, when compared to NMDA alone. One way ANOVA followed by Tukey post- 
hoc test.
c) MK-801 alone- The subcutaneous administration of the NMDA receptor 
antagonist MK-801 (0.1 mg/kg) caused no significant change from the 
subcutaneous saline control in all of the timepoints tested (n=7) (fig. 4.5).
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Fig. 4.5- The effects o f subcutaneous MK-801 (red, 0.1 mg/kg, n=7) and subcutaneous saline 
(black, 0.25ml, n=l 1) on rat paw withdrawal latency following thermal stimuli. BL depicts pre­
drug baseline responses.
d) MK-801+NMDA- The subcutaneous administration of MK-801 (0.1 mg/kg) 
twenty-five minutes before intrathecal NMDA (0.3pg) in the MK-801+NMDA 
treated rats prevented the occurrence of NMDA-induced thermal hypersensitivity 
at timepoint 5 minutes (p<0.05, n=8) (fig. 4.6).
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Fig. 4.6- The effects o f the combination o f MK-801+NMDA (blue, n=8) and NMDA alone (red, 
0.3|ng, n=8), MK-801 alone (purple, O.lmg/kg, n=7) and saline control (black, 24pl, n=6) on the 
rat paw withdrawal latency following thermal stimuli. BL depicts pre-drug baseline responses. 
NMDA caused a significant thermal hypersensitivity, when compared to saline control and MK- 
801 on its own. MK-801, when administered prior to NMDA, significantly inhibited the NMDA- 
induced thermal hypersensitivity, returning the response to baseline level, and significantly 
increased paw withdrawal latency to thermal stimuli at timepoint 15min, when compared to 
saline control and MK-801 on its own. *P<0.05, where a significant increase in paw withdrawal 
latency was caused by MK-801+NMDA, when compared to NMDA alone. #P<0.05, where a 
significant decrease in paw withdrawal latency was caused by NMDA, when compared to saline 
control and MK-801 on its own. tP<0.05, where a significant increase in paw withdrawal latency 
was caused by MK-801+NMDA, when compared to saline. One way ANOVA followed by 
Tukey post-hoc test.
iv) NK-1 experiments
a) Sar-SP alone- Three doses of Sar-SP, 9, 3 and 1 pg, were tested on the thermal 
response, in order to choose which one caused a significant thermal 
hypersensitivity with a short-lived BSL behaviour which would not interfere 
greatly with the testing. Doses 9pg and lpg both caused 55±5 minutes of BSL 
behaviour, whereas dose 3pg, as well as causing significant thermal 
hypersensitivity, only led to 21 ±7 minutes of BSL behaviour (fig. 4.7).
Therefore, Sar-SP dose 3pg was used for the subsequent experiments.
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Fig. 4.7- The effects of doses 9 (red), 3 (blue) and 1 |ixg (purple) Sar-SP and intrathecal saline 
(black, 24pl, n=6) on the rat paw withdrawal latency following thermal stimuli. BL depicts pre­
drug baseline responses.
When compared to the intrathecal saline control, intrathecal Sar-SP (3pg) caused 
a significant decrease in paw withdrawal latency to heat stimuli, and thus thermal 
hypersensitivity (p<0.05, n=7) (fig. 4.8).
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Fig. 4.8- The effects o f intrathecal Sar-SP (red, 3 jig, n=7) and intrathecal saline (black, 24jil, 
n=6) on rat paw withdrawal latency following thermal stimuli. BL depicts pre-drug baseline 
responses. Sar-SP caused thermal hypersensitivity when compared to the saline control. *P<0.05, 
where a significant decrease in paw withdrawal latency caused by Sar-SP, when compared to the 
saline control, is seen, /-test.
b) Morphine+Sar-SP- The subcutaneous administration of morphine (3mg/kg) 
ten minutes prior to intrathecal Sar-SP (3pg) in the morphine+Sar-SP treated rats 
resulted in a significant increase in paw withdrawal latency to thermal stimuli 
(p<0.05, n=7) (fig.4.9), when compared to the Sar-SP treated rats. This increase 
in paw withdrawal latency in the morphine+Sar-SP treated rats shifted the whole 
response back to baseline level, but not to the same level as when morphine was 
administered alone, except at timepoints 45 and 50 minutes, when morphine 
administered on its own was resuming baseline levels. Finally, there was an 
increase in the baseline in the morphine+Sar-SP treated rats, following morphine 
administration, which was significantly different to the old baseline before any 
drug addition, and this new baseline was the one used in the statistical analysis.
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Fig. 4.9- The effects o f the combination o f morphine+Sar-SP (blue, n=7) and Sar-SP alone (red, 
3pg, n=7), morphine alone (purple, 3mg/kg, n=l 1) and saline control (black, 24pl, n=6) on the rat 
paw withdrawal latency following thermal stimuli. BL depicts pre-drug baseline responses. Sar- 
SP significantly decreased paw withdrawal latency to thermal simuli, when compared to saline 
control. Morphine, when administered prior to Sar-SP, significantly inhibited the Sar-SP-induced 
thermal hypersensitivity, returning the response to baseline level. §P<0.05, where a significant 
increase from the baseline is seen following morphine administration (blue), /-test. *P<0.05, 
where a significant increase in paw withdrawal latency caused by morphine+Sar-SP, when 
compared to Sar-SP alone, is seen. #P<0.05, where a significant increase in paw withdrawal 
latency caused by morphine on its own, when compared to Sar-SP, saline control and the 
combined administration o f morphine+Sar-SP is seen. tP<0.05, where a significant increase in 
paw withdrawal latency is seen following morphine on its own, when compared to saline control. 
One way ANOVA followed by Tukey post-hoc test.
c) RP-67,580 experiments- Initially, it seemed that the intrathecal administration 
of RP-67,580 (3pg) alone caused a significant increase in paw withdrawal 
latencies to thermal stimuli at timepoints 50 and 60 minutes (p<0.05, n=6) (fig. 
4.10), when compared to the intrathecal saline control. Therefore, the timing of 
the administration of each of RP-67,580 (3 pg) and Sar-SP (3 pg) intheRP- 
67,580+Sar-SP treated rats, so that both agents peaked together, was based on the 
aforementioned, in that RP-67,580 was given 30 minutes prior to Sar-SP. 
However, this protocol turned out to be inaccurate, as when RP-67,580 was 
given 30 minutes before Sar-SP, in the RP-67,580+Sar-SP treated rats, it did not
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reverse the thermal hypersensitivity seen due to Sar-SP (fig. 4.11). Therefore, 
another dosing protocol was used, where RP-67,580 was administered 10 
minutes prior to Sar-SP in the RP-67,580+Sar-SP treated rats. This was based on 
a previous study which showed the significant effects of RP-67,580 in reversing 
thermal hypersensititivity following intrathecal SP (Hua, Chen et al. 1999). With 
the new dosing protocol, RP-67,580 was able to significantly reverse the thermal 
hypersensitivity seen following Sar-SP administration, in the RP-67,580+Sar-SP 
treated rats (p<0.05, n=6) (fig. 4.12), thus showing that there was no true effect 
of RP-67,580 on paw withdrawal latency following thermal stimuli.
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Fig. 4.10- The effects of intrathecal RP-67,580 (red, 3pg) and intrathecal saline (black, 24(0.1) on 
rat paw withdrawal latency following thermal stimuli. n= 6. BL depicts pre-drug baseline 
responses. RP-67,580 caused a significant increase in paw withdrawal latency to thermal stimuli 
when compared to the saline control. *P<0.05, where a significant increase in paw withdrawal 
latency caused by RP-67,580, when compared to the saline control, is seen, /-test.
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Fig. 4.11- The effects of the combination of RP-67,580+Sar-SP (blue, n=12) and Sar-SP alone 
(red, 3|ig, n=7), RP-67,580 alone (purple, 3pg, n=6) and saline control (black, 24pl, n=6) on the 
rat paw withdrawal latency following thermal stimuli, when RP-67,580 is administered 30 
minutes prior to Sar-SP in the RP-67,580+Sar-SP treated rats, which showed that RP67,580 had 
no effect on the Sar-SP-induced thermal hypersensitivity. BL depicts pre-drug baseline responses
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Fig. 4.12- The effects of the combination of RP-67,580+Sar-SP (blue, n=6) and Sar-SP alone 
(red, 3(ig, n=7), RP-67,580 alone (purple, 3pg, n=6) and saline control (black, 24pl, n=6) on the 
rat paw withdrawal latency following thermal stimuli, when RP-67,580 is administered 10 
minutes prior to Sar-SP in the RP-67,580+Sar-SP treated rats. BL depicts pre-drug baseline 
responses. Sar-SP caused a significant decrease in paw withdrawal latency to thermal stimuli, 
when compared to saline control. RP-67,580, when administered prior to Sar-SP, was seen to 
significantly inhibit the Sar-SP-induced thermal hypersensitivity, returning the response to 
baseline level. *P<0.05, where a significant increase in paw withdrawal latency caused by RP- 
67,580+Sar-SP, when compared to Sar-SP alone, is seen. #P<0.05, where a significant decrease 
in paw withdrawal latency was caused by Sar-SP, when compared to saline control. tP<0.05, 
where a significant increase in paw withdrawal latency was seen, when comparing RP-67,580 to 
Sar-SP. §P<0.05, where a significant increase in paw withdrawal latency was seen, when 
comparing RP-67,580 to the combined effect o f RP-67,580+Sar-SP. One way ANOVA followed 
by Tukey post-hoc test.
d) DMSO alone- Since RP-67,580 was dissolved in 20% DMSO, it was essential 
to investigate whether this agent caused any effects when administered on its 
own. I found that 20% DMSO resulted in no significant change in paw 
withdrawal latency to thermal stimuli, when compared to the intrathecal saline 
control (n=6) (fig. 4.13).
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Fig. 4.13- The lack o f effect o f intrathecal DMSO (red, 24pl) and intrathecal saline (black, 24pl) 
on rat paw withdrawal latency following thermal stimuli. n= 6. BL depicts pre-drug baseline 
responses.
4.3.3 Behavioural response to tactile stimuli using von Frey monofilaments
i) Saline control experiments
Neither the subcutaneous (n=l 1), nor the intrathecal (sterile, n=10) 
administration of saline resulted in a significant change from the baseline in the 
paw withdrawal threshold following tactile stimuli. Furthermore, no significant 
change in the paw withdrawal threshold was seen when the two routes of saline 
administration were compared (figs 4.14).
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Fig. 4.14- The lack of effect o f subcutaneous (black, 0.25ml, n=l 1) and intrathecal (red, 24pl, 
n=10) saline on the rat paw withdrawal threshold following tactile stimuli. BL depicts pre-drug 
baseline responses.
ii) Morphine experiments
When compared to the subcutaneous saline control, the subcutaneous 
administration of morphine (3mg/kg) caused a significant increase in paw 
withdrawal threshold to mechanical stimuli, and thus analgesia, at timepoint 30 
minutes (p<0.05, n=l 1) (fig. 4.15).
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Fig. 4.15- The effects o f subcutaneous morphine (red, 3mg/kg) and subcutaneous saline (black, 
0.25ml) on rat paw withdrawal threshold following tactile stimuli, n=l 1. BL depicts pre-drug 
baseline responses. Morphine caused a significant increase in paw withdrawal threshold when 
compared to the saline control. *P<0.05, where a significant increase in paw withdrawal 
threshold caused by morphine, when compared to the saline control, is seen, /-test.
iii) NMDA experiments
a) NMDA alone- The intrathecal administration of NMDA (0.3 pg) on its own 
caused a significant decrease in paw withdrawal threshold, and thus caused 
tactile hypersensitivity, at timepoint 5 minutes (p<0.05, n=8), when compared to 
the intrathecal saline control (4.16).
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Fig. 4.16- The effects of intrathecal NMDA (red, 0.3(ng, n=8) and intrathecal saline (black, 24pl, 
n=10) on rat paw withdrawal threshold following tactile stimuli. BL depicts pre-drug baseline 
responses. NMDA caused tactile hypersensitivity when compared to the saline control. *P<0.05, 
where a significant decrease in paw withdrawal threshold caused by NMDA, when compared to 
the saline control, is seen, Mest.
b) Morphine+NMDA- The subcutaneous administration of morphine (3mg/kg) 
twenty-five minutes prior to the intrathecal administration of NMDA (0.3 pg) in 
the morphine+NMDA treated rats caused analgesia, increasing the paw 
withdrawal threshold, when compared to the NMDA treated rats (fig. 4.17).
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Fig. 4.17- The effects of the combination of morphine+NMDA (blue, n=8) and NMDA alone 
(red, 0.3pg, n=8), morphine alone (purple, 3mg/kg, n=l 1) and saline control (black, 24pl, n=10) 
on the rat paw withdrawal threshold following tactile stimuli. BL depicts pre-drug baseline 
responses. NMDA caused a significant decrease in paw withdrawal threshold, when compared to 
saline control, and to morphine on its own. Morphine, when administered prior to NMDA, 
prevented the NMDA-induced tactile hypersensitivity, returning the response to higher than 
saline control level. *P<0.05, where a significant increase in paw withdrawal threshold is caused 
by morphine+NMDA, when compared to NMDA alone, is seen. #P<0.05, where a significant 
decrease in paw withdrawal threshold was caused by NMDA, when compared to saline control. 
§P<0.05, where a significant increase in paw withdrawal threshold was seen when comparing 
morphine on its own to saline control. tP<0.05, where a significant increase in paw withdrawal 
threshold was seen when comparing morphine on its own to NMDA on its own. One way 
ANOVA followed by Tukey post-hoc test.
c) MK-801 alone- The subcutaneous administration of MK-801 (0.1 mg/kg) did 
not cause the paw withdrawal threshold to significantly change, when compared 
with the subcutaneous saline control (n=8) (fig. 4.18).
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Fig. 4.18- The lack of effect o f subcutaneous MK-801 (red, O.lmg/kg, n=8) and subcutaneous 
saline (black, 0.25ml, n=l 1) on rat paw withdrawal threshold following tactile stimuli. BL depicts 
pre-drug baseline responses.
d) MK-801+NMDA- The subcutaneous administration of MK-801 (O.lmg/kg) 
twenty-five minutes before the intrathecal administration of NMDA (0.3 pg) in 
the MK-801+NMDA treated rats caused a significant increase in paw withdrawal 
threshold at timepoint 5 minutes (p<0.05, n=8), when compared to the NMDA 
treated rats (fig. 4.19).
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Fig. 4.19- The effects o f the combination of MK-801+NMDA (blue, n=8) and NMDA alone (red, 
0.3pg, n=8), MK-801 alone (purple, 0.1 mg/kg, n=8) and saline control (black, 24pl, n=10) on the 
rat paw withdrawal threshold following tactile stimuli. BL depicts pre-drug baseline responses. 
NMDA caused a significant decrease in paw withdrawal threshold, when compared to saline 
control and to MK-801 on its own. MK-801, when administered prior to NMDA, prevented the 
NMDA-induced tactile hypersensitivity, but did not return the response to baseline level.
*P<0.05, where a significant increase in paw withdrawal threshold caused by MK-801+NMDA, 
when compared to NMDA alone, is seen. #P<0.05, where a significant decrease in paw 
withdrawal threshold was caused by NMDA, when compared to saline control and MK-801 on its 
own. One way ANOVA followed by Tukey post-hoc test.
iv) NK-1 experiments
a) Sar-SP alone- When compared to the subcutaneous saline control, the 
intrathecal administration of Sar-SP (3pg) caused a significant decrease in paw 
withdrawal threshold at timepoints 5 and 20 minutes (p<0.05, n=6) (fig. 4.20). 
The greater tactile hypersensitivity seen at timepoint 20 minutes could be seen as 
further proof that the activity of Sar-SP peaks at this time.
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Fig. 4.20- The effects of intrathecal Sar-SP (red, 3pg, n=8) and intrathecal saline (black, 24|_il, 
n=10) on rat paw withdrawal threshold following tactile stimuli. BL depicts pre-drug baseline 
responses. Sar-SP caused tactile hypersensitivity when compared to the saline control. *P<0.05, 
where a significant decrease in paw withdrawal threshold caused by Sar-SP, when compared to 
the saline control, is seen, /-test.
b) Morphine+Sar-SP- The subcutaneous administration of morphine (3mg/kg) 
twenty-five minutes before the intrathecal administration of Sar-SP (3pg) in the 
morphine+Sar-SP treated rats caused analgesia at timepoints 20 minutes (p<0.05, 
n=8), when compared to the Sar-SP treated rats (fig. 4.21). This increase was 
enough to make the paw withdrawal threshold at this timepoint at the same level 
as when the rats were treated only with morphine.
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Fig. 4.21- The effects of the combination of morphine+Sar-SP (blue, n=8) and Sar-SP alone (red, 
3pg, n=8), morphine alone (purple, 3mg/kg, n=l 1) and saline control (black, 24pl, n=10) on the 
rat paw withdrawal threshold following tactile stimuli. BL depicts pre-drug baseline responses. 
Sar-SP caused a significant decrease in paw withdrawal threshold, when compared to saline 
control and to morphine on its own. Morphine, when administered prior to Sar-SP, prevented the 
Sar-SP-induced tactile hypersensitivity, returning the response to higher than saline control level. 
*P<0.05, where a significant increase in paw withdrawal threshold caused by morphine+Sar-SP, 
when compared to Sar-SP alone, is seen. #P<0.05, where Sar-SP caused a significant decrease in 
paw withdrawal threshold, when compared to saline control. tP<0.05, where Sar-SP caused a 
significant decrease in paw withdrawal threshold, when compared to morphine on its own. 
§P<0.05, where morphine on its own, and when combined with Sar-SP, caused a significant 
increase in paw withdrawal threshold, when compared to saline control. One way ANOVA 
followed by Tukey post-hoc test.
c) RP-67,580 experiments- The intrathecal administration of RP-67,580 (3pg) on 
its own did not cause any significant difference in the paw withdrawal threshold 
following mechanical stimuli, when compared with the intrathecal saline control 
(n=7) (fig. 4.22).
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Fig. 4.22- The lack of effect o f intrathecal RP-67,580 (red, 3pg, n=7) and intrathecal saline 
(black, 24pl, n=10) on rat paw withdrawal threshold following tactile stimuli. BL depicts pre­
drug baseline responses.
The intrathecal administration of RP-67,580 (3jng), thirty minutes prior to that of 
Sar-SP(3pg), in the RP-67,580+Sar-SP treated rats caused a significant increase 
in the paw withdrawal threshold at timepoint 20 minutes, when compared to the 
Sar-SP treated rats (p<0.05, n=8) (fig. 4.23).
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Fig. 4.23- The effects of the combination of RP-67,580+Sar-SP (blue, n=6) and Sar-SP alone 
(red, 3pg, n=8), RP-67,580 alone (purple, 3pg, n=7) and saline control (black, 24pl, n=10) on the 
rat paw withdrawal threshold following tactile stimuli, when RP-67,580 is administered 10 
minutes prior to Sar-SP in the RP-67,580+Sar-SP treated rats. BL depicts pre-drug baseline 
responses. Sar-SP caused a significant increase in paw withdrawal threshold, when compared to 
saline control. RP-67,580, when administered prior to Sar-SP, prevented the Sar-SP-induced 
tactile hypersensitivity, returning the response to baseline level. *P<0.05, where a significant 
increase in paw withdrawal threshold caused by RP-67,580+Sar-SP, when compared to Sar-SP 
alone, is seen. #P<0.05, where Sar-SP caused a significant decrease in paw withdrawal threshold, 
when compared to saline control and to RP-67,580 on its own. One way ANOVA followed by 
Tukey post-hoc test.
d) DMSO alone- The intrathecal administration of 20% DMSO did not cause any 
significant change in the paw withdrawal threshold when compared to the 
intrathecal saline control (n=10) (fig. 4.24).
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Fig. 4.24- The lack o f effect o f intrathecal DMSO (red, 24pl) and intrathecal saline (black, 24|il) 
on rat paw withdrawal threshold following tactile stimuli. n= 10 for both. BL depicts pre-drug 
baseline responses.
4.3.4 Rotarod experiments
i) Morphine experiment
Morphine (3mg/kg) was the only drug used in this study which significantly 
increased both the paw withdrawal latency to thermal stimuli and the paw 
withdrawal threshold following mechanical stimuli, before the chemical 
induction of hyperalgesia with NMDA and Sar-SP. Therefore, rotarod 
experiments were performed on rats injected with morphine (3mg/kg), and 
compared to subcutaneous saline controls, to make sure that morphine at this 
dose and via this route was not causing sedation. In agreement with an earlier 
study (Urch, Donovan-Rodriguez et al. 2005), these experiments showed that 
there was no significant difference in the time spent on the beam between the rats 
that were injected with subcutaneous saline (n=6) and those that were injected 
with subcutaneous morphine (n=7) (fig. 4.25).
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Fig. 4.25- The time in seconds taken to fall off the rotarod beam following subcutaneous saline 
(black, 0.25ml, n=6) and subcutaneous morphine (red, 3mg/kg, n=7) administration in normal 
rats. BL depicts pre-drug baseline responses.
ii) MK-801 experiment
MK-801 (0.1 mg/kg) has been shown to cause motor disturbances by a previous 
study (Coderre and Van Empel 1994), which is why I have tested if the dose used 
in this study had any effects on ambulation, using the rotarod. These results show 
that there was no significant difference in the time spent on the beam between the 
rats that were injected with subcutaneous saline (n=6) and those that were 
injected with 0.1 mg/kg subcutaneous MK-801 (n=8) (fig. 4.26).
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Fig. 4.26- The time taken to fall off the rotarod beam following subcutaneous saline (black, 
0.25ml, n=6) and subcutaneous MK-801 (red, 3mg/kg, n=8) administration in normal rats. BL 
depicts pre-drug baseline responses.
4.4 Discussion
I have shown in my study that the activation of both NMD A and NK-1 receptors 
caused biting, scratching and licking behaviour. However, grooming was only 
observed after NK-1 receptor activation, which also induced a longer lasting 
nociceptive hypersensitivity. Each respective antagonist used was more effective 
in inhibiting the hypersensitivities than the biting, scratching and licking 
behavioural response. Furthermore, even though morphine significantly inhibited 
the thermal and tactile hypersensitivity which arose following the activation of 
these two receptors, morphine was more effective in inhibiting the NMDA 
receptor activation induced events, than the ones due to NK-1 receptor 
activation.
4.4.1 Biting, scratching and licking behaviour
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NMDA is a very potent and selective NMDA receptor agonist, and Sar-SP is an 
NK-1 selective agonist which is more potent and longer lasting than SP (Yip and 
Chahl 1999), thus ensuring that each receptor was selectively activated by its 
respective agonist. Whereas the intrathecal administration of NMDA caused 5 
minutes of biting, scratching and licking behaviour, that of Sar-SP caused 21 
minutes of intense biting, scratching, licking and grooming behaviour which kept 
breaking through after the first 21 minutes, for the whole duration of the 
experiment. Intrathecal SP has been shown to cause biting, scratching and licking 
behaviour in rats, which does not exceed 3 minutes (Seybold, Hylden et al.
1982).
i) NMDA receptor activation and BSL
An important point which needs to be made is that even though glycine, and 
glutamate are available in the spinal cord to act on the NMDA receptor, this 
receptor still needs the summation of the depolarisations caused by glutamate 
and SP, acting on non-NMDA receptors and the NK-1 receptor respectively, in 
order for the magnesium block to be removed and the receptor’s activation to 
occur (Thompson, King et al. 1990; Xu, Dalsgaard et al. 1992). However, the 
intrathecal administration of NMDA in this and previous studies (Aanonsen, Lei 
et al. 1990; Davis and Inturrisi 2001) did cause a short-lasting hyperalgesia, 
following the BSL behaviour, which means that the receptor was activated and 
did move the dorsal horn spinal cord into increased excitability.
Several subunits of the NMDA receptor exist, with different sensitivities to the 
Mg2+ block. The NR2D subunit has a low sensitivity to Mg2+ block, but it is 
mostly found extrasynaptic in the spinal cord, with lower levels found in the 
central terminal of primary afferent fibres. However, the two subunits found 
mostly in the spinal cord are the NR2A and NR2B subunits, and they have a high 
sensitivity to the Mg block (Petrenko, Yamakura et al. 2003). Therefore, I will 
postulate, like the study of Chapman et al suggested, in 1994, that the NMDA 
receptor activation could be submaximal and still lead to facilitation in dorsal 
horn neuronal responses (Chapman, Dickenson et al. 1994). Additionally, it
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could be that the BSL behaviour which arises immediately after the 
administration of intrathecal NMDA, is responsible for aiding in the activation of 
the NMDA receptor and the resulting hypersensitivities (discussed in more detail 
below in paragraph v).
ii) The effect of morphine on BSL behaviour
In my study, morphine only significantly decreased the behaviour which arised 
following the activation of the NMDA receptor, but did not abolish it. This was 
also true in the study by (Aanonsen and Wilcox 1987), which used intrathecal 
morphine and NMDA in mice, and showed that a higher dose of morphine was 
needed to block the behavioural response following intrathecal NMDA, than that 
needed to reduce the hyperalgesic response. Furthermore, the finding in my study 
that intrathecal morphine did not inhibit the behaviour due to the activation of the 
NK-1 receptor was also shown in the study by Bossut et al, using intrathecal SP 
to activate the NK-1 receptor (Bossut, Frenk et al. 1988).
iii) The effect of the antagonists on BSL behaviour
Previous studies have shown that the spinal NK-1 and NMDA receptors interact, 
since the co-administration of SP and NMDA potentiate each other’s effects. The 
latter was shown in previous behavioural studies, where the intrathecal co­
administration of SP and NMDA, each in a lower dose that did not lead to effects 
in mice, caused the potentiation of the biting and scratching response, as well as 
the potentiation of both phases of the formalin response (Mjellem-Joly, Lund et 
al. 1991; Mjellem-Joly, Lund et al. 1992), which could also mean that the effects 
seen after the activation of one of these receptors is partly due to the activation of 
the other. Indeed, one behavioural study has shown that the intrathecal 
administration of an NMDA antagonist decreases the biting, scratching and 
licking behaviour which occurs following both intrathecal SP and NMDA in rats 
(Okano, Kuraishi et al. 1993). In addition, the intrathecal administration of each 
of SP and NMDA facilitated the flexor reflex in decrebrated rats, and the 
administration of an NMDA antagonist was effective in reducing both the SP-
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and NMDA-induced facilitation of the flexor reflex (Xu, Dalsgaard et al. 1992). 
Furthermore, the nociceptive behaviour which occurred following intrathecal 
NMDA was partly reduced by the NK-1 receptor antagonist RP-67,580 (Tan-No, 
Esashi et al. 2004).
The concentration of the NK-1 and NMDA antagonists used in this study, RP- 
67,580 and MK-801, respectively, must have been too low to inhibit the 
behaviour seen due to the activation of any of the NK-1 and NMDA receptors. 
The lack of effect of low-dose MK-801 on the BSL behaviour was shown in 
previous studies, the first using intrathecal D-APV in mice (Aanonsen and 
Wilcox 1987), and the second using intrathecal CPP in rats (Alvarez-Vega, 
Baamonde et al. 2000), where it was shown that higher doses of NMDA receptor 
antagonists are needed to inhibit the behavioural response than those needed to 
inhibit the hyperalgesic and analgesic responses following intrathecal NMDA, 
respectively. The low dose of MK-801 was chosen in order to cause significant 
block of the NMDA receptor, whilst avoiding the motor effects associated with 
higher doses of MK-801 (Coderre and Van Empel 1994). Additionally, the dose 
and route of administration of RP-67,580 were also based on a previous study, 
which reported a weak CNS penetration of RP-67,580 after systemic 
administration (Parsons, Honda et al. 1996; Pawlak, Schmidt et al. 2001; 
Rupniak, Carlson et al. 2003). Therefore, RP-67,580 was administered 
intrathecally.
Earlier studies have shown that each of SP and Glutamate enhance each other’s 
release (Malcangio, Fernandes et al. 1998; Hua, Chen et al. 1999), and that the 
NK-1 antagonist RP-67,580 was able to significantly reduce part of the BSL 
behaviour arising from intrathecal NMDA (Liu, Mantyh et al. 1997). However, 
in my study, the intrathecal administration of saline (0.9%) did not cause any of 
the BSL behaviour, and the behaviour which occurred following the activation of 
each of the NK-1 and NMDA receptors was different in quality, with NMDA 
receptor activation causing biting, scratching and licking, whereas NK-1 receptor 
activation causing BSL as well as excessive grooming. Therefore, I conclude that 
the BSL following the activation of each of the NK-1 and NMDA receptor is due
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partly to the activation of each receptor by its agonist, and partly due to the 
effects of the other receptor.
iv) What does BSL behaviour show?
A previous study has shown that excitatory amino acids which do not cause 
nociception and which do not act on the NMDA receptor also cause the BSL 
behaviour seen in this study (Aanonsen and Wilcox 1987), and that only if 
morphine or any other known analgesic can reduce that behaviour, should the 
behaviour be linked to pain sensation. Furthermore, other studies postulated that 
the behaviour elicited by intrathecal SP, as opposed to that elicited by intrathecal 
glutamate, is not indicative of pain, but rather, that this behaviour indicates a 
motoneuron response (Nagy, Maggi et al. 1993), and a spinal convulsive state 
(Bossut, Frenk et al. 1988). The latter study also showed that spinalisation did 
not affect the SP-induced behaviour, whereas spinalisation potentiated the 
behaviour due to intrathecal glutamate. Additionally, the same behaviour seen 
following intrathecal SP is also seen following acetic acid (0.1N) or hypertonic 
saline (6%) administration (Wilcox 1988). Therefore, care must be taken when 
extrapolating from any BSL behaviour.
Higher doses of intrathecal NMDA have led to vocalisation (Aanonsen and 
Wilcox 1987; Wilcox 1988), but not excessive grooming, whereas even the 
highest dose of intrathecal SP does not cause vocalisation (Wilcox 1988), and in 
my study, low to high doses of Sar-SP all cause grooming and no vocalisation, 
whereas the dose of NMDA used here was not enough to cause vocalisation. If 
vocalisation is a marker for the sensation of pain, and since morphine only 
inhibited the BSL behaviour due to the activation of the NMDA receptor, then 
one could postulate that only the BSL behaviour which occurs following the 
NMDA receptor activation depicts pain sensation (Aanonsen and Wilcox 1987; 
Wilcox 1988; Alvarez-Vega, Baamonde et al. 2000).
v) Conclusion
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Even though the activation of each the NMDA and the NK-1 receptors caused 
thermal and tactile hypersensitivities, BSL behaviour due to the activation of 
each of these receptors still constitutes a grey area as to which sensation is being 
depicted.
However, since it has been shown by my study, as well as previous ones, that 
lower doses of antagonist or morphine were required to reduce the hyperalgesic 
responses seen following the activation of each of the NK-1 and the NMDA 
receptor, than the dose needed to block the behaviour seen following the 
activation of each of these receptors (Aanonsen and Wilcox 1987; Wilcox 1988; 
Alvarez-Vega, Baamonde et al. 2000), then one could postulate that the 
secondary mechanisms underlying BSL behaviour and hypersensitive responses 
could be distinct, even though both responses partly begin with the activation of 
the receptor in question.
In addition, since the BSL behaviour following the activation of one receptor can 
be partly inhibited by antagonists at the other receptor (Okano, Kuraishi et al. 
1993; Liu, Mantyh et al. 1997; Tan-No, Esashi et al. 2004), and since other 
compounds besides those acting at the NK-1 and the NMDA receptors may also 
lead to BSL behaviour (Aanonsen and Wilcox 1987; Wilcox 1988), this 
behaviour which arises immediately following the intrathecal administration of 
each agonist can serve to ‘prime’ the spinal cord dorsal horn neurons into 
excitability, by aiding to remove the Mg block of the NMDA receptor for 
example, and thus causing the manifestation of the hypersensitivities seen in 
previous studies, as well as mine.
4.4.2 NMDA and NK-1 receptor activation and hypersensitivity response
Each of NMDA and Sar-SP caused thermal hypersensitivity in the rats, which 
manifested itself as a decrease in the latency of paw withdrawal to radiant heat. 
However, NMDA only caused 5 minutes of such a hypersensitive response, and 
then caused analgesia for some minutes, until the response returned to baseline,
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whereas Sar-SP caused a more prolonged hypersensitivity to thermal stimuli, 
which lasted for half of the duration of the experiment.
Furthermore, each of NMDA and Sar-SP also caused tactile hypersensitivity in 
the rats. Again, whereas NMDA only caused 5 minutes of tactile hypersensitivity 
in the rats, with the response normalising 30 minutes after its administration, Sar- 
SP caused significant tactile hypersensitivity at both 5 and 20 minutes following 
its administration.
i) NMDA receptor activation
The dose of NMDA used in this study was based on a previous study showing 
that this dose caused both BSL and thermal hyperalgesia (Davis and Inturrisi
2001). The biphasic effect of NMDA receptor activation has been shown by 
previous studies, both electrophysiological (Chapman, Dickenson et al. 1994) 
and behavioural (Raigorodsky and Urea 1987; Kolhekar, Meller et al. 1993). The 
analgesia seen following the administration of NMDA could be due to the 
activation of descending inhibitions. Descending inhibitions, as discussed in 
section 1.8.2, originate from the RVM and are thought to inhibit spinal cord 
dorsal horn excitability (Millan 2002). NMDA administration in the rat PAG has 
been previously shown to cause analgesia (Jacquet 1988), and in agreement with 
my study, intrathecal NMDA has been previously shown to have a bidirectional 
effect causing both nociception and antinociception (Raigorodsky and Urea 
1987; Chapman, Dickenson et al. 1994). Indeed, in one study, spinalisation 
blocked the NMDA-induced inhibition in a previous behavioural study 
(Kolhekar, Meller et al. 1993). However, in another study, spinalisation seemed 
to enhance NMDA-mediated analgesia, which was taken to mean that the 
mechanisms underlying NMDA-induced analgesia could be spinal (Raigorodsky 
and Urea 1987). The differences between these last two studies are the area and 
method of spinalisation, whereas Kolkehar et al spinalised the rats reversibly by 
cold block at the segments T8-T10, Raigorodsky et al transected the spinal cord 
at the T5-T7 segments.
183
ii) NK-1 receptor activation
The hypersensitive effects of Sar-SP seem to be distinct from its behavioural 
BSL action: the latter starts immediately after administration and lasts for 21 
minutes. In fact, it seems as though the hypersensitive action of Sar-SP starts 
when its behavioural action subsides, because even though it might seem that the 
BSL behaviour could be masking the hypersensitivity in the hargreaves test, the 
mechanical test involving the von Frey monofilaments showed that the peak 
action of Sar-SP was at 20 minutes following its intrathecal administration. 
Therefore, as was confirmed in a previous study (Rygh, Suzuki et al. 2006), 
intrathecal Sar-SP exerted its maximal hypersensitive effect 20 minutes after 
administration.
4.4.3 Antagonist studies
In my study, the administration of each of MK-801 and RP-67,580 on its own did 
not alter the baseline level of pain transmission, but did reduce the thermal and 
tactile hypersensitivity which occurred following the administration of each of 
NMDA and Sar-SP, respectively. This is in agreement with many studies which 
showed that neither the NMDA (Dickenson and Sullivan 1987; Haley, Sullivan 
et al. 1990; Davar, Hama et al. 1991; Yamamoto and Yaksh 1992; Ma, Allchome 
et al. 1998) nor the NK-1 receptor (Seguin, Le Marouille-Girardon et al. 1995; 
Parsons, Honda et al. 1996; Coudore-Civiale, Courteix et al. 1998; Ma,
Allchome et al. 1998) is thought to be involved in the baseline transmission of 
noxious stimuli.
These previous studies showed that antagonists at each of the NMDA and the 
NK-1 receptor are effective in decreasing hyperalgesia due to: surgical (Davar, 
Hama et al. 1991; Yamamoto and Yaksh 1992; Coudore-Civiale, Courteix et al.
1998) or diabetes-induced neuropathy (Coudore-Civiale, Courteix et al. 1998), 
the second but not the first phase of the formalin response (Seguin, Le Marouille- 
Girardon et al. 1995) and in the CFA model of inflammation (Parsons, Honda et 
al. 1996; Ma, Allchome et al. 1998), as well as decreasing the second but not
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first phase of dorsal horn neuronal excitability following formalin (Haley, 
Sullivan et al. 1990), and the hyperexcitability of spinal cord dorsal horn neurons 
(Dickenson and Sullivan 1987), but not baseline responses. The fact that each of 
MK-801 and RP-67,580 reversed the thermal and tactile hypersensitivity due to 
the administration of each of NMDA and Sar-SP, respectively, shows that each 
of the nociceptive responses seen in this study was due to the activation of each 
specific receptor.
4.4.4 Morphine modulation of the thermal and tactile hypersensitivity
The administration of morphine on its own led to analgesia, causing significant 
increases in paw withdrawal latency and threshold to thermal and tactile stimuli, 
respectively, to levels higher than baseline responses. With the morphine dose 
used in my study, which was based on previous studies (Field, McCleary et al. 
1999; Urch, Donovan-Rodriguez et al. 2005), the analgesia due to morphine 
occurred without sedation. The lack of sedation was demonstrated when I 
showed that the rats injected with this dose of morphine stayed on the rotarod 
beam for the same period of time as those injected with saline.
i) Thermal hypersensitivity
When morphine was administered with each of NMDA and Sar-SP, it was 
effective in increasing the latency of paw withdrawal to radiant heat.
However, the effect of morphine, when NMDA activation had occurred, was 
even greater than when morphine was acting on its own, thus showing some kind 
of synergism between the analgesic effects of the p-opioid receptor and those of 
the NMDA receptor, as the increase in morphine analgesia when the NMDA 
receptor was activated, correlated well in time with the analgesia due to when 
only the NMDA receptor was activated. As was previously mentioned above, 
supraspinal (Jacquet 1988) and spinal (Raigorodsky and Urea 1987; Chapman, 
Dickenson et al. 1994) NMDA receptor activation has been shown to cause 
antinociception, and morphine exerts part of its analgesic action via supraspinal 
sites (Heinricher 1997). Contrary to the synergism with NMDA, the effect of
185
morphine, when the NK-1 receptor was activated, only extended to normalising 
the response to baseline, and was less than when morphine was administered on 
its own.
ii) Tactile hypersensitivity
When morphine and each of NMDA and Sar-SP were administered together, 
morphine significantly increased the responses to tactile stimuli to levels higher 
than baseline in each case.
4.4.5 NMDA versus NK-1
The activation of each of the spinal NMDA and NK-1 receptors has been shown 
to be involved in wind-up and central sensitisation (see sections 1.7.4 and 3.4.2) 
(Xu, Dalsgaard et al. 1992; Dougherty, Palecek et al. 1993; Rusin, Bleakman et 
al. 1993; Rusin, Jiang et al. 1993; Yaksh, Hua et al. 1999). Central sensitisation 
is thought to underlie abnormal pain sensations, such as hyperalgesia and 
allodynia, seen in models of chronic pain states, such as neuropathic pain.
However, although the behaviour arising after intrathecal NMDA and Sar-SP is 
quite distinct in quality and time, numerous studies have shown that the 
activation of one of the NMDA or NK-1 receptors ultimately leads to the 
activation of the other, since presynaptic NMDA receptors cause further release 
of SP from primary afferent terminals (Liu, Wang et al. 1994; Liu, Mantyh et al. 
1997; Malcangio, Fernandes et al. 1998), and since SP and glutamate co-exist on 
some primary afferent terminals (Battaglia and Rustioni 1988; De Biasi and 
Rustioni 1988). In addition, following a strong stimulus/injury, the activation of 
each of NMDA and NK-1 will cause the phosphorylation and activation of the 
other, as well as the synthesis of nitric oxide which will retrogradely release 
more transmitter from the primary afferent terminals (Rusin, Bleakman et al. 
1993; Hua, Chen et al. 1999; Yaksh, Hua et al. 1999). Therefore, this means that 
part of the response involved with the spinal activation of one receptor is due to 
the enhanced spinal activation of, and interaction with, the other.
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Since the activation of one of the NMDA and NK-1 receptors ultimately leads to 
the activation of the other, one could postulate that an agent which reduces the 
effects of the activation of one receptor should, at least partly, reduce the effects 
of the activation of the other. However, even though morphine significantly 
reduced both thermal and tactile hypersensitivity following the activation of each 
of the NMDA and the NK-1 receptors, morphine was more effective in reducing 
the behavioural and thermal hypersensitivity response due to the activation of the 
NMDA receptor, than those same responses following the NK-1 activation. This 
could show that even though the spinal NMDA and NK-1 receptors interact, this 
interaction is probably only at the spinal level, at the initiation of the central 
sensitisation cascade.
Subsequently, the activation of each receptor is then responsible for the 
activation of a distinct secondary pathway/cascade of events that lead to the full 
response seen with each receptor activation. One proof for this is that the 
activation of the NMDA receptor causes analgesia after the hyperalgesia, and it 
has been shown that spinalisation reduced this analgesic response (Kolhekar, 
Meller et al. 1993), which could mean that the response following the NMDA 
receptor activation is greatly dependent on a pathway/secondary mechanisms 
which activates descending inhibitions. This activation of descending inhibitions 
is in contrast with what happens when the NK-1 receptor is activated, since it has 
been shown that 80% of the lamina I neurons which express the NK-1 receptor 
project to the parabrachial area and are the origin of the spino-bulbo-spinal loop, 
which predominantly drives descending serotonergic facilitations (Todd, McGill 
et al. 2000; Suzuki, Morcuende et al. 2002; Todd 2002; Todd, Puskar et al.
2002), although it has been postulated that the NK-1-expressing lamina I 
projection neurons also play a small role in driving descending adrenergic 
inhibitions (Rahman et al, unpublished observations). Therefore, although 
descending inhibitions and facilitations are both physiologically active at any one 
time, some chronic pathological pain states (Kauppila, Kontinen et al. 1998), or 
perhaps even acute activation of different spinal receptors may shift the
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activation of one descending pathway more than the other (Rahman et al, 
unpublished observations).
Even though my study was not done on spinalised rats, the activation of the NK- 
1 receptor in my study led to a longer behavioural response and thermal 
hypersensitivity than the NMDA-mediated response, and only the NMDA 
receptor activation led to analgesia after the initial hypersensitivity. Although 
morphine also acts in the RVM to activate OFF cells, inhibit ON cells, causing 
analgesia via its supraspinal p-opioid receptors (see section 1.8.2 iv) (Fields, 
Heinricher et al. 1991; Heinricher 1997; Porreca, Burgess et al. 2001), the 
predominant activation of descending facilitations driven by the activation of the 
NK-1 receptor, could be the reason behind the reduced efficacy of systemic 
morphine, on the Sar-SP-induced hypersensitivity: morphine was still effective, 
yet less so than following the activation of the NMDA receptor.
Finally, I could extrapolate from my results that since morphine was effective in 
reducing abnormal pain due to the activation of each of the NMDA and NK-1 
receptors, therefore morphine could be effective in treating the types of pain 
which involve the activation of these two receptors. Neuropathic pain is an 
example of such pain states, and was initially thought of as refractory to 
morphine (Amer and Meyerson 1988). Therefore, provided morphine is given 
via the right dose, route and at the right time of injury (Suzuki, Chapman et al.
1999), this drug can be effective in decreasing abnormal pain which occurs 
following nerve injury.
4.4.6 Conclusion
I have found that morphine, via the route and non-sedating dose used in this 
study, to be effective in inhibiting the thermal and tactile hypersensitivity which 
arise following the activation of each of the NMDA and the NK-1 receptor, but 
more effective following the NMDA receptor activation.
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Therefore, the NMDA receptor activation might require secondary pathways 
which are more sensitive to morphine inhibition, than those following the NK-1 
receptor activation. This could mean that even though these two receptors are 
involved with the activation of the postsynaptic drive, and the central 
sensitisation associated with it, there are differences in how each receptor is 
modulated, and the neural pathways each receptor is involved in and thus how 
each receptor is involved with central sensitisation in chronic pain states.
In the next chapter, the involvement of peripheral NMDA receptors in the 
hypersensitivity arising following the spinal nerve ligation model will be 
investigated.
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Chapter 5:
A study investigating whether peripheral NMDA 
receptors play a role in the hypersensitivity 
following peripheral nerve injury
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5. A study investigating whether peripheral NMDA receptors play a role in 
the hypersensitivity following peripheral nerve injury
5.1 Introduction
The composition of the functional NMDA receptor includes the NR1 subunit, 
with one of the NR2 subunits (A-D) (Petrenko, Yamakura et al. 2003). Centrally, 
NMDA receptors have been shown to play a role in plasticity due to chronic 
pain, as well as central hypersensitivity. Peripherally, recent studies have 
suggested that NMDA receptors may be functional, since they were acutely 
activated by the intraplantar injection of NMDA, causing mechanical 
hyperalgesia, which was blocked by the intraplantar administration of the 
NMDA receptor antagonist MK-801 (Zhou, Bonasera et al. 1996), and may be 
implicated in peripheral sensitisation due to inflammation (Wang, Liu et al.
1997; Carlton and Coggeshall 1999) (see sections 1.73.1 ii b and 1.7.3.1 iii). 
Indeed, peripheral NMDA receptors have been identified on the peripheral 
terminals of primary afferent axons in both rat hairy and glabrous skin, using 
immunohistochemical techniques which stained only for the NR1 subunit 
(Carlton, Hargett et al. 1995; Coggeshall and Carlton 1998).
Furthermore, the intraplantar injection of NMDA administration has been shown 
to cause c-Fos expression in the dorsal horn side ipsilateral to the injection, 
whereas intraplantar MK-801, an NMDA receptor antagonist, has been shown to 
decrease c-Fos expression following intraplantar formalin (Wang, Liu et al. 
1997). Other studies that used the formalin model also showed that glutamate 
receptor antagonists, including the NMDA receptor antagonists ketamine and 
MK-801, decreased the lifting and licking behaviour seen in this model 
(Davidson, Coggeshall et al. 1997; Davidson and Carlton 1998). Another study 
showed that following carrageenan inflammation, the intraplantar administration 
of the NMDA receptor antagonist MK-801, or the AMPA/kainate antagonist 
CNQX, decreased the thermal hyperalgesia seen in this model (Jackson, Graff et 
al. 1995). Additionally to these inflammatory models, other studies have used the 
Freund’s complete adjuvant (CFA) model of inflammation and have shown that
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the NMDA, AMPA and kainate receptors significantly increase 48 hours 
following the induction of the CFA model (Carlton and Coggeshall 1999), that 
NMDA receptors increase and decrease according to the level of CFA 
inflammation (Du, Zhou et al. 2003), and that intraplantar MK-801 reduced the 
mechanical hyperalgesia seen in this model (Leem, Hwang et al. 2001).
Only one study on peripheral NMDA receptors and neuropathic pain in animals 
has been undertaken to date, and it showed that the intraplantar administration of 
MK-801 reduced the mechanical hyperalgesia which occurred following L5 
spinal nerve ligation, which was preceded by L5 dorsal rhizotomy (Jang, Kim et 
al. 2004). The L5 dorsal rhizotomy was performed in order to prevent the ectopic 
activity which arises following a nerve injury from reaching the spinal cord, and 
thus permitting only peripheral access of the spinal nerve ligation signals.
Normally, endogenous glutamate has been shown to originate from sources 
which include macrophages and Schwann cells (Kinkelin, Brocker et al. 2000). 
However, electrical stimulation of the sciatic nerve, with an intensity to activate 
both low- (Ap fibres) and high-threshold (A8 and C fibres), has been shown to 
increase the content of glutamate in the dialysate collected from the rat hindpaw 
(deGroot, Zhou et al. 2000), showing that glutamate may be released peripherally 
following the electrical stimulation of the sciatic nerve (deGroot, Zhou et al. 
2000; Jin, Nishioka et al. 2006). Furthermore, glutamate has been shown to be 
released peripherally following heat stimulation and capsaicin administration to 
the rat hindstep (Jin, Nishioka et al. 2006).
These peripheral NMDA receptors could be located on either injured or 
uninjured fibres in the periphery. Therefore, if by a process akin to the axon 
reflex, whereby SP is released from the peripheral terminals of primary afferent 
fibres, primary afferent fibres could release glutamate peripherally, following 
peripheral nerve injury, then the local administration of NMDA receptor 
antagonists could block the activation, and thus the ensuing hyperalgesia and 
allodynia. Clinically, this could be of great advantage, since the peripheral 
administration of NMDA receptor antagonists can reduce the incidence of
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unacceptable central side-effects, which include hallucinations and motor-effects, 
and which previously limited the use of these agents (Coderre and Van Empel 
1994).
Therefore, the aim of this part of my study was to determine whether peripheral 
NMDA receptors could be activated and blocked pharmacologically, in normal 
animals, and then if peripheral NMDA receptors have a role in the tactile and 
cold hypersensitivity seen following peripheral nerve injury, using the spinal 
nerve ligation model.
5.2 Methods
The methods used in this chapter are detailed in sections 2.1, 2.4 and the drugs 
used in section 2.6.3.
Briefly, peripheral NMDA receptors were activated and blocked by the 
intraplantar administration of NMDA, and the NMDA receptor antagonist MK- 
801 respectively, and the responses to thermal and tactile stimuli were 
investigated. Subsequently, the spinal nerve ligation model described by Kim and 
Chung in 1992 was used, intraplantar MK-801 was administered and the 
responses to tactile and cold stimuli were investigated.
In the first part of the study investigating the pharmacological activation of the 
peripheral NMDA receptor with exogenous NMDA, I used 0.7, 3.7 and 7.3 pg, 
which was based on doses reported in a previous study (Zhou, Bonasera et al. 
1996). The dose of MK-801 used was 0.4pg, and was also based on a previous 
study (Du, Zhou et al. 2003) and the morphine dose used, 3mg/kg, was the same 
non-sedating dose used in the previous chapter of my study. Morphine was 
administered systemically, and was injected 25 minutes before intraplantar 
NMDA, in order for the peak effects of both agents to coincide, as the effects of 
morphine have been shown to be maximal at 30 minutes, whereas those of 
NMDA have been shown to be maximal at 5 minutes post administration, by my
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study (see chapter 4) and a previous study (Davis and Inturrisi 2001). In 
conjunction with a previous study which showed that intraplantar MK-801 may 
block peripheral NMDA receptor activation when administered at the same time 
as NMDA (Zhou, Bonasera et al. 1996), MK-801 (0.4pg) was co-administered 
into the same paw with NMDA (7.3pg). Furthermore, in order to rule out 
systemic effects, MK-801 was also administered into the paw contralateral to the 
one which received NMDA. Paw withdrawal to tactile and thermal stimuli was 
done in the same manner as in chapter four (detailed in sections 2.3.3 and 2.3.4), 
with testing being done every 5 minutes for 60 minutes in the Hargreaves test, 
and at 5, 30 and 60 minutes in the mechanical test using von Frey filaments, post 
drug administration.
In the second part of this study, peripheral nerve injury was achieved by ligating 
spinal nerves L5 and L6, as described by the Kim and Chung study, in 1992 
(Kim and Chung 1992). Following spinal nerve ligation or sham surgery, the rats 
were monitored for normal weight gain and behaviour. Rats with nerve ligation 
showed abnormal ipsilateral hindpaw posture, but no dragging.
Paw withdrawal following tactile stimuli, using von Frey 1, 5 and 9g, and 
following cold stimuli, using an acetone drop, was tested in both ipsilateral or 
contralateral to the nerve injury paw. A positive response was noted when the rat 
lifted its paw, licked it or withdrew it. Data was plotted as the average difference 
in paw withdrawal between ipsilateral and contralateral paws, with the number of 
contralateral paw lifts being subtracted from the ipsilateral paw lifts, thus 
providing a ‘difference score’. In the graphs, the difference score was a positive 
value, showing that rats with spinal nerve ligation lifted the paw ipsilateral to 
nerve injury more than they did the paw contralateral to nerve injury, 
demonstrating that hypersensitivity to thermal, tactile and cold stimuli was 
present. The antinociceptive effects of morphine and ondansetron were shown 
when the difference score was reduced, and thus, when the rats were not lifting 
their ipsilateral paw as much as they did prior to drug(s) administration.
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The same dose of MK-801 was used in the rats with nerve injury, and paw 
withdrawal to tactile stimuli was also tested at 5, 30, 45 and 60 minutes post drug 
administration. Throughout this chapter, all intraplantar saline and drug 
administration was given in a 50pl volume. Additionally, the pH of intraplantar 
saline and NMDA was neutralised to pH 7 with IN sodium hydroxide.
5.3 Results
5.3.1 Intraplantar injections in normal rats
i) Intraplantar saline
The intraplantar administration of saline in normal rats did not cause any 
significant change from the baseline response, whether using thermal (fig. 5.1) or 
tactile (fig. 5.2) stimuli.
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Fig. 5.1- The lack of effect o f saline administered in the left hindpaw (black) and in the right paw 
(red, 50pl) on paw withdrawal latency following thermal stimuli. n=6. BL depicts pre-drug 
baseline responses.
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Fig. 5.2- The lack o f effect o f saline administered in the left hindpaw (black) and in the right paw 
(red, 50pl) on paw withdrawal threshold following tactile stimuli. n=6. BL depicts pre-drug 
baseline responses.
ii) Peripheral NMDA receptor activation
a) Intraplantar injection of NMDA alone- None of the doses of NMDA caused 
any change in the latency to paw withdrawal with thermal stimuli (fig. 5.3). The 
highest dose, 7.3 pg NMDA, significantly but transiently reduced the paw 
withdrawal threshold with tactile stimuli (p<0.05, n=6) (fig. 5.4).
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Fig. 5.3- The lack o f effect o f intraplantar NMDA (n=6 for all) doses 0.7 (red), 3.7 (blue) and 
7.3pg (purple) on paw withdrawal latency following thermal stimuli, when compared to the 
saline control (black, 50pl, n=12). BL depicts pre-drug baseline responses.
Fig. 5.4- The effect o f intraplantar NMDA doses 0.7 (red, n=8), 3.7 (blue, n=12) and 7.3 pg 
(purple, n=6) on paw withdrawal latency following tactile stimuli when compared to the saline 
control (black, 50pl n=6). BL depicts pre-drug baseline responses. The largest dose of 
intraplantar NMDA caused significant tactile hypersensitivity, when compared to the saline 
control. *P<0.05, where a significant decrease by NMDA dose 7.3 pg from the saline control is 
seen, one way ANOVA followed by Dunnett’s post-hoc test.
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b) Intraplantar injection of NMD A and systemic morphine administration- The 
tactile hypersensitivitiy seen following intraplantar NMDA (dose 7.3 pg) was 
significantly inhibited by morphine (3 mg/kg), as morphine increased the paw 
withdrawal threshold (p<0.05, n=6) (fig. 5.5), thus showing that morphine at this 
dose is effective in inhibiting the effects seen following peripheral NMDA 
receptor activation.
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Fig. 5.5- A comparison o f the effect o f the combination o f systemic morphine 3mg/kg with 
intraplantar NMDA 7.3pg (blue, n=6), with intraplantar NMDA alone 7.3pg (red, n=6), 
morphine alone (purple, 3mg/kg, n=l 1) and saline control (black, 50pl, n=6) on the rat paw 
withdrawal threshold following tactile stimuli. BL depicts pre-drug baseline responses. 
Intraplantar NMDA caused a significant decrease in paw withdrawal threshold, when compared 
to saline control and to morphine on its own. Systemic morphine, when administered prior to 
intraplantar NMDA, prevented the NMDA-induced tactile hypersensitivity when compared to the 
saline control. *P<0.05, where the decrease of paw withdrawal threshold produced by NMDA 
was prevented by morphine. #P<0.05, where intraplantar NMDA caused a significant decrease in 
paw withdrawal threshold when compared to saline control. tP<0.05, where intraplantar NMDA 
caused a significant decrease in paw withdrawal threshold when compared to morphine on its 
own. One way ANOVA followed by Tukey post-hoc test.
c) Intraplantar NMDA and MK-801 administration- When the NMDA receptor 
antagonist MK-801 (0.4pg) was administered alone by the intraplantar route, no 
significant change from the saline control values was seen (fig. 5.6). However,
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when MK-801 was co-administered with NMDA (7.3^g) in the same hindpaw, it 
significantly blocked the NMDA-induced tactile hypersensitivity (fig. 5.6), by 
increasing the paw withdrawal threshold. Additionally, when MK-801 was 
administered alone, contralateral to the paw that received NMDA, no effect on 
the NMDA-induced tactile hypersensitivity was seen (fig. 5.7). This shows that 
the tactile hypersensitivity seen following intraplantar NMDA administration is 
due to the activation of peripheral NMDA receptors, since MK-801 was acting 
locally and not systemically.
NMDA left paw 
MK-801 left paw
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Fig. 5.6- A comparison o f the effects of the co-administration o f MK-801 (0.4pg) and NMDA 
(7.3 pg) into the same paw (blue), with intraplantar NMDA alone (red, 7.3 pg), intraplantar MK- 
801 alone (purple, 0.4pg) and intraplantar saline control (black, 50pl) on the rat paw withdrawal 
threshold following tactile stimuli. BL depicts pre-drug baseline responses. n=6. Intraplantar 
injection of MK-801 in the same paw that received NMDA prevented the NMDA-induced tactile 
hypersensitivity. *P<0.05, where the significant decrease in paw withdrawal threshold by 
NMDA, was prevented by MK-801. <P<0.05, where intraplantar NMDA caused a significant 
decrease in paw withdrawal threshold, when compared to intraplantar saline control and 
intraplantar MK-801 on its own. /-Test.
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Fig. 5.7- A comparison o f the effects of the administration o f MK-801 (0.4pg) into the right paw 
and NMDA (7.3pg) into the left paw (blue), with intraplantar NMDA alone (red, 7.3pg), MK- 
801 alone (purple, 0.4pg) and saline control (black, 50pl) on the rat paw withdrawal threshold 
following tactile stimuli. BL depicts pre-drug baseline responses. n=6.
5.3.2 Hypersensitivity following spinal nerve ligation model
Rats with spinal nerve ligation had a greater difference between ipsilateral and 
contralateral paw withdrawal to tactile (fig. 5.8) and cold stimuli (fig. 5.9), 
exhibiting greater ipsilateral paw withdrawal, when compared to sham-operated 
rats and their own baseline, which was tested before the surgery. In order to 
calculate the difference score, the number of times the rat withdrew its 
contralateral paw following tactile (out of 10 times) and cold stimuli (out of 5 
times) was subtracted from the number of times the rat withdrew its ipsilateral 
paw following the same stimuli.
Indeed, in rats with spinal nerve ligation, the difference score between ipsilateral 
and contralateral paw withdrawal to von Frey 1 g was increased to a maximum of 
2±1, to von Frey 5g was increased to a maximum of 8±1 and to von Frey 9g was 
increased to a maximum of 10±0, from a difference score of 0±0 seen in sham- 
operated rats, and pre-surgery baseline levels. The difference score to cold
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stimuli in rats with spinal nerve ligation was increased to a maximum of 4±1, 
from a difference score of 0±0 seen in sham-operated rats and pre-surgery 
baseline levels.
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Fig. 5.8- The difference score between ipsilateral and contralateral rat hindpaw to von Frey 1 
(purple), 5 (green) and 9g (yellow), in peripheral nerve injured rats (n=7). Tactile hypersensitivity 
is shown as an increase in difference score values. Since there was no difference in the score 
between ipsilateral and contralateral hindpaws during the pre-surgery baseline (BL) testing o f the 
spinal nerve ligated rats (open circle) and for the sham-operated rats (small open rectangles), 
these appear as zero difference score (n=6).
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Fig. 5.9- A graph showing the difference score between ipsilateral and contralateral rat hindpaw 
to cold stimuli, in peripheral nerve injured rats (red, n=7). Cold hypersensitivity is shown as an 
increase in difference score values. Since there was no difference in the score between ipsilateral 
and contralateral hindpaws during the pre-surgery baseline (BL) testing of the spinal nerve 
ligated rats (open circle) and for the sham-operated rats (small open rectangles), these appear as 
zero difference score (n=6).
5.3.3 Peripheral MK-801 following spinal nerve ligation
In order to determine whether peripheral NMDA receptors play a role in the 
tactile and cold hypersensitivity that occurs following peripheral nerve injury, the 
NMDA receptor antagonist MK-801 (0.4pg) was administered intraplantar in the 
paw ipsilateral to the injury.
The intraplantar administration of MK-801 did not cause any significant 
inhibition of the hypersensitivity to von Frey 1 (fig. 5.10), 5 (fig. 5.11), 9g (fig. 
5.12) and to cold stimuli (fig. 5.13).
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Fig. 5.10- The lack o f effect o f MK-801 (0.4pg) administered in the ipsilateral paw (blue), and 
the contralateral paw (purple) on different withdrawal score to von Frey lg, when compared to 
saline administered in the ipsilateral paw (black) and the contralateral paw (red, 50pl), in spinal 
nerve ligated rats (n=7). Tactile hypersensitivity is shown as an increase in difference score 
values. The responses o f the sham-operated rats which received saline and MK-801 in the 
ipsilateral and contralateral paws are represented by the open squares linked with a black line 
(n=6). BL depicts pre-drug baseline responses.
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Fig. 5.11- A graph showing the lack o f effect o f MK-801 (0.4pg) administered in the ipsilateral 
paw (blue), and the contralateral paw (purple) on different withdrawal score to von Frey 5g, when 
compared to saline administered in the ipsilateral paw (black) and the contralateral paw (red, 
50pl), in spinal nerve ligated rats (n=7). Tactile hypersensitivity is shown as an increase in 
difference score values. The responses of the sham-operated rats which received either saline or 
MK-801 in the ipsilateral paw, and the responses o f the sham-operated rats which received saline 
in the contralateral paw are represented by the open squares linked with a black line. The 
responses of the sham-operated rats which received MK-801 in the contralateral paw are 
represented by the open triangle linked with an orange line (n=6). BL depicts pre-drug baseline 
responses.
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Fig. 5.12- A graph showing the lack o f effect o f MK-801 (0.4pg) administered in the ipsilateral 
paw (blue), and the contralateral paw (purple) on different withdrawal score to von Frey 9g, when 
compared to saline administered in the ipsilateral paw (black) and the contralateral paw (red, 
50pl), in spinal nerve ligated rats (n=7). Tactile hypersensitivity is shown as an increase in 
difference score values. The responses o f  the sham-operated rats which received MK-801 in the 
ipsilateral and contralateral paw are represented by the open squares linked with a black line. The 
responses of the sham-operated rats which received saline in the ipsilateral paw are represented 
by the open triangle linked with an orange line, and the responses o f the sham-operated rats 
which received saline in the contralateral paw are represented by the inverse open triangle linked 
with a pink line (n=6). BL depicts pre-drug baseline responses.
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Fig. 5.13- A graph showing the lack o f effect o f MK-801 (0.4pg) administered in the ipsilateral 
paw (blue), and the contralateral paw (purple) on different withdrawal score to cold stimuli, when 
compared to saline administered in the ipsilateral paw (black) and the contralateral paw (red, 
50pl), n=7. Cold hypersensitivity is shown as an increase in difference score values. The 
responses o f the sham-operated rats which received saline and MK-801 in the ipsilateral and 
contralateral paws are represented by the open squares linked with a black line (n=6). BL depicts 
pre-drug baseline responses.
5.4 Discussion
In my study, peripheral NMDA receptors were activated by a large dose of 
NMDA, causing tactile hypersensitivity, and this activation was blocked by MK- 
801 acting locally. However, although it has been postulated that peripheral 
NMDA receptors may be involved in the mechanical hypersensitivity seen 
following peripheral nerve injury (Jang, Kim et al. 2004), in my study, the same 
dose of MK-801 that could normalise the hypersensitive response to tactile 
stimuli following intraplantar NMDA administration in normal rats was unable to 
reduce tactile and cold hypersensitivity seen following the spinal nerve ligation 
model. Therefore, even though they may be pharmacologically activated, 
peripheral NMDA receptors do not seem to be pathophysiologically active in the 
spinal nerve ligation model.
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5.4.1 Peripheral NMDA receptors when activated by intraplantar NMDA
Immunohistochemical techniques which stained for the NR1 subunit at the 
peripheral terminal of both unmyelinated and myelinated primary afferent fibres 
of rat glabrous and hairy skin, as well as in human hairy skin, has led to the 
stipulation that the NMDA receptor is located at the periphery (Carlton, Hargett 
et al. 1995; Coggeshall and Carlton 1998; Kinkelin, Brocker et al. 2000). 
However, the lack of evidence for the presence of the NR2 subunit may suggest 
that these peripheral NMDA receptors may not be functional.
In previous studies, intraplantar glutamate administration caused both tactile and 
thermal hypersensitivity (Carlton, Hargett et al. 1995; Jackson, Graff et al. 1995; 
Zhou, Bonasera et al. 1996; Leem, Hwang et al. 2001; Jang, Kim et al. 2004). 
However, whereas intraplantar NMDA has been shown to cause tactile 
hypersensitivity in a previous study using von Frey filaments in awake rats 
(Zhou, Bonasera et al. 1996), intraplantar NMDA has only been shown to 
sensitise nociceptors to thermal stimuli in an in vitro skin-nerve preparation (Du, 
Koltzenburg et al. 2001). In my study, the intraplantar administration of NMDA 
caused hypersensitivity to tactile, but not thermal, stimuli. Therefore, intraplantar 
glutamate causing thermal hypersensitivity (Jackson, Graff et al. 1995), and 
sensitisation of nociceptors to thermal stimuli (Du, Koltzenburg et al. 2001), 
could be an effect of glutamate on one of its other peripheral receptors.
Indeed, this is the first study that investigated the effect of intraplantar NMDA on 
paw withdrawal to tactile and thermal stimuli in normal awake animals. An 
earlier study investigated the effect of NMDA on peripheral NMDA receptors, 
using an in vitro skin preparation, and found that the same dose of NMDA as the 
one used in this study sensitised nociceptors in normal and inflamed skin to heat 
(Du, Zhou et al. 2003). The discrepancy between my study and the study by Du 
et al, could be due to the difference in techniques. Whereas they used the in vitro 
skin preparation and recorded the response of isolated C-fibre units in dissected 
skin, using a broad range of temperatures including supra-threshold
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temperatures, my study used behavioural techniques in whole, awake, free- 
moving animals and used threshold temperature.
However, the activation of the peripheral NMDA receptor causing tactile 
hypersensitivity in this study is in agreement with many previous studies that 
used intraplantar glutamate (Carlton, Hargett et al. 1995), intraplantar NMDA 
(Zhou, Bonasera et al. 1996), and intraplantar MK-801 to block the tactile 
hypersensitivity following inflammation (Jackson, Graff et al. 1995; Leem, 
Hwang et al. 2001), and nerve injury (Jang, Kim et al. 2004). Furthermore, the 
reduction in NMDA-induced tactile hypersensitivity, in my study, by intraplantar 
MK-801, is also in agreement with a previous study which activated the 
peripheral NMDA receptor with intraplantar NMDA administration (Zhou, 
Bonasera et al. 1996). Moreover, the effects of the NMDA receptor antagonist 
seem to be acting solely locally, since the contralateral administration of MK-801 
had no effect.
To conclude, the fact that in my study, intraplantar NMDA administration caused 
tactile and not thermal hypersensitivity could be hypothesised to be due to the 
NMDA receptor channel in the periphery being expressed on nociceptive 
primary afferent fibres which do not convey a response due to thermal stimuli, 
perhaps a subset of the non-peptidergic, IB4-positive A5-fibres (Snider and 
McMahon 1998; Caterina, Gold et al. 2005; Meyer, Ringkamp et al. 2006). 
However, since immunohistochemical data is not available yet, the conclusion is 
purely speculative at this point.
5.4.2 Peripheral NMDA receptors and neuropathic pain
In my study, as in previous studies (Kim and Chung 1992; Chapman, Suzuki et 
al. 1998), the spinal nerve ligation model caused the long-lasting behavioural 
manifestation of tactile and cold hypersensitivity.
Previous studies have implicated the peripheral NMDA receptor to have a role in 
inflammation. One study showed the reduction in c-Fos expression, following
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formalin, when intraplantar NMDA and MK-801 are administered together 
(Wang, Liu et al. 1997). Another study showed the reduction of the lifting and 
licking behaviour seen following formalin administration, by intraplantar NMDA 
antagonists, such as MK-801 and ketamine (Davidson, Coggeshall et al. 1997; 
Davidson and Carlton 1998). Additionally, other studies showed that intraplantar 
MK-801 reduced both the thermal hypersensitivity seen following carrageenan 
inflammation (Jackson, Graff et al. 1995), and mechanical hypersensitivity seen 
following Freund’s complete adjuvant (CFA) inflammation (Leem, Hwang et al. 
2001). Finally, peripheral NMDA receptor subunits have been shown to be 
upregulated in both myelinated and unmyelinated primary afferent fibres, 48 
hours following CFA inflammation in the ipsilateral, and not the contralateral 
paw (Carlton and Coggeshall 1999).
Despite the mechanisms underlying inflammation being different from those 
underlying neuropathic pain, the spinal NMDA receptor plays a role in the 
central sensitisation which occurs following both inflammation and neuropathy 
(Dickenson 1997). Therefore, one could postulate that since the peripheral 
NMDA receptor plays a role in inflammation, this receptor could also play a role 
in the hypersensitivity seen following neuropathic pain. A study by deGroot et al 
has shown that following electrical stimulation of the sciatic nerve, the glutamate 
content in the dialysate collected from the rat hindpaw increased significantly.
Jin et al further showed that glutamate is released peripherally from primary 
afferent fibres following each of electrical stimulation of the sciatic nerve, as 
well as heat stimulation and capsaicin administration to the rat hindpaw instep 
(Jin, Nishioka et al. 2006), by measuring the level of glutamate in the perfusate 
collected from the rat hindpaw instep using in vivo microdyalisis.
Since SP, via the axon reflex, has been shown to be released by primary afferent 
fibres at the periphery (Bumstock 1977; Hagermark, Hokfelt et al. 1978), 
glutamate may be released via a similar mechanism, from injured primary 
afferent fibres, and could then activate the NMDA receptors located on uninjured 
fibres, causing some of the hyperalgesia and allodynia seen following 
neuropathic pain. However, although following inflammation, peripheral
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sensitisation and the release of SP by the axon reflex have been proven to occur, 
the basis for this possible action in neuropathy is unclear. One could postulate 
that there could be ectopic activity firing antidromically back to the periphery 
following nerve injury, which could lead to peripheral glutamate release from the 
injured nerve. This glutamate could then act on the NMDA receptors at the 
periphery, activate them, and the signal could be transmitted centrally through 
the uninjured fibres.
In my study, intraplantar NMDA only caused tactile and not thermal (heat) 
hypersensitivity, therefore, once peripheral nerve injury was established, the 
effect of MK-801 was tested on tactile hypersensitivity. However, in keeping 
with previous studies which investigated the spinal nerve ligation model of nerve 
injury (Chapman, Suzuki et al. 1998; Matthews and Dickenson 2002), cold 
hypersensitivity was also investigated.
I found that the intraplantar administration of MK-801, which was previously 
shown to decrease tactile hypersensitivity due to intraplantar NMDA, was 
ineffective in reducing the tactile and cold hypersensitivity following peripheral 
nerve injury. This finding differs from the only other study which investigated 
peripheral NMDA receptors in neuropathic pain (Jang, Kim et al. 2004), where a 
lower dose than the one used in my study of intraplantar MK-801, was shown to 
reduce tactile hypersensitivity following L5 spinal nerve ligation. The 
discrepancy between my study and that of Jang et al, could be due to the fact that 
the nerve injury model was different, as they only ligated the L5 spinal nerve, 
and preceded that ligation with an L5 dorsal rhizotomy, whereas both the L5 and 
L6 spinal nerves were ligated in my study and no dorsal rhizotomy was 
performed. Therefore, in my study, ectopic signals from the neuromas on the 
damaged nerves reached the dorsal hom and caused central sensitisation, 
whereas in the Jang et al study, any ectopic activity from the neuroma could not 
reach the dorsal hom.
Clinically, it would have been very important to find a role for the peripheral 
NMDA receptors in neuropathic pain, since the use of NMDA antagonists is
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riddled with undesirable side-effects, such as hallucinations, which limit their use 
(Dickenson 1997). Two studies by Lynch et al were performed, using a cream 
containing ketamine, amitriptyline and a combination of both, in patients with 
neuropathic pain. The first study showed that there was no effect of ketamine or 
amitriptyline cream on the pain rating in patients with neuropathic pain in the 
placebo-controlled two day trial, but that there was a significant decrease in 
patients using the combination cream in the seven day trial which did not have a 
placebo control (Lynch, Clark et al. 2003), and the second study, also lacking a 
control, showed the effectiveness of the combination cream when used for 6-12 
months (Lynch, Clark et al. 2005). Unfortunately, both these studies, as well as 
not having controls, also allowed patients to keep taking any previous analgesics, 
including opioids and non-steroidal anti-inflammatory drugs, which means that 
more rigidly controlled clinical studies are needed before conclusions can be 
drawn.
5.4.3 Conclusion
Previous studies have shown the existence of the NR1 subunit of the NMDA 
receptor at the peripheral terminals of primary afferent fibres (Carlton, Hargett et 
al. 1995; Coggeshall and Carlton 1998). However, the functional NMDA 
receptor needs both the NR1 and the NR2 subunit (Petrenko, Yamakura et al. 
2003). These peripheral NMDA receptors were pharmacologically activated 
following the administration of a large dose of agonist, however, they do not 
seem to play a role in the tactile and cold hypersensitivity seen in the spinal 
nerve ligation model.
However, one could speculate that since intraplantar NMDA administration 
caused tactile, and not thermal hypersensitivity, and since this static 
hypersensitivity has been shown by previous studies to be conveyed mostly by 
A8-fibres (Field, Bramwell et al. 1999; Ossipov, Bian et al. 1999), therefore the 
peripheral NMDA receptor channel may be expressed in a subset of A8-fibres 
which do not express the channels which transduce thermal stimuli, such as the
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TRPV family of channels (Caterina, Schumacher et al. 1997; Snider and 
McMahon 1998; Meyer, Ringkamp et al. 2006). This hypothesis could be tested 
by repeating my experiments using capsaicin-treated rats.
In the next chapter, I will investigate the role of descending serotonergic 
facilitations in the hypersensitivities which arise following the SNL model, as 
well as whether the blockade of these descending facilitations causes synergism 
with the effects of morphine in this model.
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Chapter 6:
A study investigating the roles of each of morphine 
and ondansetron, and their combination, on the 
hypersensitivity which occurs following the spinal 
nerve ligation model
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6. A study investigating the roles of each of morphine and ondansetron, and 
their combination, on the hypersensitivity which occurs following the spinal 
nerve ligation model
6.1 Introduction
Previous clinical studies have debated the efficacy of morphine in neuropathic 
pain states. Initially, it was stated that opioids were ineffective in some types of 
neuropathic pain, as only 1 in 8 patients responded positively to opioids (Amer 
and Meyerson 1988). That initial study led to debate from other studies, which is 
still ongoing in clinical (Portenoy, Foley et al. 1990; Rowbotham, Reisner-Keller 
et al. 1991; Jadad, Carroll et al. 1992) as well as in animal studies (Backonja, 
Miletic et al. 1995; Suzuki, Chapman et al. 1999; Joshi, Hernandez et al. 2006), 
as per the efficacy of opioids in neuropathic pain, and even the authors of the 
original study had to state that although the title of their paper had a ‘provocative 
phrasing’, they did not mean that all types of neuropathic pain were resistant to 
opioids and that opioids should never be withheld from patients with chronic 
neuropathic pain (Amer and Meyerson 1991).
Indeed, the study by Rowbotham et al showed that intravenous morphine was 
effective in reducing pain intensity in patients with postherpetic neuralgia, 
whereas the study by Jadad et al showed that half the patients with neuropathic 
pain responded well to intravenous morphine. In addition, the study by Attal et al 
showed that intravenous morphine was effective in reducing dynamic allodynia 
in patients with spinal cord injury, but that not many of the patients kept taking 
morphine in the long-term (Attal, Guirimand et al. 2002). Furthermore, the study 
by Gilron et al showed that systemic morphine was effective in patients with 
neuropathic pain, but that the combination of gabapentin with morphine was 
more effective in these patients, at doses lower than those that were effective 
singly (Gilron, Bailey et al. 2005). Therefore, type of neuropathic pain and dose 
titration play a role in neuropathic pain ‘responding’ to morphine and opioids 
(Portenoy, Foley et al. 1990; Dellemijn 1999; Sindrup and Jensen 1999; Hansson
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and Dickenson 2005), as well as route of administration (Bian, Nichols et al. 
1995; Suzuki, Chapman et al. 1999).
However, the study by Amer et al did point to a significant finding: that 
neuropathic pain is less responsive to morphine than acute or inflammatory pain, 
(Lemberg, Kontinen et al. 2006). This was shown by the finding that dynamic 
allodynia, an important nociceptive manifestation of neuropathic pain, remains 
mostly unaffected by morphine control (Field, McCleary et al. 1999). Indeed, 
even though systemic morphine acts on p-opioid receptors located on primary 
afferent fibres, spinal and supraspinal sites, neuropathic pain has so many 
underlying mechanisms, such as increased spinal afferent drive (Ossipov, Lopez 
et al. 1995), changes in levels o f spinal transmitters and receptors (Honore, 
Rogers et al. 2000; Wang, Sun et al. 2002) and alterations in descending controls 
(Porreca, Burgess et al. 2001; Suzuki, Rahman et al. 2004), that it is quite 
difficult for one drug to decrease all of the symptoms which arise with this 
disease (Hansson and Dickenson 2005; Dickenson and Kieffer 2006) (see 
sections 1.6.2 iv, 1.6.5,1.6.6 ii and tv, 1.6.7 ii, 1.7.5,1.7.7,1.8.2 vi and vii and 
1.9.4).
Furthermore, the ‘numbers needed to treat’, a method used to assess the clinical 
efficacy of analgesics and which shows how many patients need to be treated 
before one patient shows more than 50% pain relief, of morphine and other drugs 
used to treat neuropathic pain, is approximately 3, and the use of these drugs at 
effective doses is still hampered by unacceptable side effects, such as respiratory 
depression and sedation for morphine (Sindrup and Jensen 1999). Therefore, 
drug combinations are required, in order to decrease the side effects of each drug 
on its own whilst maintaining its efficacy, to treat neuropathic pain.
Ondansetron, a 5HT3 antagonist, has long been licensed as an anti-emetic. The 
analgesic properties of this drug have only been recently investigated, which is 
not surprising since serotonin (5-HT) has the confusing dual property of being 
both anti- (Jordan, Kenshalo et al. 1978; Yaksh and Wilson 1979; Alhaider, Lei 
et al. 1991; Crisp, Stafinsky et al. 1991; Oyama, Ueda et al. 1996; Jones, Peters
215
et al. 2005) and pro-nociceptive (Jordan, Kenshalo et al. 1978; Ali, Wu et al. 
1996; Oyama, Ueda et al. 1996; Calejesan, Ch’ang et al. 1998; Green, Scarth et 
al. 2000; Zeitz, Guy et al. 2002; Suzuki, Rahman et al. 2004), depending on 
which one of its many receptors is being activated. The terminals of the 
descending fibres from RVM neurons are an important source of 5-HT in the 
spinal cord (Fasmer, Berge et al. 1983; Besson and Chaouch 1987). Furthermore, 
the descending controls which were previously investigated were predominantly 
of the inhibitory type (Reynolds 1969; Besson and Chaouch 1987) and it has 
only been recently shown, that in some chronic pain states such as neuropathic 
pain, descending serotonergic facilitations predominate and serve to maintain the 
abnormal pain seen following nerve injury (Urban and Gebhart 1999; Porreca, 
Burgess et al. 2001; Suzuki, Rahman et al. 2004; Suzuki, Rahman et al. 2005). 
Indeed, it has been now shown that descending serotonergic facilitations are part 
of a spino-bulbo-spinal loop that has, at its origins, NK-1-expressing lamina I 
neurons which project to the parabrachial area, which relays to the RVM, and 
then back down from the RVM onto the spinal cord, thus affecting pain 
transmission at the level of the spinal cord (Mantyh, Rogers et al. 1997; Todd, 
McGill et al. 2000; Suzuki, Morcuende et al. 2002; Todd 2002; Todd, Puskar et 
al. 2002; Rahman, Suzuki et al. 2003; Conte, Legg et al. 2005; Dickenson and 
Kieffer 2006).
In animal models, ondansetron has been shown to reduce the at-level mechanical 
allodynia which arises in spinal cord injury (Oatway, Chen et al. 2004), as well 
as the mechanical and thermal evoked responses of spinal cord dorsal hom 
neurons in rats with cancer-induced bone pain (Donovan-Rodriguez, Urch et al. 
2006) and spinal nerve ligation (Suzuki, Rahman et al. 2004). Additionally, in a 
clinical study, a single dose of intravenous ondansetron also caused analgesia in 
patients with chronic neuropathic pain (McCleane, Suzuki et al. 2003).
One cannot predict the onset of a nerve injury, but can focus on treating the 
mechanisms which underlie the maintenance o f the pain seen following nerve 
injury (Porreca, Burgess et al. 2001). Furthermore, ondansetron has never been 
tested in rats with spinal nerve ligation in a behavioural setting. Therefore, it is of
216
clinical relevance to investigate what effects blocking descending serotonergic 
facilitations with the spinal administration of the 5-HT3 antagonist ondansetron 
could have on the maintenance of the hypersensitivities seen following nerve 
injury. Therefore, in the next series of experiments, the effects of spinal 
ondansetron, alone and in combination with systemic morphine, will be 
investigated in animals with spinal nerve ligation.
6.2 Methods
The methods used in this chapter are detailed in sections 2.1,2.3.1, 2.4, 2.5, and 
the drugs used in section 2.6.4.
Briefly, normal rats were intrathecally cannulated using a method based on the 
work of Storkson et al, and the effects of different doses of ondansetron (10 and 
20pg/10pl) on paw withdrawal latency to thermal stimuli and paw withdrawal 
threshold to tactile stimuli, were investigated.
Following that, rats underwent a combination of either spinal nerve ligation (Kim 
and Chung 1992) and intrathecal cannulation, or sham-operation and intrathecal 
cannulation. The effects of morphine, ondansetron and their combination on paw 
hypersensitivity to thermal, tactile and cold stimuli were investigated in these 
animals. In the case of tactile and cold stimuli, the response was plotted as 
‘difference score’. The ‘difference score’ is calculated as the subtraction of the 
number of times the rat withdrew its contralateral paw from the number of times 
the rat withdrew its ipsilateral paw, out of a total of 10 times, following 
mechanical stimuli and 5 times, following cold stimuli. The reason for choosing 
two different methods to determine tactile hypersensitivity, such as the paw 
withdrawal threshold for normal animals and the ‘difference score’ of withdrawal 
to von Frey 1, 5 and 9g, is because the latter cannot be used in normal animals, 
since normal animals do not respond to innocuous tactile stimuli, whereas it is 
also an efficient way of showing tactile hypersensitivity in rats with the SNL 
model of nerve injury.
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In rats with spinal nerve ligation and sham-operation, the concentration of 
systemic morphine used was 3 mg/kg and the dose of spinal ondansetron used 
was 20pg. The total volume used for intrathecal injections was 24pi. Saline was 
administered subcutaneously, intrathecally and both subcutaneously and 
intrathecally as a control for each of morphine, ondansetron and their 
combination, respectively. Both morphine and ondansetron showed a peak action 
at 30 minutes following their administration, therefore, they were administered at 
the same time. Since hypersensitivity to tactile and cold stimuli is measured as 
the ‘difference score’, then this hypersensitivity is represented on the graph as an 
increase in difference score, and the antihyperalgesic effects of morphine and 
ondansetron will be shown as a reduction in the ‘difference score’.
6.3 Results
6.3.1 Ondansetron in normal animals
Intrathecal ondansetron at doses 10 and 20pg, did not cause any significant 
change in paw withdrawal latency to thermal stimuli (fig. 6.1), and paw 
withdrawal threshold to tactile stimuli (fig. 6.2), in normal animals, when 
compared to the responses following intrathecal saline.
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Fig. 6.1- The lack o f effect o f ondansetron doses 10 (red) and 20pg (blue), on paw withdrawal 
latency following thermal stimuli, when compared to saline control (black, 24pl). BL depicts pre­
drug baseline responses.
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Fig. 6.2- The lack o f effect o f ondansetron doses 10 (red) and 20pg (blue), on paw withdrawal 
threshold following tactile stimuli, when compared to saline control (black, 24pl). BL depicts 
pre-drug baseline responses.
6.3.2 Response to thermal, tactile and cold stimuli in rats with spinal nerve 
ligation and an intrathecal cannula
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Rats which had the spinal nerve ligation, whether or not they were cannulated, 
exhibited greater ipsilateral paw withdrawal to thermal (fig. 6.3), tactile (fig 6.4) 
and cold stimuli (fig. 6.5), than contralateral paw withdrawal and than their sham 
counterparts. Paw withdrawal to thermal stimuli was reduced from 12±1 in 
sham-operated rats (ipsilateral and contralateral) and in the contralateral paw of 
rats with spinal nerve ligation, to 6±0 seconds (and 6±1 seconds on day 5), in the 
ipsilateral paw of rats with spinal nerve ligation. The difference score to tactile 
stimuli between the ipsilateral and contralateral paw was reduced in rats with 
spinal nerve ligation from a maximum of 2±1, when testing with von Frey lg, 
from a maximum of 7±1, when testing with von Frey 5g, and from a maximum 
of 9±0, when testing with von Frey 9g, to 0±0 when testing all the 
aforementioned von Frey forces in sham-operated rats. The difference score to 
cold stimuli was reduced from a maximum of 2±1 in rats with spinal nerve 
ligation, to 0±0 in sham-operated rats. Additionally, whether cannulated or not, 
rats with spinal nerve ligation also exhibited greater ipsilateral paw withdrawal to 
all three stimuli when compared to their baseline response.
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Fig. 6.3- The decrease in paw withdrawal latency to thermal stimuli in the ipsilateral paw (purple, 
n=16) of rats with spinal nerve ligation, when compared to the contralateral paw 
(contralateral=blue, n=16) and sham-operated rats (ipsilateral=black, contralateral=red, n=6). All 
rats also underwent intrathecal cannulation. BL depicts pre-surgery baseline responses.
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Fig. 6.4- The difference score between ipsilateral and contralateral rat hindpaw to von Frey 1 
(purple), 5 (green) and 9g (yellow, n=16 for all), in peripheral nerve injured rats. All rats also 
underwent intrathecal cannulation. Tactile hypersensitivity is shown as an increase in the value o f 
the difference score. Since there was no difference in the score between ipsilateral and 
contralateral hindpaws during the pre-surgery baseline (BL) testing o f spinal nerve ligated rats 
(open circle) and for the sham-operated rats (small open rectangles), these appear as zero 
difference score fn=6Y
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Fig. 6.5- A graph showing the difference score between ipsilateral and contralateral rat hindpaw 
to cold stimuli, in peripheral nerve injured rats (red, n=16). All rats also underwent intrathecal 
cannulation. Cold hypersensitivity is shown as an increase in the value o f the difference score. 
Since there was no difference in the score between ipsilateral and contralateral hindpaws during 
the pre-surgery baseline (BL) testing o f the spinal nerve ligated rats (open circle) and for the 
sham-operated rats (small open rectangles), these appear as zero difference score (n=6).
6.3.3 Saline experiments
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Saline was administered via the subcutaneous, intrathecal and both subcutaneous 
and intrathecal routes together. There was no significant difference in the 
responses to thermal, tactile and cold stimuli, when the three different routes of 
saline administration were compared.
i) Thermal response
In rats with spinal nerve ligation, there was no significant difference in paw 
withdrawal threshold to thermal stimuli, following subcutaneous (fig. 6.6), 
intrathecal (fig. 6.7) and both subcutaneous and intrathecal saline administration 
(6 .8).
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Fig. 6.6- The lack o f effect o f  subcutaneous saline on paw withdrawal latency following thermal 
stimuli in rats with spinal nerve ligation (ipsilateral=purple, contralateral=blue, n=10, 0.25ml), 
and rats with sham surgery (ipsilateral=red, contralateral=black, n=6, 0.25ml). All rats also 
underwent intrathecal cannulation. BL depicts pre-drug baseline responses.
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Fig. 6.7- The lack o f effect o f intrathecal saline on paw withdrawal latency following thermal 
stimuli in rats with spinal nerve ligation (ipsilateral=purple, contraIateral=blue, n=9, 24pl), and 
rats with sham surgery (ipsilateral=red, contralateral=black, n=6, 24|il). All rats also underwent 
intrathecal cannulation. BL depicts pre-drug baseline responses.
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Fig. 6.8- The lack o f effect o f the combined administration of intrathecal (24pl) and subcutaneous 
(0.25ml) saline on paw withdrawal latency following thermal stimuli in rats with spinal nerve 
ligation (ipsilateral=purple, contralateraHblue, n=7), and rats with sham surgery (ipsilateral=red, 
contralateral=black, n=6). All rats also underwent intrathecal cannulation. BL depicts pre-drug 
baseline responses.
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ii) Tactile response
None of the subcutaneous (fig. 6.9), intrathecal (fig. 6.10) and both subcutaneous 
and intrathecal saline administration (fig. 6.11) caused any significant difference 
in paw withdrawal to tactile stimuli, in rats with spinal nerve ligation.
a>i-oo
CO
a>oca>
IQ­
S'
6-
a, 2-
-2-
|  injection
A
□ & ■b -
- i — r-
BL 10
T "
20
n r
30
-T-
40
"l”
50
Time (min)
60
Fig. 6.9- The lack o f effect o f subcutaneous saline (0.25ml) on the difference score between 
ipsilateral and contralateral rat hindpaw to von Frey 1 (red), 5 (black) and 9g (blue, n=10), in 
peripheral nerve injured rats. All rats also underwent intrathecal cannulation. Tactile 
hypersensitivity is demonstrated by the increase in difference score. Since there was no 
difference in the score between ipsilateral and contralateral hindpaws for the sham-operated rats 
(n=6), these appear as zero difference score (open squares), even after saline administration. BL 
depicts pre-drug baseline responses.
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Fig. 6.10- The lack o f effect o f  intrathecal saline (24pl) on the difference score between 
ipsilateral and contralateral rat hindpaw to von Frey 1 (red), 5 (black) and 9g (blue, n=9), in 
peripheral nerve injured rats. All rats also underwent intrathecal cannulation. Tactile 
hypersensitivity is demonstrated by the increase in difference score. Since there was no 
difference in the score between ipsilateral and contralateral hindpaws for the sham-operated rats 
(n=6), these appear as zero difference score (open squares), even after saline administration. BL 
depicts pre-drug baseline responses.
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Fig. 6.11- The lack o f effect o f  the combined administration o f intrathecal (24pl) and 
subcutaneous saline (0.25ml) on the difference score between ipsilateral and contralateral rat 
hindpaw to von Frey 1 (red), 5 (black) and 9g (blue, n=7), in peripheral nerve injured rats. All 
rats also underwent intrathecal cannulation. Tactile hypersensitivity is demonstrated by the 
increase in difference score. Since there was no difference in the score between ipsilateral and 
contralateral hindpaws for the sham-operated rats (n=6), these appear as zero difference score 
(open squares), even after saline administration. BL depicts pre-drug baseline responses.
iii) Cold response
Saline administration in neuropathic animals did not cause any significant 
difference in paw withdrawal to cold stimuli, whether via the subcutaneous route, 
the intrathecal route or both the intrathecal and subcutaneous routes together (fig. 
6 .12).
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Fig. 6.12- The lack o f effect o f subcutaneous (red, n=8, 0.25ml), intrathecal (blue, n=7, 24pl) and 
the combined administration o f intrathecal (24pl) and subcutaneous (0.25ml) saline (purple, n=7) 
on the difference score between ipsilateral and contralateral rat hindpaw to cold stimuli, in 
peripheral nerve injured rats. All rats also underwent intrathecal cannulation. Cold 
hypersensitivity is demonstrated by the increase in difference score. Since there was no 
difference in the score between ipsilateral and contralateral hindpaws for the sham-operated rats 
(n=6), these appear as zero difference score (open squares), even after saline administration. BL 
depicts pre-drug baseline responses.
6.3.4 Morphine experiments
i) Thermal response
The subcutaneous administration of morphine, in neuropathic and sham-operated 
rats, caused a significant increase in the paw withdrawal latency to thermal 
stimuli. In neuropathic rats, ipsilateral paw withdrawal latency to thermal stimuli 
significantly increased at 15 and 30 minutes following morphine administration, 
when compared to the ipsilateral saline control. Contralateral paw withdrawal 
latency to thermal stimuli was significantly increased by morphine at 5, 15, 30 
and 45 minutes post-administration, when compared to the contralateral saline 
control (fig. 6.13). Therefore, in rats with nerve injury, morphine had a delayed 
onset and shorter-lasting effects in the ipsilateral paw when compared to the
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contralateral paw. In sham-operated rats, morphine significantly increased both 
ipsilateral and contralateral paw withdrawal latency with thermal stimuli at all 
timepoints (fig. 6.14), which was more comparable to the effect of morphine on 
the contralateral paw in rats with nerve injury than those on the ipsilateral paw of 
nerve-injured rats.
30-
25-
£  2CH(/>
>»oc
CD+■*
15-
10-
5-
0
injection
i—
BL
"T“
10
T"
20
T"
30
T “
40
"1“
50
"I
60
Time (min)
Fig. 6.13- A comparison o f the effect o f morphine on paw withdrawal latency to thermal stimuli 
(ipsilateral=purple, contra lateral^ blue, 3mg/kg, n=6), with saline (ipsilateral=red, 
contralateral=black, 0.25ml, n=10), in rats with spinal nerve ligation. BL depicts pre-drug 
baseline responses. Spinal nerve ligation caused thermal hypersensitivity in the paw ipsilateral to 
nerve injury. Morphine caused a significant increase in both ipsilateral and contralateral paw 
withdrawal latency following thermal stimuli, when compared to saline control, however, this 
significant increase was at more timepoints in the contralateral than the ipsilateral paw. *P<0.05, 
where a significant increase in ipsilateral paw withdrawal latency is seen following morphine 
administration, when compared to saline control. “P<0.05, where a significant increase in 
contralateral paw withdrawal latency is seen following morphine administration, when compared 
to saline control, f  P<0.05, where spinal nerve ligation caused a significant decrease in ipsilateral 
paw withdrawal latency to thermal stimuli, when compared to contralateral paw withdrawal 
latency, during baseline testing. §P<0.05, where morphine administration caused a significant 
increase in contralateral paw withdrawal latency, when compared to ipsilateral paw withdrawal 
latency following saline. #P<0.05, where there was a significant decrease in ipsilateral paw 
withdrawal latency in the group which received morphine, when compared to the contralateral 
paw withdrawal latency in the group which received saline. AP<0.05 contralateral paw 
withdrawal versus ipsilateral paw withdrawal latency, in the group that received morphine. 
tP<0.05 contralateral paw withdrawal versus ipsilateral paw withdrawal latency, in the group 
that received saline. One way ANOVA followed by Tukey post-hoc test.
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Fig. 6.14- A comparison o f the effect o f morphine on paw withdrawal latency to thermal stimuli 
(ipsilateral=purple, contralateral=blue, 3mg/kg, n=6), with saline (ipsilateral=red, 
contralateral=black, 0.25ml, n=6), in sham-operated rats. BL depicts pre-drug baseline responses. 
Morphine significantly increased paw withdrawal latency to thermal stimuli at all timepoints 
tested in both ipsilateral and contralateral paws in rats with sham surgery, when compared to 
saline control. *P<0.05, where a significant increase in ipsilateral paw withdrawal latency is seen 
following morphine administration, when compared to saline control. tP<0.05, where a 
significant increase in contralateral paw withdrawal latency is seen following morphine 
administration, when compared to ipsilateral and contralateral paw withdrawal latency in the 
group that received saline. #P<0.05, where morphine caused a significant increase in ipsilateral 
paw withdrawal latency, when compared to contralateral paw withdrawal latency in the group 
that received saline. One way ANOVA followed by Tukey post-hoc test.
ii) Tactile response
The subcutaneous administration of morphine, in neuropathic rats, caused a 
significant decrease in the difference score following von Frey 5 (fig. 6.16) and 
9g (fig. 6.17), but not following von Frey lg (fig. 6.15), and thus a significant 
reduction in tactile hypersensitivity. In the case of the response following von 
Frey 5g, morphine significantly decreased ipsilateral paw withdrawal to tactile 
stimuli at 30 minutes following its administration, which was shown as a
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decrease in the difference score from 5±1 with saline to 2±1 with morphine, 
whereas following von Frey 9g, morphine significantly decreased ipsilateral paw 
withdrawal to tactile stimuli at 15 and 30 minutes following its administration, 
from a difference score of 7±1 with saline to 4±1 and 3±1 with morphine, 
respectively.
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Fig. 6.15- The lack o f significant effect o f morphine (red, 3mg/kg, n=6) on the difference score 
between ipsilateral and contralateral paw to von Frey lg, when compared to the saline control 
(black, 0.25ml, n=10), in neuropathic rats. Tactile hypersensitivity to von Frey lg  was not very 
pronounced to begin with, in rats with nerve injury, which was demonstrated as a low difference 
score baseline value. Since there was no difference in the score between ipsilateral and 
contralateral hindpaws for the sham-operated rats (n=6), these appear as zero difference score 
(open squares), even after saline and morphine administration. BL depicts pre-drug baseline 
responses.
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Fig. 6.16- A graph comparing the effect o f morphine (red, 3mg/kg, n=6) on the difference score 
between ipsilateral and contralateral paw to von Frey 5g, when compared to the saline control 
(black, 0.25ml, n=10). Morphine significantly reduced tactile hypersensitivity in the ipsilateral 
paw of rats with nerve injury, as demonstrated by a decrease in the difference score. Since there 
was no difference in the score between ipsilateral and contralateral hindpaws for the sham- 
operated rats (n=6), these appear as zero difference score (open squares), even after saline and 
morphine administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase in 
difference score after spinal nerve ligation was prevented by morphine administration (red), when 
compared to saline control (black). Mann-Whitney test.
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Fig. 6.17- A graph comparing the effect o f morphine (red, 3mg/kg, rr=6) on the difference score 
between ipsilateral and contralateral paw to von Frey lOg, when compared to the saline control 
(black, 0.25ml, n=10). Morphine significantly reduced tactile hypersensitivity in the ipsilateral 
paw o f rats with nerve injury, as demonstrated by a decrease in the difference score. Since there 
was no difference in the score between ipsilateral and contralateral hindpaws for the sham- 
operated rats (n=6), these appear as zero difference score (open squares), even after saline and 
morphine administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase in 
difference score after spinal nerve ligation was prevented by morphine administration (red), when 
compared to saline control (black). Mann-Whitney test.
iii) Cold response
The subcutaneous administration of morphine, in neuropathic rats, significantly 
decreased the difference score between ipsilateral and contralateral paw 
following cold stimuli, 30 minutes after its administration (fig. 6.18), when 
compared to the saline control, from 1±1 to 0±0. Morphine showed maximal 
activity 30 minutes following its administration, when each of thermal, tactile 
and cold was tested.
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Fig. 6.18- The effect o f morphine (red, 3mg/kg, n=6) on the difference score between ipsilateral 
and contralateral paw to cold stimuli, when compared to the saline control (black, 0.25ml, n=10), 
in neuropathic rats. Morphine significantly reduced cold hypersensitivity in the ipsilateral paw of 
rats with nerve injury, as demonstrated by a decrease in the difference score. Since there was no 
difference in the score between ipsilateral and contralateral hindpaws for the sham-operated rats 
(n=6), these appear as zero difference score (open squares), even after saline and morphine 
administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase in 
difference score after spinal nerve ligation was prevented by morphine administration (red), when 
compared to saline control (black). Mann-Whitney test.
6.3.5 Ondansetron experiments
i) Thermal response
In spinal nerve-ligated rats, the intrathecal administration of ondansetron did not 
significantly change the thermal hypersensitivity seen following neuropathy, 
when compared to the saline control (fig. 6.19). In sham-operated rats, 
ondansetron did not significantly change paw withdrawal latency to thermal 
stimuli, when compared to the saline control (fig. 6.20)
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Fig. 6.19- The lack o f effect o f ondansetron on paw withdrawal latency following thermal stimuli 
(ipsilateral=purple, contralateral=blue, 20pg, n=9), when compared to the saline control 
(ipsilateral=red, contralateral=black, 24pl, n=9), in rats with spinal nerve ligation. BL depicts 
pre-drug baseline responses.
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Fig. 6.20- The lack o f effect o f ondansetron on paw withdrawal latency following thermal stimuli 
(ipsilateral=purple, contralateral=blue, 20pg, n=6), when compared to the saline control 
(ipsilateral=red, contralateral=black, 24pl, n=6), in sham-operated rats. BL depicts pre-drug 
baseline responses.
ii) Tactile response
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Even though ondansetron, via the intrathecal route, did not significantly change 
the ipsilateral paw withdrawal to von Frey lg (fig. 6.21) in rats with spinal nerve 
ligation, ondansetron did overall significantly reduce the tactile hypersensitivity 
in the ipsilateral paw, as it decreased ipsilateral paw withdrawal to von Frey 5g 
(fig. 6.22), 30 minutes after its administration. Ondansetron also significantly 
reduced ipsilateral paw withdrawal to von Frey 9g (fig. 6.23), 30 and 45 minutes 
after its administration. Ondansetron, like morphine, showed maximal effect 30 
minutes following its administration, thus justifying the timing of administration 
when both drugs were used. The lack of effect of ondansetron on thermal 
hypersensitivity, as opposed to its significant effects on tactile hypersensitivity, 
could be a reflection of the primary afferent fibre types that the 5HT3 receptor is 
expressed on, which is a subset of the myelinated primary afferent fibres 
(Maxwell, Kerr et al. 2003).
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Fig. 6.21- The lack o f significant effect o f ondansetron (red, 20pg, n=9) on the difference score 
between ipsilateral and contralateral paw to von Frey lg, when compared to the saline control 
(black, 24pl, n=9). Tactile hypersensitivity to von Frey lg  was not very pronounced to begin 
with, in rats with nerve injury, which was demonstrated as a low difference score baseline value. 
Since there was no difference in the score between ipsilateral and contralateral hindpaws for the 
sham-operated rats (n=6), these appear as zero difference score (open squares), even after saline 
and ondansetron administration. BL depicts pre-drug baseline responses.
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Fig. 6.22- A comparison of the effect o f ondansetron (red, 20pg, n=9) on the difference score 
between ipsilateral and contralateral paw to von Frey 5g, when compared to the saline control 
(black, 24pi, n=9). Ondansetron significantly reduced tactile hypersensitivity in the ipsilateral 
paw of rats with nerve injury, as demonstrated by a decrease in the difference score. Since there 
was no difference in the score between ipsilateral and contralateral hindpaws for the sham- 
operated rats (n=6), these appear as zero difference score (open squares), even after saline and 
ondansetron administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase 
in difference score after spinal nerve ligation was prevented by ondansetron administration (red), 
when compared to saline control (black). Mann-Whitney test.
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Fig. 6.23- A comparison o f the effect o f  ondansetron (red, 20pg, n=9) on the difference score 
between ipsilateral and contralateral paw to von Frey 9g, when compared to the saline control 
(black, 24pl, n=9). Ondansetron significantly reduced tactile hypersensitivity in the ipsilateral 
paw o f rats with nerve injury, as demonstrated by a decrease in the difference score. Since there 
was no difference in the score between ipsilateral and contralateral hindpaws for the sham- 
operated rats (n=6), these appear as zero difference score (open squares), even after saline and 
ondansetron administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase 
in difference score after spinal nerve ligation was prevented by ondansetron administration (red), 
when compared to saline control (black). Mann-Whitney test.
iii) Cold response
In rats with spinal nerve ligation, ondansetron, via the intrathecal route, did not 
significantly change the hypersensitivity to cold stimuli in the ipsilateral paw, 
when compared to the saline control (fig. 6.24).
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Fig. 6.24- The lack o f significant effect o f  ondansetron (red, 20pg, n=9) on the difference score 
between ipsilateral and contralateral paw to cold stimuli, when compared to the saline control 
(black, 24|il, n=9). Since there was no difference in the score between ipsilateral and contralateral 
hindpaws for the sham-operated rats (n=6), these appear as zero difference score (open squares), 
even after saline and ondansetron administration. BL depicts pre-drug baseline responses.
6.3.6 Morphine and ondansetron in combination
i) Thermal response
Subcutaneous morphine and intrathecal ondansetron together led to a significant 
increase in paw withdrawal latency in response to thermal stimuli, in rats with 
spinal nerve ligation. Ipsilateral paw withdrawal latency to thermal stimuli 
significantly increased at 15, 30, 45 and 60 minutes following morphine and 
ondansetron administration, when compared to the ipsilateral saline control, and 
contralateral paw withdrawal latency to thermal stimuli was also significantly 
increased by morphine and ondansetron at 5, 15 and 30 minutes post­
administration, when compared to the contralateral saline control (fig. 6.25). In 
sham-operated rats, morphine and ondansetron also led to analgesia in the 
response to thermal stimuli at timepoints 5, 15, 30 and 45 minutes (fig. 6.26). 
Therefore, the combination of morphine and ondansetron inhibited thermal 
hypersensitivity to the same extent in both the ipsilateral and the contralateral 
paw of rats with nerve injury, and this effect was also comparable to that seen in
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sham-operated rats. However, the effect of this drug combination on the 
ipsilateral paw withdrawal latency in nerve-injured rats also had a delayed onset, 
as was previously seen with morphine alone. The effects of the drug combination 
on paw withdrawal latency may be attributed to both morphine and ondansetron, 
since they are longer-lasting in the paw ipsilateral to nerve injury than when 
morphine was administered on its own.
Fig. 6.25- A comparison the effect o f  morphine (3mg/kg) and ondansetron (20pg) on paw 
withdrawal latency to thermal stimuli (ipsilateral=purple, contralateral=blue, n=7), with saline 
(ipsilateral=red, contralateral=black, 0.25ml and 24pi, n=7), in rats with spinal nerve ligation. 
Spinal nerve ligation caused thermal hypersensitivity in the paw ipsilateral to nerve injury. The 
combination o f morphine and ondansetron caused a significant increase in paw withdrawal 
latency to thermal stimuli to the same extent in both the ipsilateral and the contralateral paw in 
rats with nerve injury, when compared to saline control. BL depicts baseline responses. *P<0.05, 
where a significant increase in ipsilateral paw withdrawal latency is seen following morphine and 
ondansetron administration, when compared to saline control. “P<0.05, where a significant 
increase in contralateral paw withdrawal latency is seen following morphine and ondansetron 
administration, when compared to saline control. tP<0.05, where a significant increase in 
contralateral paw withdrawal latency was caused by morphine+ondansetron, when compared to 
ipsilateral paw withdrawal latency in the group that received saline. §P<0.05, contralateral versus 
ipsilateral paw withdrawal latency in the group that received morphine+ondansetron. #P<0.05, 
contralateral versus ipsilateral paw withdrawal latency in the group that received saline, f  P<0.05, 
where spinal nerve ligation caused a significant decrease in ipsilateral paw withdrawal latency to 
thermal stimuli, when compared to contralateral paw withdrawal latency, during baseline testing. 
One way ANOVA followed by Tukey post-hoc test.
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Fig. 6.26- A comparison o f the effects o f morphine (3mg/kg) and ondansetron (20Dg) on paw 
withdrawal latency to thermal stimuli (ipsilateral=purple, contralateral=blue, n=6), with saline 
(ipsilateral=red, contralateral=black, 24Dl and 0.25ml, n=6), in sham-operated rats. BL depicts 
pre-drug baseline responses. The combination o f morphine and ondansetron significantly 
increased paw withdrawal latency to thermal stimuli at almost all o f  the timepoints tested in both 
ipsilateral and contralateral paws in rats with sham surgery, when compared to saline control. 
*P<0.05,where a significant increase in ipsilateral paw withdrawal latency is seen following 
morphine and ondansetron administration, when compared to saline control, f  P<0.05, where a 
significant increase in contralateral paw withdrawal latency is seen following morphine and 
ondansetron administration, when compared to saline control. §P<0.05, where 
morphine+ondansetron caused a significant increase in contralateral paw withdrawal latency, 
when compared to ipsilateral paw withdrawal latency in the group that received saline. #P<0.05, 
where morphine+ondansetron caused a significant increase in ipsilateral paw withdrawal latency, 
when compared to contralateral paw withdrawal latency in the group that received saline. One 
way ANOVA followed by Tukey post-hoc test.
ii) Tactile response
Subcutaneous morphine and intrathecal ondansetron together significantly 
decreased tactile hypersensitivity in the ipsilateral paw following von Frey 5 (fig. 
6.28) and 9g (fig. 6.29), but not following von Frey lg (fig. 6.27), in rats with 
spinal nerve ligation. The significant reductions in ipsilateral paw withdrawal
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were seen at 15, 30 and 45 minutes following morphine and ondansetron 
administration, which was longer in duration than when each of morphine and 
ondansetron was administered on its own.
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Fig. 6.27- The lack of significant effect of morphine (3mg/kg) and ondansetron (20pg) (red, n=7) 
on the difference score between ipsilateral and contralateral paw to von Frey lg, when compared 
to the saline control (black, 24pl and 0.25ml, n=7). Tactile hypersensitivity to von Frey lg  was 
not very pronounced to begin with, in rats with nerve injury, which was demonstrated as a low 
difference score baseline value. Since there was no difference in the score between ipsilateral 
and contralateral hindpaws for the sham-operated rats (n=6), these appear as zero difference score 
(open squares), even after saline, and morphine and ondansetron administration. BL depicts pre­
drug baseline responses.
241
oo
CO
0oc
0L.0
5
20 40
Time (min)
Fig. 6.28- A comparison o f the effect o f  morphine (3mg/kg) and ondansetron (20pg) (red, n=7) 
on the difference score between ipsilateral and contralateral paw to von Frey 5g, when compared 
to the saline control (black, 24pl and 0.25ml, n=7). The combination o f morphine and 
ondansetron significantly reduced tactile hypersensitivity in the ipsilateral paw o f rats with nerve 
injury, as demonstrated by a decrease in the difference score. Since there was no difference in the 
score between ipsilateral and contralateral hindpaws for the sham-operated rats (n=6), these 
appear as zero difference score (open squares), even after saline and morphine and ondansetron 
administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase in 
difference score after spinal nerve ligation was prevented by morphine and ondansetron 
administration (red), when compared to saline control (black). Mann-Whitney test.
242
10-|
<Du.oo
CO
0)oc<1)V-<D
5
20 30 40 50
Time (min)
Fig. 6.29- A comparison o f the effect o f morphine (3mg/kg) and ondansetron (20pg) (red, n=7) 
on the difference score between ipsilateral and contralateral paw to von Frey 9g, when compared 
to the saline control (black, 24pl and 0.25ml, n=7). The combination o f morphine and 
ondansetron significantly reduced tactile hypersensitivity in the ipsilateral paw o f rats with nerve 
injury, as demonstrated by a decrease in the difference score. Since there was no difference in the 
score between ipsilateral and contralateral hindpaws for the sham-operated rats (n=6), these 
appear as zero difference score (open squares), even after saline and morphine and ondansetron 
administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase in 
difference score after spinal nerve ligation was prevented by morphine and ondansetron 
administration (red), when compared to saline control (black). Mann-Whitney test.
iii) Cold response
The combination of systemic morphine and intrathecal ondansetron also caused a 
significant decrease in ipsilateral paw withdrawal in rats with spinal nerve 
ligation (fig. 6.30), as seen by a reduction in the difference score, 30 minutes 
following the administration of both morphine and ondansetron.
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Fig. 6.30- A comparison o f  the effect o f  morphine (3mg/kg) and ondansetron (20pg) (red, n=7) 
on the difference score between ipsilateral and contralateral paw to cold stimuli, when compared 
to the saline control (black, 24pl and 0.25ml, n=6). The combination o f morphine and 
ondansetron significantly reduced cold hypersensitivity in the ipsilateral paw o f rats with nerve 
injury, as demonstrated by a decrease in the difference score. Since there was no difference in the 
score between ipsilateral and contralateral hindpaws for the sham-operated rats (n=6), these 
appear as zero difference score (open squares), even after saline and morphine and ondansetron 
administration. BL depicts pre-drug baseline responses. *P<0.05, where the increase in 
difference score after spinal nerve ligation was prevented by morphine and ondansetron 
administration (red), when compared to saline control (black). Mann-Whitney test.
6.3.7 A comparison between morphine, ondansetron and the combination of 
the two
i) Thermal response
Systemic morphine alone and in combination with intrathecal ondansetron, was 
significantly more effective than ondansetron alone, and saline control, in 
reducing ipsilateral (fig. 6.31) and contralateral (fig. 6.32) paw withdrawal to 
thermal stimuli, in rats with spinal nerve ligation. In addition, when the 
combination of morphine and ondansetron was compared to morphine alone, the
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combination seemed to cause a non-significant increase in the inhibition of 
ipsilateral paw withdrawal to thermal stimuli in rats with spinal nerve ligation 
(fig. 6.31).
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Fig. 6.31- An area under the curve comparing the effects o f each o f morphine (red, 3mg/kg, n=6, 
saline control=black, 0.25ml, n=6), ondansetron (purple, 20pg, n=7, saline control=blue, 24pl, 
n=7) and their combination (yellow, n=7, saline control=green, 24pl and 0.25ml, n=7) on 
ipsilateral paw withdrawal to thermal stimuli, in rats with spinal nerve ligation. Morphine, and 
the combination o f  morphine and ondansetron, were effective in reducing thermal 
hypersensitivity in the ipsilateral paw o f rats with nerve injury, which was demonstrated by a 
significant increase in the area under the curve, when compared to ondansetron alone and saline 
controls. *P<0.05, where a significant difference is seen between two groups linked with the 
lines, /-test.
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Fig. 6.32- An area under the curve comparing the effects o f  each o f morphine (red, 3mg/kg, n=6, 
saline control=black, 0.25ml, n=6), ondansetron (purple, 20pg, n=7, saline control=blue, 24pl, 
n=7) and their combination (yellow, n=7, saline control=green, 24pl and 0.25ml, n=7) on 
contralateral paw withdrawal to thermal stimuli, in rats with spinal nerve ligation. Morphine, and 
the combination o f morphine and ondansetron, were effective in reducing thermal 
hypersensitivity in the contralateral paw o f rats with nerve injury, which was demonstrated by a 
significant increase in the area under the curve, when compared to ondansetron alone and saline 
controls. *P<0.05, where a significant difference is seen between two groups linked with the 
lines, /-test.
ii) Tactile response
Systemic morphine and intrathecal ondansetron, whether alone or in 
combination, exerted the same effects on ipsilateral paw withdrawal to tactile 
stimuli, in rats with spinal nerve ligation (fig. 6.33-6.35). However, there was a 
non-significant tendency for the drug combination to cause more analgesia than 
each drug alone to von Frey 9g (fig. 6.35) in rats with spinal nerve ligation, as 
seen by the lower difference score area produced by the combination of 
morphine and ondansetron.
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Fig. 6.33- An area under the curve comparing the effects o f  each o f  morphine (red, 3mg/kg, n=6, 
saline control=black, 0.25ml, n=6), ondansetron (purple, 20pg, n=7, saline control=blue, 24pl, 
n=7) and their combination (yellow, n=7, saline control=green, 24pl and 0.25ml, n=7) on the 
difference score between ipsilateral and contralateral paw withdrawal to von Frey lg , in rats with 
spinal nerve ligation.
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Fig. 6.34- An area under the curve comparing the effects o f each o f morphine (red, 3mg/kg, n=6, 
saline control=black, 0.25ml, n=6), ondansetron (purple, 20(ig, n=7, saline control=blue, 24pl, 
n=7) and their combination (yellow, n=7, saline control=green, 24pl and 0.25ml, n=7) on the 
difference score between ipsilateral and contralateral paw withdrawal to von Frey 5g, in rats with 
spinal nerve ligation. Morphine and ondansetron, alone or in combination, significantly reduced 
tactile hypersensitivity to von Frey 5g in the ipsilateral paw in rats with nerve injury, which was 
demonstrated by a decrease in the area under the curve o f the difference score, when compared to 
saline control. *P<0.05, where a significant difference is seen between two groups linked with the 
lines. Mann-Whitney test.
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Fig. 6.35- An area under the curve comparing the effects o f  each o f morphine (red, 3mg/kg, n=6, 
saline control=black, 0.25ml, n=6), ondansetron (purple, 20pg, n=7, saline controHblue, 24pl, 
n=7) and their combination (yellow, n=7, saline control=green, 24pl and 0.25ml, n=7) on the 
difference score between ipsilateral and contralateral paw withdrawal to von Frey 9g, in rats with 
spinal nerve ligation. Morphine and ondansetron, alone or in combination, significantly reduced 
tactile hypersensitivity to von Frey 9g in the ipsilateral paw in rats with nerve injury, which was 
demonstrated by a decrease in the area under the curve o f  the difference score, when compared to 
saline control. *P<0.05, where a significant difference is seen between two groups linked with 
the lines. Mann-Whitney test.
iii) Cold response
Morphine alone, and in combination with ondansetron, was significantly more 
effective than ondansetron alone, in reducing ipsilateral paw withdrawal to cold 
stimuli, in rats with spinal nerve ligation (fig. 6.36).
249
.. X
x
sal mor sal
"T" I
ond sal mor+ond
Fig. 6.36- An area under the curve comparing the effects o f  each o f  morphine (red, 3mg/kg, n=6, 
saline control=black, 0.25ml, n=6), ondansetron (purple, 20pg, n=7, saline control=blue, 24pl, 
n=7) and their combination (yellow, n=7, saline control=green, 24pl and 0.25ml, n=7) on the 
difference score between ipsilateral and contralateral paw withdrawal to cold stimuli, in rats with 
spinal nerve ligation. Morphine alone, and in combination with ondansetron, significantly 
reduced cold hypersensitivity in the ipsilateral paw in rats with nerve injury, which was 
demonstrated by a decrease in the area under the curve o f  the difference score, when compared to 
saline control. *P<0.05, where a significant difference is seen between two groups linked with the 
lines. Mann-Whitney test.
6.4 Discussion
In my study, the ligation of the L5 and L6 spinal nerves led to the manifestation 
of all of thermal, tactile and cold hypersensitivities in the injured paw, which also 
occurred in previous studies which investigated this model of nerve injury (Kim 
and Chung 1992; Wegert, Ossipov et al. 1997; Chapman, Suzuki et al. 1998; 
Ossipov, Bian et al. 1999).
Ondansetron, in normal rats, did not cause any analgesia. However, when 
ondansetron was administered in rats with peripheral nerve injury, it significantly 
decreased the hypersensitivity to tactile stimuli, in the injured paw. Morphine
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alone was analgesic in normal rats (see chapter 4) and was also analgesic in 
neuropathic rats, significantly decreasing ipsilateral paw hypersensitivity to 
thermal, tactile and cold stimuli. The combination of morphine and ondansetron 
significantly reduced the hypersensitivity of the ipsilateral paw to thermal, tactile 
and cold stimuli. In comparison with each drug on its own, the combination of 
morphine and ondansetron increased the length of time the hypersensitivity of 
the paw to thermal and tactile stimuli was reduced. However, there was no 
significant difference in the efficacy of the combination when compared to each 
drug on its own, except for the case of thermal hypersensitivity, which was 
decreased more effectively by either morphine alone, or the combination of 
morphine and ondansetron, when compared to ondansetron alone.
6.4.1 Ondansetron in normal and neuropathic rats
Initial electrical and microinjection studies in the RVM showed that descending 
inhibitions were activated (Reynolds 1969; Fields and Heinricher 1985). Indeed, 
it was previously thought that descending inhibitions predominate over 
descending facilitations. Following that however, it became apparent that 
different doses and frequencies used in the RVM, also led to descending 
facilitations becoming activated (Besson and Chaouch 1987; Urban and Gebhart 
1999; Zhuo and Gebhart 2002). It has now been shown that both inhibitions and 
facilitations descend from the RVM at any one time, and the intensity of each is 
dictated by the pathophysiological state of the animal and the stimulus modality 
used (Kauppila, Kontinen et al. 1998; Wei, Dubner et al. 1999; Zhuo and 
Gebhart 2002).
5-HT was found to be both antinociceptive (Alhaider, Lei et al. 1991; Peng, Lin 
et al. 1996; Tsuchiya, Yamazaki et al. 1999), and pronociceptive (Jordan, 
Kenshalo et al. 1978; Ali, Wu et al. 1996; Oyama, Ueda et al. 1996; Calejesan, 
Ch'ang et al. 1998; Green, Scarth et al. 2000; Zeitz, Guy et al. 2002; Suzuki, 
Rahman et al. 2004), in the spinal cord dorsal horn. The RVM is the primary 
source of 5-HT in the spinal cord dorsal horn (Fasmer, Berge et al. 1983; Besson 
and Chaouch 1987), however, neither ON nor OFF cells seem to contain 5-HT
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(Gao and Mason 2000). Furthermore, descending facilitations have been shown 
to be enhanced following chronic pain states, since treatment with the 5HT3 
antagonist ondansetron decreased tactile hypersensitivity in rats with spinal cord 
injury (Oatway, Chen et al. 2004), and decreased thermal and tactile evoked 
dorsal horn responses in rats with peripheral nerve injury (Suzuki, Rahman et al. 
2004), and cancer-induced bone pain (Donovan-Rodriguez, Urch et al. 2006) as 
well as caused analgesia in patients with neuropathic pain (McCleane, Suzuki et 
al. 2003).
My study shows that the 5HT3 receptor does not play an important role in 
thermal and cold responses. The subset of myelinated primary afferent A8 fibres 
where the 5HT3 receptor is predominantly located (Maxwell, Leranth et al. 1983; 
Kidd, Laporte et al. 1993; Tecott, Maricq et al. 1993; Zeitz, Guy et al. 2002; 
Maxwell, Kerr et al. 2003; Conte, Legg et al. 2005) may be one of the reasons 
this receptor is not involved in thermal and cold responses, since the receptors 
which convey these modalities, TRPV1 and TRPA1 respectively, are 
predominantly located on unmyelinated, peptidergic fibres (Caterina,
Schumacher et al. 1997; Magerl, Fuchs et al. 2001; Patapoutian, Peier et al. 2003; 
Lee, Lee et al. 2005; Meyer, Ringkamp et al. 2006). Indeed, the study by 
Maxwell et al in 2003, using immunohistochemistry, shows that the 5HT3-A 
receptor subunit, which forms functional homopentameric receptors, is not 
located on peptidergic primary afferent fibres, thus supporting my findings. 
Furthermore, the TRPV2 receptor which is located primarily on myelinated 
fibres, codes a suprathreshold heat (Patapoutian, Peier et al. 2003; Meyer, 
Ringkamp et al. 2006), which was not tested in this study.
Furthermore, even though a previous study using in vivo electrophysiology 
showed that ondansetron reduced the thermal evoked response of dorsal horn 
neurons, the dose of ondansetron used was lOOpg, which was higher than the 
dose used in my study (Suzuki, Rahman et al. 2004). Additionally, the latter 
study also showed that the effect of ondansetron on mechanical evoked dorsal 
horn neuronal responses was more pronounced in rats with peripheral nerve
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injury than sham-operated rats, and that the effects of ondansetron on the thermal 
evoked response were less pronounced, since ondansetron reduced the thermal 
evoked response of dorsal horn neurons in both neuropathic and sham-operated 
rats to the same extent (Suzuki, Rahman et al. 2004).
Furthermore, in my study, the 5HT3 antagonist ondansetron decreased paw 
hypersensitivity to tactile stimuli in neuropathic rats, with no effect on normal 
rats. Although previous electrophysiological studies showed that ondansetron 
also reduced mechanical evoked dorsal horn neuronal responses in sham- 
operated rats, which were considered the control ‘normal’ rats, they used doses 
50 and lOOpg of ondansetron (Suzuki, Rahman et al. 2004), whereas I used doses 
10 and 20pg in normal rats, and only dose 20pg in spinal nerve ligated and 
sham-operated rats.
Therefore, my study confirms that the status of descending serotonergic 
facilitations is enhanced following nerve injury (Burgess, Gardell et al. 2002; 
Suzuki, Rahman et al. 2004; Vera-Portocarrero, Zhang et al. 2006), and that 
when the increased surge of 5-HT acts on the spinal 5HT3 receptor, it causes 
nociception (Ali, Wu et al. 1996; Calejesan, Ch'ang et al. 1998; Green, Scarth et 
al. 2000; Zeitz, Guy et al. 2002).
6.4.2 Morphine in neuropathic rats
Some studies showed that spinal morphine has reduced efficacy in neuropathic 
pain and that systemic and supraspinal morphine are more effective (Bian, 
Nichols et al. 1995; Lee, Chaplan et al. 1995; Nichols, Bian et al. 1995; Nichols, 
Lopez et al. 1997; Wegert, Ossipov et al. 1997; Bian, Ossipov et al. 1999; 
Pertovaara and Wei 2003), whereas other studies show that spinal morphine is 
effective in neuropathic pain (Yamamoto and Yaksh 1991; Suzuki, Chapman et 
al. 1999; Suzuki and Dickenson 2002; Zhao, Tall et al. 2004). Two important 
events which have been attributed to the ‘reduced’ efficacy of spinal morphine in 
neuropathic pain are the increases in levels of spinal dynorphin (Bian, Ossipov et
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al. 1999; Ossipov, Lai et al. 2000; Dickenson and Kieffer 2006) and 
cholecystokinin (Xu, Puke et al. 1993; Nichols, Bian et al. 1995; Zhang, Bao et 
al. 1998) (see section 1.7.7 ii).
In my study, systemic morphine was used, since it acts at all three sites where p- 
opioid receptors are located: on primary afferent fibres, to decrease 
neurotransmitter release, in the dorsal horn, to decrease synaptic transmission, 
and on RVM neurons to activate OFF cells, inhibit ON cells and have an overall 
inhibitory effect on the spinal cord pain transmission (Fields, Heinricher et al. 
1991; Dickenson 1994; Heinricher 1997; Porreca, Burgess et al. 2001; Dickenson 
and Kieffer 2006).
No study has disputed the effectiveness of morphine in inhibiting thermal 
hyperalgesia in numerous nerve injury models, however, the effectiveness of 
morphine on tactile allodynia has been questioned. Morphine (systemic and 
spinal) effectively inhibited thermal hyperalgesia in the chronic constriction 
model (Yamamoto and Yaksh 1991; Lee, Kayser et al. 1994; Backonja, Miletic 
et al. 1995) and the spinal nerve ligation model (Wegert, Ossipov et al. 1997), as 
well as in my study. In addition, morphine reduced c-Fos expression following 
noxious thermal stimuli, in the spinal cord dorsal horn side ipsilateral to the 
chronic constriction of the sciatic nerve (Catheline, Le Guen et al. 2001). The 
effectiveness of morphine on this stimulus modality is due to the fact that 
thermal stimuli has been shown to be mostly conveyed by channels of the TRPV 
family, which reside on the peripheral terminals o f C-fibres (Caterina, 
Schumacher et al. 1997; Ossipov, Bian et al. 1999), the central terminals of 
which are p-opioid receptor rich (Besse, Lombard et al. 1992; deGroot, 
Coggeshall et al. 1997; Zhang, Bao et al. 1998).
There are two types of tactile allodynia, dynamic allodynia, which has been 
shown to be conveyed mostly by A[3- and capsaicin-insensitive A5-fibres, and 
static allodynia, which was measured in my study and which has been shown to 
be conveyed mostly by A5-fibres (Field, Bramwell et al. 1999). Static allodynia,
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as measured by a decrease in paw withdrawal threshold to von Frey 
monofilaments, has been shown to be inhibited by systemic and supraspinal, but 
not spinal, morphine in the spinal nerve ligation model (Bian, Nichols et al.
1995; Lee, Chaplan et al. 1995; Pertovaara and Wei 2003) and in the streptozocin 
model (Field, McCleary et al. 1999), whereas spinal morphine was shown to be 
effective in a behavioural study using the spared nerve injury model (Zhao, Tall 
et al. 2004). In addition, systemic morphine was shown to decrease vocalisation 
due to mechanical pressure, in the chronic constriction model (Attal, Chen et al. 
1991). However, other studies have shown that systemic morphine was only 
effective in reducing static allodynia, as measured by changes in the paw 
withdrawal threshold (Joshi, Hernandez et al. 2006), and paw pressure test 
(Lemberg, Kontinen et al. 2006), when used at sedating doses, in the spinal nerve 
ligation model, whereas another study has shown the reduced efficacy of 
systemic morphine, even at sedating doses, to inhibit static allodynia, also 
measured as a decrease in paw withdrawal threshold, in the spinal nerve ligation 
model (Kontinen, Paananen et al. 1998).
In my study, systemic morphine, at a non-sedating dose (see section 4.3.4 i), was 
effective in reducing static allodynia, which has been shown previously in studies 
investigating the chronic constriction model (CCI) (Field, Bramwell et al. 1999) 
and the streptozocin model of nerve injury (Field, McCleary et al. 1999), as well 
as in a study investigating cancer-induced bone pain (Urch, Donovan-Rodriguez 
et al. 2005). The channels which transduce mechanosensation are less known 
than their thermal and chemical transducing counterparts, but are thought to 
include the bacterial osmosensitive ion channels MscL and MscS, TRPV4 and 
P2X3 (Wood, Abrahamsen et al. 2004). Of these, the P2X3 channel has been 
shown to be expressed in non-peptidergic, IB4 positive primary afferent fibres, 
which are mostly A6-fibres (Tsuda, Shigemoto-Mogami et al. 2003; Tsuda,
Inoue et al. 2005; Meyer, Ringkamp et al. 2006), which confirms the other 
studies that show that static allodynia is mostly conveyed by A5-fibres (Field, 
Bramwell et al. 1999; Ossipov, Bian et al. 1999). However, tactile allodynia 
following nerve injury has been shown by many previous studies (see section
255
1.7.7 iii) to be mediated mostly supraspinally, since it was mostly inhibited by 
systemic and supraspinal, but not spinal morphine (Wegert, Ossipov et al. 1997; 
Ossipov, Bian et al. 1999), and thus the effectiveness of systemic morphine in 
inhibiting tactile hypersensitivity in my study.
The effect of morphine on cold allodynia has not been investigated by many 
studies. Cold stimuli has been found to be coded for by the TRPM8 and the 
TRPA1 channels, the latter of which is found mostly colocalised with TRPV1, on 
the peripheral terminals of C-fibres (Patapoutian, Peier et al. 2003; Wood 2004; 
Lee, Lee et al. 2005), which renders this stimulus modality partly sensitive to 
morphine control. In my study, morphine was effective at significantly reducing 
cold allodynia, however, two previous studies also using systemic morphine 
(Lee, Kayser et al. 1994; Kontinen, Paananen et al. 1998) have found the drug to 
be ineffective in reducing cold allodynia. Whereas the study by Lee et al used the 
chronic constriction model of nerve injury, as well as paw immersion in a 10°C 
water bath to test for cold allodynia, the study by Kontinen et al used both the 
same nerve injury model, species and the same cold allodynia test as the ones 
used in my study. The only difference between the Kontinen et al study and my 
study was the dose of morphine used, I used 3mg/kg, whereas they used an acute 
systemic dose of lOmg/kg, as well as slow-release pellets resulting in a total dose 
of 75, 150 and 375mg. However, cold allodynia in the SNL model has been 
shown to be variable and not strongly demonstrated in some cases (Ossipov, Lai 
et al. 2006). The study by Kontinen et al also could not find a manifestation of 
thermal hyperalgesia following nerve injury.
Systemic morphine, as was previously discussed, acts on p-opioid receptors 
which are located on primary afferent fibres, on dorsal horn neurons, as well as 
on supraspinal sites, such as the RVM, to exert its effects (Dickenson 1994; 
Dickenson and Kieffer 2006), whereas intrathecal ondansetron only acts on the 
5HT3 receptors which are mostly located in the vicinity of the superficial dorsal 
horn (Maxwell, Leranth et al. 1983; Maxwell, Kerr et al. 2003). Therefore, the 
fact that systemic morphine was more effective in my study, than spinal
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ondansetron in reducing hypersensitivity to all of thermal, tactile and cold stimuli 
following peripheral nerve injury, was not surprising.
6.4.3 Morphine and ondansetron in neuropathic pain
Descending serotonergic facilitations are part of a spino-bulbo-spinal loop, which 
has NK-1-expressing lamina I projection neurons at its origin. These projection 
neurons ascend to the parabrachial area, which has fibres that activate 
pronociceptive pathways from the RVM onto the spinal cord (Bester, Matsumoto 
et al. 1997; Mantyh, Rogers et al. 1997; Bester, Chapman et al. 2000; Gauriau 
and Bernard 2002; Todd 2002; Rahman, Suzuki et al. 2003; Suzuki, Rahman et 
al. 2004; Hunt and Bester 2005). The fact that ondansetron, acting on spinal 
5HT3 receptors, has been shown to decrease tactile hypersensitivity (Oatway, 
Chen et al. 2004) and dorsal horn neuronal excitability (Suzuki, Rahman et al. 
2004; Donovan-Rodriguez, Urch et al. 2006; Rahman, Suzuki et al. 2006) 
following chronic pain states, whilst affecting baseline transmission to a lesser 
extent, shows that descending serotonergic facilitations are enhanced, following 
some chronic pain states, including those of a neuropathic nature (Suzuki, 
Rahman et al. 2004).
Indeed, it has been shown that following peripheral nerve injury, continuous 
afferent input initiates spinal sensitisation, and 6 days following nerve injury, 
descending facilitations are enhanced and serve to maintain central sensitisation 
(Kauppila, Kontinen et al. 1998; Burgess, Gardell et al. 2002; Vera-Portocarrero, 
Zhang et al. 2006). Furthermore, the ablation of p-expressing cells in the RVM 
with dermorphin-saporin, which are thought to include ON cells, decreased 
hypersensitivity due to nerve injury and did not affect normal pain, which means 
that these p-expressing cells are also involved in the increased descending 
facilitations seen after nerve injury (Porreca, Burgess et al. 2001; Porreca, 
Ossipov et al. 2002; Vera-Portocarrero, Zhang et al. 2006). If these p-opioid 
receptor expressing cells are inhibited by morphine, therefore, following nerve 
injury, systemic morphine should inhibit the increased descending facilitations at
257
a supraspinal level, and ondansetron should inhibit the enhanced descending 
serotonergic facilitations at a spinal level and therefore, the combination of 
morphine with ondansetron was postulated to be more effective than each drug 
on its own, in reducing the hypersensitivity seen following peripheral nerve 
injury. In addition, this drug combination could be clinically beneficial in 
reducing the dose of morphine used and thus the unwanted side-effects seen with 
high doses of morphine, such as sedation and respiratory depression (Dickenson 
1994).
In my study, the combination of morphine and ondansetron only served to 
increase the efficacy of ondansetron alone in reducing the thermal and cold 
hypersensitivity seen following nerve injury, since ondansetron alone only 
reduced the tactile hypersensitivity. Additionally, the combination of morphine 
and ondansetron in my study increased the duration of analgesia for both thermal 
and tactile hypersensitivity, when compared to each drug alone. Indeed, thermal 
hypersensitivity, when the combination was used, was reduced for 45 minutes, as 
opposed to when only morphine was used, where the reduction was seen for only 
15 minutes. Tactile hypersensitivity on the other hand was reduced by the 
combination of morphine and ondansetron for 30 minutes, whereas when each 
drug was acting alone, the reduction of tactile hypersensitivity only lasted for 
half that time.
Even though morphine was administered via the systemic route in my study, 
previous studies have shown, using spinal morphine, that thermal 
hypersensitivity following nerve injury is mediated mostly spinally (see section
1.7.7 iii) (Yamamoto and Yaksh 1991; Yamamoto and Yaksh 1992). Therefore, 
the fact that morphine, whether alone or in combination with ondansetron, was 
more effective than ondansetron alone in decreasing the thermal and cold 
hypersensitivity seen following neuropathic pain could be further proof that 
thermal and cold hypersensitivity are predominantly conveyed by the 
unmyelinated, capsaicin-sensitive C-fibres, since most of the p-opioid receptors 
are expressed on these fibres (Wegert, Ossipov et al. 1997; Ossipov, Bian et al.
1999), whereas only a small amount of 5HT3 receptors is found on these fibres
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(Maxwell, Leranth et al. 1983; Kidd, Laporte et al. 1993; Tecott, Maricq et al. 
1993; Zeitz, Guy et al. 2002; Maxwell, Kerr et al. 2003; Conte, Legg et al. 2005).
However, when comparing the area under the curve for each drug alone and the 
combination, the only significant decrease seen was between morphine with 
ondansetron alone, and the combination with ondansetron alone, in decreasing 
the thermal response following peripheral nerve injury, even though there was a 
non-significant trend for the drug combination to be more effective than each 
drug in inhibiting thermal hypersensitivity and hypersensitivity to von Frey 9g. 
The lack of synergism seen in my study could be due to the fact that the doses of 
morphine and ondansetron used were already effective doses, whereas previous 
studies investigating the synergism between two drugs usually use the 
combination of an ineffective dose of each drug (Mjellem-Joly, Lund et al. 1991; 
Matthews and Dickenson 2002).
Furthermore, synergism studies tend to use more than one dose of each drug and 
construct an isobologram, whereby the different doses of each drug are plotted 
against each other and the ED50, the effective dose required to produce a specific 
effect in 50% of an animal population, of each drug is calculated (van Rijn, Sun 
et al. 2004). Nevertheless, since only one dose of each drug was used in this 
study, an area under the curve, normally reserved to determine the total exposure 
of the body to a given drug over time, was used to compare whether an overall 
effect had occurred with each drug and drug combination used.
6.4.4 Conclusion
Even though the doses used in my study did not allow for a proper judgement to 
be made on whether there is synergy between morphine and ondansetron, the 
combination of the two drugs provided a longer-lasting reduction of the 
hypersensitivities seen following nerve injury, which could translate into longer- 
lasting analgesia for patients with neuropathic pain.
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Furthermore, morphine alone, the gold standard of pain control, was shown to be 
more effective than ondansetron alone in my study, which could be due to the 
fact that morphine acts on the p-opioid receptors found on primary afferent 
fibres, spinal cord dorsal horn neurons and supraspinal sites, and thus on all three 
important sites o f the pain transmission pathway (Dickenson 1997; Dickenson 
and Kieffer 2006). Therefore, morphine is effective in decreasing some of the 
pain abnormalities which occur in neuropathic pain states (Rowbotham, Reisner- 
Keller et al. 1991; Yamamoto and Yaksh 1992; Sindrup and Jensen 1999;
Suzuki, Chapman et al. 1999; Attal, Guirimand et al. 2002; Hansson and 
Dickenson 2005). However, clinical testing should be done with different doses 
of morphine and ondansetron together, before the final ruling is made on this 
drug combination.
260
Chapter 7: 
Discussion
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7. Discussion
7.1 Summary
In my study, morphine was found to inhibit: dorsal horn neuronal responses 
following the activation of the spinal NK-1 receptor, thermal and mechanical 
hypersensitivity following the activation of each of the spinal NMDA and NK-1 
receptor, tactile hypersensitivity following the activation of the peripheral 
NMDA receptor as well as thermal, tactile and cold hypersensitivity following 
the spinal nerve ligation model. Therefore overall, morphine was able to inhibit 
the excitatory transmission in the spinal cord, when this excitatory transmission 
was directly activated by specific agonists at excitatory receptors, and when 
activated secondary to nerve injury.
In addition, peripheral NMDA receptors were found to be pharmacologically 
activated by a high dose of NMDA, but not pathophysiologically involved in the 
tactile hypersensitivity seen following the spinal nerve ligation model, whereas 
descending serotonergic facilitations were found to be enhanced following this 
model of nerve injury, as blocking the spinal 5HT3 receptor with ondansetron 
reduced tactile hypersensitivity in neuropathic animals, with no effect in normal 
animals.
Finally, there was no synergy observed, when morphine and ondansetron were 
administered together, on thermal, tactile and cold hypersensitivity following the 
spinal nerve ligation model.
7.2 General discussion
An earlier study has been done to attempt to gauge the importance of pre- versus 
postsynaptic effects of morphine on inhibiting dorsal horn neuronal responses 
(Lombard et al., 1989), by investigating the potency of the same dose of systemic 
morphine on the spontaneous hyperactivity o f dorsal horn neurons in the 
spinalised, decrebrated rats, when primary afferent fibres are left intact or
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removed. They concluded that the efficacy of morphine to inhibit responses 
whereby morphine can act predominantly on its presynaptic p-opioid receptors, 
is more than when morphine has to act mostly on its postsynaptic p-opioid 
receptors. This finding was postulated to be due to the fact that at the spinal cord 
level, as has been revealed by dorsal rhizotomy (Besse et al., 1990), peripheral 
axotomy (deGroot et al., 1997; Zhang et al., 1998) and expression studies 
(Mansour et al., 1994), the number of presynaptic p-opioid receptors is larger 
than postsynaptic p-opioid receptors.
Furthermore, in previous studies (Chapman et al., 1992; Chapman et al., 1994b; 
Dickenson et al., 1986; Suzuki et al., 1999), as well as in my study, it was shown 
that the dorsal horn neuronal responses which reflect the action of morphine on 
its presynaptic receptors include electrically evoked input, a measure of neuronal 
activity after the first electrical stimulus and prior to any hyperexcitability (Urch 
et al., 2003a), and C-fibre responses. Even though the final C-fibre response 
measured in all these studies occurs following the 16th electrical stimuli, and thus 
following some hyperexcitability, most o f the presynaptic p-opoid receptors have 
been shown to reside on the central terminals of these fibres and therefore, this 
response is highly sensitive to morphine control (Besse et al., 1990; deGroot et 
al., 1997; Mansour et al., 1994; Zhang et al., 1998).
However, electrically evoked Ap-fibre response has been shown to represent a 
response which would require morphine to act predominantly on its postsynaptic 
p-opioid receptors to inhibit it (Chapman et al., 1992; Chapman et al., 1994b; 
Dickenson et al., 1986), since it has been shown that there are hardly any p- 
opioid receptors found on Ap-fibres. The latter was revealed in studies which 
showed that most p-opioid receptors are found located in the superficial dorsal 
horn of the spinal cord, an area where Ap-fibres do not terminate in (Besse et al., 
1990; Zhang et al., 1998).
Another response which would require morphine to act partly via its postsynaptic 
p-opioid receptors is wind-up. Wind-up is the frequency dependent potentiation
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of deep dorsal horn neurons after C-fibre stimulation (Mendell, 1966), and 
includes both a pre- and a postsynaptic-dependent component. Indeed, wind-up 
response has been shown to occur due to the activation of the NMDA receptor 
channel, since this response was inhibited by an NMDA receptor antagonist 
(Dickenson, 1990; Dickenson et al., 1990; Dickenson et al., 1987). Furthermore, 
the activation of the NK-1 receptor is also needed for the full expression of the 
wind-up response, since the administration of an NK-1 antagonist has been 
shown to partly decrease wind-up response (Xu et a l, 1992). Both the NMDA 
and the NK-1 receptors are mostly found on the spinal cord dorsal horn neurons 
(Coggeshall et al., 1997a), where postsynaptic p-opioid receptors are fewer in 
numbers (Besse et al., 1992; Besse et a l,  1990; Zhang et a l,  1998).
However, wind-up generation is also due to the electrical stimulation of the 
neuron at 3x the C-fibre threshold and requires input, a presynaptic component 
which is sensitive to morphine control, to activate the postsynaptic NMDA 
receptor. Therefore, previous studies have concluded that morphine is not 
completely ineffective in inhibiting wind-up response, but that a higher dose of 
morphine is required than that needed to inhibit presynaptic-mediated dorsal horn 
neuronal responses. The latter is due to the fact that with a lower dose of 
morphine, the small amount o f electrically evoked input response which is left is 
able to break through, and is enough to generate wind-up (Chapman, 1994; 
Chapman et a l ,  1992; Chapman et al., 1994b; Dickenson et a l,  1986).
Since wind-up leads to the sensitisation of dorsal horn neuronal responses, and 
since both the NMDA and the NK-1 receptors are involved in this response, the 
hypothesis of the first part of my study was that the activation of each of these 
two excitatory receptors, the NMDA and the NK-1 receptor, by its respective 
agonist, would cause the facilitation of some of the dorsal horn neuronal 
responses, which has been shown in previous studies and discussed in chapters 3 
and 4 (Chapman et al., 1994a; Dougherty et al., 1991; Henry, 1976). In addition, 
due to the fact that both the NMDA and the NK-1 receptors are located mostly 
postsynaptic (Coggeshall et al., 1997a) on the spinal cord dorsal horn neurons, 
and due to the above-mentioned electrophysiological studies showing that
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morphine was less able to exert its effect when acting mostly on its postsynaptic 
p-opioid receptors (Chapman, 1994; Chapman et a l, 1992; Chapman et a l, 
1994b; Dickenson et a l, 1986; Lombard et a l, 1989), then it was of relevance to 
investigate which dorsal horn neuronal responses morphine could effectively 
inhibit when administered alone, and compare these to when morphine was 
administered following the administration of each receptor agonist.
Furthermore, the NMDA and NK-1 receptors not only play a role in the wind-up 
response of dorsal horn neurons, but also play a role in longer-lasting models of 
central sensitisation. Central sensitisation is thought to underlie abnomal pain 
sensations such as hyperalgesia and allodynia seen in chronic pain states such as 
neuropathic pain (Treede et a l,  1992). The activation of both the spinal NK-1 
and the NMDA receptors are thought to be involved in the abnormal pain 
sensations following nerve injury, since these hypersensitivities are reduced 
following the administration of NK-1- (Cahill et a l,  2002; Coudore-Civiale et 
a l, 2000; Field et a l, 1998) and NMDA receptor antagonists (Davar et a l, 1991; 
Malcangio et a l , 1998b; Wang et a l ,  2001; Wegert et a l,  1997; Yamamoto et 
a l , 1992b). Moreover, abnormal dorsal horn neuronal activity following nerve 
injury is also reduced by NK-1- (Cumberbatch et a l, 1998) and NMDA receptor 
antagonists (Suzuki et a l,  2001). Therefore, it was interesting to investigate and 
compare the effects of the activation of each of these receptors in an acute model 
of nociception, and their modulation by morphine.
In the part of my study using in vivo electrophysiology however, due to either 
the frequency of C-fibre stimulation (Chapman et a l ,  1994a), the neuronal 
population used, the dosage of each agonist used or a combination of these 
factors, the only dorsal horn neuronal response which was facilitated was the 
45°C thermal evoked response with the NK-1 receptor agonist Sar-SP, and 
morphine was able to inhibit the same responses it was effective in inhibiting 
when acting alone, including the thermal-evoked response, and to the same 
extent. This could lead to the conclusion that morphine is effective in inhibiting 
the dorsal horn neuronal responses, once the NK-1 receptor is activated, or that
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this part of my study should remain inconclusive, and investigated using 
behavioural techniques.
In the part o f my study using behavioural techniques, I show that intrathecal Sar- 
SP (3pg) causes both thermal and mechanical hypersensitivity, as well as long- 
lasting biting, scratching and licking (see chapter 4). One of the reasons that a 
facilitation of mechanical evoked neuronal responses tested was not seen in my 
electrophysiological study could be due to the fact that electrophysiological and 
behavioural studies measure different parameters, and we cannot always 
corroborate the findings fully. Behavioural studies measure threshold responses 
in whole animals, as the response is usually terminated by the free-moving 
animal withdrawing its paw from the stimulus, whereas in electrophysiological 
studies, supra-threshold stimuli to a single neuron is measured, since the animals 
are anaesthetised (Suzuki et al., 1999). However, numerous von Frey forces were 
used in the electrophysiological part of my study, ranging from innocuous to 
noxious, and yet there was no significant excitatory effect o f Sar-SP on any of 
them. Therefore, threshold versus suprathreshold mechanical stimulation could 
not be the reason why Sar-SP did not facilitate the mechanical-evoked response 
in this part of my study.
Therefore, since 3pg o f Sar-SP effectively caused both thermal and mechanical 
hypersensitivity in my chapter using behavioural techniques, then the most 
probable reason for the lack of effect o f Sar-SP on the mechanical evoked 
response of dorsal horn neurons is that there is a fine line between the dose of 
Sar-SP which excites and that which is ineffective in nociceptive transmission, 
causing 1 pg of this agonist to be sufficient to excite only some of the thermal, 
and not the mechanical evoked responses, whereas 1 Opg would have been an 
ineffective dose. To date, this is the first study investigating the effects of Sar-SP 
(1 and 10pg), using in vivo electrophysiology, on mechanically-evoked spinal 
cord dorsal horn neuronal responses.
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Furthermore, in my chapter using behavioural techniques, (see chapter 4), 0.3 pg 
of intrathecal NMDA caused all of BSL behaviour, thermal and mechanical 
hypersensitivity, 5 minutes after administration, followed by analgesia. The fact 
that the intrathecal administration of NMDA (5, 50 and 500ng) did not cause any 
significant excitation of the electrical evoked responses in my study using in vivo 
electrophysiology could be attributed to the fact that electrical stimulation was 
made at 3x the C-fibre threshold, whereas it should have been done at 1.5x the C- 
fibre threshold (Chapman et al., 1994a), and that different doses of intrathecal 
NMDA should have been used to cause increases in some of the natural evoked 
responses of deep dorsal horn neurons (Sher et al., 1990). Additionally, shorter 
testing times might have been needed to show the effects of NMDA, since I 
showed in my behavioural study that the excitatory effects of intrathecal NMDA 
disappear after 5 minutes, and in the study by Chapman et al, only ten minutes 
were given between each set of testing. However, due to the fact that in this part 
of my study, all of electrical, brush, von Frey and heat evoked responses were 
measured, a 20 minute gap between testing was needed to fit in all these stimuli, 
as well as give the neuron time to recuperate.
The results that arose following the behavioural part o f my study (chapter 4) 
showed that even though the activation o f each of the NMDA and the NK-1 
receptor caused an initial BSL response, followed by thermal and tactile 
hypersensitivity, that each receptor led to a different quality of BSL behaviour, as 
well as different extents of thermal hypersensitivity (which was observed more 
closely than the tactile response, due to the ease o f the thermal stimulus 
administration). In my study, NMDA receptor activation leads to caudal biting, 
scratching and licking behaviour, whereas NK-1 receptor activation leads to 
caudal biting, scratching, licking and also excessive grooming behaviour. Indeed, 
whereas the spinal NMDA receptor activation has been previously thought to be 
nociceptive (Aanonsen et al., 1987; Davis et al., 2001; Wilcox, 1988), the spinal 
NK-1 receptor activation has yielded different conclusions, as per its role in 
nociceptive transmission, with some studies labelling SP as a neuromodulator, 
rather than a neurotransmitter (Chapman et al., 1996; Dougherty et al., 1995; 
Kellstein et al., 1990), and with other studies concluding that the BSL behaviour
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following SP is indicative of a spinal convulsive state, rather than pain, since no 
vocalisation occurs and since the BSL is not inhibited by morphine (Bossut et al., 
1988a; Wilcox, 1988).
It could be argued that the fact that morphine, in my study, was more efficient in 
inhibiting those responses following the NMDA receptor activation rather than 
the NK-1 receptor activation means that only the NMDA receptor activation led 
to nociception (Wilcox, 1988). I however, concluded that both these receptors 
participate in the pain response, but that each receptor leads to the activation of 
different secondary mechanisms/pathways which are either more, or less, 
susceptible to morphine control. Indeed, the NMDA receptor activation caused 
inhibition after the initial hypersensitivity, which could mean that NMDA 
receptor activation resulted in the activation of descending inhibitions onto the 
spinal cord (Kolhekar et al., 1993), and which could be one reason why 
morphine synergised with the intrathecal NMDA administered, to cause an even 
larger inhibition of the response than when morphine acted on its own. Even 
though I did not use spinalised rats, the study by Kolkehar et al in 1993 showed 
that spinalisation blocked the NMDA-induced analgesia.
In the case of the NK-1 receptor activation, previous studies have shown that 
NK-1-expressing lamina I projection neurons are at the origin of the spinal- 
bulbo-spinal loop (Todd, 2002), which predominantly drive descending 
serotonergic facilitations needed to maintain neuropathic pain (Burgess et al., 
2002; Suzuki et al., 2002b; Suzuki et al., 2004a; Suzuki et al., 2005) and these 
neurons are needed for the expression o f LTP in deep dorsal horn neurons (Rygh 
et al., 2006). Therefore, even though the NK-1-expressing lamina I projection 
neurons have been shown to play a role in driving descending noradrenergic 
inhibitions in normal animals (Rahman et al, unpublished observations), I will 
speculate that in my study, the activation of the NK-1 receptor could have shifted 
the descending control balance towards facilitations, leading to an acute increase 
in descending serotonergic facilitations, via the activation of the NK-1 receptors 
on lamina I projection neurons. Consequently, even though morphine was able to 
inhibit the effects following the activation of the NK-1 receptor with Sar-SP, this
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was to a lesser degree than when morphine inhibited the effects following 
intrathecal NMDA. Could this reduced efficacy of morphine in inhibiting the 
NK-1-mediated responses be compared to the reduced efficacy of morphine in 
neuropathic pain reported in some studies? (Field et a l, 1999b; Gilron et a l, 
2005; Joshi et al., 2006; Kontinen et al., 1998; Lemberg et al., 2006).
Neuropathic pain is a chronic pain state that displays numerous symptoms, such 
as sensory deficits, spontaneous and touch-evoked pain (Suzuki et al., 2000a), 
which have complex mechanisms that underlie their basis (see chapter 1).
Indeed, pain following nerve injury involves a peripheral, spinal and supraspinal 
component (Attal et al., 1999; Porreca et al., 2001). Peripherally, ongoing 
‘ectopic’ activity arises and has been shown to mostly involve changes in the 
expression and generation of Na+ channels, an example of which is the 
upregulation of the Nayl .3 in injured neurons (Amir et al., 2006; Dickenson et 
al., 2002a), and which is sensitive to block with local anaesthetics and 
anticonvulsants (Dickenson et al., 2002a; Ossipov et al., 1995; Rowbotham et 
al., 1991). In the spinal cord, numerous changes occur, such as the increase in 
dynorphin and cholecystokinin (CCK), two neuropeptides which have been 
shown to be ‘morphine-resistant’. Indeed, the anti-allodynic efficacy of spinal 
morphine was restored, following nerve injury, when morphine was administered 
with an antiserum against dynorphin (Wu et al., 2005) or with a CCKb receptor 
antagonist (Nichols et a l,  1995).
Whereas most previous studies have concentrated on peripheral and spinal 
mechanisms underlying neuropathic pain, less studies have focussed on 
investigating the role of descending serotonergic facilitations following nerve 
injury (McCleane et a l,  2003; Suzuki et a l, 2004a), as well as investigating 
whether peripheral NMDA receptors play a role in neuropathic pain (Jang et al., 
2004). Therefore, in my study, I investigated the role of descending serotonergic 
facilitations in the maintenance of hypersensitivities following nerve injury, and 
whether peripheral NMDA receptors play a role in hypersensitivity following 
nerve injury.
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Clinically, it would be beneficial for pain due to nerve injury to be caused by 
peripheral factors, as that would make drug administration easy and free of 
unacceptable side-effects. Initial studies have shown that the intraplantar 
administration of NMDA receptor antagonists reduced the lifting and licking 
behaviour which occurs following formalin administration (Davidson et al.,
1998; Davidson et al., 1997), the thermal hyperalgesia seen following 
carrageenan inflammation (Jackson et al., 1995) and the mechanical hyperalgesia 
seen following CFA inflammation (Leem et al., 2001), indicating a role for the 
peripheral NMDA receptors in inflammation. To date, only one study has 
investigated the role of peripheral NMDA receptors in neuropathic pain and 
showed that blocking peripheral NMDA receptors with an antagonist led to the 
reduction in tactile hypersensitivity following nerve injury (Jang et al., 2004), 
and no studies have been undertaken yet to determine whether the levels of 
peripheral NMDA receptors change following nerve injury.
In my study, I investigated whether peripheral NMDA receptors are involved in 
the tactile and cold hypersensitivity seen following the spinal nerve ligation 
model. I showed that, in normal animals, following a high dose of intraplantar 
NMDA, tactile, but not thermal hypersensitivity arose, which was blocked with 
the intraplantar administration of the NMDA receptor antagonist MK-801. The 
fact that tactile and not thermal hypersensitivity resulted following the activation 
of the peripheral NMDA receptor could show that peripheral NMDA receptors 
are expressed on nociceptive primary afferent fibres which do not transmit 
thermal sensation, thus maybe a subset o f the non-peptidergic, IB4-positive A8- 
fibres (Caterina et al., 2005; Meyer et al., 2006; Snider et al., 1998).
However, following peripheral nerve injury, MK-801 was ineffective in reducing 
the tactile and cold hypersensitivity which arose in the spinal nerve ligation 
model. The discrepancy between my study and that of Jang et al could have been 
due to the fact that different nerve injury models were used, whereas I used the 
L5 and L6 spinal nerve ligation model, the study by Jang et al used an L5 spinal 
nerve ligation, which was preceded by an L5 dorsal rhizotomy, to avoid the 
central effects of nerve injury. Since the initiation of neuropathic pain has been
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shown to depend on ongoing-input, due to ectopic activity, from the injured 
nerve onto the spinal cord (Attal et al., 1999; Ossipov et al., 1995), which leads 
to the sensitisation of spinal cord neurons (Salter, 2005) and subsequently, to 
increased descending facilitations to maintain the pain (Burgess et al., 2002), the 
model by Jang et al is not a true representation of the mechanisms which underlie 
neuropathic pain in the clinical setting.
Descending serotonergic facilitations have been shown to exert their excitatory 
effects via their action on the ionotropic 5HT3 receptor, which is predominantly 
located on a subset of myelinated primary afferent fibres which terminate in the 
superficial dorsal horn, thus of the A5-fibre type, and which are predominantly 
not peptidergic (Conte et al., 2005; Maxwell et al., 1983; Zeitz et a l, 2002). 
Previous studies investigating the role of descending serotonergic facilitations in 
neuropathic pain have found that these are enhanced following nerve injury, 
since the administration of spinal ondansetron, a 5HT3 receptor antagonist, 
causes a more pronounced reduction o f the mechanical-evoked responses of 
dorsal horn neurons in rats with nerve injury than in the controls (Suzuki et a l , 
2004a). Indeed, another study showed that depleting endogenous spinal 5-HT 
reduces both tactile and cold hypersensitivity following spinal nerve ligation, and 
this effect was seen on day 5 following nerve injury, further proving the role of 
descending serotonergic facilitations in maintaining pain following nerve injury 
(Rahman et al., 2006a).
Furthermore, as mentioned previously, descending serotonergic facilitations are 
driven by NK-1-expressing lamina I projections neurons via a spino-bulbo-spinal 
loop, which relays in supraspinal sites that include the parabrachial area and the 
thalamus (Suzuki et al., 2005). Each o f the ablation of the NK-1-expressing 
projection neurons, with SP-SAP, and the blockade of the spinal 5HT3 receptors 
with ondansetron leads to similar electrophysiological changes following nerve 
injury, further proving the role of this loop in neuropathic pain (Suzuki et al., 
2004a; Suzuki et al., 2005). In addition, gabapentin, a drug licensed for the 
treatment of neuropathic pain, needs the NK-1-expressing lamina I projection
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neurons to be intact, or the 5HT3 receptors on primary afferent fibres to be 
active, in order to be fully effective (Suzuki et al., 2005).
In the case of descending serotonergic facilitations and their role in the spinal 
nerve ligation model, I found, as has been shown before, that descending 
serotonergic facilitations are enhanced following peripheral nerve injury (Suzuki 
et al., 2004a), and that by blocking their effects with spinal ondansetron, the 
static hypersensitivity seen following nerve injury was reduced. However, 
neither thermal, nor cold hypersensitivity which arose following nerve injury 
were affected by ondansetron, which could be could be due to the low dose of 
ondansetron used in my study, or a reflection of the type of primary afferent 
fibres on which the 5HT3 receptor is found. Indeed, the 5HT3 receptor is 
predominantly found on a subset of myelinated primary afferent fibres (A8- 
fibres), whereas thermal and cold responses are transduced mainly by the TRPV1 
and the TRPM8 receptors, which are predominantly located on unmyelinated 
primary afferent fibres (Conte et al., 2005; Maxwell et al., 1983; Zeitz et al., 
2002).
In my study, morphine was more effective than ondansetron. This was not 
surprising, since morphine acts at the three pain transmission levels altered by 
nerve injury: the first synapse at the primary afferent fibres, where it inhibits 
transmitter release, the spinal cord dorsal horn, where it inhibits synaptic 
transmission and at supraspinal sites, where it inhibits ON cells and disinhibits 
OFF cells in the RVM, thus causing an overall inhibitory effect (Dickenson, 
1994; Fields et al., 1991; Heinricher, 1997; Porreca et al., 2001). Therefore, even 
though some studies have shown that neuropathic pain is less responsive to 
morphine (Amer et al., 1988), I have shown, using systemic morphine in the 
spinal nerve ligation model, that this is not the case, in agreement with numerous 
studies which have shown that the responsiveness of neuropathic pain to 
morphine depends on route of administration, dose titration and type of nerve 
injury (Bian et al., 1995; Hansson et al., 2005; Jadad et al., 1992; Portenoy et al., 
1990; Rowbotham et a l,  1991; Suzuki et a l, 1999). Furthermore, it seems that 
there is only one neuropathic pain symptom which remains resistant to morphine
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control, at the dose used in a previous study, and that is dynamic allodynia (Field 
et al., 1999b).
What was surprising in my study however, was the fact that the combination of 
morphine and ondansetron did not yield a greater inhibition of the 
hypersensitivities seen following nerve injury, than each drug alone. One reason 
for the latter could be that the dose of each drug used was already effective, and 
in order to assess drug synergism, lower doses of each drug should have been 
administered (Matthews et al., 2002; Mjellem-Joly et al., 1991).
7.3 Future studies
In chapter 3 ,1 showed that morphine was effective in inhibiting the mechanical 
evoked response to von Frey 5g, an innocuous mechanical response. Innocuous 
mechanical responses, such as touch and brush, are conveyed by Ap-fibres, 
which do not express p-opioid receptors (Besse et al., 1990; Zhang et al., 1998) 
and are less sensitive to morphine control (Dickenson et al., 1986). One future 
study could involve investigating which primary afferent fibre(s) is involved in 
conveying the von Frey 5g evoked response, to determine whether this response 
is conveyed purely via Ap-fibres, or via a combination of Ap- and A5-fibres, by 
using a teased-fibre technique to record from single primary afferent fibres in the 
rat hindpaw (Leem et al., 1993; Slugg et al., 2000).
Moreover, it would be interesting to investigate the effects o f ondansetron on the 
5HT3 receptors located on primary afferent fibres, using patch-clamping 
techniques, and to measure how much ondansetron affects calcium flow into the 
cell, via both patch-clamping and fluorescent techniques, in normal and 
neuropathic rats.
Furthermore, dynamic allodynia is clinically the most debilitating response in 
patients with nerve injury, because normal daily routines, such as wearing 
clothes, becomes painful (Rasmussen et al., 2004), and remains the most
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resistant nociceptive response to morphine control (Field et al., 1999b). In animal 
studies, dynamic allodynia is determined by lightly stroking the plantar surface 
of the rat hindpaw with a wisp of cotton from a cotton bud: if flinching occurs 
before 8 seconds, then dynamic allodynia is present, and the cut-off time is 15 
seconds (Field et al., 1999b).
Therefore, another future study could involve investigating dynamic allodynia in 
the spinal nerve ligation model and assessing whether morphine or ondansetron, 
each on its own and in combination (in lower doses) can inhibit this response. 
Following that, more clinical studies using different doses of ondansetron alone 
and in combination with morphine, could be carried out.
In addition, studies using functional magnetic resonance imaging (fMRI) could 
also be carried out in humans to assess and compare the effects of each of 
ondansetron and morphine and their combination, on the brain processing 
following different stimuli in normal individuals as well as in patients with 
neuropathic pain. Indeed, in a former study which investigated the effects of 
gabapentin (GBP) in normal and capsaicin-sensitised skin, using fMRI, it was 
found that GBP was more effective in decreasing neural transmission in central 
sensitisation states than in normal pain transmission states (Dickenson et al., 
2005; Iannetti et al., 2005)
274
References
A a n o n s e n ,  L.M., L ei, S. &  W ilc o x ,  G.L. (1990). E x c ita to ry  am ino  acid
receptors and nociceptive neurotransmission in rat spinal cord. Pain., 41, 
309-21 .
A a n o n s e n ,  L.M. & W ilc o x ,  G.L. (1987). Nociceptive action of excitatory 
amino acids in the mouse: effects of spinally administered opioids, 
phencyclidine and sigma agonists. J  Pharmacol Exp Ther, 243,9-19.
A k o p ia n , A.N., S o u s l o v a ,  V., E n g l a n d ,  S., O k u s e ,  K., O g a t a ,  N., U r e ,  J., 
S m ith , A., K e r r ,  B.J., M c M a h o n , S.B., B o y c e ,  S., H i l l ,  R., S t a n f a ,  
L.C., D ic k e n s o n ,  A.H. & W o o d , J.N. (1999). The tetrodotoxin-resistant 
sodium channel SNS has a specialized function in pain pathways. Nat 
Neurosci., 2, 541-8.
A lh a i d e r ,  A.A., L ei, S.Z. & W ilc o x ,  G.L. (1991). Spinal 5-HT3 receptor- 
mediated antinociception: possible release o f GABA. J  Neurosci., 11, 
1881-8.
Ali, Z., W u , G., K o z l o v ,  A. & B a r a s i ,  S. (1996). The role of 5HT3 in
nociceptive processing in the rat spinal cord: results from behavioural and 
electrophysiological studies. Neurosci Lett., 208, 203-7.
A l v a r e z - V e g a ,  M., B a a m o n d e ,  A., G u t i e r r e z ,  M., H i d a l g o ,  A. &
M e n e n d e z , L. (2000). Intrathecal N-methyl-D-aspartate (NMDA) 
induces paradoxical analgesia in the tail-flick test in rats. Pharmacol 
Biochem Behav., 65,621-5.
A l v a r e z - V e g a ,  M., B a a m o n d e ,  A., G u t i e r r e z ,  M., H i d a l g o ,  A. &
M e n e n d e z , L. (1998). Comparison of the effects o f calmidazolium, 
morphine and bupivacaine on N-methyl-D-aspartate- and septide-induced 
nociceptive behaviour. Naunyn Schmiedebergs Arch Pharmacol, 358, 
628-34.
A m ir, R., A r g o f f ,  C.E., B e n n e t t ,  G.J., C u m m in s , T.R., D u r i e u x ,  M.E.,
G e r n e r ,  P ., G o l d ,  M.S., P o r r e c a ,  F. & S t r i c h a r t z ,  G.R. (2006). The 
role of sodium channels in chronic inflammatory and neuropathic pain. J  
Pain., 7, S I -29.
A r n e r ,  S. & M e y e r s o n ,  B.A. (1991). Genuine resistance to opioids-fact or 
fiction? Pain., 47, 116-21.
A r n e r ,  S. & M e y e r s o n ,  B .A . (1988). L ack  o f  a n a lg e s ic  e f fe c t  o f  o p io id s  on  
n eu ro p a th ic  and  id io p a th ic  fo rm s o f  pain . Pain, 33, 11-23.
A t t a l ,  N . &  B o u h a s s i r a ,  D . (1999). Mechanisms o f  pain in peripheral
neuropathy. Acta Neurol Scand Suppl., 173, 12-24; discussion 48-52.
A t t a l ,  N., C h e n , Y.L., K a y s e r ,  V. & G u i lb a u d ,  G. (1991). Behavioural 
evidence that systemic morphine may modulate a phasic pain-related 
behaviour in a rat model of peripheral mononeuropathy. Pain, 47,65-70.
A t t a l ,  N., G u ir im a n d ,  F., B r a s s e u r ,  L., G a u d e ,  V., C h a u v i n ,  M. & 
B o u h a s s i r a ,  D. (2002). Effects of IV morphine in central pain: a 
randomized placebo-controlled study. Neurology., 58, 554-63.
B a c k o n ja ,  M.M., M il e t i c ,  G. & M il e t i c ,  V. (1995). The effect o f continuous 
morphine analgesia on chronic thermal hyperalgesia due to sciatic 
constriction injury in rats. Neurosci Lett., 196, 61-4.
275
B a r d i n ,  L., B a r d i n ,  M., L a v a r e n n e ,  J. & E s c h a l i e r ,  A. (1997). Effect of 
intrathecal serotonin on nociception in rats: influence of the pain test 
used. Exp Brain Res., 113, 81-7.
B a s b a u m ,  A.I. & F i e l d s ,  H.L. (1984). Endogenous pain control systems:
b ra in s te m  sp in a l p a th w ay s and  endo rph in  c ircu itry . Annu Rev Neurosci., 
7, 309 -38 .
B a t t a g l i a ,  G . &  R u s t io n i ,  A . (1988). C o ex is tence  o f  g lu tam ate  and  substance 
P in  d o rsa l ro o t g an g lio n  neu ro n s o f  th e  ra t and  m onkey . J  Comp Neurol, 
277, 3 0 2 -12 .
B e n t l e y ,  G.N. & G e n t ,  J.P. (1995). Neurokinin actions on substantia gelatinosa 
neurones in an adult longitudinal spinal cord preparation. Brain Res, 673, 
101- 11.
B e s s e , D ., L o m b a r d ,  M.C., P e r r o t ,  S. & B e s s o n ,  J.M. (1992). R egula tion  o f  
o p io id  b in d in g  s ite s  in  th e  superfic ia l do rsa l ho rn  o f  th e  ra t sp inal cord  
fo llo w in g  lo o se  lig a tio n  o f  th e  sc ia tic  nerve : co m p ariso n  w ith  scia tic  
n e rv e  se c tio n  an d  lu m b ar do rsa l rh izo tom y. Neuroscience, 50,921-33 .
B e s s e ,  D ., L o m b a r d ,  M.C., Z a j a c ,  J.M., R o q u e s ,  B .P . &  B e s s o n , J.M. (1990). 
Pre- a n d  p o s tsy n a p tic  lo ca tio n  o f  m u , d e lta  an d  k ap p a  o p io id  recep tors in 
th e  su p erfic ia l lay e rs  o f  th e  do rsa l h o rn  o f  th e  ra t sp inal cord . Prog Clin 
Biol Res, 328, 183-6.
B e s s o n ,  J.M. & C h a o u c h ,  A. (1987). Descending serotoninergic systems. Pain 
Headache., 9, 64-100.
B e s t e r ,  H., C h a p m a n ,  V., B e s s o n ,  J .M . &  B e r n a r d ,  J.F . (2000). Physiological 
properties o f the lamina I spinoparabrachial neurons in the rat. J  
Neurophysiol, 83, 2239 -59 .
B e s t e r ,  H., M a t s u m o t o ,  N., B e s s o n ,  J.M. & B e r n a r d ,  J.F. (1997). Further 
evidence for the involvement o f the spinoparabrachial pathway in 
nociceptive processes: a c-Fos study in the rat. J  Comp Neurol, 383,439- 
58.
B e s t e r ,  H., M e n e n d e z ,  L., B e s s o n ,  J.M. &  B e r n a r d ,  J.F. (1995). Spino 
(trigemino) parabrachiohypothalamic pathway: electrophysiological 
evidence for an involvement in pain processes. J  Neurophysiol., 73, 568- 
85.
B i a n ,  D., N i c h o l s ,  M.L., O s s i p o v ,  M.H., L a i ,  J. & P o r r e c a ,  F .  (1995).
Characterization o f the antiallodynic efficacy of morphine in a model of 
neuropathic pain in rats. Neuroreport., 6, 1981-4.
B ia n , D ., O s s ip o v , M.H., I b ra h im , M., R a f f a ,  R .B ., T a l l a r i d a ,  R .J ., M a la n ,  
T .P ., J r . ,  L a i, J. &  P o r r e c a ,  F . (1999). L oss o f  an tia llo d y n ic  and  
an tin o c icep tiv e  sp in a l/su p rasp in a l m o rp h in e  synergy  in  n erve-in ju red  
rats: re s to ra tio n  b y  MK-801 o r  dyn o rp h in  an tise rum . Brain Res., 831 , 55- 
63.
B i a n ,  D . ,  O s s i p o v ,  M . H . ,  Z h o n g ,  C . ,  M a l a n ,  T . P . ,  J r . &  P o r r e c a ,  F .  (1998). 
T a c t i l e  a l l o d y n i a ,  b u t  n o t  t h e r m a l  h y p e r a l g e s i a ,  o f  t h e  h i n d l i m b s  i s  
b l o c k e d  b y  s p i n a l  t r a n s e c t i o n  i n  r a t s  w i t h  n e r v e  i n j u r y .  Neurosci Lett., 
241, 79-82 .
B i n n s ,  B.C., H u a n g ,  Y., G o e t t l ,  V.M., H a c k s h a w ,  K.V. & S t e p h e n s ,  R.L., 
J r .  (2005 ). G lu tam ate  up tak e  is a ttenuated  in  sp inal deep  do rsa l and  
ven tra l h o rn  in  the  ra t sp inal nerve  liga tion  m odel. Brain Res., 1041, 38- 
47.
276
B o s s u t ,  D . ,  F r e n k , H .  &  M a y e r ,  D . J .  (1988a). Is substance P a primary afferent 
neurotransmitter for nociceptive input? II. Spinalization does not reduce 
and intrathecal morphine potentiates behavioral responses to substance P. 
Brain Res., 455, 232-9.
B o s s u t ,  D., F r e n k ,  H. & M a y e r ,  D.J. (1988b). Is substance P a primary afferent 
neurotransmitter for nociceptive input? IV. 2-Amino-5- 
phosphonovalerate (APV) and [D-Pro2,D-Trp7,9]-substance P exert 
different effects on behaviors induced by intrathecal substance P, 
strychnine and kainic acid. Brain Res., 455, 247-53.
B o u c h e r ,  T . J .  &  M c M a h o n ,  S . B .  (2001). N e u r o t r o p h i c  f a c t o r s  a n d  n e u r o p a t h i c  
p a i n .  Curr Opin Pharmacol., 1,66-72.
B u r g e s s ,  S.E., G a r d e l l ,  L.R., O ss ip o v , M.H., M a l a n ,  T.P., J r . ,  V a n d e r a h ,  
T .W ., L a i, J. &  P o r r e c a ,  F . (2002). Time-dependent descending 
facilitation from the rostral ventromedial medulla maintains, but does not 
initiate, neuropathic pain. J  Neurosci, 22, 5129-36 .
B u r n s t o c k ,  G. (1977). Autonomic neuroeffector junctions—reflex 
vasodilatation of the skin. J  Invest Dermatol., 69,47-57.
C a h i l l ,  C.M. & C o d e r r e ,  T.J. (2002). Attenuation of hyperalgesia in a rat
model of neuropathic pain after intrathecal pre- or post-treatment with a 
neurokinin-1 antagonist. Pain, 95,277-85.
C a h u s a c ,  P.M., E v a n s ,  R.H., H i l l ,  R.G., R o d r i q u e z ,  R.E. & S m i t h ,  D.A. 
(1984). The behavioural effects of an N-methylaspartate receptor 
antagonist following application to the lumbar spinal cord of conscious 
rats. Neuropharmacology, 23, 719-24.
C a l e j e s a n ,  A.A., C h ' a n g ,  M.H. & Z h u o ,  M. (1998). Spinal serotonergic
receptors mediate facilitation of a nociceptive reflex by subcutaneous 
formalin injection into the hindpaw in rats. Brain Res., 798,46-54.
C a m e r o n ,  A.A., C l i f f e r ,  K.D., D o u g h e r t y ,  P.M., G a r r i s o n ,  C.J., W i l l i s , 
W.D. & C a r l t o n ,  S.M. (1997). Time course of degenerative and 
regenerative changes in the dorsal horn in a rat model of peripheral 
neuropathy. J  Comp Neurol, 379,428-42.
C a m p b e l l ,  J.N., R a j a ,  S.N., M e y e r ,  R.A. & M a c k i n n o n ,  S.E. (1988).
Myelinated afferents signal the hyperalgesia associated with nerve injury. 
Pain., 32, 89-94.
C a r l t o n ,  S.M. & C o g g e s h a l l ,  R.E. (1999). Inflammation-induced changes in 
peripheral glutamate receptor populations. Brain Res., 820,63-70.
C a r l t o n ,  S.M., H a r g e t t ,  G.L. & C o g g e s h a l l ,  R.E. (1995). Localization and 
activation of glutamate receptors in unmyelinated axons of rat glabrous 
skin. Neurosci Lett., 197,25-8.
C a r p e n t e r ,  K.J. & D i c k e n s o n ,  A.H. (2001). Amino acids are still as exciting as 
ever. Curr Opin Pharmacol, 1, 57-61.
C a r p e n t e r ,  K.J. & D i c k e n s o n ,  A.H. (1999). NMDA receptors and pain—hopes 
for novel analgesics. Reg Anesth Pain Med, 24, 506-8.
C a t e r i n a ,  M.J., G o l d ,  M.S. & M e y e r ,  R.A. (2005). Molecular biology of 
nociceptors. In The Neurobiology o f  Pain (Molecular and Cellular 
Neurobiology), eds Hunt, S.P. & Koltzenburg, M. pp. 1-33. Oxford: 
Oxford University Press.
C a t e r i n a ,  M.J., L e f f l e r ,  A., M a l m b e r g ,  A.B., M a r t i n ,  W.J., T r a f t o n ,  J., 
P e t e r s e n - Z e i t z ,  K.R., K o l t z e n b u r g ,  M., B a s b a u m ,  A.I. & J u l i u s ,  D.
277
(2000). Impaired nociception and pain sensation in mice lacking the 
capsaicin receptor. Science., 288, 306-13.
C a t e r in a , M.J., S c h u m a c h e r , M.A., T o m in a g a , M., R o s e n , T.A., L e v in e , J.D. 
&  J u l iu s , D. (1997). The capsaicin receptor: a heat-activated ion channel 
in the pain pathway. Nature., 389, 816-24.
C a t h e l in e , G ., L e  G u e n , S. &  B e s s o n , J.M. (2001). Intravenous morphine does 
not modify dorsal horn touch-evoked allodynia in the mononeuropathic 
rat: a Fos study. Pain., 92,389-98.
C h a p l a n , S.R., M a l m b e r g , A.B. & Y a k s h , T.L. (1997). Efficacy of spinal 
NMD A receptor antagonism in formalin hyperalgesia and nerve injury 
evoked allodynia in the rat. J  Pharmacol Exp Ther, 280, 829-38.
C h a p m a n , V. (1994). Electrophysiological studies on the pharmacology of the 
processing of inflammatory nociception in the rat. In Pharmacology, pp. 
146-160. London: University College London.
C h a p m a n , V ., B u r it o v a , J., H o n o r e , P . &  B e s s o n , J.M. (1996). Physio log ical 
c o n trib u tio n s  o f  n eu ro k in in  1 recep to r ac tiva tion , an d  in terac tions w ith  
NMDA recep to rs , to  in flam m ato ry -ev o k ed  sp ina l c -F os expression . J  
Neurophysiol., 76, 1817-27.
C h a p m a n , V . &  D ic k e n s o n , A.H. (1992). T h e  co m b in a tio n  o f  NMDA
antagonism and morphine produces profound antinociception in the rat 
dorsal horn. Brain Res, 573, 321-3.
C h a p m a n , V. &  D ic k e n s o n , A.H. (1993). The effect of intrathecal
administration of RP67580, a potent neurokinin 1 antagonist on 
nociceptive transmission in the rat spinal cord. Neurosci Lett, 157, 149- 
52.
C h a p m a n , V. &  D ic k e n s o n , A.H. (1995). Time-related roles of excitatory
amino acid receptors during persistent noxiously evoked responses of rat 
dorsal horn neurones. Brain Res, 703,45-50.
C h a p m a n , V., D ic k e n s o n , A.H. & T jo l s e n , A. (1994a). Bi-directional effects 
of intrathecal NMDA and substance P on rat dorsal horn neuronal 
responses. Neurosci Lett, 178,90-4.
C h a p m a n , V., H a l e y , J.E. & D ic k e n s o n , A.H. (1994). Electrophysiologic
analysis o f preemptive effects of spinal opioids on N-methyl-D-aspartate 
receptor-mediated events. Anesthesiology, 81, 1429-35.
C h a p m a n , V., S u z u k i, R. & D ic k e n s o n , A.H. (1998). Electrophysiological
characterization of spinal neuronal response properties in anaesthetized 
rats after ligation of spinal nerves L5-L6. J  Physiol, 507, 881-94.
C h e n , L. &  H u a n g , L.Y. (1992). Protein kinase C reduces Mg2+ block of
NMDA-receptor channels as a mechanism o f modulation. Nature., 356, 
521-3.
C h e n , Q., K in g , T., V a n d e r a h , T.W., O ss ip o v , M.H., M a l a n , T.P., J r ., L a i , J. 
&  P o r r e c a , F. (2004). Differential blockade of nerve injury-induced 
thermal and tactile hypersensitivity by systemically administered brain- 
penetrating and peripherally restricted local anesthetics. J  Pain, 5,281-9.
C h e u n s u a n g , O., M a x w e l l , D. & M o r r is , R. (2002). Spinal lamina I neurones 
that express Neurokinin 1 receptors: II. Electrophysiological 
characteristics, responses to primary afferent stimulation and effects of a 
selective pu-opioid receptor agonist. Neuroscience, 111, 423-434.
278
C h iz h , B.A., C u m b e r b a t c h , M.J., B ir c h , P.J. & H e a d l e y , P.M. (1995). 
Endogenous modulation of excitatory amino acid responsiveness by 
tachykinin NK1 and NK2 receptors in the rat spinal cord. Br J  
Pharmacol., 115, 1013-9.
C iz k o v a , D., M a r s a l a , J., L u k a c o v a , N., M a r s a l a , M., J e r g o v a , S.,
O r e n d a c o v a ,  J. & Y a k s h ,  T.L. (2002). Localization of N-type Ca2+ 
channels in the rat spinal cord following chronic constrictive nerve injury. 
Exp Brain Res, 147,456-63.
C o d e r r e ,  T.J. & V an E m p e l, I. (1994). The utility of excitatory amino acid 
(EAA) antagonists as analgesic agents. I. Comparison of the 
antinociceptive activity of various classes o f EAA antagonists in 
mechanical, thermal and chemical nociceptive tests. Pain, 59,345-52.
C o g g e s h a l l , R.E. & C a r l t o n , S.M. (1997). Receptor localization in the
mammalian dorsal horn and primary afferent neurons. Brain Res Brain 
Res Rev., 24, 28-66.
C o g g e s h a l l ,  R.E. & C a r l t o n ,  S.M. (1998). Ultrastructural analysis of NMDA, 
AMPA, and kainate receptors on unmyelinated and myelinated axons in 
the periphery. J  Comp Neurol., 391, 78-86.
C o g g e s h a l l ,  R.E., Z h o u ,  S. & C a r l t o n ,  S.M. (1997b). Opioid receptors on 
peripheral sensory axons. Brain Res., 764, 126-32.
C o g h il l , R.C., M a y e r , D.J. & P r ic e , D.D. (1993). Wide dynamic range but not 
nociceptive-specific neurons encode multidimensional features of 
prolonged repetitive heat pain. Journal o f  Neurophysiology, 69, 703-716.
C o n t e , D., L e g g , E.D., M c C o u r t , A.C., S il a jd z ic , E., N a g y , G.G. &
M a x w e l l ,  D.J. (2005). Transmitter content, origins and connections of 
axons in the spinal cord that possess the serotonin (5-hydroxytryptamine) 
3 receptor. Neuroscience., 134, 165-73.
COUDORE-ClVIALE, M., COURTEIX, C ., BOUCHER, M., FlALIP, J. & ESCHALIER, A.
(2000). Evidence for an involvement of tachykinins in allodynia in 
streptozocin-induced diabetic rats. Eur J  Pharmacol, 401,47-53.
COUDORE-ClVIALE, M.A., COURTEIX, C ., ESCHALIER, A. & FlALIP, J. (1998). 
Effect o f tachykinin receptor antagonists in experimental neuropathic 
pain. Eur J  Pharmacol, 361,175-84.
C r a ig , A.D. (2002). How do you feel? Interoception: the sense of the
physiological condition o f the body. Nat Rev Neurosci., 3,655-66.
C r a ig ,  A.D. (2003). Pain mechanisms: labeled lines versus convergence in 
central processing. Annu Rev Neurosci, 26, 1-30. Epub 2003 Mar 6.
C r a ig , A .D ., Z h a n g , E .T . &  B l o m q v is t , A . (2002 ). A sso c ia tio n  o f
spinothalamic lamina 1 neurons and their ascending axons with calbindin- 
immunoreactivity in monkey and human. Pain, 97, 105-15.
C r is p , T ., St a f in s k y , J .L ., S p a n o s , L .J., U r a m , M ., P e r n i, V .C . &  D o n e p u d i, 
H.B. (1991). Analgesic effects of serotonin and receptor-selective 
serotonin agonists in the rat spinal cord. Gen Pharmacol., 22,247-51.
C u m b e r b a t c h , M .J ., C a r l s o n , E ., W y a t t , A., B o y c e , S., H il l , R.G. &
R u p n ia k ,N .M . (1998). Reversal of behavioural and electrophysiological 
correlates of experimental peripheral neuropathy by the NK1 receptor 
antagonist GR205171 in rats. Neuropharmacology., 37, 1535-43.
279
C u m b e r b a t c h , M.J., C h iz h , B.A. & H e a d l e y , P.M. (1995). Modulation of
excitatory amino acid responses by tachykinins and selective tachykinin 
receptor agonists in the rat spinal cord. Br J  Pharmacol, 115, 1005-12.
C u r t is , D.R., P h il l is , J.W. & W a t k in s , J.C. (1960). The chemical excitation of 
spinal neurones by certain acidic amino acids. J  Physiol, 150,656-82.
D a v a r ,  G., H a m a , A., D e y k in ,  A., Vos, B. &  M a c ie w ic z , R. (1991). MK-801 
blocks the development of thermal hyperalgesia in a rat model of 
experimental painful neuropathy. Brain Res, 553,327-30.
D a v id s o n , E.M. & C a r l t o n , S.M. (1998). Intraplantar injection of dextrorphan, 
ketamine or memantine attenuates formalin-induced behaviors. Brain 
Res., 785, 136-42.
D a v id s o n , E.M., C o g g e s h a l l , R.E. & C a r l t o n , S.M. (1997). Peripheral
NMDA and non-NMDA glutamate receptors contribute to nociceptive 
behaviors in the rat formalin test. Neuroreport., 8,941-6.
D a v is , A.M. & In t u r r is i , C.E. (2001). Attenuation of hyperalgesia by
LY235959, a competitive N-methyl-D-aspartate receptor antagonist. 
Brain Res, 894, 150-3.
D a v is , A.M. & In t u r r is i , C.E. (1999). d-Methadone blocks morphine tolerance 
and N-methyl-D-aspartate-induced hyperalgesia. J  Pharmacol Exp Ther, 
289, 1048-53.
D e B ia s i, S. & R u s t io n i, A. (1988). Glutamate and substance P coexist in
primary afferent terminals in the superficial laminae of spinal cord. Proc 
Natl Acad Sci U S A ,  85, 7820-4.
d eG r o o t , J., Z h o u , S. & C a r l t o n , S.M. (2000). Peripheral glutamate release in 
the hindpaw following low and high intensity sciatic stimulation. 
Neuroreport., 11,497-502.
d eG r o o t , J.F., C o g g e s h a l l , R.E. & C a r l t o n , S.M. (1997). The reorganization 
of mu opioid receptors in the rat dorsal hom following peripheral 
axotomy. Neurosci Lett, 233, 113-6.
D e l l e m ijn , P. (1999). Are opioids effective in relieving neuropathic pain? Pain., 
80,453-62.
D ia z , A. & D ic k e n s o n , A.H. (1997). Blockade of spinal N - and P-type, but not 
L-type, calcium channels inhibits the excitability of rat dorsal hom 
neurones produced by subcutaneous formalin inflammation. Pain., 69, 
93-100.
D ic k e n s o n , A.H. (1990). A cu re  fo r w in d  up: NMDA recep to r an tagon is ts  as 
p o ten tia l ana lgesics . Trends Pharmacol Sci, 11, 307-9.
D ic k e n s o n , A.H. (1997a). Mechanisms of central hypersensitivity: excitatory 
amino acid mechanisms and their control. In The pharmacology o f  pain. 
eds Dickenson, A.H. & Besson, J.M. pp. 167-210. Berlin: Springer- 
Verlag.
D ic k e n s o n , A.H. (1997b). Plasticity: implications for opioid and other
pharmacological interventions in specific pain states. Behav Brain Sci, 
20, 392-403; discussion 435-513.
D ic k e n s o n , A.H. (1995). Spinal cord pharmacology of pain. B rJ  Anaesth, 75, 
193-200.
D ic k e n s o n , A.H. (1994). Where and how do opioids act? In Proceedings o f  the 
7th world congress on pain, progress in pain research and management.
280
ed. Gebhart, G.F., Hammond, D.L. & Jensen, T.S. pp. 525-552. Paris, 
France: I ASP press, Seattle.
D ic k e n s o n , A.H., C h a p m a n , V. & G r e e n ,  G.M. (1997). The pharmacology of 
excitatory and inhibitory amino acid-mediated events in the transmission 
and modulation of pain in the spinal cord. Gen Pharmacol, 28,633-8.
D ic k e n so n , A.H. & K ie ffe r , B.L. (2006). Opiates: basic mechanisms. In
Textbook o f Pain, eds McMahon, S.B. & Koltzenburg, M. pp. 427-442. 
London: Elsevier Churchill Livingstone.
D ic k e n so n , A.H., M a t t h e w s , E.A. & S u z u k i, R. (2002). Neurobiology of
neuropathic pain: mode of action of anticonvulsants. Eur J  Pain, 6, 51- 
60.
D ic k e n s o n , A.H. & S u l l i v a n ,  A.F. (1990). Differential effects of excitatory 
amino acid antagonists on dorsal hom nociceptive neurones in the rat. 
Brain Res., 506,31 -9.
D ic k e n s o n , A.H. & S u l l i v a n ,  A.F. (1987). Evidence for a role of the NMDA 
receptor in the frequency dependent potentiation of deep rat dorsal hom 
nociceptive neurones following C fibre stimulation. Neuropharmacology, 
26, 1235-8.
D ic k e n s o n , A.H. & S u l l i v a n ,  A.F. (1986). Electrophysiological studies on the 
effects of intrathecal morphine on nociceptive neurones in the rat dorsal 
hom. Pain, 24,211-222.
D ic k e n s o n , A.H. & S u z u k i, R. (2005). Opioids in neuropathic pain: clues from 
animal studies. Eur J  Pain, 9, 113-6.
D ic k e n s o n , A.H. & T a y l o r , F.C. (2002). Interaction of NMDA and other 
neurotransmitter receptor systems in modulation of nociception. In 
NMDA antagonists as potential analgesic drugs, eds J.S., D., 
Sirinathsinghji, D. & Hill, R.G. pp. 129-146. Basel: Birkhauser Verlag.
D o b o s , I., T o t h , K ., K e k e s i, G ., J o o , G ., C s u l l o g , E ., K l im s c h a , W .,
B e n e d e k , G . &  H o r v a t h ,  G . (2003). T he s ign ificance  o f  in tra thecal 
ca the te r location  in  rats. Anesth Analg, 96,487-92 , tab le  o f  conten ts.
D o n o v a n - R o d r ig u e z ,  T., D ic k e n s o n ,  A.H. & U r c h ,  C.E. (2005). Gabapentin 
normalizes spinal neuronal responses that correlate with behavior in a rat 
model of cancer-induced bone pain. Anesthesiology, 102,132-40.
D o n o v a n -R o d r ig u e z , T ., U r c h , C.E. & D ic k e n s o n , A.H. (2006). Evidence o f  
a role for descending serotonergic facilitation in a rat model of cancer- 
induced bone pain. Neurosci Lett., 393,237-42. Epub 2005 Oct 25.
D o s t r o v s k y , J.O. & C r a ig , A.D. (2006). Ascending projection systems. In 
Textbook o f  Pain, eds McMahon, S.B. & Koltzenburg, M. pp. 187-203. 
London: Elsevier Churchill Livingstone.
D o s t r o v s k y ,  J.O. & C r a ig ,  A.D. (1996). Cooling-specific spinothalamic 
neurons in the monkey. J  Neurophysiol., 76,3656-65.
D o u g h e r t y , P.M., P a l e c e k , J., P a l e c k o v a , V., So r k in , L.S. & W il l is , W.D. 
(1992). The role of NMDA and non-NMDA excitatory amino acid 
receptors in the excitation of primate spinothalamic tract neurons by 
mechanical, chemical, thermal, and electrical stimuli. J  Neurosci., 12, 
3025-41.
D o u g h e r t y , P.M., P a l e c e k , J., P a l e c k o v a , V. & W il l is , W.D. (1995).
Infusion of substance P or neurokinin A by microdialysis alters responses
281
of primate spinothalamic tract neurons to cutaneous stimuli and to 
iontophoretically released excitatory amino acids. Pain., 61,411-25.
D o u g h e r t y , P.M., P a l e c e k , J., Z o r n , S. & W il l is , W.D. (1993). Combined 
application of excitatory amino acids and substance P produces long- 
lasting changes in responses of primate spinothalamic tract neurons.
Brain Res Brain Res Rev., 18, 227-46.
D o u g h e r t y , P.M. & W il l is , W.D. (1991). Enhancement of spinothalamic
neuron responses to chemical and mechanical stimuli following combined 
micro-iontophoretic application of N-methyl-D-aspartic acid and 
substance P. Pain., 47, 85-93.
D o y l e , C .A . &  H u n t , S.P. (1999). Substance P receptor (neurokinin-1)-
expressing neurons in lamina I of the spinal cord encode for the intensity 
of noxious stimulation: a c-Fos study in rat. Neuroscience, 89, 17-28.
D r a y , A. (1997). Pharmacology of peripheral afferent terminals. In Anesthesia: 
Biologic Foundations, ed Yaksh, T.L. pp. 543-556. Philadelphia: 
Lippincott-Raven.
Du, J., K o l t z e n b u r g , M. & C a r l t o n , S.M. (2001). Glutamate-induced
excitation and sensitization o f nociceptors in rat glabrous skin. Pain., 89, 
187-98.
Du, J., Z h o u , S., C o g g e s h a l l , R.E. & C a r l t o n , S.M. (2003). N-methyl-D- 
aspartate-induced excitation and sensitization of normal and inflamed 
nociceptors. Neuroscience, 118, 547-62.
D u b in , A.E., H u v a r , R., D'A n d r e a , M.R., P y a t i, J., Z h u , J.Y., Jo y , K.C., 
W il s o n , S.J., G a l in d o , J.E., G l a s s , C.A., Luo, L., J a c k s o n , M.R., 
Lo v e n b e r g , T.W. & E r l a n d e r , M.G. (1999). The pharmacological and 
functional characteristics of the serotonin 5-HT(3A) receptor are 
specifically modified by a 5-HT(3B) receptor subunit. J  Biol Chem., 274, 
30799-810.
D u g g a n , A.W., H a l l , J.G. & H e a d l e y , P.M. (1977). Suppression of
transmission of nociceptive impulses by morphine: selective effects of 
morphine administered in the region of the substantia gelatinosa. Br J  
Pharmacol, 61,65-76.
D u g g a n , A.W. & N o r t h , R.A. (1983). Electrophysiology of opioids. Pharmacol 
Rev, 35,219-81.
E id e , P.K. & H o l e , K. (1989). Subsensitivity o f serotonin and substance P 
receptors involved in nociception after repeated administration of a 
serotonin receptor agonist. J  Neural Transm., 77, 1-10.
Fa s m e r , O.B., B e r g e , O.G. & H o l e , K. (1985). Changes in nociception after 
lesions of descending serotonergic pathways induced with 5,6- 
dihydroxytryptamine. Different effects in the formalin and tail-flick tests. 
Neuropharmacology., 24, 729-34.
F a s m e r , O.B., B e r g e , O.G. & H o l e , K. (1983a). Similar behavioural effects of 
5-hydroxytryptamine and substance P injected intrathecally in mice. 
Neuropharmacology., 22,485-7.
F a s m e r , O.B., B e r g e , O.G., W a l t h e r , B. & H o l e , K. (1983b). Changes in
nociception after intrathecal administration o f 5,6-dihydroxytryptamine in 
mice. Neuropharmacology., 22,1197-201.
F a s m e r , O.B. & Po s t , C . (1983c). Behavioural responses induced by intrathecal 
injection of 5-hydroxytryptamine in mice are inhibited by a substance P
282
antagonist, D-Pro2, D-Trp7,9-substance P. Neuropharmacology., 22, 
1397-400.
F i e l d ,  M.J., B r a m w e l l ,  S ., H u g h e s , J. & S in g h , L. (1999a). D etection  o f  static  
an d  d y n am ic  co m ponen ts  o f  m echan ica l a llo d y n ia  in  ra t m odels o f  
n e u ro p a th ic  pain : a re  they  s igna lled  by  d istin c t p rim ary  sensory  
n eu ro n es?  Pain., 83, 303-11.
F i e l d ,  M.J., M c C l e a r y ,  S ., B o d e n , P., S u m a n -C h a u h a n ,  N., H u g h e s , J. & 
S in g h , L. (1998 ). Involvement of the central tachykinin NK1 receptor 
during maintenance of mechanical hypersensitivity induced by diabetes in 
the rat. J  Pharmacol Exp Ther, 2 85 ,1226-32.
F i e l d ,  M.J., M c C l e a r y ,  S., H u g h e s ,  J. & S i n g h ,  L. (1999b). Gabapentin and 
pregabalin, but not morphine and amitriptyline, block both static and 
dynamic components of mechanical allodynia induced by streptozocin in 
the rat. Pain., 80, 391-8.
F i e l d s ,  H.L. & B a s b a u m ,  A.I. (1978). Brainstem control of spinal pain- 
transmission neurons. Annu Rev Physiol, 40,217-48.
F ie l d s , H .L . &  H e in r ic h e r , M.M. (1985). A n ato m y  an d  physio lo g y  o f  a
nociceptive modulatory system. Philos Trans R Soc Lond B Biol Sci.,
308, 361-74.
F i e l d s ,  H.L., H e i n r i c h e r ,  M.M. & M a s o n ,  P. (1991). Neurotransmitters in 
nociceptive modulatory circuits. Annu Rev Neurosci., 14,219-45.
F l e e t w o o d -W a l k e r , S .M ., M it c h e l l , R ., H o p e , P .J., E l-Y a s s ir , N ., M o l o n y , 
V. & B l a d o n , C.M. (1990). The involvement of neurokinin receptor 
subtypes in somatosensory processing in the superficial dorsal hom of the 
cat. Brain Res., 519, 169-82.
F r e n k ,  H., B o s s u t ,  D. & M a y e r ,  D.J. (1988a). Is substance P a primary afferent 
neurotransmitter for nociceptive input? III. Valproic acid and 
chlordiazepoxide decrease behaviors elicited by intrathecal injection of 
substance P and excitatory compounds. Brain Res., 455,240-6.
F r e n k ,  H., B o s s u t ,  D., U r c a ,  G. & M a y e r ,  D.J. (1988b). Is substance P a
primary afferent neurotransmitter for nociceptive input? I. Analysis of 
pain-related behaviors resulting from intrathecal administration of 
substance P and 6 excitatory compounds. Brain Res., 455,223-31.
G a o ,  K. &  M a s o n ,  P. (2000). Serotonergic Raphe magnus cells that respond to 
noxious tail heat are not ON or OFF cells. J  Neurophysiol., 84, 1719-25.
G a r r e t , C ., C a r r u e t t e , A ., F a r d in , V ., M o u s s a o u i, S ., P e y r o n e l , J .F .,
B l a n c h a r d ,  J.C. & L a d u r o n ,  P.M. (1991). Pharmacological properties 
of a potent and selective nonpeptide substance P antagonist. Proc Natl 
Acad Sci US A ,  88, 10208-12.
G a r r y ,  M.G. & T a n e l i a n ,  D.T. (1997). Afferent activity in injured afferent
nerves. In Anesthesia: Biologic Foundations. eds Yaksh, T.L., Lynch III, 
C., Zapol, W.M., Maze, M., Biebuyck, J.F. & Saidman, L.J. pp. 531-542. 
Philadelphia: Lippincott-Raven.
G a u r i a u ,  C. & B e r n a r d ,  J.F. (2002). Pain pathways and parabrachial circuits in 
the rat. Exp Physiol, 87,251-8.
G il r o n , I., B a il e y , J.M., Tu, D., H o l d e n , R.R., W e a v e r , D.F. & H o u l d e n ,
R.L. (2005). Morphine, gabapentin, or their combination for neuropathic 
pain. N  Engl J  M ed, 352, 1324-34.
283
G o f f ,  J.R., B u r k e y ,  A.R., G o f f ,  D.J. & J a s m i n ,  L. (1998). Reorganization of 
the spinal dorsal hom in models of chronic pain: correlation with 
behaviour. Neuroscience, 82, 559-74.
G o n z a l e z ,  M.I., F i e l d ,  M.J., H u g h e s ,  J. & S i n g h ,  L. (2000). Evaluation of 
selective NK(1) receptor antagonist Cl-1021 in animal models of 
inflammatory and neuropathic pain. J  Pharmacol Exp Ther, 294,444-50.
G r e e n ,  G.M., S c a r t h ,  J. & D i c k e n s o n ,  A. (2000). An excitatory role for 5-HT 
in spinal inflammatory nociceptive transmission; state-dependent actions 
via dorsal hom 5-HT(3) receptors in the anaesthetized rat. Pain., 89, 81- 
88 .
G u t m a n , G.A., C h a n d y , K.G., A d e l m a n , J.P., A iy a r , J., B a y l is s , D.A., 
C l a p h a m , D .E ., C o v a r r iu b ia s , M., D e s ir , G.V., F u r u ic h i, K., 
G a n e t z k y , B., G a r c ia , M.L., G r is s m e r , S ., J a n , L.Y., K a r s c h in , A ., 
K im , D ., K u p e r s c h m id t , S ., K u r a c h i, Y ., L a z d u n s k i, M., L e sa g e , F., 
L e s t e r , H .A ., M c K in n o n , D ., N ic h o l s , C .G ., O ’K e l l y , I., R o b b in s , J., 
R o b e r t s o n , G.A., R u d y , B., S a n g u in e t t i, M., S e in o , S ., S t u e h m e r ,
W., T a m k u n ,  M.M., V a n d e n b e r g ,  C.A., W e i ,  A., W u l f f ,  H. & 
W y m o r e ,  R.S. (2003). International Union of Pharmacology. XLI. 
Compendium of voltage-gated ion channels: potassium channels. 
Pharmacol Rev., 55, 583-6.
H a g e r m a r k ,  O., H o k f e l t ,  T. &  P e r n o w ,  B. (1978). Flare and itch induced by 
substance P in human skin. J  Invest Dermatol., 71, 233-5.
H a l e y ,  J.E., S u l l i v a n ,  A.F. & D i c k e n s o n ,  A.H. (1990). Evidence for spinal N -  
methyl-D-aspartate receptor involvement in prolonged chemical 
nociception in the rat. Brain Research, 518,218-226.
H a n ,  Z.S., Z h a n g ,  E.T. & C r a i g ,  A.D. (1998). Nociceptive and thermoreceptive 
lamina I neurons are anatomically distinct. Nat Neurosci, 1,218-25.
H a n s s o n ,  P.T. & D i c k e n s o n ,  A.H. (2005). Pharmacological treatment of
p erip h era l n eu ro p a th ic  p a in  c o n d itio n s  b ased  o n  shared  com m onalities  
desp ite  m u ltip le  e tio lo g ies . Pain, 1 1 3 ,2 5 1 -4 .
H a o , J.X. & Xu, X.J. (1996). Treatment of a chronic allodynia-like response in 
spinally injured rats: effects of systemically administered excitatory 
amino acid receptor antagonists. Pain, 6 6 ,279-85 .
H a r g r e a v e s ,  K., D u b n e r ,  R., B r o w n ,  F., F l o r e s ,  C. & J o r i s ,  J. (1988). A new 
and sensitive method for measuring thermal nociception in cutaneous 
hyperalgesia. Pain, 32, 77-88.
H e i n r i c h e r ,  M.M. (1997). Organizational characteristics of supraspinally 
mediated responses to nociceptive input. In Anesthesia: Biologic 
Foundations, ed Yaksh, T.L. pp. 643-661. Philadelphia: Lippincott- 
Raven.
H e n r y ,  J.L. (1976). Effects of substance P on functionally identified units in cat 
spinal cord. Brain Res, 114,439-51.
H e n r y ,  J.L. (1980). Substance P and pain: an updating. Trends in Neurosciences, 
3, 95-97.
H o k f e l t ,  T ., Z h a n g ,  X . &  W ie s e n f e l d - H a l l i n ,  Z . (1994). M essen g er 
p las tic ity  in  p rim ary  senso ry  n eu ro n s  fo llo w in g  ax o to m y  an d  its 
functional im p lica tions. Trends Neurosci, 17,22-30.
284
H o l l a n d ,  L.N., G o l d s t e i n ,  B.D. & A r o n s t a m ,  R.S. (1993). Substance P 
receptor desensitization in the dorsal hom: possible involvement of 
receptor-G protein complexes. Brain Res, 600, 89-96.
H o n o r e ,  P., M e n n i n g ,  P.M., R o g e r s ,  S.D., N i c h o l s ,  M.L., B a s b a u m ,  A . I . ,  
B e s s o n ,  J.M. & M a n t y h ,  P.W. (1999). Spinal substance P receptor 
expression and internalization in acute, short-term, and long-term 
inflammatory pain states. J  Neurosci, 19, 7670-8.
H o n o r e ,  P., R o g e r s ,  S.D., S c h w e i ,  M.J., S a l a k - J o h n s o n ,  J.L., L u g e r ,  N.M., 
S a b i n o ,  M.C., C l o h i s y ,  D.R. & M a n t y h ,  P.W. (2000). Murine models 
of inflammatory, neuropathic and cancer pain each generates a unique set 
of neurochemical changes in the spinal cord and sensory neurons. 
Neuroscience, 98, 585-98.
H u a ,  X . Y . ,  C h e n ,  P., M a r s a l a ,  M. & Y a k s h ,  T.L. (1999). Intrathecal substance 
P-induced thermal hyperalgesia and spinal release of prostaglandin E2 
and amino acids. Neuroscience, 89, 525-34.
H u n t ,  S.P. & B e s t e r ,  H. (2005). The ascending pain pathways. In The
Neurobiology o f  Pain, eds Hunt, S.P. & Koltzenburg, M. pp. 165-184. 
Oxford: Oxford University Press.
H u n t ,  S.P. & M a n t y h ,  P.W. (2001). The molecular dynamics of pain control. 
Nat Rev Neurosci, 2, 83-91.
H w a n g ,  J.H. & Y a k s h ,  T.L. (1997). The effect of spinal GABA receptor
agonists on tactile allodynia in a surgically-induced neuropathic pain 
model in the rat. Pain., 70, 15-22.
H y l d e n ,  J.L. & W i l c o x ,  G.L. (1982). Intrathecal opioids block a spinal action 
of substance P in mice: functional importance of both mu- and delta- 
receptors. Eur J  Pharmacol, 86, 95-8.
H y l d e n ,  J.L. & W i l c o x ,  G.L. (1983). Pharmacological characterization of 
substance P-induced nociception in mice: modulation by opioid and 
noradrenergic agonists at the spinal level. J  Pharmacol Exp Ther, 226, 
398-404.
I a n n e t t i ,  G.D., Z a m b r e a n u ,  L., W i s e ,  R.G., B u c h a n a n ,  T.J., H u g g i n s ,  J.P., 
S m a r t ,  T.S., V e n n a r t ,  W. & T r a c e y ,  I. (2005). Pharmacological 
modulation of pain-related brain activity during normal and central 
sensitization states in humans. Proc Natl Acad Sci USA. ,  102, 18195- 
200. Epub 2005 Dec 5.
I k e d a ,  H . ,  H e i n k e ,  B . ,  R u s c h e w e y h ,  R .  &  S a n d k u h l e r ,  J. (2003). S y n a p t i c
plasticity in spinal lamina I projection neurons that mediate hyperalgesia. 
Science, 299, 1237-40.
J a c k s o n ,  D.L., G r a f f ,  C.B., R i c h a r d s o n ,  J.D. & H a r g r e a v e s ,  K.M. (1995). 
Glutamate participates in the peripheral modulation of thermal 
hyperalgesia in rats. Eur J  Pharmacol., 284, 321-5.
J a c q u e t ,  Y.F. (1988). The NMDA receptor: central role in pain inhibition in rat 
periaqueductal gray. Eur J  Pharmacol, 154,271-6.
J a d a d ,  A.R., C a r r o l l ,  D., G l y n n ,  C.J., M o o r e ,  R.A. & M c Q u a y ,  H.J. (1992). 
Morphine responsiveness of chronic pain: double-blind randomised 
crossover study with patient-controlled analgesia. Lancet., 339, 1367-71.
J a n g ,  J.H., K i m ,  D.W., S a n g  N a m ,  T., S e  P a i k ,  K. & L e e m ,  J.W. (2004).
Peripheral glutamate receptors contribute to mechanical hyperalgesia in a 
neuropathic pain model of the rat. Neuroscience, 128,169-76.
285
J e s s e l l ,  T.M. & I v e r s e n ,  L.L. (1977). Opiate analgesics inhibit substance P 
release from rat trigeminal nucleus. Nature, 268, 549-51.
J i ,  R . R .  &  S t r i c h a r t z ,  G .  (2004). Cell signaling and the genesis of neuropathic 
pain. Sci STKE., 2004, reE14.
J i n ,  Y . H . ,  N i s h i o k a ,  H . ,  W a k a b a y a s h i ,  K . ,  F u j i t a ,  T .  &  Y o n e h a r a ,  N .  (2006). 
Effect o f morphine on the release of excitatory amino acids in the rat hind 
instep: Pain is modulated by the interaction between the peripheral opioid 
and glutamate systems. Neuroscience., 138, 1329-39. Epub 2006 Feb 10.
J o n e s ,  C . K . ,  P e t e r s ,  S.C. & S h a n n o n ,  H.E. (2005). Efficacy of duloxetine, a
potent and balanced serotonergic and noradrenergic reuptake inhibitor, in 
inflammatory and acute pain models in rodents. J  Pharmacol Exp Ther, 
312, 726-32. Epub 2004 Oct 19.
J o r d a n ,  L.M., K e n s h a l o ,  D.R., J r . ,  M a r t i n ,  R.F., H a b e r ,  L.H. & W i l l i s ,
W.D. (1978). Depression of primate spinothalamic tract neurons by 
iontophoretic application of 5-hydroxytryptamine. Pain., 5,135-42.
J o s h i ,  S . K . ,  H e r n a n d e z ,  G . ,  M i k u s a ,  J.P., Z h u ,  C . Z . ,  Z h o n g ,  C., S a l y e r s ,  A . ,  
W i s m e r ,  C.T., C h a n d r a n ,  P., D e c k e r ,  M . W .  & H o n o r e ,  P. (2006). 
Comparison of antinociceptive actions of standard analgesics in 
attenuating capsaicin and nerve-injury-induced mechanical 
hypersensitivity. Neuroscience., 143,587-96. Epub 2006 Sep 8.
J u l i u s ,  D. & M c C l e s k e y ,  E.W. (2006). Cellular and molecular properties of 
primary afferent neurons. In Textbook o f  Pain, eds McMahon, S.B. & 
Koltzenburg, M. pp. 35-48. London: Elsevier: Churchill Livingstone.
K a j a n d e r ,  K.C., W a k i s a k a ,  S. & B e n n e t t ,  G.J. (1992). Spontaneous discharge 
originates in the dorsal root ganglion at the onset of a painful peripheral 
neuropathy in the rat. Neurosci Lett, 138,225-8.
K a n g r g a ,  1. & R a n d i c ,  M. (1991). Outflow of endogenous aspartate and
glutamate from the rat spinal dorsal hom in vitro by activation of low- 
and high-threshold primary afferent fibers. Modulation by mu-opioids. 
Brain Res, 553, 347-52.
K a u p p i l a ,  T .  (1997 ). S p i n a l i z a t i o n  i n c r e a s e s  t h e  m e c h a n i c a l  s t i m u l a t i o n - i n d u c e d  
w i t h d r a w a l  r e f l e x  t h r e s h o l d  a f t e r  a  s c i a t i c  c u t  i n  t h e  r a t .  Brain Res., 770 , 
310-2 .
K a u p p i l a ,  T . ,  K o n t i n e n ,  V . K .  & P e r t o v a a r a ,  A .  (1998). Influence o f
sp in a liz a tio n  o n  sp ina l w ithd raw al re flex  resp o n ses  varies  depend ing  on  
the  su b m o d a lity  o f  the  te s t s tim u lu s  an d  the  experim en tal 
p a th o p h y sio lo g ica l c o n d itio n  in  th e  rat. Brain Res., 7 9 7 ,2 3 4 -4 2 .
K a y s e r ,  V ., C h e n ,  Y.L. & G u i lb a u d ,  G . (1991). B ehav ioura l ev idence  fo r a  
pe rip h era l c o m p o n en t in  th e  en h an ced  an tin o c icep tiv e  e ffec t o f  a  low  
d o se  o f  sy stem ic  m orph ine  in  ca rrag een in -in d u ced  hypera lgesic  rats. 
Brain Res, 560, 237-44.
K e l l s t e i n ,  D.E., P r i c e ,  D.D., H a y e s ,  R.L. & M a y e r ,  D.J. (1990). Evidence 
that substance P selectively modulates C-fiber-evoked discharges of 
dorsal hom nociceptive neurons. Brain Res., 526,291-8.
K e w , J .N . &  K e m p , J .A . (2005). Iono trop ic  and  m etab o tro p ic  g lu tam ate  recep to r 
s tru c tu re  an d  pharm aco logy . Psychopharmacology (Berl). 1 7 9 ,4 -2 9 . 
E pub  2005 F eb  25.
K haw aja, A.M. & R o g e r s ,  D.F. (1996). Tachykinins: receptor to effector. In tJ  
Biochem Cell Biol., 28, 721-38.
286
K a j a n d e r ,  K.C., W a k is a k a ,  S. & B e n n e t t ,  G.J. (1992). Spontaneous discharge 
originates in the dorsal root ganglion at the onset o f a painful peripheral 
neuropathy in the rat. Neurosci Lett, 138,225-8.
K a n g r g a , I. & R a n d ic , M. (1991). Outflow of endogenous aspartate and
glutamate from the rat spinal dorsal hom in vitro by activation of low- 
and high-threshold primary afferent fibers. Modulation by mu-opioids. 
Brain Res, 553, 347-52.
K a u p p i l a ,  T. (1997). Spinalization increases the mechanical stimulation-induced 
withdrawal reflex threshold after a sciatic cut in the rat. Brain Res., 770, 
310-2.
K a u p p il a , T ., K o n t in e n , V .K . &  P e r t o v a a r a , A . (1998). In fluence  o f
sp in a liz a tio n  o n  sp ina l w ithd raw al reflex  responses varies depend ing  on  
th e  su b m o d a lity  o f  th e  te s t stim u lus and  the  experim ental 
p a th o p h y s io lo g ic a l co n d itio n  in  the  rat. Brain Res., 7 9 7 ,2 3 4 -4 2 .
K a y s e r ,  V ., C h e n ,  Y .L . &  G u i lb a u d ,  G . (1991). B ehav ioural ev idence  fo r a  
p e rip h e ra l co m p o n e n t in  th e  enhanced  an tinocicep tive  e ffec t o f  a  low  
d o se  o f  sy s tem ic  m o rp h in e  in  carrageen in-induced  hyperalgesic  rats. 
Brain Res, 560,237-44.
K e l l s t e i n ,  D.E., P r ic e ,  D.D., H a y e s ,  R .L . &  M a y e r ,  D.J. (1990). Evidence 
that substance P selectively modulates C-fiber-evoked discharges of 
dorsal hom nociceptive neurons. Brain Res., 526,291-8.
K em p, J.A., F o s t e r ,  A.C. & W o n g , E.H.F. (1987). Non-competitive antagonists 
of excitatory amino acid receptors. Trends in Neurosciences, 10,294-299.
K e w , J.N. & K e m p , J.A. (2005). Ionotropic and metabotropic glutamate receptor 
structure and pharmacology. Psychopharmacology (Berl). 179,4-29. 
Epub 2005 Feb 25.
K h a w a j a ,  A.M. & R o g e r s ,  D.F. (1996). Tachykinins: receptor to effector. In tJ  
Biochem Cell B iol, 28, 721-38.
K ia , H.K., M iq u e l , M.C., M c K e r n a n , R.M., L a po r t e , A.M., Lo m b a r d , M.C., 
B o u r g o in , S., H a m o n , M. & V e r g e , D. (1995). Localization of 5-HT3 
receptors in the rat spinal cord: immunohistochemistry and in situ 
hybridization. Neuroreport., 6,257-61.
K id d , B.L. & U r b a n ,  L.A. (2001). Mechanisms of inflammatory pain. B rJ  
Anaesth., 87, 3-11.
K id d , E.J., L a p o r t e , A.M., L a n g l o is , X., F a t t a c c in i, C.M., D o y e n , C.,
L o m b a r d ,  M.C., G o z l a n ,  H. & H a m o n , M. (1993). 5-HT3 receptors in 
the rat central nervous system are mainly located on nerve fibres and 
terminals. Brain Res., 612,289-98.
K i m ,  S.H. & C h u n g ,  J.M. (1992). An experimental model for peripheral
neuropathy produced by segmental spinal nerve ligation in the rat. Pain, 
50, 355-63.
K in k e l in , I., B r o c k e r , E .B ., K o l t z e n b u r g , M. & C a r l t o n , S.M. (2000). 
Localization of ionotropic glutamate receptors in peripheral axons of 
human skin. Neurosci Lett., 283, 149-52.
K o l h e k a r , R., M e l l e r , S.T. & G e b h a r t , G.F. (1993). Characterization of the 
role of spinal N-methyl-D-aspartate receptors in thermal nociception in 
the rat. Neuroscience., 57,385-95.
K o l t z e n b u r g ,  M . &  S c a d d in g ,  J. (2001). N eu ro p a th ic  pa in . Curr Opin 
Neurol., 14,641-7 .
287
K o l t z e n b u r g ,  M., T o r e b j o r k ,  H.E. & W a h r e n ,  L.K. (1994). Nociceptor
modulated central sensitization causes mechanical hyperalgesia in acute 
chemogenic and chronic neuropathic pain. Brain., 117, 579-91.
K o n t i n e n ,  V.K. & D i c k e n s o n ,  A.H. (2000). Effects of midazolam in the spinal 
nerve ligation model of neuropathic pain in rats. Pain., 85,425-31.
K o n t i n e n ,  V.K., P a a n a n e n ,  S. & K a l s o ,  E. (1998). Systemic morphine in the 
prevention of allodynia in the rat spinal nerve ligation model of 
neuropathic pain. Eur J  Pain, 2,35-42.
K o n t i n e n ,  V.K., S t a n f a ,  L.C., B a s u ,  A. & D i c k e n s o n ,  A.H. (2001).
Electrophysiologic evidence for increased endogenous gabaergic but not 
glycinergic inhibitory tone in the rat spinal nerve ligation model of 
neuropathy. Anesthesiology, 94,333-9.
K o s t e r l i t z ,  H.W. (1985). The Wellcome Foundation lecture, 1982. Opioid 
peptides and their receptors. Proc R Soc Lond B Biol Sci, 225,27-40.
L a m o t t e ,  C., P e r t ,  C.B. & S n y d e r ,  S.H. (1976). Opiate receptor binding in 
primate spinal cord: distribution and changes after dorsal root section. 
Brain Res, 112,407-12.
L a n e u v i l l e ,  O., D o r a i s ,  J. & C o u t u r e ,  R. (1988). Characterization of the 
effects produced by neurokinins and three agonists selective for 
neurokinin receptor subtypes in a spinal nociceptive reflex of the rat. Life 
Sci, 42, 1295-305.
L a o ,  L.J., S o n g ,  B. & M a r v i z o n ,  J.C. (2003). Neurokinin release produced b y  
capsaicin acting on the central terminals and axons of primary afferents: 
relationship with N-methyl-D-aspartate and GABA(B) receptors. 
Neuroscience, 121, 667-80.
L e  B a r s ,  D., G o z a r i u ,  M. & C a d d e n ,  S.W. (2001). Animal models of 
nociception. Pharmacol Rev., 53, 597-652.
L e e ,  S.H., K a y s e r ,  V., D e s m e u l e s ,  J. & G u i l b a u d ,  G. (1994). Differential
action of morphine and various opioid agonists on thermal allodynia and 
hyperalgesia in mononeuropathic rats. Pain., 57,233-40.
L e e ,  W.T., S o h n ,  M.K., P a r k ,  S.H., A h n ,  S.K., L e e ,  J.E. & P a r k ,  K.A. (2001). 
Studies on the changes of c-fos protein in spinal cord and 
neurotransmitter in dorsal root ganglion of the rat with an experimental 
peripheral neuropathy. Yonsei Med J, 42, 30-40.
L e e ,  Y., L e e ,  C.H. & Oh, U. (2005). Painful channels in sensory neurons. Mol 
Cells., 20, 315-24.
L e e ,  Y.W., C h a p l a n ,  S.R. & Yaksh, T.L. (1995). Systemic and supraspinal, but 
not spinal, opiates suppress allodynia in a rat neuropathic pain model. 
Neurosci Lett., 199, 111-4.
L e e ,  Y.W., Park , K.A. & L e e ,  W.T. (2002). Effects of MK-801 and morphine 
on spinal C-Fos expression during the development of neuropathic pain. 
Yonsei MedJ., 43, 370-6.
L e e m ,  J.W., H w a n g ,  J.H., H w a n g ,  S.J., P a r k ,  H., K i m ,  M.K. & C h o i ,  Y.
(2001). The role of peripheral N-methyl-D-aspartate receptors in Freund's 
complete adjuvant induced mechanical hyperalgesia in rats. Neurosci 
Lett., 297, 155-8.
L e e m ,  J.W., W i l l i s ,  W.D. & C h u n g ,  J.M. (1993). Cutaneous sensory receptors 
in the rat foot. J  Neurophysiol., 69, 1684-99.
288
L e m b e r g ,  K., K o n t i n e n ,  V.K., V i l j a k k a ,  K., K y l a n l a h t i ,  I., Y l i -
K a u h a l u o m a ,  J. & K a l s o ,  E. (2006). Morphine, oxycodone, methadone 
and its enantiomers in different models of nociception in the rat. Anesth 
Analg., 102, 1768-74.
Li, H.S. & Z h a o ,  Z.Q. (1998). Small sensory neurons in the rat dorsal root
ganglia express functional NK-1 tachykinin receptor. Eur J  Neurosci, 10, 
1292-9.
L i g h t ,  A.R. & P e r l ,  E.R. (1979a). Reexamination of the dorsal root projection 
to the spinal dorsal hom including observations on the differential 
termination o f coarse and fine fibers. Journal o f  Comparative Neurology, 
186, 117-132.
L i g h t ,  A.R. & P e r l ,  E.R. (1979b). Spinal termination of functionally identified 
primary afferent neurons with slowly conducting myelinated fibers. 
Journal o f  Comparative Neurology, 186,133-150.
L i m a ,  D. & C o i m b r a ,  A. (1986). A Golgi study of the neuronal population of the 
marginal zone (lamina I) of the rat spinal cord. J  Comp Neurol, 244, 53- 
71.
L iu , H., M a n t y h ,  P.W. & B a s b a u m ,  A.I. (1997). NMDA-receptor regulation of 
substance P release from primary afferent nociceptors. Nature, 386, 721 -
4.
L iu , H., W a n g ,  H., S h e n g ,  M., J a n ,  L.Y., J a n ,  Y.N. & B a s b a u m ,  A.I. (1994). 
Evidence for presynaptic N-methyl-D-aspartate autoreceptors in the 
spinal cord dorsal hom. Proc Natl Acad Sci USA. ,  91, 8383-7.
L iu , X .G . &  S a n d k u h l e r , J. (1998). Activation of spinal N-methyl-D-aspartate 
or neurokinin receptors induces long-term potentiation of spinal C-fibre- 
evoked potentials. Neuroscience., 86, 1209-16.
L o m b a rd ,  M.C. & B e s s o n ,  J.M. (1989). A ttem p ts  to  gauge the  rela tive 
im p o rtan ce  o f  p re- an d  p o stsy n ap tic  e ffec ts  o f  m orph ine  o n  the 
tra n sm iss io n  o f  n o x io u s  m essages  in  the  dorsal h o m  o f  the  ra t sp inal cord. 
Pain, 37, 335-45.
L y n c h ,  M .E ., C l a r k ,  A.J. & S a w y n o k ,  J. (2003). A p ilo t study  exam in ing  
to p ica l am itrip ty lin e , k e tam in e , and  a  co m b in a tio n  o f  bo th  in  the  
trea tm en t o f  n eu ro p a th ic  pa in . Clin J  Pain., 19,323-8.
L y n c h ,  M.E., C l a r k ,  A.J., S a w y n o k ,  J. & S u l l i v a n ,  M.J. (2005). Topical
am itrip ty lin e  an d  k e tam in e  in  n eu ropa th ic  p a in  syndrom es: an  open-label 
s tudy . J  Pain., 6 , 644-9 .
Ma, Q.P., A l l c h o r n e ,  A.J. & W o o l f ,  C.J. (1998). Morphine, the NMDA
rec e p to r  an tag o n is t MK801 an d  th e  tach y k in in  NK1 recep to r an tagon ist 
RP67580 a tten u a te  the  d ev e lo p m en t o f  in flam m atio n -in d u ced  p rog ressive  
tac tile  hypersensitiv ity . Pain, 11, 49-57.
M a ,  Q.P. & W o o l f ,  C.J. (1997). Tachykinin NK1 receptor antagonist RP67580 
attenuates progressive hypersensitivity of flexor reflex during 
experimental inflammation in rats. Eur J  Pharmacol, 322, 165-71.
M a g e r l ,  W., F u c h s ,  P.N., M e y e r ,  R.A. & T r e e d e ,  R.D. (2001). Roles of 
capsaicin-insensitive nociceptors in cutaneous pain and secondary 
hyperalgesia. Brain, 124, 1754-64.
M a l c a n g io , M . &  B o w e r y , N .G . (1999). P ep tide  au to recep to rs: does  an
autoreceptor for substance P exist? Trends Pharmacol Sci, 20,405-7.
289
M a l c a n g i o ,  M., F e r n a n d e s ,  K. & T o m l i n s o n ,  D.R. (1998a). NMDA receptor 
activation modulates evoked release of substance P from rat spinal cord.
Br J  Pharmacol., 125, 1625-6.
M a l c a n g i o ,  M. & T o m l i n s o n ,  D.R. (1998b). A pharmacologic analysis of
mechanical hyperalgesia in streptozotocin/diabetic rats. Pain, 76, 151-7.
M a l m b e r g ,  A.B. & B a s b a u m ,  A.I. (1998). Partial sciatic nerve injury in the 
mouse as a model of neuropathic pain: behavioral and neuroanatomical 
correlates. Pain, 76,215-22.
M a n s i k k a ,  H. & P e r t o v a a r a ,  A. (1997). Supraspinal influence on hindlimb 
withdrawal thresholds and mustard oil-induced secondary allodynia in 
rats. Brain Res Bull., 42,359-65.
M a n s i k k a ,  H., S h e t h ,  R.N., D e V r i e s ,  C., L e e ,  H., W i n c h u r c h ,  R. & R a j a ,
S.N. (2000). Nerve injury-induced mechanical but not thermal 
hyperalgesia is attenuated in neurokinin-1 receptor knockout mice. Exp 
Neurol, 162, 343-9.
M a n s o u r ,  A., F o x ,  C.A., T h o m p s o n ,  R.C., A k i l ,  H. & W a t s o n ,  S.J. (1994).
mu-Opioid receptor mRNA expression in the rat CNS: comparison to mu- 
receptor binding. Brain Res, 643,245-65.
M a n t y h ,  P.W., R o g e r s ,  S . D . ,  H o n o r e ,  P., A l l e n ,  B.J., G h i l a r d i ,  J.R., L i ,  J . ,  
D a u g h t e r s ,  R.S., L a p p i ,  D.A., W i l e y ,  R.G. & S i m o n e ,  D.A. (1997). 
Inhibition of hyperalgesia by ablation of lamina I spinal neurons 
expressing the substance P receptor. Science, 278,275-9.
M a r i c q ,  A.V., P e t e r s o n ,  A.S., B r a k e ,  A.J., M y e r s ,  R . M .  &  J u l i u s ,  D .  (1991). 
Primary structure and functional expression of the 5HT3 receptor, a 
serotonin-gated ion channel. Science., 254,432-7.
M a r v i z o n ,  J.C., M c R o b e r t s ,  J.A., E n n e s ,  H.S., S o n g ,  B., W a n g ,  X., J i n t o n , 
L., C o r n e l i u s s e n ,  B. & M a y e r ,  E.A. (2002). Two N-methyl-D- 
aspartate receptors in rat dorsal root ganglia with different subunit 
composition and localization. J  Comp Neurol., 446,325-41.
M a t t h e w s ,  E.A. & D i c k e n s o n ,  A.H. (2002). A combination of gabapentin and 
morphine mediates enhanced inhibitory effects on dorsal hom neuronal 
responses in a rat model of neuropathy. Anesthesiology., 96,633-40.
M a t t h e w s ,  E.A. & D i c k e n s o n ,  A.H. (2001a). Effects of ethosuximide, a T-type 
Ca(2+) channel blocker, on dorsal hom neuronal responses in rats. Eur J  
Pharmacol., 415, 141-9.
M a t t h e w s ,  E.A. & D i c k e n s o n ,  A.H. (2001b). Effects of spinally delivered N- 
and P-type voltage-dependent calcium channel antagonists on dorsal hom 
neuronal responses in a rat model of neuropathy. Pain., 92,235-46.
M a x w e l l ,  D.J., K e r r ,  R., R a s h i d ,  S. & A n d e r s o n ,  E. (2003). Characterisation 
of axon terminals in the rat dorsal hom that are immunoreactive for 
serotonin 5-HT3A receptor subunits. Exp Brain Res., 149, 114-24. Epub 
2003 Jan 11.
M a x w e l l ,  D.J., L e r a n t h ,  C. & V e r h o f s t a d ,  A.A. (1983). Fine structure of 
serotonin-containing axons in the marginal zone of the rat spinal cord. 
Brain Res., 266,253-9.
M a x w e l l ,  L . ,  M a x w e l l ,  D.J., N e i l s o n ,  M .  & K e r r ,  R .  (1996). A  c o n f o c a l
microscopic survey of serotoninergic axons in the lumbar spinal cord of 
the rat: co-localization with glutamate decarboxylase and neuropeptides. 
Neuroscience., 75,471-80.
290
M c C l e a n e , G.J., S u z u k i, R . &  D ic k e n s o n , A .H . (2003). D oes a  single
intravenous injection of the 5HT3 receptor antagonist ondansetron have 
an analgesic effect in neuropathic pain? A double-blinded, placebo- 
controlled cross-over study. Anesth Analg., 97, 1474-8.
M c C l e s k e y ,  E.W. (2003). Neurobiology: new player in pain. Nature., 424, 729-
30.
M e l z a c k , R. & W a l l , P.D. (1965). Pain mechanisms: a new theory. Science, 
150, 971-9.
M e n d e l l ,  L.M. (1966). Physiological properties of unmyelinated fiber 
projection to the spinal cord. Exp Neurol, 16,316-32.
M e n e t r e y , D ., G ie s l e r , G.J., Jr . &  B e sso n , J.M. (1977). A n  analysis  o f
response properties of spinal cord dorsal hom neurones to nonnoxious 
and noxious stimuli in the spinal rat. Exp Brain Res, 27, 15-33.
M e r s k e y ,  H . &  B o g d u k ,  N . (1994). Classification of Chronic Pain. In IASP 
Task Force on Taxonomy, pp. 209-214. Seattle: IASP press.
M e u n i e r ,  J.C. (1997). Nociceptin/orphanin FQ and the opioid receptor-like 
ORL1 receptor. Eur J  Pharmacol, 340,1-15.
M e y e r , R.A. & C a m p b e l l , J.N. (1981). Myelinated nociceptive afferents
account for the hyperalgesia that follows a bum to the hand. Science.,
213, 1527-9.
M e y e r , R .A ., R in g k a m p , M., C a m p b e l l , J.N. & R a ja , S.N. (2006). Peripheral 
mechanisms of cutaneous nociception. In Textbook o f Pain, eds 
McMahon, S.B. & Koltzenburg, M. pp. 3-34. London: Elsevier Churchill 
Livingstone.
M i l l a n ,  M.J. (2002). Descending control of pain. Prog Neurobiol, 66,355-474.
M i l l a n ,  M.J. (1999). The induction of pain: an integrative review. Prog 
Neurobiol, 57, 1-164.
M je l l e m -Jo l y , N., L u n d , A., B e r g e , O .-G . &  H o l e , K. (1992). Intrathecal co­
administration o f substance P and NMDA augments nociceptive 
responses in the formalin test. Pain, 51, 195-198.
M je l le m - J o ly ,  N., L u n d ,  A., B e r g e ,  O.G. & H o le ,  K. (1991). Potentiation of a 
behavioural response in mice by spinal coadministration of substance P 
and excitatory amino acid agonists. Neurosci Lett., 133,121-4.
M o a l e m , G., G r a f e , P. & T r a c e y , D.J. (2005). Chemical mediators enhance 
the excitability of unmyelinated sensory axons in normal and injured 
peripheral nerve of the rat. Neuroscience., 134, 1399-411.
M o g il , J.S. & C r a g e r , S.E. (2004). What should we be measuring in behavioral 
studies of chronic pain in animals? Pain., 112, 12-5.
M o r a l e s , M. & W a n g , S.D. (2002). Differential composition of 5-
hydroxytryptamine3 receptors synthesized in the rat CNS and peripheral 
nervous system. J  Neurosci., 22,6732-41.
N a g y , G .G ., W a t a n a b e , M., F u k a y a , M. & T o d d , A .J. (2004). S ynaptic
distribution of the NR1, NR2A and NR2B subunits of the N-methyl-d- 
aspartate receptor in the rat lumbar spinal cord revealed with an antigen- 
unmasking technique. Eur J  Neurosci, 20, 3301-12.
N a g y ,  I., M a g g i ,  C.A., D r a y ,  A., W o o l f ,  C.J. & U r b a n ,  L. (1993). The role of 
neurokinin and N-methyl-D-aspartate receptors in synaptic transmission 
from capsaicin-sensitive primary afferents in the rat spinal cord in vitro. 
Neuroscience., 52, 1029-37.
291
N a h i n ,  R.L., R e n ,  K., D e  L e o n ,  M. & R u d a ,  M. (1994). Primary sensory
neurons exhibit altered gene expression in a rat model of neuropathic 
pain. Pain, 58, 95-108.
N a k a t s u k a ,  T .  & Gu, J.G. (2006). P2X purinoceptors and sensory transmission. 
Pflugers Arch, 452, 598-607. Epub 2006 Mar 18.
N a s s a r , M.A., L e v a t o , A., St ir l in g , L.C. & W o o d , J.N. (2005). Neuropathic 
pain develops normally in mice lacking both Navi .7 and Navi .8. Mol 
Pain., 1, 24.
N i c h o l s ,  M.L., B ia n , D., O ss ip o v , M.H., L a i, J. & P o r r e c a ,  F. (1995).
Regulation of morphine antiallodynic efficacy by cholecystokinin in a 
model o f neuropathic pain in rats. J  Pharmacol Exp Ther., 275, 1339-45.
N ic h o l s , M.L., Lo p e z , Y., O s s ip o v , M.H., B ia n , D. & P o r r e c a , F. (1997).
Enhancement of the antiallodynic and antinociceptive efficacy of spinal 
morphine by antisera to dynorphin A (1-13) or MK-801 in a nerve- 
ligation model of peripheral neuropathy. Pain., 69, 317-22.
O ' m a l l e y ,  P.J., C a l l i g a r o ,  D.O. & M o n n ,  J.A. (1991). Substance P and 
polyamines modulate the NMDA receptor operated ion channel by 
similar mechanisms. In Society for Neuroscience Abstracts.
O a t w a y ,  M.A., C h e n ,  Y. & W e a v e r ,  L.C. (2004). The 5-HT3 receptor
facilitates at-level mechanical allodynia following spinal cord injury. 
Pain., 110, 259-68.
O k a n o ,  K., K u r a i s h i ,  Y. & S a t o h ,  M. (1993). Pharmacological evidence for 
involvement of excitatory amino acids in aversive responses induced by 
intrathecal substance P in rats. Biol Pharm Bull, 16, 861-5.
O s s i p o v ,  M.H., B ia n , D., M a l a n ,  T.P., J r . ,  L a i, J. & P o r r e c a ,  F. (1999). Lack 
of involvement of capsaicin-sensitive primary afferents in nerve-ligation 
injury induced tactile allodynia in rats. Pain., 79, 127-33.
O s s ip o v , M.H., L a i , J ., M a l a n , T .P ., J r . &  P o r r e c a , F. (2000). Spinal and
supraspinal mechanisms of neuropathic pain. Ann N Y  Acad Sci, 909, 12- 
24.
O s s ip o v , M.H., L a i , J., M a l a n , T.P., J r ., V a n d e r a h , T.W. & P o r r e c a , F.
(2001). Tonic descending facilitation as a mechanism o f  neuropathic 
pain. Seattle: IASP press.
Ossipov, M. H., J. Lai, et al. (2006). Mechanisms of experimental neuropathic 
pain: integration from animal models. Textbook of Pain. S. B. McMahon 
and M. Koltzenburg. London, Elsevier Churchill Livingstone: 929-946.
O s s ip o v , M.H., L o p e z , Y., N ic h o l s , M.L., B ia n , D. & P o r r e c a , F. (1995). The 
loss of antinociceptive efficacy of spinal morphine in rats with nerve 
ligation injury is prevented by reducing spinal afferent drive. Neurosci 
Lett, 199, 87-90.
O y a m a , T ., U e d a , M., K u r a is h i, Y ., A k a ik e , A . &  Sa t o h , M. (1996). D ual
effect of serotonin on formalin-induced nociception in the rat spinal cord. 
Neurosci Res., 25, 129-35.
P a l m e r , C.L., C o t t o n , L. & H e n l e y , J.M. (2005). T he m o lecu la r
pharmacology and cell biology of alpha-amino-3-hydroxy-5-methyl-4- 
isoxazolepropionic acid receptors. Pharmacol Rev., 57, 253-77.
P a r s o n s , A.M., H o n d a , C.N., J ia , Y.P., B u d a i, D., X u , X.J., W ie se n fe l d -
H a l l in , Z . &  S e y b o l d , V.S. (1996). Spinal NK 1 receptors contribute to
292
the increased excitability of the nociceptive flexor reflex during persistent 
peripheral inflammation. Brain Res, 739,263-75.
P a s s m o r e ,  G.M., S e l y a n k o ,  A.A., M i s t r y ,  M., A l - Q a t a r i ,  M., M a r s h ,  S.J., 
M a t t h e w s ,  E.A., D i c k e n s o n ,  A.H., B r o w n ,  T.A., B u r b i d g e ,  S.A., 
M a i n ,  M. & B r o w n ,  D.A. (2003). KCNQ/M currents in sensory neurons: 
significance for pain therapy. J  Neurosci., 23, 7227-36.
P a t a p o u t i a n ,  A., P e i e r ,  A.M., S t o r y ,  G.M. & V i s w a n a t h ,  V. (2003).
ThermoTRP channels and beyond: mechanisms of temperature sensation. 
Nat Rev Neurosci, 4, 529-39.
P a w l a k ,  M., S c h m i d t ,  R.F., H e p p e l m a n n ,  B. & H a n e s c h ,  U. (2001). The
neurokinin-1 receptor antagonist RP 67580 reduces the sensitization of 
primary afferents by substance P in the rat. Eur J  Pain, 5,69-79.
P e n g ,  Y.B., L i n ,  Q. & W i l l i s ,  W.D. (1996). The role of 5-HT3 receptors in 
periaqueductal gray-induced inhibition of nociceptive dorsal hom 
neurons in rats. J  Pharmacol Exp Ther., 276,116-24.
P e r t o v a a r a ,  A. & W e i ,  H .  (2003). A d i s s o c i a t i v e  c h a n g e  i n  t h e  e f f i c a c y  o f  
s u p r a s p i n a l  v e r s u s  s p i n a l  m o r p h i n e  i n  t h e  n e u r o p a t h i c  r a t .  Pain., 101, 
237-50.
P e r t o v a a r a ,  A., W e i ,  H. & H a m a l a i n e n ,  M.M. (1996). Lidocaine in the 
rostroventromedial medulla and the periaqueductal gray attenuates 
allodynia in neuropathic rats. Neurosci Lett., 218,127-30.
P e t r e n k o ,  A.B., Y a m a k u r a ,  T., B a b a ,  H. & S h i m o j i ,  K. (2003). The role of N -  
methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg, 
97, 1108-16.
P i c a r d ,  P., B o u c h e r ,  S . ,  R e g o l i ,  D., G i t t e r ,  B.D., H o w b e r t ,  J.J. & C o u t u r e , 
R. (1993). Use o f non-peptide tachykinin receptor antagonists to 
substantiate the involvement of NK1 and NK2 receptors in a spinal 
nociceptive reflex in the rat. Eur J  Pharmacol, 232, 255-61.
P o r r e c a ,  F . ,  B u r g e s s ,  S . E . ,  G a r d e l l ,  L.R., V a n d e r a h ,  T.W., M a l a n ,  T.P., 
J r . ,  O s s i p o v ,  M.H., L a p p i ,  D.A. & L a i ,  J. (2001). Inhibition of 
neuropathic pain by selective ablation of brainstem medullary cells 
expressing the mu-opioid receptor. J  Neurosci., 21, 5281-8.
P o r r e c a ,  F., O s s i p o v ,  M.H. & G e b h a r t ,  G.F. (2002). Chronic pain and 
medullary descending facilitation. Trends Neurosci., 25, 319-25.
P o r r e c a ,  F., T a n g ,  Q.B., B i a n ,  D., R i e d l ,  M., E l d e ,  R. & L a i ,  J. (1998). Spinal 
opioid mu receptor expression in lumbar spinal cord of rats following 
nerve injury. Brain Res, 795, 197-203.
P o r t e n o y ,  R.K., F o l e y ,  K.M. & I n t u r r i s i ,  C.E. (1990). The nature of opioid 
responsiveness and its implications for neuropathic pain: new hypotheses 
derived from studies of opioid infusions. Pain, 43,273-86.
P r i c e ,  D.D., B e n n e t t ,  G.J. & R a f i i ,  A. (1989). Psychophysical observations o n  
patients with neuropathic pain relieved by a sympathetic block. Pain., 36, 
273-88.
R a h m a n ,  W., S u z u k i ,  R. & D i c k e n s o n ,  A. (2003). Pains, Brains and Spinal 
Gains: Facilitatory Mechanisms Underlying Altered Pain States. The 
International Journal o f  Pain Medicine and Palliative Care, 2, 82-89.
R a h m a n ,  W., S u z u k i ,  R., R y g h ,  L.J. & D i c k e n s o n ,  A.H. (2004). Descending 
serotonergic facilitation mediated through rat spinal 5HT3 receptors is
293
unaltered following carrageenan inflammation. Neurosci Lett., 361,229-
31.
R a h m a n ,  W . ,  S u z u k i ,  R . ,  W e b b e r ,  M . ,  H u n t ,  S . P .  &  D i c k e n s o n ,  A.H.
(2006a). Depletion of endogenous spinal 5-HT attenuates the behavioural 
hypersensitivity to mechanical and cooling stimuli induced by spinal 
nerve ligation. Pain., 123,264-74. Epub 2006 Apr 27.
R a h m a n ,  W., S u z u k i ,  R., W e b b e r ,  M., H u n t ,  S.P. & D i c k e n s o n ,  A.H.
(2006b). Depletion of endogenous spinal 5-HT attenuates the behavioural 
hypersensitivity to mechanical and cooling stimuli induced by spinal 
nerve ligation. Pain, 24, 24.
R a s m u s s e n ,  P.V., S i n d r u p ,  S.H., J e n s e n ,  T.S. & B a c h ,  F . W .  (2004). Symptoms 
and signs in patients with suspected neuropathic pain. Pain., 110,461-9.
R a i g o r o d s k y ,  G. & U r c a ,  G. (1987). Intrathecal N-methyl-D-aspartate
(NMDA) activates both nociceptive and antinociceptive systems. Brain 
Res, 422, 158-62.
R a j a ,  S.N., C a m p b e l l ,  J.N. & M e y e r ,  R.A. (1984). Evidence for different
mechanisms of primary and secondary hyperalgesia following heat injury 
to the glabrous skin. Brain., 107, 1179-88.
R a j a ,  S.N. & H a y t h o r n t h w a i t e ,  J.A. (2005). Combination therapy for
neuropathic pain- Which drugs, which combination, which patients? New 
England Journal o f  Medicine, 352,1373-1375.
R a n d i c ,  M. & M i l e t i c ,  V. (1977). Effect of substance P in cat dorsal hom 
neurones activated by noxious stimuli. Brain Res, 128,164-9.
R e e v e ,  A.J., D i c k e n s o n ,  A.H. & K e r r ,  N.C. (1998). Spinal effects of
bicuculline: modulation of an allodynia-like state by an Al-receptor 
agonist, morphine, and an NMDA-receptor antagonist. J  Neurophysiol., 
79, 1494-507.
R e x e d ,  B. (1952). The cytoarchitectonic organization of the spinal cord in the 
cat . J  Comp Neurol, 96,414-95.
R e y n o l d s ,  D.V. (1969). Surgery in the rat during electrical analgesia induced by 
focal brain stimulation. Science., 164,444-5.
R o w b o t h a m ,  M.C., R e i s n e r - K e l l e r ,  L.A. & F i e l d s ,  H.L. (1991). Both 
intravenous lidocaine and morphine reduce the pain of postherpetic 
neuralgia. Neurology, 41, 1024-8.
R u p n i a k ,  N.M., C a r l s o n ,  E . J . ,  S h e p h e a r d ,  S., B e n t l e y ,  G., W i l l i a m s ,  A.R., 
H i l l ,  A., S w a i n ,  C . ,  M i l l s ,  S.G., D i  S a l v o ,  J . ,  K i l b u r n ,  R., C a s c i e r i , 
M.A., K u r t z ,  M.M., T s a o ,  K.L., G o u l d ,  S.L. & C h i c c h i ,  G.G. (2003). 
Comparison o f the functional blockade of rat substance P (NK1) 
receptors by GR205171, RP67580, SR140333 and NKP-608. 
Neuropharmacology, 45, 231 -41.
R u s i n ,  K.I., B l e a k m a n ,  D., C h a r d ,  P.S., R a n d i c ,  M. & M i l l e r ,  R.J. (1993a). 
Tachykinins potentiate N-methyl-D-aspartate responses in acutely 
isolated neurons from the dorsal hom. J  Neurochem., 60,952-60.
R u s i n ,  K.I., J i a n g ,  M.C., C e r n e ,  R. & R a n d i c ,  M. (1993b). Interactions
between excitatory amino acids and tachykinins in the rat spinal dorsal 
hom. Brain Res Bull., 30,329-38.
R u s i n ,  K.I., R y u ,  P.D. & R a n d i c ,  M. (1992). Modulation of excitatory amino
acid responses in rat dorsal hom neurons by tachykinins. J  Neurophysiol., 
68,265-86.
294
R y g h ,  L.J., S u z u k i ,  R . ,  R a h m a n ,  W . ,  W o n g ,  Y . ,  V o n s y ,  J.L., S a n d h u ,  H., 
W e b b e r ,  M., H u n t ,  S. & D i c k e n s o n ,  A.H. (2006). Local and 
descending circuits regulate long-term potentiation and zif268 expression 
in spinal neurons. Eur J  Neurosci., 24, 761-72.
S a k u r a d a ,  T . ,  M a n o m e ,  Y . ,  T a n - N o ,  K . ,  S a k u r a d a ,  S .  &  K i s a r a ,  K .  (1990). 
The effects o f substance P analogues on the scratching, biting and licking 
response induced by intrathecal injection of N-methyl-D-aspartate in 
mice. Br J  Pharmacol, 101,307-10.
S a l t ,  T.E. (1986). Mediation of thalamic sensory input by both NMDA 
receptors and non-NMDA receptors. Nature., 322,263-5.
S a l t e r ,  M. W. (2005). Cellular signalling pathways of spinal pain neuroplasticity 
as targets for analgesic development. Curr Top Med Chem., 5, 557-67.
S c h u g ,  S.A. & G a n d h a m ,  N. (2006). Opioids: clinical use. In Textboof o f Pain. 
eds McMahon, S.B. & Koltzenburg, M. pp. 443-457. London: Elsevier 
Churchill Livingstone.
S e a g r o v e ,  L.C., S u z u k i ,  R. & D i c k e n s o n ,  A.H. (2004). Electrophysiological 
characterisations of rat lamina I dorsal hom neurones and the 
involvement of excitatory amino acid receptors. Pain, 108, 76-87.
S e g u i n ,  L., L e  M a r o u i l l e - G i r a r d o n ,  S. & M i l l a n ,  M.J. (1995).
Antinociceptive profiles of non-peptidergic neurokinin 1 and neurokinin2 
receptor antagonists: a comparison to other classes of antinociceptive 
agent. Pain, 61, 325-43.
S e v o s t i a n o v a ,  N. & D a n y s z ,  W. (2006). Analgesic effects of mGlul and
mGlu5 receptor antagonists in the rat formalin test. Neuropharmacology, 
19, 19.
S e y b o l d ,  V . S . ,  H y l d e n ,  J.L. & W i l c o x ,  G.L. (1982). Intrathecal substance P 
and somatostatin in rats: behaviors indicative of sensation. Peptides, 3, 
49-54.
S h e r ,  G.D. & M i t c h e l l ,  D. (1990). Intrathecal N-methyl-D-aspartate induces 
hyperexcitability in rat dorsal hom convergent neurones. Neurosci Lett., 
119, 199-202.
S i e g h a r t ,  W., F u c h s ,  K., T r e t t e r ,  V., E b e r t ,  V., J e c h l i n g e r ,  M., H o g e r ,  H. 
& A d a m i k e r ,  D. (1999). Structure and subunit composition of GABA(A) 
receptors. Neurochem Int., 34, 379-85.
S i n d r u p ,  S.H. & J e n s e n ,  T.S. (1999). Efficacy of pharmacological treatments of 
neuropathic pain: an update and effect related to mechanism of chug 
action. Pain., 83,389-400.
S l o n i m s k i ,  M., A b r a m ,  S.E. & Z u n i g a ,  R.E. (2004). Intrathecal baclofen in 
pain management. Reg Anesth Pain Med., 29,269-76.
S l u g g ,  R.M., M e y e r ,  R.A. & C a m p b e l l ,  J.N. (2000). Response of cutaneous A- 
and C-fiber nociceptors in the monkey to controlled-force stimuli. J  
Neurophysiol, 8 3 ,2179-91.
S n i d e r ,  W.D. & M c M a h o n ,  S.B. (1998). Tackling pain at the source: new ideas 
about nociceptors. Neuron, 20, 629-32.
S o m m e r ,  C. & M y e r s ,  R.R. (1995). Neurotransmitters in the spinal cord dorsal 
hom in a model of painful neuropathy and in nerve crush. Acta 
Neuropathol (Berl), 9 0 ,478-85.
S o n g ,  X.J., Hu, S.J., G r e e n q u i s t ,  K.W., Z h a n g ,  J.M. &  L a M o t t e ,  R.H.
(1999). Mechanical and thermal hyperalgesia and ectopic neuronal
295
discharge after chronic compression of dorsal root ganglia. J  
Neurophysiol, 8 2 ,3347-58.
S o r k i n ,  L.S. & C a r l t o n ,  S.M. (1997). Spinal anatomy and pharmacology of
afferent processing. In Anesthesia: Biologic Foundations, ed Yaksh, T.L. 
pp. 577-609. Philadelphia: Lippincott-Raven.
S t e w a r t ,  W. & M a x w e l l ,  D.J. (2000). Morphological evidence for selective 
modulation by serotonin of a subpopulation of dorsal hom cells which 
possess the neurokinin-1 receptor. Eur J  Neurosci., 12,4583-8.
S t o r k s o n ,  R.V., K j o r s v i k ,  A., T j o l s e n ,  A. & H o l e ,  K. (1996). Lumbar
ca th e te riza tio n  o f  th e  sp ina l subarachnoid  space in  the  rat. J  Neurosci 
Methods, 6 5 , 167-72.
S u l l i v a n ,  A.F., H e w e t t ,  K. & D i c k e n s o n ,  A.H. (1994). Differential
m o d u la tio n  o f  a lp h a  2 -ad renerg ic  and  op io id  spinal an tinocicep tion  by  
ch o le cy s to k in in  and  cho lecystok in in  an tagon ists in  the  ra t dorsal hom : an 
e lec tro p h y sio lo g ica l study . Brain Res, 6 6 2 ,1 4 1 -7 .
S u z u k i ,  R., C h a p m a n ,  V. & D i c k e n s o n ,  A.H. (1999). The effectiveness of
sp ina l an d  sy stem ic  m o rp h in e  o n  ra t dorsal h o m  neuronal responses in  the 
sp ina l n e rv e  lig a tio n  m odel o f  neuropath ic  pain . Pain, 80 ,215-28.
S u z u k i ,  R. & D i c k e n s o n ,  A.H. (2006). Differential pharmacological modulation 
of the spontaneous stimulus-independent activity in the rat spinal cord 
following peripheral nerve injury. Exp Neurol., 198,72-80. Epub 2005 
Dec 5.
S u z u k i ,  R. & D i c k e n s o n ,  A.H. (2002a). Nerve injury-induced changes in opioid 
modulation of wide dynamic range dorsal column nuclei neurones. 
Neuroscience, 111,215-28.
S u z u k i ,  R. & D i c k e n s o n ,  A . H .  (2000a). Neuropathic pain: nerves bursting with 
excitement. Neuroreport, 11, R17-21.
S u z u k i ,  R., H unt, S.P. & D i c k e n s o n ,  A.H. (2003). The coding of noxious 
mechanical and thermal stimuli of deep dorsal hom neurones is 
attenuated in NK1 knockout mice. Neuropharmacology, 45 , 1093-100.
S u z u k i ,  R . ,  K o n t i n e n ,  V . K . ,  M a t t h e w s ,  E., W i l l i a m s ,  E. & D i c k e n s o n ,  A . H .  
(2000b). Enlargement o f the receptive field size to low intensity 
mechanical stimulation in the rat spinal nerve ligation model of 
neuropathy. Exp Neurol, 163,408-13.
S u z u k i ,  R., M a t t h e w s ,  E.A. & D i c k e n s o n ,  A.H. (2001). Comparison of the 
effects of MK-801, ketamine and memantine on responses of spinal 
dorsal hom neurones in a rat model of mononeuropathy. Pain, 9 1 ,101-9.
S u z u k i ,  R., M o r c u e n d e ,  S., W e b b e r ,  M., H u n t ,  S.P. & D i c k e n s o n ,  A.H.
(2002b). Superficial NK1-expressing neurons control spinal excitability 
through activation of descending pathways. Nat Neurosci, 5,1319-26.
S u z u k i ,  R ., R a h m a n , W ., H u n t ,  S .P . &  D ic k e n s o n , A .H . (2004a). D escend ing  
fac ilita to ry  con tro l o f  m echan ica lly  e v o k ed  resp o n ses  is enhanced  in  deep 
do rsa l h o m  n eu ro n es fo llow ing  p eriphera l nerve  in ju ry . Brain Res., 1019, 
68-76.
S u z u k i ,  R., R a h m a n ,  W., R y g h ,  L.J., W e b b e r ,  M., H u n t ,  S.P. & D i c k e n s o n , 
A.H. (2005). Spinal-supraspinal serotonergic circuits regulating 
neuropathic pain and its treatment with gabapentin. Pain., 117,292-303.
296
S u z u k i, R., R y g h ,  L.J. & D ic k e n s o n , A.H. (2004b). Bad news from the brain: 
descending 5-HT pathways that control spinal pain processing. Trends 
Pharmacol Sci., 25,613-7.
T a n -N o , K ., E s a s h i, A., N a k a g a w a s a i, O ., N iijim a , F ., Sa k u r a d a , C ., 
S a k u r a d a , T ., B a k a l k in , G ., T e r e n iu s , L. & T a d a n o , T . (2004). 
Nociceptive behavior induced by poly-L-lysine and other basic 
compounds involves the spinal NMDA receptors. Brain Res, 1008,49-53.
T e c o t t , L.H., M a r ic q , A.V. & J u l iu s , D. (1993). Nervous system distribution 
of the serotonin 5-HT3 receptor mRNA. Proc Natl Acad Sci USA. ,  90, 
1430-4.
T o d d ,  A.J. (2002). Anatomy of primary afferents and projection neurones in the 
rat spinal dorsal hom with particular emphasis on substance P and the 
neurokinin 1 receptor. Exp Physiol, 87,245-9.
T o d d , A .J . &  K o e r b e r , H . (2006). N euroanatom ical substra tes o f  spinal
nociception. In Textbook o f  Pain, eds McMahon, S.B. & Koltzenburg, M. 
pp. 73-90. London: Elsevier Churchill Livingstone.
T o d d , A.J., M c G il l , M.M. & S h e h a b , S .A. (2000). N eu rok in in  1 recep tor 
ex p re ss io n  by  n eu ro n s  in  lam inae  I, III and  IV o f  the  ra t sp inal dorsal 
h o m  th a t p ro jec t to  th e  b ra instem . Eur J  Neurosci, 12,689-700.
T o d d , A.J., P u s k a r , Z., S pik e , R.C., H u g h e s , C., W a t t , C. & F o r r e s t , L.
(2002). Projection neurons in lamina I of rat spinal cord with the 
neurokinin 1 receptor are selectively innervated by substance p- 
containing afferents and respond to noxious stimulation. J  Neurosci, 22, 
4103-13.
T h o m p s o n , S.W., K in g , A.E. & W o o l f , C.J. (1990). Activity-Dependent
Changes in Rat Ventral Hom Neurons in vitro; Summation of Prolonged 
Afferent Evoked Postsynaptic Depolarizations Produce a d-2-Amino-5- 
Phosphonovaleric Acid Sensitive Windup. Eur J  Neurosci, 2, 638-649.
T r a f t o n , J.A., A b b a d ie , C ., M a r c h a n d , S ., M a n t y h , P.W. & B a sb a u m , A.I. 
(1999). Spinal o p io id  analgesia : h o w  critica l is the  regu la tion  o f  
su b s tan ce  P signa ling?  J  Neurosci, 19,9642-53.
T r a f t o n , J.A. & B a s b a u m , A.I. (2000). The contribution of spinal cord 
neurokinin-1 receptor signaling to pain. J  Pain, 1, 57-65.
T r e e d e , R.D., M e y e r , R.A., R a ja , S.N. & C a m p b e l l , J.N. (1992). Peripheral 
and central mechanisms of cutaneous hyperalgesia. Prog Neurobiol, 38, 
397-421.
T s u c h iy a , M ., Y a m a z a k i, H. & H o r i, Y. (1999). Enkephalinergic neurons 
express 5-HT3 receptors in the spinal cord dorsal hom: single cell RT- 
PCR analysis. Neuroreport., 10,2749-53.
T s u d a , M., In o u e , K. & S a l t e r , M.W. (2005). Neuropathic pain and spinal 
microglia: a big problem from molecules in "small'* glia. Trends 
Neurosci, 28, 101-7.
T s u d a ,  M ., S h ig e m o to -M o g a m i, Y ., K o izu m i, S ., M iz o k o s h i ,  A ., K o h s a k a ,  
S., S a l t e r ,  M .W . &  I n o u e , K . (2003). P 2X 4  recep to rs  induced  in  sp inal 
m ic ro g lia  ga te  tac tile  a llo d y n ia  a fte r nerve  in ju ry . Nature., 424,778-83.
U r b a n ,  L. & R a n d i c ,  M. (1984). Slow excitatory transmission in rat dorsal 
hom: possible mediation by peptides. Brain Res., 290, 336-41.
U r b a n ,  M.O. & G e b h a r t ,  G . F .  (1999a). Supraspinal contributions to 
hyperalgesia. Proc Natl Acad Sci USA,  96, 7687-92.
297
U r b a n , M.O., J ia n g , M.C. & G e b h a r t , G .F . (1996). Participation of central 
descending nociceptive facilitatory systems in secondary hyperalgesia 
produced by mustard oil. Brain Res, 737,83-91.
U r b a n ,  M.O., Z a h n ,  P.K. & G e b h a r t ,  G.F. (1999b). Descending facilitatory 
influences from the rostral medial medulla mediate secondary, but not 
primary hyperalgesia in the rat. Neuroscience, 90, 349-52.
U r c h ,  C.E. & D i c k e n s o n ,  A.H. (2003a). In vivo single unit extracellular
recordings from spinal cord neurones of rats. Brain Res Brain Res Protoc, 
12, 26-34.
U r c h ,  C.E., D o n o v a n - R o d r i g u e z ,  T .  &  D i c k e n s o n ,  A.H. (2003b). Alterations 
in dorsal horn neurones in a rat model of cancer-induced bone pain. Pain, 
106, 347-56.
U s h i d a ,  T., T a n i ,  T., K a n b a r a ,  T., Z i n c h u k ,  V.S., K a w a s a k i ,  M. &
Y a m a m o t o ,  H. (2002). Analgesic effects of ketamine ointment in 
patients with complex regional pain syndrome type 1. RegAnesth Pain 
Med., 27, 524-8.
V a n e g a s ,  H. & S c h a i b l e ,  H. (2000). Effects of antagonists to high-threshold 
calcium channels upon spinal mechanisms of pain, hyperalgesia and 
allodynia. Pain., 85, 9-18.
v a n  R i j n ,  C.M., S u n ,  M.S., D e c k e r s ,  C.L., E d e l b r o e k ,  P.M., K e y s e r ,  A., 
R e n i e r ,  W. & M e i n a r d i ,  H. (2004). Effects of the combination of 
valproate and ethosuximide on spike wave discharges in WAG/Rij rats. 
Epilepsy Res., 59, 181-9.
V e r a - P o r t o c a r r e r o ,  L.P., Z h a n g ,  E.T., O s s i p o v ,  M.H., X i e ,  J.Y., K i n g ,  T., 
L a i ,  J. & P o r r e c a ,  F .  (2006). Descending facilitation from the rostral 
ventromedial medulla maintains nerve injury-induced central 
sensitization. Neuroscience., 140,1311-20. Epub 2006 May 2.
W a n g , Z ., G a r d e l l , L .R ., O ss ip o v , M.H., V a n d e r a h , T .W ., B r e n n a n , M.B., 
H o c h g e s c h w e n d e r , U ., H r u b y , V.J., M a l a n , T .P ., J r ., L a i, J. & 
P o r r e c a , F. (2001). Pronociceptive actions of dynorphin maintain 
chronic neuropathic pain. J  Neurosci., 2 1 ,1779-86.
W a n g ,  H., L i u ,  R.J., Z h a n g ,  R.X. & Q i a o ,  J.T. (1997). Peripheral NMDA
receptors contribute to activation of nociceptors: a c-fos expression study 
in rats. Neurosci Lett., 221, 101-4.
W a n g ,  H., S u n ,  H., D e l l a  P e n n a ,  K., B e n z ,  R.J., Xu, J., G e r h o l d ,  D.L., 
H o l d e r ,  D.J. & K o b l a n ,  K.S. (2002a). Chronic neuropathic pain is 
accompanied by global changes in gene expression and shares 
pathobiology with neurodegenerative diseases. Neuroscience., 114, 529- 
46.
W a n g ,  X. & M a r v i z o n ,  J.C. (2002b). Time-course of the internalization and
recycling of neurokinin 1 receptors in rat dorsal horn neurons. Brain Res, 
944,239-47.
W a t k i n s ,  J.C. & E v a n s ,  R.H. (1981). Excitatory amino acid transmitters. Annu 
Rev Pharmacol Toxicol, 21, 165-204.
W e g e r t ,  S . ,  O s s i p o v ,  M.H., N i c h o l s ,  M.L., B i a n ,  D., V a n d e r a h ,  T . W . ,  
M a l a n ,  T . P . ,  J r . &  P o r r e c a ,  F .  (1997). Differential activities of 
intrathecal MK-801 or morphine to alter responses to thermal and 
mechanical stimuli in normal or nerve-injured rats. Pain, 71 ,57-64.
298
W ei, F ., D u b n e r , R . &  R e n , K . (1999). L am inar-se lec tive  noradrenerg ic  and  
se ro to n in e rg ic  m odu la tion  includes sp inoparabrach ia l ce lls  a fter 
in flam m ation . Neuroreport., 10, 1757-61.
W i l c o x ,  G.L. (1988). Pharmacological studies of grooming and scratching
behavior elicited by spinal substance P and excitatory amino acids. Ann N  
Y Acad Sci, 525,228-36 .
W i l c o x ,  G.L. & S e y b o l d ,  V. (1997). Pharmacology of spinal afferent
processing. In Anesthesia: Biologic Foundations, ed Yaksh, T.L. pp. 557- 
576. Philadelphia: Lippincott-Raven.
W i l l i s ,  W.D. (1985). Nociceptive pathways: anatomy and physiology of
nociceptive ascending pathways. Philos Trans R Soc LondB Biol Sci.,
308, 253-70 .
W i l l i s ,  W.D. & W e s t l u n d ,  K.N. (1997). Neuroanatomy of the pain system and 
of the pathways that modulate pain. J  Clin Neurophysiol, 14,2-31.
W o o d ,  J.N. (2004). Recent advances in understanding molecular mechanisms of 
primary afferent activation. Gut, 53, ii9-12.
W o o d , J.N., A b r a h a m s e n , B ., B a k e r , M.D., B o o r m a n , J.D., D o n ie r , E .,
D r e w , L.J., N a s s a r , M.A., O k u se , K., S e e r e e r a m , A., S t ir l in g , C.L.
&  Z h a o , J. (2004). Ion channel activities implicated in pathological pain. 
Novartis Found Symp., 261,32-40; discussion 40-54.
W o o d ,  J.N. & B a k e r ,  M. (2001). Voltage-gated sodium channels. Curr Opin 
Pharmacol. ,1,17-21.
W o o d r u f f , G.N., Fo s t e r , A.C., G il l , R ., K e m p , J.A., W o n g , E .H . &  Iv e r s e n , 
L.L. (1987). The interaction between MK-801 and receptors for N- 
methyl-D-aspartate: functional consequences. Neuropharmacology, 26, 
903-9.
W o o l f ,  C.J. (2004). Dissecting out mechanisms responsible for peripheral 
neuropathic pain: implications for diagnosis and therapy. Life Sci, 74, 
2 605 -10 .
W o o l f ,  C.J. & M a n n i o n ,  R.J. (1999). Neuropathic pain: aetiology, symptoms, 
mechanisms, and management. Lancet, 353,1959-64.
W o o l f , C .J . & S a l t e r , M.W. (2000). N eu rona l p lastic ity : increasing  the  gain  in  
p a in . Science, 2 8 8 ,1765-9.
W o o l f , C.J., S h o r t l a n d , P. & C o g g e s h a l l , R.E. (1992). Peripheral nerve
injury triggers central sprouting of myelinated afferents. Nature, 355, 75- 
8 .
W o o l f , C.J. & W a l l , P.D. (1986). Morphine-sensitive and morphine-insensitive 
actions of C-fibre input on the rat spinal cord. Neurosci Lett, 64 ,221-5.
W u , H .E ., S c h w a s in g e r , E .T ., H o n g , J.S. & T s e n g , L .F . (2005). Pretreatment 
with antiserum against dynorphin, substance P, or cholecystokinin 
enhances the morphine-produced anti-allodynia in the sciatic nerve 
ligated mice. Neurosci Lett., 386,46-51 .
W u , Z .Z ., G u a n , B.C., Li, Z .W ., Y a n g , Q ., L iu , C.J. & C h e n , J.G. (2004).
Sustained potentiation by substance P of NMDA-activated current in rat 
primary sensory neurons. Brain Res., 1010, 117-26.
Xu, X.J., D a l s g a a r d , C.J. & W ie s e n fe l d -H a l l in , Z . (1992). Spinal substance 
P and N-methyl-D-aspartate receptors are coactivated in the induction of 
central sensitization of the nociceptive flexor reflex. Neuroscience., 51, 
641-8 .
299
Xu, X.J., P u k e ,  M.J., V e r g e ,  V.M., W i e s e n f e l d - H a l l i n ,  Z., H u g h e s ,  J. &
H o k f e l t ,  T. (1993). Up-regulation of cholecystokinin in primary sensory 
neurons is associated with morphine insensitivity in experimental 
neuropathic pain in the rat. Neurosci Lett., 152, 129-32.
Y a k s h ,  T.L. (2006). Central pharmacology of nociceptive transmission. In
Textbook o f  Pain, eds McMahon, S.B. & Koltzenburg, M. pp. 371-414. 
London: Elsevier Churchill Livingstone.
Y a k s h ,  T.L. (1997). Pharmacology and mechanisms of opioid analgesic activity. 
In Anesthesia: Biologic Foundations, ed Yaksh, T.L. pp. 921-934. 
Philadelphia: Lippincott-Raven.
Y a k s h ,  T.L., H u a ,  X . Y . ,  K a l c h e v a ,  I . ,  N o z a k i - T a g u c h i ,  N .  &  M a r s a l a ,  M .  
(1999). The spinal biology in humans and animals of pain states 
generated by persistent small afferent input. Proc Natl Acad Sci U S A ,
96, 7680-6.
Y a k s h ,  T.L., J e s s e l l ,  T.M., G a m s e ,  R., M u d g e ,  A.W. & L e e m a n ,  S.E. (1980). 
Intrathecal morphine inhibits substance P release from mammalian spinal 
cord in vivo. Nature, 286, 155-7.
Yaksh, T. L. and T. A. Rudy (1976). "Chronic catheterization of the spinal 
subarachnoid space." Physiol Behav 17(6): 1031-6.
Y a k s h ,  T.L. & W i l s o n ,  P.R. (1979). Spinal serotonin terminal system mediates 
antinociception. J  Pharmacol Exp Ther., 208,446-53.
Y a m a m o t o ,  T., S h i m o y a m a ,  N .  &  M i z u g u c h i ,  T. (1993). Role of the i n j u r y
discharge in the development of thermal hyperesthesia after sciatic nerve 
constriction injury in the rat. Anesthesiology, 79,993-1002; discussion 
28A.
Y a m a m o t o ,  T. & Y a k s h ,  T.L. (1992a). Comparison of the antinociceptive
effects of pre- and posttreatment with intrathecal morphine and MK801, 
an NMDA antagonist, on the formalin test in the rat. Anesthesiology, 77, 
757-63.
Y a m a m o t o ,  T. & Y a k s h ,  T.L. (1991). Spinal pharmacology of thermal
hyperesthesia induced by incomplete ligation of sciatic nerve. I. Opioid 
and nonopioid receptors. Anesthesiology., 75, 817-26.
Y a m a m o t o ,  T. & Y a k s h ,  T.L. (1992b). Studies on the spinal interaction of 
morphine and the NMDA antagonist MK-801 on the hyperesthesia 
observed in a rat model of sciatic mononeuropathy. Neurosci Lett., 135, 
67-70.
Y i p , J. & C h a h l ,  L.A. (1999). Distribution of Fos-like immunoreactivity in
guinea-pig brain following administration of the neurokinin-1 receptor 
agonist, [SAR9,MET(02)1 ljsubstance P. Neuroscience, 94,663-73.
Y o s h i m u r a ,  M. & Y o n e h a r a ,  N. (2001). Influence of capsaicin cream in rats 
with peripheral neuropathy. Pharmacol Res, 44, 105-11.
Z e i t z ,  K . P . ,  G u y ,  N . ,  M a l m b e r g ,  A.B., D i r a j l a l ,  S . ,  M a r t i n ,  W.J., S u n ,  L . ,  
B o n h a u s ,  D.W., S t u c k y ,  C . L . ,  J u l i u s ,  D. & B a s b a u m ,  A.I. (2002). The 
5-HT3 subtype of serotonin receptor contributes to nociceptive 
processing via a novel subset of myelinated and unmyelinated 
nociceptors. J  Neurosci., 22,1010-9.
Z h a n g , X ., B a o , L ., S h i, T .J., J u , G ., E l d e , R . & H o k f e l t , T . (1998). Down-
regulation of mu-opioid receptors in rat and monkey dorsal root ganglion
300
neurons and spinal cord after peripheral axotomy. Neuroscience, 82, 223- 
40.
301
